SMILES,log2CL,log2CL_pred,Name,CAS #,human VDss (L/kg),human CL (mL/min/kg),"fraction unbound 
in plasma (fu)",MRT (h),terminal  t1/2 (h),Reference,Comments ,Notes,Year of first disclosure,MW,HBA,HBD,TPSA_NO,RotBondCount,moka_ionState7.4,MoKa.LogP,MoKa.LogD7.4
Brc1ccc2NC(=O)CN=C(c3ccccn3)c2c1,-0.9714308478032292,1.3810811,Bromazepam,1812-30-2,0.85,0.51,0.48,28.0,21.0,"Raaflaub VJ and Speiser-Courvoisier J (1974) Zur pharmakokinetik von bromazepam beim menschen.  Arz. Forsch. 24: 1841-1844.  Lucek RW and Coutinho CB (1976) The role of substituents in the hydrophobic binding of the 1,4-benzodiazepines by human plasma proteins.    Molec. Pharmacol. 12: 612-619.",Parameters calculated from C vs t data provided in the reference.,,1962,316.15,4,1,54.3,1,neutral,2.0,2.0
C(=O)(NC(=N)N)c1c(n(nc1)c1c2c(ccc1)nccc2)C1CC1,4.392317422778761,2.8763974,Zoniporide,241800-98-6,1.7,21.0,0.34,1.3,2.0,"Cross-Species Comparison of the Metabolism and Excretion of Zoniporide: Contribution of Aldehyde Oxidase to Interspecies Differences. Deepak Dalvie, Chenghong Zhang, Weichao Chen, Teresa Smolarek, R. Scott Obach, and Cho-Ming Loi. DRUG METABOLISM AND DISPOSITION, 2010,38:641–654.// ppb: Zientek M, Jiang Y, Youdim, K, and Obach RS (2010) In vitro-in vivo correlation for intrinsic clearance for drugs metabolized by human aldehyde oxidase.  Drug Metab. Dispos. 38: 1322-1327.","MRT from clearance and VDss. 80 mg, 1 h infusion.",,1999,320.35,7,3,109.7,4,neutral,1.0,1.0
"C(=O)([C@@H](COC)NC(=O)C)NCc1ccccc1
",-0.8109661756099832,2.3209047,Lacosamide,175481-36-4,0.58,0.57,0.85,17.2,12.3,"Bioequivalence of Intravenous and Oral Formulations of the Antiepileptic Drug Lacosamide. Willi Cawello, Rainer Bonn, Hilmar Boekens. Pharmacology 2012;90:40-46 . ppb: < 15% as reported by PDR. http://www.pdr3d.com/detail.php?c=130625#section-14. Accessed December 30 2014.","Data after 200 mg 15 min infusion (N=16, mean BW = 77.3 kg) digitized from Fig 1 reported in Willi Cawello, Rainer Bonn, Hilmar Boekens. Bioequivalence of Intravenous and Oral Formulations of the Antiepileptic Drug Lacosamide Pharmacology 2012, 90, 40–46. Reported data: AUC(0–t), h*µg/ml 72.33 (±17.4), AUC(0–inf), h*µg/ml 75.40 (±17.0), T1/2, h 12.6, Calculated data, AUCINF_obs h*ug/mL 76.41",,1996,250.29,5,2,67.4,6,neutral,-0.2,-0.2
C(=O)([C@@H](NC(=O)c1ccc(cc1)NC[C@@H]1N(c2c(=O)nc([nH]c2NC1)N)C=O)CCC(=O)O)O,2.035623909730721,0.90351814,Levoleucovorin,68538-85-2,0.27,4.1,,1.1,1.1,"Eberhard Schleyer á Karl Lenhard Rudolph, Jan Braess á Michael Unterhalt á Gerhard Ehninger Wolfgang Hiddemann á Wolfgang Kern, Impact of the simultaneous administration of the (+)- and (-)-forms
of formyl-tetrahydrofolic acid on plasma and intracellular pharmacokinetics of (-)-tetrahydrofolic acid. Cancer Chemother Pharmacol (2000) 45: 165-171","Structure and CAS number referring to free acid. Also reported as dl-CF. N=4, 100 mg/m2, 70 kg weight assumed, 10' infusion, MRT from VDss and clearance.",,1948,473.44,14,7,219.8,9,anionic,-2.0,-7.7
C(=O)([O-])C(=C1\[C@@H](OC(=O)C)C[C@@]2([C@@]3(CC[C@H]4[C@@H]([C@@H](CC[C@@]4(C)[C@@H]3[C@H](O)C[C@@H]12)O)C)C)C)\CC\C=C(\C)C,-1.5145731728297585,0.9160902,Fusidate sodium,751-94-0,0.23,0.35,0.02,10.6,9.8,"A. M. Taburet, J. Gufbert, M. D. Kitris, H. Sorensen, J. F. Acar and E. Singes. Pharmacokinetics of sodium fusidate after single and repeated infusions and oral administration of a new formulation. Journal of Antimicrobial Chemotherapy (1990) 25, Suppl. B, 23-31.//ppb: Markus A. Zeitlinger, Hartmut Derendorf, Johan W. Mouton, Otto Cars, William A. Craig, David Andes, and Ursula Theuretzbacher. Protein Binding: Do We Ever Learn? ANTIMICROB AGENTS CHEMOTHER., 2011, 55, 3067–3074.","N=8, 61.6 kg average weight, dose 500 mg 2 hr infusion. VDss calculated from MRT and clearance from first dose.",,1962,515.7,6,2,106.9,6,anionic,5.7,3.3
C(=O)(c1ccc(c(c1)OCC1CC1)OC(F)F)Nc1c(cncc1Cl)Cl,1.1375035237499351,2.4704945,Roflumilast,162401-32-3,1.92,2.2,0.01,14.5,15.1,"High absolute bioavailability of the new oral phosphodiesterase-4 inhibitor roflumilast T.D. Bethke and G. Lahu. Int. J.of Clin. Pharmacol. and Therapeutics, 2011,  49, 51-57."," Calculated from digitized plot. Median weight 75kg. Reported AUC(-inf)= 14.1 ug*h/L.Calculated AUC 15.1 ng*h/mL. 150 ug dose, N=12.",,1995,403.21,5,1,60.4,7,neutral,3.5,3.5
C(C(C)C)CCCCCCC(=O)N[C@H]1[C@H](Oc2c3cc4[C@H](C(N[C@@H]5c6cc(c7c([C@@H](NC([C@H]([C@@H](c8cc(c(O3)cc8)Cl)O[C@H]3[C@@H]([C@H]([C@H](O)[C@H](O3)CO)O)NC(C)=O)NC5=O)=O)C(=O)O)cc(O)cc7O[C@H]3O[C@@H]([C@@H](O)[C@@H]([C@@H]3O)O)CO)c(cc6)O)=O)NC([C@@H]3c5cc(Oc6cc(ccc6O)[C@@H](C(N[C@@H](C(N3)=O)Cc3cc(c(Oc2c4)cc3)Cl)=O)N)cc(c5)O)=O)O[C@@H]([C@H](O)[C@@H]1O)CO,-3.473931188332412,-2.367359,Teicoplanin A2-5,91032-38-1,0.42,0.09,0.033,78.2,66.8,"Bernareggi A, Borgonovi M, Del Favero A, Rosina R, and Gavanaghi L (1991)  Teicoplanin binding in plasma following administration of increasing intravenous doses to healthy volunteers.  Eur. J. Drug Metab. Pharmacokinet. 256-260.",Dosed as mixture of all components but PK reported separately for each compound.N=5. MRT from VDss and clearance.,,1983,1893.68,42,24,662.4,20,anionic,1.4,-1.3
C(C(F)(F)F)(C(F)(F)F)(F)F,9.206306225009923,3.659885,Perflutren,76-19-7,1.6,590.71,,0.05,0.02,"https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21-064_Definity_biopharmr.pdf.
 Accessed May 18 2017.","Definity.PFC 218. Data in blood. It may be assumed that bl/pl is =1. N=8, healthy volunteers. 70 kg average weight assumed.",,1930,188.02,0,0,0.0,0,neutral,2.5,2.5
C(C1CCCC1)(c1ccccc1)(C(=O)OC1C[N+](CC1)(C)C)O.[Br-],4.070389327891398,1.7930361,Glycopyrrolate bromide,596-51-0,0.37,16.8,,0.37,0.65,"Penttilä J et al. Pharmacokinetic-pharmacodynamic model for the anticholinergic effect of glycopyrrolate. Eur J Clin Pharmacol, 2001, 57, 153-158","Data from Table 1. micro dose (5 µg/kg), N=8, 3 compartments. MRT calculated from VDss and CL. T1/2 compartment 3. Body weights 60-80kg. ",CL renal ~68% ,1960,398.33,4,1,46.5,5,neutral,-0.23,-0.23
C(CC(C)(N)C)(N[C@H](C(N[C@@H](Cc1c[nH]cn1)C(N[C@H]([C@H]([C@@H](O)CC(C)C)O)CC1CCCCC1)=O)=O)Cc1ccc(cc1)OC)=O,-1.15200309344505,2.1034148,Enalkiren,113082-98-7,0.11,0.45,0.07,3.1,1.72,"Gupta, SK; Granneman, GR; Boger, RS; Hollenberg, NK; Luther, RR. Simultaneous modeling of the pharmacokinetics and pharmacodynamic properties of enalkiren (Abbott-64662, a new renin inhibitor) I: single dose study. Drug Metab. Disp. 1992, 20, 821-825.ppb: Brian D. Dayton, Herman H. Stein, Jerome Cohen, William R. Baker, Steven A. Boyd, Stephen L. Condon, B. Gregory Donner, Anthony K. L. Fung, Jay R. Luly, Saul H. Rosenberg, Keith W. Woods, and Hollis D. Kleinert. Effects of Angiotensinase Inhibitors on Plasma Protein Binding and IC50 Determinations of Renin Inhibitors. CLIN. CHEM. 1992, 38, 2239-2243.","Abbott-64662. N=16, 70 kg average weight reported. 90 minutes infusion. Average dose 15.32 mg. VDss from 7 subjects. Data taken from Table 1.",,1979,656.86,12,7,191.7,18,cationic,2.5,0.16
C(CCC(NCCCCCN(C(C)=O)O)=O)(N(CCCCCNC(CCC(N(CCCCCN)O)=O)=O)O)=O,3.058316495590823,0.57539105,Desferrioxamine,70-51-9,1.35,8.33,,2.7,3.05,"P. LEE, N. MOHAMMED, L. MARSHALL, A. D. ABEYSINGHE, A. C. HIDER, J. B. PORTER, AND S. SINGH. INTRAVENOUS INFUSION PHARMACOKINETICS OF DESFERRIOXAMINE IN
THALASSAEMIC PATIENTS. Drug Metab. Disp. 1993, 21, 640-644.","Deferoxamine. EC 200-738-5. N=11, clearance as dose over AUC appears to be correct. Dose 50 mg/kg/24hr over 48 hours. MRT appears a bit smaller than when calculated from reported AUMC, AUC and clearance. AUC0-inf 354 umol.h.L-1; AUMC0-inf  9170 umol.h2.L-1. All data taken as is from paper. MW 560.69",,1960,560.68,14,6,205.8,23,cationic,-2.6,-5.8
C(CON(=O)=O)N1COc2ccccc2C1=O,4.887037791419196,3.0441697,Sinitrodil,143248-63-9,0.68,29.59,,0.38,0.38,"Monzani MV, Coltro G, Sala A, Sardina M., Pharmacokinetics of ITF 296 (Sinitrodil) a novel organic nitrate, in healthy volunteers. Eur J Pharm Sci, 1999, 7, 179-184. ","Data from 10 mg dose 30-min iv infusion, N=11, 78.08 kg average weight",,1992,238.2,7,0,84.6,4,neutral,1.8,1.8
C(CO[N+](=O)[O-])(CO[N+](=O)[O-])O[N+](=O)[O-],7.602142090697982,2.1502187,Nitroglycerin,55-63-0,,194.3,0.4,,4.5,"Nitroglycerin - FDA Approval Package
Clinical Pharmacology and Biopharmaceutics Review 021359/S-000. Accessed through Pharmapendium.","70 kg assumed. Vd reported as 3 L/kg, but without label. Likely to be VDz. T1/2 ranged from 1.5 to 7.5 minutes. Median point taken.",,1946,227.09,12,0,157.1,8,neutral,1.7,1.7
C(N1CCN(c2nc(nc(n2)NCC=C)NCC=C)CC1)(c1ccc(F)cc1)c1ccc(F)cc1,-0.043943347587597,1.2433474,Almitrine,27469-53-0,35.37,0.97,0.01,607.0,1344.0,"Bernhard R. Winkelmann, Thomas H. Kullmer, Dieter G. Kneissi, Dietmar Trenk, Hartmut Kronenberger. Low-dose Almitrine Bismesylate in the Treatment of Hypoxemia due to Chronic Obstructive Pulmonary Disease. Chest, 1994; 105, 1383-1391.////ppb: Bromet N; Singlas E. Clinical pharmacokinetics of almitrine dimesylate. Presse medicale, 1984, 13, 2071-2077.","N=7, average weight 64 kg. 60 mg dose. VD reported taken as VDss after calculation from clearance and t 1/2 yielded a much higher value. MRT from clearance and VDss.",,1970,477.55,7,2,69.2,10,neutral,6.0,6.0
C(O)CCN1c2c(cc(C[C@H](NCCOc3c(cccc3)OCC(F)(F)F)C)cc2CC1)C(=O)N,1.4854268271702415,2.6952326,Silodosin,160970-54-7,,2.8,0.05,,3.6,"Silodosin - EMA Approval Package
Assessment Report EMEA/H/C/001209. Accessed through Pharmapendium.",2 mg dose administered as iv infusion 0.8 L/kg reported as VD after iv dose but likely to be VDz.,No conclusive data in EMA package,1994,495.53,7,3,97.1,13,cationic,3.0,2.3
C(O)[C@@]12[C@H](C3=CC[C@H]4[C@@]([C@@]3(C[C@H]2O)C)(C)CC[C@@H]2[C@]4(C)CC[C@@H]([C@@]2(CO)C)O[C@H]2[C@H](O[C@@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O)[C@@H](O)[C@@H]([C@H](O2)C(=O)O)O[C@@H]2O[C@H](CO)[C@H]([C@@H]([C@H]2O)O)O)CC([C@H]([C@@H]1OC(=O)C)OC(=O)/C(=C/C)/C)(C)C,0.722466024471091,-0.52227575,Escin Ia,123748-68-5,0.28,1.65,,2.85,2.4,"A liquid chromatography–tandem mass spectrometry method for the simultaneous quantification of escin Ia and escin Ib in human plasma: application to a pharmacokinetic study after intravenous administration. Lidong Liu, Xiujun Wu,Dan Wu, Yingwu Wang, Pengfei Li, Yantong Sun, Yan Yang, Jingkai Gua and Yimin Cui. Biomed. Chromatogr. 2010; 24: 1309–1315",Data digitized from plots reported. 3 mg dose. N=10 70 kg average weight assumed. ,,1989,1131.26,24,13,388.0,16,anionic,-1.2,-4.5
C(O)[C@@]12[C@H](C3=CC[C@H]4[C@@]([C@@]3(C[C@H]2O)C)(C)CC[C@@H]2[C@]4(C)CC[C@@H]([C@@]2(CO)C)O[C@H]2[C@H](O[C@@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O)[C@@H](O)[C@@H]([C@H](O2)C(=O)O)O[C@@H]2O[C@H](CO)[C@H]([C@@H]([C@H]2O)O)O)CC([C@H]([C@@H]1OC(=O)C)OC(=O)/C(=C\C)/C)(C)C,1.3504972470841332,-0.52227575,Escin Ib,26339-90-2,0.23,2.55,,1.5,1.8,"A liquid chromatography–tandem mass spectrometry method for the simultaneous quantification of escin Ia and escin Ib in human plasma: application to a pharmacokinetic study after intravenous administration. Lidong Liu, Xiujun Wu,Dan Wu, Yingwu Wang, Pengfei Li, Yantong Sun, Yan Yang, Jingkai Gua and Yimin Cui. Biomed. Chromatogr. 2010; 24: 1309–1315",Data digitized from plots reported. 2 mg dose reported. Clearance not corresponding to calculated while AUC within 10%.  N=10 70 kg average weight assumed. ,,1989,1131.26,24,13,388.0,16,anionic,-1.2,-4.5
C(OC(/C=C/C(=C1NC(/C=C/C(O)=O)=O)C=C(C=C1)O)=O)[C@@](C([C@@]([C@]1(C(O)=O)CC2)(CC2(C)C)[H])=CC2)([C@@](C)([C@]2([C@](C)([C@@]2(C(C)(C)C(C3)=O)[H])C3)[H])CC2)CC1,2.925999418556223,0.3241582,S-0139,162059-95-2,1.45,7.6,,3.18,,"Prolonged pharmacodynamic effects of S-0139, an intravenously administered endothelin A (ETA) antagonist, in the human forearm blood flow model  Lunnon, Martin W.; Wallace, Sharon M. L.; Palmer, Joanne E.; Francis-Lang, Andrew; Laurijssens, Bart E.; Mistry, Prafull; Albala, Bruce; Nagafuji, Toshiaki; Wilkinson, Ian B.; Maltby, Kay  British Journal of Clinical Pharmacology (2010), 69(3), 252-261.",Average of 3 doses and 19 subjects total. Data from 3 hours infusion.  VDss from reported Css and dose. No t1/2 reported. MRT = VDss/CL,,1994,729.9,10,4,167.3,9,anionic,6.8,1.7
C(S(=O)(=O)O)CS,4.357552004618084,1.5791878,Mesna,19767-45-4,0.65,20.5,,0.52,0.36,"C. A. JAMES, T. G. K. MANT and  H. J. ROGERS. Pharmacokinetics of intravenous and oral sodium 2-mercaptoethane sulphonate (mesna) in normal subjects  Br. J. clin. Pharmac. (1987), 23, 561-568","N=6, 800 mg dose, first order behavior. VD reported as VDz but taken as VDss. CAS number of the sodium salt and smiles of the free acid.",,1954,142.2,3,1,54.4,2,anionic,-0.71,-4.2
C(SP(O)(O)=O)CNCCCN,4.937815168803419,2.526336,Amifostine,20537-88-6,0.09,30.65,,0.05,0.15," LESLIE M. SHAW, PH.D., ANDREW T. TURRISI, M.D., DONNA J. GLOVER, M.D., HEATHER S. BONNER, B.S., A. LORRAINE NORFLEET, B.S., CLARE WEILER, R.N.
AND MORTON M. KLIGERMAN, M.D. HUMAN PHARMACOKINETICS OF WR-2721. Int. J. Radiation Oncology Bio. Phys.. 1986, 12, 1501-1504.","WR-2721, NSC 296961. 12 patients with different types of tumor. 70.8 kg average weight. 150 mg/m2, 10 seconds injection.",,1969,214.22,5,4,95.6,7,cationic,-1.4,-3.8
C([C@@H](C(N[C@@H](C(N[C@@H](C(N[C@@H](C(N[C@@H](C(N[C@@H](C(N[C@@H](C(N[C@@H](C(N[C@@H](C(N[C@@H](C(N[C@@H](C(N[C@@H](C(N[C@@H](C(N[C@@H](C(N[C@@H](C(N[C@@H](C(N[C@@H](C(N[C@@H](C(N[C@@H](C(NCC(N[C@@H](C(N[C@@H](C(C)C)C(O)=O)=O)CC(C)C)=O)=O)CCC(N)=O)=O)CC(C)C)=O)CC(C)C)=O)CCCNC(N)=N)=O)CCC(N)=O)=O)CC(C)C)=O)CCCNC(N)=N)=O)C)=O)CO)=O)CC(O)=O)=O)CCCNC(N)=N)=O)CC(C)C)=O)CCCNC(N)=N)=O)CO)=O)CC(C)C)=O)CCC(O)=O)=O)CO)=O)[C@@H](C)O)=O)NC([C@@H](NC(CNC([C@@H](NC([C@@H](NC([C@@H](Cc1[nH]ccn1)N)=O)CO)=O)CC(O)=O)=O)=O)[C@@H](C)O)=O)c1ccccc1,2.572889668420581,0.25676468,Secretin (porcine),1393-25-5,0.03,5.95,,0.08,0.13,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-136_SecreFlo_BioPharmr.pdf. Accessed on May 17 2017,"Secreflo. Secretin (porcine), 15-L-glutamic acid-16-glycine-. ChiRoClin. MW= 3056.42. Synthetic but identical to porcine peptide. Cross-over study with human peptide N=12, 0.4 ug/kg iv in human. 77.2 kg average weight. Data digitized from plot reported in biopharmaceutics review. No AUC reported. Clearance reported as 487 mL/min. Converted in units of mL.min-1.kg-1 yields 6.31 mL.min-1.kg-1. 6% difference",,1907,3056.39,85,52,1415.7,109,zwitterionic,-9.0,-9.0
C([C@@H](CO)O)O[N+](=O)[O-],1.859969548221026,2.934256,Glyceryl 1-nitrate,624-43-1,0.76,3.63,,4.12,2.5,"H. LAUFEN, M. LEITOLD. Glyceryl-1-nitrate pharmacokinetics in healthy volunteers. Br. J. Clin. Pharmac. (1987), 23, 287-293.","N=10, 20 mg kg dose administered via 1hr infusion, 77.9 kg average weight.",,1949,137.09,6,2,92.8,4,neutral,-0.51,-0.51
"C([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](Cc1ccc(O)cc1)N)=O)C)=O)CC(O)=O)=O)C)=O)[C@@H](CC)C)=O)C(N[C@@H](C(N[C@@H](C(N[C@@H](C(N[C@@H](Cc1ccc(O)cc1)C(N[C@@H](C(N[C@@H](C(N[C@@H](C(N[C@@H](C(NCC(N[C@@H](C(N[C@@H](C(N[C@@H](C(N[C@@H](C(N[C@@H](C(N[C@@H](C(N[C@@H](C(N[C@@H](C(N[C@@H](C(N[C@@H](C(N[C@@H](C(N[C@@H](C(N[C@@H](C(N[C@@H](CCCNC(N)=N)C(N)=O)=O)CO)=O)CCSC)=O)[C@@H](CC)C)=O)CC(O)=O)=O)CCC(N)=O)=O)CC(C)C)=O)CC(C)C)=O)CCCCN)=O)CCCNC(N)=N)=O)C)=O)CO)=O)CC(C)C)=O)CCC(N)=O)=O)=O)CC(C)C)=O)C(C)C)=O)CCCCN)=O)CCCNC(N)=N)=O)=O)CO)=O)CC(N)=O)=O)[C@@H](C)O)=O)c1ccccc1
",5.2964574073712445,1.7198126,Sermorelin,86168-78-7,0.34,39.3,,0.14,0.19,Sermorelin Acetate - FDA Approval Package Administrative documents 020443. Accessed through Pharmapendium. ,"Data digitized and VDss calculations performed via Phoenix. Average of 3 doses (0.25, 0.5 and 1 mg). N=12.",no metabolism studies performed in humans.,1982,3357.88,86,52,1446.9,118,cationic,-9.0,-9.0
C([C@@H](N[C@H]1CCc2c(cccc2)N(CC(O)=O)C1=O)CCCCN)(O)=O,0.2986583155645151,1.681377,Libenzapril,109214-55-3,1.98,1.23,,29.3,,"Gregory M. Kochak, PhD, R. Leslie Choi, PhD, Jacqueline K. deSilva, MD, and P. Reydel-Bax, BS. Pharmacodynamic Dependent Disposition of the Angiotensin Converting Enzyme Inhibitor, Libenzapril.J. ClIn Pharmacol 1990;30:138-143","Doses of 1.7 and 4 mg. N=12 73.1 kg average weight. Non linear behavior for MRT and VDss at 12 mg dose, but clearance stable. Data at 1.7 and 4 mg weight-averaged (N=4 and 8, respectively). T1/2 not reported.",,1985,363.41,8,4,133.0,9,anionic,0.21,-2.4
C([C@@H](c1cc(Oc2ccccc2)ccc1)C)(=O)O,-0.7369655941662062,1.2931328,Fenoprofen,29679-58-1,0.1,0.6,0.02,2.8,2.24," Physiological disposition of fenoprofen in man.  II.  Plasma and Urine Pharmacokinetics after Oral and Intravenous Administration. Rubin, Alan; Rodda, Bruce E.; Warrick, Patricia; Ridolfo, Anthony; Gruber, Charles M.  Journal of Pharmaceutical Sciences (1971), 60(12), 1797-801. ppb: Physiological disposition of fenoprofen in man.  III.  Metabolism and protein binding of fenoprofen. Rubin, Alan; Warrick, Patricia; Wolen, Robert L.; Chernish, Stanley M.; Ridolfo, Anthony S.; Gruber, Charles M., Jr. J. Pharmacol. Exp. Ther.  1972, 183, 449-457. ","N=4, data calculated as average of V1+V2; microconstant also available. Median weight 67.5 kg.  MRT = VDss/CL. One-compartment model data used.",,1970,242.27,3,1,46.5,4,anionic,3.2,0.48
C([C@H]1N(CCC1)C([C@@H](Cc1ccccc1)N)=O)(=O)N[C@H](C(N1[C@H](C(=O)NCC(=O)NCC(NCC(=O)NCC(=O)N[C@H](C(NCC(=O)N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(=O)N2[C@@H](CCC2)C(=O)N[C@H](C(N[C@H](C(N[C@@H](Cc2ccc(O)cc2)C(N[C@@H](CC(C)C)C(=O)O)=O)=O)CCC(O)=O)=O)CCC(O)=O)[C@H](CC)C)=O)CCC(O)=O)=O)CCC(O)=O)=O)Cc2ccccc2)=O)CC(O)=O)=O)CC(=O)N)=O)CCC1)=O)CCCNC(N)=N,3.017921907997262,0.6398122,Bivalirudin,128270-60-0,0.27,8.1,1.0,0.43,0.42,"Guixiang Pana, Xiaoming Wang, Yuhong Huang, Xiumei Gao, Yuefei Wang. Development and validation of a LC–MS/MS method for determination of bivalirudin in human plasma: Application to a clinical pharmacokinetic study J.Pharm. Biomed. Anal.. 2010, 52 105–109.//CHA IDong, WANG Rui, BA INan, CA IYun LIANG B ei- bei. Pharmacokinetics of bivalirudin injections in Chinese healthy volunteers. Chin. J. Clin Pharmacol. 2011, 27, 280-282.// ppb: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/090816s000lbl.pdf. Accessed July 14 2014.",Weighted average of data from both papers. N=9 (pana et al) and N=36 (Chai et al.) Doses from 0.5 to 1.05 mg/kg infusion//ppb from fda label. Bivalirudin does not bind to plasma proteins (other than thrombin) or to red blood cells.,,1990,2180.29,57,28,901.6,67,anionic,-6.6,-9.0
C(\[C@@H]1[C@@H]([C@@H](Cl)C[C@@H]1O)C\C=C\CCCC(O)=O)=C\[C@@H](C(CCCC)(C)C)O,3.7224660244710903,1.3017354,Nocloprost,79360-43-3,0.16,13.2,,0.2,0.8,"U. Tiiuber, M. Brudny-Kltippei , U. J akobs , C. Madetzki , and M. Mahler. Pharmacokinetics of nocloprost in human volunteers and its relation to dose. Eur J Clin Pharmacol (1993) 44:497-500",5 ug iv dose. N=10,,1981,400.98,4,3,77.8,12,anionic,5.1,2.6
C(\[C@@H]1[C@H]([C@@H](O)C[C@H]1O)C\C=C/CCCC(=O)NCC)=C\[C@H](CCc1ccccc1)O,4.643856189774724,2.6071045,Bimatoprost,155206-00-1,0.67,25.0,0.12,,0.45,PDR. Accessed February 18 2013. http://www.pdr3d.com/detail.php?c=85286#section-10,"Clearance in blood but no B/P reported. MRT not yet calculable. Following an intravenous dose of radiolabeled bimatoprost (3.12 mcg/kg) to six healthy subjects, the maximum blood concentration of unchanged drug was 12.2 ng/mL and decreased rapidly with an elimination half-life of approximately 45 minutes. The total blood clearance of bimatoprost was 1.5 L/hr/kg. Up to 67% of the administered dose was excreted in the urine while 25% of the dose was recovered in the feces. No true mass balance reported to show whether bimatoprost was intact or not.",,1994,415.57,5,4,89.8,12,neutral,3.3,3.3
C(c1ccco1)(=O)O[C@]1([C@@]2([C@H]([C@@H]3[C@]([C@@]4(C(=CC(=O)C=C4)CC3)C)(Cl)[C@H](C2)O)C[C@H]1C)C)C(CCl)=O,3.6667565918848033,2.64008,Mometasone Furoate,83919-23-7,2.2,12.7,0.01,2.9,4.4,Mometasone Furoate - FDA Approval PackageClinical Pharmacology and Biopharmaceutics Review 021067/S-000. Accessed through Pharmapendium on March7 2013. VDss reported on label in the same package.,70 kg assumed. 400 ug dose.,,1982,521.43,6,1,94.1,5,neutral,4.5,4.5
C1(=O)N2[C@@H]([C@H]1[C@H](O)C)SC(COC(N)=O)=C2C(=O)[O-].[Na+],2.9164766444377164,1.4203713,Ritipenem ,84845-58-9,0.24,7.55,0.72,0.54,0.54,". Weighted data for diverse doses and number of patients (N=61) from Table XII (BW 65-80 kg) in Lovering, A. M.; White, L. O.; Lewis, D. A.; MacGowan, A. P.; Routh, K. R.; Pickin, D. M.; Reeves, D. S.  Pharmacokinetics of FCE 22101 in man following different modes of administration.    Journal of Antimicrobial Chemotherapy  (1989),  23(Suppl. C),  179-95; and from Table 2 in Jannuzzo, M. G.; Mandelli, M.; Strolin Benedetti, M.; Moro, E.; Carnovali, M.; Vaiani, R.; Sassella, D.  Pharmacokinetics and tolerance of a new penem antibiotic, FCF 22101, in healthy volunteers after a single intravenous dose.    European Journal of Clinical Pharmacology  (1989),  36(6),  633-635.    fu in Efthymiopoulos, C.; Battaglia, R.; Strolin Benedetti, M.  Animal pharmacokinetics and interspecies scaling of FCE 22101, a penem antibiotic.    Journal of Antimicrobial Chemotherapy  (1991),  27(4),  517-26.",FCE-22101. In Jannuzzo et al the renal CL = 1.94 mL/min/kg was also reported. CAS number reported refers to sodium salt. Parent compound CAS 84845-57-8.,,1982,310.26,8,2,133.0,5,anionic,-2.1,-5.6
C1(=O)[C@H]([C@@H]2N1C(=C(CS2)Sc1scc(n1)c1cc[n+](cc1)C)C(=O)[O-])NC(=O)/C(=N\OCC)c1nc(sn1)NP(=O)(O)O,6.38543103719352,0.27171683,Ceftaroline fosamil,229016-73-3,0.53,83.6,0.8,0.11,0.09,"Ref. through PP. 2010-Oct-15  PDF(2616k)
Clinical Pharmacology and Biopharmaceutics Review 200327/S-000 Part 01 ","N=18, averaged across 3 doses at 50, 100 and 250 mg (N=6 each).",All metabolic (prodrug),1999,684.68,16,4,223.2,11,anionic,-4.6,-7.1
C1(C2=C([C@H](C[C@]1([C@H]([C@H]1[C@](C(=O)[C@@H]2OC)([C@H](C[C@@H]2[C@]1(CO2)OC(=O)C)OC)C)OC(=O)c1ccccc1)O)OC(=O)[C@@H]([C@H](c1ccccc1)NC(=O)OC(C)(C)C)O)C)(C)C,3.4594316186372973,2.1176324,Cabazitaxel,183133-96-2,48.0,11.0,0.24,72.7,74.5,"Mita, Alain C.; Denis, Louis J.; Rowinsky, Eric K.; DeBono, Johann S.; Goetz, Andrew D.; Ochoa, Leonel; Forouzesh, Bahram; Beeram, Muralidhar; Patnaik, Amita; Molpus, Kathleen; Semiond, Dorothee; Besenval, Michele; Tolcher, Anthony W. Phase I and Pharmacokinetic Study of XRP6258 (RPR 116258A), a Novel Taxane, Administered as a 1-Hour Infusion Every 3 Weeks in Patients with Advanced Solid Tumors. Clin.Cancer Res. 2009, 15,723-730. ppb: Men, Lei; Lin, Hong-li; Shao, Yan-jie; Zhao, Yun-li; Zhao, Xing; Tang, Xing; Yu, Zhi-guo. Determination of human plasma protein binding rate of cabazitaxel by UPLC-​MS​/MS. Zhongguo Xinyao Yu Linchuang Zazhi, 2014, 33, 379-383. Data from abstract and using mid-concentration range. 2-fold lower at high concentration range (fu 0.12) but similar at low concentration. Taken from abstract in English.","XRP6258 or RPR116258A or Jevtana. 23 patients overall. Doses from 10 to 25 mg/m2 as 1 hour infusion. Weighted average and 1.73m2/70kg factor used. Reported (weighted) average of clearance and VDss 26.77 L/h/m2 and 1942.8 L/m2, respectively. MRT=VDss/Cl.",,1996,835.93,15,3,202.4,14,neutral,4.0,4.0
C1(C=C[C@@]2([C@H]3[C@H](C[C@@]4([C@@]5([C@@H](C[C@@H]4[C@@H]3CCC2=C1)O[C@H](C1CCCCC1)O5)C(COC(C(C)C)=O)=O)C)O)C)=O,5.0574502721839,1.572339,Ciclesonide,126544-47-6,2.9,33.3,0.01,1.45,1.04,"Nave R. Clinical pharmacokinetic and pharmacodynamic profile of inhaled ciclesonide. Clin Pharmacokinet. 2009, 48(4), 243–252.","Data from review article Clin. Pharmacokinet. 2009, 48, 243-252, confirmed by Dr. R. Nave, e-mail 7/27/2009. VDss 2.9 L/kg and 2.0 L/h/kg.  No full publication available for this presentation/abstract. MRT from VDss and clearance.// Nave R, Bethke TD, van Marle SP, Zech K (2004) Pharmacokinetics of [14C]ciclesonide after oral and intravenous administration to healthy subjects. Clin. Pharmacokin. 43(7) 479-486.//N=6, 0.64 mg dose, 72.6 kg average weight, MW = 540.69, 10' infusion.  Lower VDss (~ 10-fold) and Cl (~ 22 mL/min/kg).","E-mail message, July 27 2009. For ciclesonide our focus is always the active metabolite. Nevertheless we have generated a few data for the parent compound ciclesonide following iv administration (reference 29 of the review manuscript). The data of this study were presented in 2002 on a congress and in the abstract the following is stated: ""The mean volume of distribution was 2.9 l/kg and the total clearance was 2.0 l/h/kg for the parent compound following intravenous administration"". Sorry, there is no full publication available for this study. 
The reference 28 is on the ADME of 14C-ciclesonide and there may be limintations in terms of PK of the parent compound (for example number of subjects and sensitivity of the bioanalytical assay). ",1992,540.69,7,1,99.1,6,neutral,4.8,4.8
C1(N2C(=C(S[C@@H]3C[S@@](CC3)=O)S[C@H]2[C@H]1[C@H](O)C)C([O-])=O)=O,2.350497247084133,1.1455125,CP-65207,96865-21-3,0.21,5.1,0.9,0.7,0.9,"Pharmacokinetics of the Penem CP-65,207 and Its Separate Stereoisomers in Humans G. FOULDS,l A. K. KNIRSCH, J. D. LAZAR, T. G. TENSFELDT, AND N. GERBER. Antimicr. Agents Chemother. 1991, 35, 665-671.//ppb: Thomas Gootz, Dennis Girard, William Schelkley, Thomas Tensfeldt, George Foulds, Michael Kellogg, John Stam, Benedict Campbell1f, John Jasys, Paul Kelbaugh, Robert Volkmann and Ernest Hamanaka. PHARMACOKINETIC STUDIES IN ANIMALS OF A NEW PARENTERAL PENEM CP-65,207 AND ITS ORAL PRODRUG ESTER. J. Antibiot. 1990, 43, 422-432"," Na salt. Na omitted from smiles. Average of single enantiomers dosed as racemate and analyzed separately, N=12 each, 1 g 10 min' infusion. Similar values found. Mean weight 74.8 kg.",,1985,348.44,6,1,97.7,4,anionic,-1.8,-4.7
C1([C@@H]2[C@@]3([C@@]([C@@H]4[C@@H]([C@@]5(CC[C@@H](O[C@@H]6O[C@@H](C)[C@@H]([C@@H](C6)O)O[C@@H]6O[C@@H](C)[C@@H]([C@@H](C6)O)O[C@@H]6O[C@@H](C)[C@@H]([C@@H](C6)O)O)C[C@@H]5CC4)C)CC3)(C[C@@H]2OC(=O)C)O)C)=CC(=O)OC1,-2.473931188332412,0.64081717,16-acetyl gitoxin,7242-07-1,0.78,0.18,0.07,72.3,51.6,"Hausten, K.-O. On the Pharmacokinetics of 16-Acetyl-gitoxin and Its Bioavailability from Pengitoxin-Containing Tablet Formulations. Int. J. Pharmacokin. Biopharm. 1986, 14, 357-364. ","16-O-acetylgitoxin. N=6, 65.3 kg average weight. 0.5 mg administered iv in 1 minute. MRT calculate from AUC and AUMC in turn calculated from C1, C2 and lamba 1 and 2. VDss then calculated from MRT and clearance reported. Fu reported by the author from own previous work. G. Hiiller, K.-O. Haustein, and D. Murawski. On the plasma-protein binding of 16-acetylgitoxin.
Int. J. Clin. Pharmacol. 19:200-202 (1981).",,1960,822.98,15,5,209.1,9,neutral,0.93,0.93
C1([C@H]2[C@@]([C@@]3(C([C@H]4[C@@](CC[C@@](C4)(C(O)=O)C)(C)CC3)=C1)C)(CC[C@@H]1[C@@]2(CC[C@@H](C1(C)C)O[C@@H]1[C@H](O[C@@H]2O[C@@H]([C@@H](O)[C@@H]([C@H]2O)O)C(O)=O)[C@H]([C@H](O)[C@H](O1)C(O)=O)O)C)C)=O,-2.9434164716336326,-1.6156176,Glycyrrhizin,1405-86-3,0.06,0.13,,7.83,8.83,"Tekla G.J. van Rossum, MD, Arnold G. Vulto, PhD, Wim C. J. Hop, MSc, PhD, Solko W. Schalm, MD, PhD Pharmacokinetics of Intravenous Glycyrrhizin After Single and Multiple Doses in Patients with Chronic Hepatitis C Infection. CLlNICALTHERAPEUTICS, 1999,21, 2080-2090","Weighted average over 4 doses (80, 160, 200, 240) from table II (Day1). N=33 overall. ",,1880,822.93,16,8,267.0,7,anionic,1.5,-7.5
C1=2[C@H]([C@H]3[C@]([C@@](C#CC)(O)CC3)(C)C[C@@H]1c1ccc(N(C)C)cc1)CCC=1C2CCC(C1)=O,-1.0,1.2468534,Mifepristone,84371-65-3,0.45,0.5,0.02,15.7,16.6,Mifepristone - http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/20687_Mifepristone_clinphrmr_P2.pdf. Ppb from label in FDA package. Accessed September 22 2015.,"70 kg assumed. 20 mg dose, N=10.",,1982,429.59,3,1,40.5,3,neutral,4.8,4.8
C1=CC([C@@H](C[C@@H]([C@@H]([C@@H](C)[C@@H](CC(O[C@@H]([C@@H](C)[C@@H]2O[C@@]12C)CC)=O)O)O[C@@H]1O[C@@H](C[C@@H]([C@@H]1O)N(C)C)C)CC=O)C)=O,3.733354340613827,2.109219,Rosaramicin,35834-26-5,2.83,13.3,,3.54,3.34,"Pharmacokinetics and Metabolism of Rosaramicin in Humans. CHIN-CHUNG LIN, MENGER CHUNG, RICHARD GURAL, DAVID SCHUESSLER, HONG-KI KIM, ELAINE
RADWANSKI, ALICEANN MARCO, CHARLES DiGIORE, AND SAMSON SYMCHOWICZ. Antimicr. Agents Chemother. 1984, 26, 522-526.",Data digitized from plot reported by Lin et al . N=12 74.4 kg average weight estimated from dose/AUC vs. clearance in mL.min-1.kg-1 reported. 500 mg dose administered as 1-hr infusion. Reported clearance 13.4 mL.min-1.kg-1 and 3.78 L/kg as Vdarea. Calculated VDz 3.86 L/kg. AUC calculated 8.38 hr*ug/mL vs. reported as 8.35 hr*ug/mL.,,1971,581.74,10,2,135.1,6,cationic,2.5,1.2
C1C(=Cc2c(O1)cc(cc2)O)c1ccc(cc1)O,5.88508622529017,2.5899308,Phenoxodiol,81267-65-4,1.55,59.1,,0.44,0.67,"Jan B Howes, Paul L de Souza, Leanne West, Li Jiu Huang, Laurence G Howes. Pharmacokinetics of phenoxodiol, a novel isoflavone, following intravenous administration to patients with advanced cancer. BMC Clinical Pharmacology 2011, 11:1-8; doi: 10.1186/1472-6904-11-1","NV06. Data for the free form ONLY. Average clearance, VDss and t1/2 reported for N=6 subjects administered 5 mg/kg as iv bolus. 70 kg assumed. MRT from VDss and clearance.",,1981,240.25,3,2,49.7,1,neutral,1.9,1.8
C1C(CCN(C1)CCCC(c1ccc(C(C(=O)O)(C)C)cc1)=O)OC(c1ccccc1)c1ccccc1,-1.3219280948873622,2.5750175,Carebastine,90729-42-3,0.41,0.4,0.05,16.7,9.8,"J.M. JANSAT, C.F. LASTRA, E.L. MARINO Comparative study of different weighting methods in non-linear regression analysis: implications in the parametrization of carebastine after intravenous administration in healthy volunteers. Int. J. Clin. Pharmacol. Ther., Vol. 1998, 36, 340-344.//ppb: A del Cuvillo, J Mullol, J Bartra, I Dávila, I Jáuregui, J Montoro, J Sastre, AL Valero. Comparative pharmacology of the H1 antihistamines. J Investig Allergol Clin Immunol 2006, 16, Suppl. 1:3-12.","Data taken from Table 1. 77 kg median weight, 10 mg total dose. N=8. VDss from MRT and clearance.",,1985,499.64,5,1,66.8,11,zwitterionic,5.9,3.0
C1CCCC(CC1)NC(P(=O)(O)O)P(=O)(O)O,1.111031312388744,0.10229698,Incadronate (acid),124351-85-5,0.24,2.16,0.9,1.85,1.82,"T. Usui, Y. Oiso, A. TOMITA , E. OGATA, T. UCHIDA, K. IKEDA , T. WATANABE I, S. HIGUCHI. Pharmacokinetics of incadronate, a new bisphosphonate, in healthy volunteers and patients with malignancy-associated hypercalcemia. Int. J. Clin. Pharmacol. Ther. 1997, 35, 239-244.
","Average of 4 subjects per dose across 4 doses. 0.2, 0.4, 0.8 and 1.6 mg. 70 kg median weight taken from range. Renal clearance ~ 63% across latter three dose. MRT from VDss and clearance.",,1989,287.19,7,5,127.1,4,anionic,-0.55,-5.8
C1CCN(C(c2cccnc2)=O)c2c1cccc2OC[C@@H](CNC(C)C)O,1.84799690655495,3.6914473,Nicainoprol,76252-06-7,0.67,3.6,,3.1,12.4,"Takashi Ishizaki, Yukio Horai, Kiyoshi Kubota, Akemi Minegishi., Hirotoshi Echizen, and Kan Chiba, Ph.D.Disposition kinetics and dynamics of nicainoprol, a new antiarrhythmic agent, in humans. Clin. Pharmacol. Ther. 1987, 42, 525-534","N=8, 100 mg in 60' infusion. Clrenal 0.56 mL/min/kg. Erroneous MRT reported in Table 1 and corrected using AUC and clerance cross-checking.",,1981,369.46,6,2,74.7,7,cationic,1.4,-0.35
C1CC[C@@H]([C@@H](C1)C(=O)N(C)CC(=O)NO)C(O)=O,2.655351828612554,0.9089774,Idrapril,127420-24-0,1.0,6.3,1.0,2.8,2.6,"Zanchi, A.; Nussberger, J.; Criscuoli, M.; Capone, P.; Brunner, H. R. Angiotensin-​converting enzyme inhibition by hydroxamic zinc-​binding idrapril in humans. Journal of Cardiovascular Pharmacology (1994), 24(2), 317-322//ppb: Criscuoli, Marco; Lippi, Annalisa; Mengozzi, Grazia; Sardelli, Giuliana; Subissi, Alessandro; Giachetti, Antonio. Pharmacokinetics and pharmacodynamics of idrapril in rats, dogs, and humans. Drug Metab. Disp. 1993, 21, 835-840.","N=8 , average BW = 74kg. 1, 5 and 25mg iv doses in sequence with 1 week of was-out interval. Repoorted PK of 1mg dose.  PK from 1mg profile in Fig. 5. Reported data in Table 3: CL = 446 mL/min (6.0 mL/min/kg) and term. T1/2 = 3h","The 5mg iv profile should be dose-proportional to 1mg based on the dose and AUC, but the reported CL in Table 3 is higher for 5mg. Not dose-proportionality for 25mg iv dose.",1989,258.27,7,3,106.9,4,anionic,-1.0,-3.5
C1CC[C@@H]2C[C@H](N([C@@H]2C1)C([C@H](C)N[C@@H](CCc1ccccc1)C(OCC)=O)=O)C(=O)O,3.643856189774725,2.396725,Trandolapril,87679-37-6,0.25,12.5,0.17,0.34,0.26,"Trandolapril - FDA Approval Package
Approval Package 020528/S-001 Part 03", 70 kg average weight assumed. MRT from VDss and clearance.,Ester cleavage transformed into trandolaprilat.,1983,430.54,7,2,95.9,10,anionic,3.2,-0.16
C1CN=C(N1)C2CC2(c3ccccc3)c4ccccc4,3.104336659814736,2.0552034,Cibenzoline,53267-01-9,4.1,8.6,0.5,7.8,7.3,"Cifenline. Aronoff G, Brier M, Mayer ML, Barbalas M, Aogaichi K, Sloan R, Brazzell R, and Massarella J (1991) Bioavailability and kinetics of cibenzoline in patients with normal and impaired renal function. J. Clin. Pharmacol. 31: 38-44.  Reidenberg MM, Lorenzo BJ, Drayer DE, Kluger J, Nestor T, Regnier JC, Kowal BA, and Bekersky I (1988) A nonradioactive iothalamate method for measuring glomerular filtration rate and its use to study the renal handling of cibenzoline.  Ther. Drug Monit. 10: 434-437.",,,1974,262.35,2,1,24.4,3,cationic,2.8,-0.64
C1CSS[C@@H]1CCCCC(=O)O,3.523561956057013,1.6930346,"Lipoic acid, R(+)-α",1200-22-2,0.1,11.5,,0.14,0.21,"Hermann, R.; Niebch, G.; Borbe, H. O.; Fieger-Bueschges, H.; Ruus, P.; Nowak, H.; Riethmueller-Winzen, H.; Peukert, M.; Blume, H. Enantioselective pharmacokinetics and bioavailability of different racemic α-lipoic acid formulations in healthy volunteers. European Journal of Pharmaceutical Sciences (1996), 4(3), 167-174.",200 mg (racemic) iv 4min infusion. N=12. Digitized from figure 3. AUC differing by 4% from reported.,,1951,206.33,2,1,37.3,5,anionic,2.4,0.038
C1CSS[C@H]1CCCCC(=O)O,3.7441610955704094,1.6930346,"Lipoic acid, S(-)-α",1077-27-6,0.11,13.4,,0.13,0.21,"Hermann, R.; Niebch, G.; Borbe, H. O.; Fieger-Bueschges, H.; Ruus, P.; Nowak, H.; Riethmueller-Winzen, H.; Peukert, M.; Blume, H. Enantioselective pharmacokinetics and bioavailability of different racemic α-lipoic acid formulations in healthy volunteers. European Journal of Pharmaceutical Sciences (1996), 4(3), 167-174.",200 mg (racemic) iv 4min infusion. N=12. Digitized from figure 3.  AUC differing by 12% from reported.,,1956,206.33,2,1,37.3,5,anionic,2.4,0.038
C1C[C@@H](N)[C@H](O[C@@H]1CNC)O[C@@H]1[C@@H]([C@H]([C@@H](C[C@@H]1N)N)O[C@@H]1[C@@H]([C@H]([C@](CO1)(O)C)NC)O)O,0.137503523749935,1.3654137,Micronomicin,52093-21-7,0.15,1.1,,2.4,2.1,"KEIZO MATSUMOTO, HARUMI SHISHIDO and ATSUSHI TAKAHASHI. PHARMACOKINETIC AND CLINICAL EVALUATIONS OF
MICRONOMICIN BY INTRAVENOUS DRIP INFUSION. 1985, 38, 135-143.","Data digitized from plot reported for 60 mg dose. N= 5, 60.1 kg average weight (all malee) 1 hour intravenous drip. AUCinf within 3% of reported.",,1973,463.57,12,8,199.7,7,cationic,-4.2,-6.9
C1C[C@@H]2[C@H]3CCC[N@+]4([C@H]3[C@@H](CCC4)CN2C(=O)C1)[O-],2.937344392150232,1.7524959,Oxymatrine,16837-52-8,0.61,7.66,,1.33,1.69,"Xiao-luan Wu, Tai-jun Hang, Jian-ping Shen, Yin-di Zhang. Determination and pharmacokinetic study of oxymatrine and its metabolite matrine in human plasma by liquid chromatography tandem mass spectrometry. Journal of Pharmaceutical and Biomedical Analysis 2006, 41, 918–924.","calculated from digitized plot. 600 mg total dose, N=10, 65 kg average weight. 0.5 h infusion.",,1958,264.36,4,0,43.4,0,neutral,0.87,0.87
C1C[C@H](CC[C@@]21c1cc(OCC)ccc1N(S(=O)(c1c(cc(C(NC(C)(C)C)=O)cc1)OC)=O)C2=O)OCCN1CCOCC1,3.6205864104518777,2.484829,Satavaptan,185913-78-4,7.0,12.3,0.1,9.4,10.4,"Satavaptan - EMA Approval Package
Withdrawal Report EMEA/CHMP/316130/2008. Accessed through Pharmapendium.","Data taken at lowest 91 mg) dose. Very tight at 5 and 10 mg doses as well. Somewhat higher (both VDss and clearance but well within two-fold) at higher doses (25, 50 and 100 mg). 70 kg assumed and MRT from VDss and clearance. ",Seemingly biliary but not clear from EMA package.,1997,643.79,11,1,123.7,10,neutral,3.5,3.2
C1[C@@H]2[C@@H](CN1NC(NS(c1ccc(C)cc1)(=O)=O)=O)CCC2,-1.286304185156641,0.39718977,Gliclazide,21187-98-4,0.43,0.41,0.03,17.5,16.4,"Complete bioavailability and lack of food-effect on pharmacokinetics of gliclazide 30 mg modified release in healthy volunteers  Delrat, P.; Paraire, M.; Jochemsen, R. Biopharmaceutics & Drug Disposition (2002), 23(4), 151-157. ppb: (from abstract in English) Xu, Shanshan; Xue, Yuehua; Tian, Ziyou; Chen, Saizhen; Wang, Zhichao; Wang, Renye. Effect of irbesartan on the plasma protein binding rate of gliclazide in vitro Zhongguo Linchuang Yaoxue Zazhi. 2013, 22, 151-155","N=2, 73 kg reported average weight. MRT = VDss/CL.",,1968,323.41,6,2,78.5,3,anionic,1.7,0.2
C1[C@@](C[C@H]([C@H]([C@@H]1OC(\C=C\c1cc(c(cc1)O)O)=O)OC(\C=C\c1cc(c(cc1)O)O)=O)O)(C(=O)O)O,5.111865963867557,0.29256135,"3,4-DCQA",14534-61-3,0.63,34.58,,0.3,0.57,"Wen-Zheng Ju,Yang Zhao,Fang Liu,Ting Wua,Jun Zhang,Shi-Jia Liu,Lin gZhou,Guo-Liang Dai,Ning-Ning Xiong,Zhu-Yuan Fang. Clinical tolerability and pharmacokinetics of Erigerontis hydroxybenzene injection: Results of a randomized phase I study in healthy Chinese volunteers. Phytomed. 2015, 22, 319–325","3,4-dicaffeoylquinic acid. Data digitized from plot reported.  All from average males/females. 6 vials EH product tested for content via HPLC.  20.4  mg total dose, N=6, 57 kg average weight. 1 hr infusion. All AUCinf data within 10% of reported.",,1961,516.45,12,7,211.3,9,anionic,2.6,-1.0
C1[C@@]2([C@@H]3[C@@](CC[C@H]2C(C)([C@H](C1)O)C)([C@@]1(C(=CC3)[C@H]2[C@@](CC1)(CC[C@H]([C@@H]2C)C)C(O)=O)C)C)C,1.9523335663696857,0.23640864,Ursolic acid,77-52-1,0.54,3.87,,2.34,4.8,"Quantitation of ursolic acid in human plasma by ultra performance liquid chromatography tandem mass spectrometry and its pharmacokinetic study. Yuanyuan Xia, Guangli Wei, Duanyun Si, Changxiao Liu. Journal of Chromatography B, 2011, 879, 219–224","Data digitized from fig. 3 in Xia et al Journal of Chromatography B, 879 (2011) 219–224. Dose 98 mg/m2 converted to 170 mg (1.73 m^2 to 70 kg).Body weight reported as 75 kg PK parameter reported in Table 3. Calculations performed via Gastroplus. Calculated AUC  =  9.753  µg-h/mL; reported AUC = 9918  ng-h/mL.",,1910,456.7,3,2,57.5,1,anionic,6.9,4.8
C=1(c2c(cccc2)CC1CCN(C)C)[C@@H](c1ccccn1)C,2.2720231890610485,3.371238,Dimetindene,5636-83-9,2.16,4.83,,5.98,4.6,"Arnera, V.; Wermeille, M.; Wellman, M.; Llull, J. B.; Althaus, M. A.; Balant, L. P. Pharmacokinetics of dimetindene after intravenous and oral administration to healthy volunteers. Arzneimittel-Forschung, 1990, 40, 1346-1348.","Data digitized from plot. AUCinf calculated within 2% of reported AUCinf. N=8, 4 mg dose, 75 kg median weight taken from reported range.",,1960,292.42,2,0,16.1,5,cationic,4.0,2.5
C=C(C[C@@H](C(=O)O)NC(=O)C1=CC=C(C=C1)CCC2=CN=C3C(=N2)C(=NC(=N3)N)N)C(=O)O,1.622930350920177,0.4852818,MDAM,176857-41-3,0.7,3.08,,3.78,8.2,"Mary Johansen, Thomas Zukowski, Paulo M. Hoff, Robert A. Newman, Dan Ni, Toni Hutto James Abbruzzeese, Elmer Berghorn Frederick Hausheer, Timothy Madden. Final results of a phase I and pharmacokinetic study of γ-methylene-10-deazaaminopterin (MDAM) administered intravenously daily for five consecutive days in patients with solid tumors. Cancer Chemother Pharmacol (2004) 53: 370–376","γ-METHYLENE-10-DEAZAAMINOPTERIN. N=16, across several dose, weight-averaged 80-300 mg/m2. 1.73m2/70 kg factor used. SD up to 100% of reported values. MRT from VDSs and clearance.",,1996,451.44,12,5,207.3,9,anionic,0.16,-6.0
CC#CCC(C)[C@H](O)\C=C\[C@H]1[C@H](O)C[C@@H]2C\C(=C/CCCC(=O)O)\C[C@H]12,4.0,1.7417899,Iloprost,78919-13-8,0.37,16.0,0.4,0.39,0.57,Krause W and Krais T (1986) Pharmacokinetics and pharmacodynamics of the prostacyclin analogue iloproset in man.  Eur. J. Clin. Pharmacol. 30: 61-68.  Hildebrand M (1997) Pharmacokinetics and tolerablity of oral iloprost in thromboangitis obliterans patients.  Eur. J. Clin. Pharmacol. 53: 51-56.  Ventavis Product Label.,VDss calculated from digitized plots.  VDss and CL data are the average of the two reports; t1/2 data are only from Hildebrandt. ,,1981,360.49,4,3,77.8,9,anionic,3.5,0.96
CC(=N)N1CC[C@@H](C1)Oc2ccc(cc2)[C@H](Cc3ccc4ccc(cc4c3)C(=N)N)C(=O)O,0.8953026213333067,2.022963,DX9065a,150612-55-8,1.55,1.86,,14.4,24.02,"Tolerability, pharmacokinetics, and pharmacodynamics of DX-9065a, a new synthetic potent anticoagulant and specific factor Xa inhibitor, in healthy male volunteers. Nobuyuki Murayama, MS, Makoto Tanaka, PhD, Satoshi Kunitada, PhD, Hirohisa Yamada, MS, Takashi Inoue, MS, Yasuko Terada, BS, Masami Fujita, MD, Yasuo Ikeda, MD. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1999, 66, 258-264.","Data for 24 patients (N=6/group) across 5, 10, 20 nd 30 mg doses. Median weight 61.7 kg reported. Structure and CAS number referring to  free base.",,1993,444.53,7,4,123.5,8,cationic,3.8,-1.3
CC(=O)CC(C1=C(O)c2ccccc2OC1=O)c3ccccc3,-4.184424571137427,0.64791644,Warfarin,81-81-2,0.13,0.055,0.0149999999999999,39.0,29.0,"Bjornsson TD, Meffin PJ, Swezey S, and Blaschke TF (1979) Clofibrate displaces warfarin from plasma proteins in man: an example of a pure displacement interaction.  J. Pharmacol. Exp. Ther. 210: 316-321.",,,1944,308.33,4,1,63.6,4,anionic,2.6,0.2
CC(=O)NC[C@H]1CN(C(=O)O1)c2ccc(N3CCOCC3)c(F)c2,0.84799690655495,2.072698,Linezolid,165800-03-3,0.58,1.8,0.69,5.4,4.5,"Stalker DJ, Jungbluth GL, Hopkins NK, and Batts DH (2003) Pharmacokinetics and tolerance of single- and multiple-dose oral and intravenous linezolid, an oxazolidinone antibiotic, in healthy volunteers.  J. Antimic. Chemother. 51: 1239-1246.  Zyvox Product Label.",,,1995,337.35,7,1,71.1,4,neutral,1.1,1.1
CC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)O,4.224966365000275,0.6517596,Seraspenide,120081-14-3,,18.7,,,0.08,"ERIC EZAN, PATRICE CARDE, JOEL LE KERNEAU, THIERRY ARDOUIN, FRANCOIS THOMAS, FRANCOISE ISNARD, EVELYNE DESCHAMPS DE PAILLETTE, AND JEAN-MARC GROGNET. PHARMACOKINETICS IN HEALTHY VOLUNTEERS AND PATIENTS OF NAc-SDKP (SERASPENIDE), A NEGATIVE REGULATOR OF HEMATOPOIESIS. Drug Metab. Disp. 1994, 22, 843-848.","Goralatide, Ac-SDKP. N=6, 69.7 kg average weight, 62.5 ug/kg/12 hr (128 nmol). Digitization yielded a much higher AUC (155 nM.hr) than reported (112 nM.hr) and  clearance and t 1/2 were taken from reported data.",Alternate smiles: C(N1CCC[C@H]1C(=O)O)(=O)[C@H](CCCCN)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)C,1988,487.5,14,7,228.5,14,anionic,-3.3,-8.6
CC(=O)Nc1nnc(s1)S(=O)(=O)N,-0.6214883767462702,1.9600608,Acetazolamide,59-66-5,0.37,0.65,0.04,9.5,13.0,"Chapron DJ, Sweeney KR, Feig PU, and Kramer PA (1985) Influence of advanced age on the disposition of acetazolamide.  Br. J. Clin. Pharmacol. 19: 363-371.",VDss and t1/2 were calculated from C vs t data obtained by digitization of plots included in the reference.,,1950,222.25,7,2,115.0,2,neutral,-1.5,-1.6
CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]3(C)[C@@H]2[C@H](OC(=O)c4ccccc4)[C@]5(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c6ccccc6)C(=C([C@@H](O)C3=O)C5(C)C)C,3.807354922057604,2.0213752,Docetaxel,114977-28-5,2.1,14.0,0.04,2.5,11.0,"Rosing H, Lustig V, van Warmerdam LJC, Huizing MT, ten Bokkel Huinink WW, Schellens JHM, Rodenhuis S, Bult A, and Beijnen JH (2000) Pharmacokinetics and metabolism of docetaxel administered as a 1-h intravenous infusion.    Cancer Chemother. Pharmacol. 45: 213-218.  Minami H, Kawada K, Sasaki Y, Igarashi T, Saeki T, Tahara M, Itoh K, and Fujii H (2006) Pharmacokinetics and pharmacodynamics of protein-unbound docetaxel in cancer patients.  Cancer Sci.  97: 235-241.",,,1988,807.88,15,5,224.4,12,neutral,3.0,3.0
CC(=O)O[C@H]1C(=O)[C@]2(C)[C@@H](O)C[C@H]3OC[C@@]3(OC(=O)C)[C@H]2[C@H](OC(=O)c4ccccc4)[C@]5(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)c6ccccc6)c7ccccc7)C(=C1C5(C)C)C,2.678071905112638,1.5035025,Paclitaxel,33069-62-4,3.0,6.4,0.12,7.8,11.0,Sonnichsen DS and Relling MV (1994) Clinical pharmacokinetics of paclitaxel.  Clin. Pharmacokinet. 27: 256-269.,"Averaged values listed in Table 1 of Sonnichsen and Relling.  For t1/2 values, used longest value reported in each reference.",,1980,853.91,15,4,221.3,14,neutral,2.9,2.9
CC(=O)O[C@H]1C[C@@H]2CC[C@@H]3[C@H](CC[C@@]4(C)[C@H]3C[C@@H]([C@@H]4OC(=O)C)[N+]5(C)CCCCC5)[C@@]2(C)C[C@@H]1[N+]6(C)CCCCC6,0.5849625007211562,1.9705844,Pancuronium,15500-66-0,0.2,1.5,0.09,2.2,1.9,"Caldwell JE, Castagnoli KP, Canfell PC, Fahey MR, Lynam DP, Fisher DM, and Miller RD (1988) Pipecuronium and pancuronium: comparison of pharmacokinetics and duration of action.  Br. J. Anaesth. 61:  693-697.  Wood M, Stone WJ, and Wood AJJ (1983)  Plasma binding of pancuronium:  effects of age, sex, and disease.  Anesth. Analg.  62: 29-32",,,1966,572.86,6,0,52.6,6,neutral,-0.36,-0.36
CC(=O)O[C@H]1[C@H](C[C@H]2[C@@H]3CC[C@H]4C[C@H](O)[C@H](C[C@]4(C)[C@H]3CC[C@]12C)N5CCOCC5)[N+]6(CC=C)CCCC6,1.8875252707415875,2.9895732,Rocuronium,143558-00-3,0.21,3.7,0.54,0.95,1.6,"Cooper RA, Maddineni VR, Mirakhur RK, Wierda JM, Brady M, and Fitzpatrick KT (1993) Time course of neuromuscular effects and pharmacokinetics of rocuronium bromide (Org 9426) during isoflurane anaethesia in patients with and without renal failure.  Br. J. Anaesth. 71: 222-226.  Roy JJ and Varin F (2004) Physicochemical Br. J. Anaesth. (2000) 85 (5): 717-723. properties of neuromuscular blocking agents and their impact on the pharmacokinetic-pharmacodynamic relationship.  Br. J. Anaesth. 93: 241-248.",Org 9426,,1989,529.77,6,1,59.0,6,cationic,0.19,-0.28
"CC(=O)Oc1ccc2c3c1O[C@@H]4[C@]35CC[N@@]([C@H](C2)[C@@H]5C=C[C@@H]4OC(=O)C)C
",7.729960561018015,4.142865,Heroin,561-27-3,1.31,212.3,,0.1,0.062,"Elisabeth J. Rook, Jan M. van Ree, Wim van den Brink, Michel J. X. Hillebrand, Alwin D. R. Huitema, Vincent M. Hendriks, Jos H. Beijnen. Pharmacokinetics and Pharmacodynamics of High Doses of Pharmaceutically Prepared Heroin, by Intravenous or by Inhalation Route in Opioid-Dependent Patients. Basic & Clinical Pharmacology & Toxicology 2006, 98, 86–96.","N=11, 73 kg average weight reported. No actual dose reported. 930 L/h average clearance at ""steady-state"" after iv doses to ""chasers"" and VD as 96 L but without specification of type of volume. VD taken as Vbeta = VDss as seemingly showing  1 compartment behavior. T1/2 of terminal phase: 3.7 minutes. MRT = t1/2/0.693.",,1906,369.41,6,0,65.1,4,cationic,1.9,1.1
CC(=O)Oc1ccccc1C(=O)O,3.584962500721156,2.0484567,Acetylsalicylic Acid,50-78-2,0.22,12.0,0.68,0.3,0.26,"Aarons L, Hopkins K, Rowland M, Brossel S, and Thiercelin JF (1989) Route of administration and sex differences in the pharmacokinetics of aspirin, administered as its lysine salt.   Pharm. Res. 6: 660-666.  Lee S, Johnson D, Klein J, and Eppler J (1995) Protein binding of acetylsalicylic acid and salicylic acid in porcine and human serum.  Vet. Human Toxicol. 37: 224-225",,,1907,180.16,4,1,63.6,3,anionic,1.6,-1.7
CC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,4.459431618637297,1.8308284,Eltanolone,128-20-1,2.0,22.0,0.01,1.5,4.7,"Dale O, Hynne H, Parivar K, Johansson E, and Widman M. Pharmacokinetics of eltanolone in male and female patients following intravenous bolus injection. Acta Anaesthesiol. Scand. 1999, 43, 415-420.",Pregnanolone. ,,1937,318.49,2,1,37.3,1,neutral,4.0,4.0
CC(C(=O)O)Oc1ccc(cc1)Oc2cnc3ccc(cc3n2)Cl,-4.321928094887363,0.37765488,XK469R,157435-10-4,0.19,0.05,0.00359999999999999,63.0,48.2,"Wendy Stock,  Samir D. Undevia, Carol Bivins, Farhad Ravandi, Olatoyosi Odenike, Stefan Faderl, Elizabeth Rich, Gautam Borthakur, Lucy Godley, Srdan Verstovsek , Andrew Artz , William Wierda, Richard A. Larson, Yanming Zhang,  Jorge Cortes, Mark J. Ratain, Francis J. Giles. A phase I and pharmacokinetic study of XK469R (NSC 698215), a quinoxaline phenoxypropionic acid derivative, in patients with refractory acute leukemia. // ppb: Alousi AM1, Boinpally R, Wiegand R, Parchment R, Gadgeel S, Heilbrun LK, Wozniak AJ, DeLuca P, LoRusso PM. A phase 1 trial of XK469: toxicity profile of a selective topoisomerase II beta inhibitor. Invest. New Drugs, 2007, 25, 147-154.",Weight averaged across 4 doses (1400 to 2750 mg) average weight assumed to be 70 kg. MRT from clearance and VDss. Both CAS number and smiles refer to free acid,,1994,344.75,6,1,81.5,5,anionic,4.0,0.79
CC(C(=O)O)c1ccc(cc1)C(=O)c2cccs2,-0.3959286763311392,0.95075464,Suprofen,40828-46-4,0.04,0.76,0.006,0.88,2.1,"Zulliger HW and Fassolt A (1985) Pharmacokinetics and bioavailability of suprofen injection solution after intravenous application versus capsules on six healthy male volunteers. Arzneim.Forsch. 35: 976-980.  Chaikin P, Chasin M, Kennedy B, and Silverman BK (1983) Suprofen concentrations in human breast milk.  J. Clin. Pharmacol. 23: 385-390.  ",All parameters were calculated from C vs t data provided in the reference.,,1957,260.31,3,1,54.4,4,anionic,2.7,-0.31
CC(C(c1ccc(cc1)O)O)N2CCC(CC2)Cc3ccccc3,6.012792121972625,3.8074987,Ifenprodil,23210-56-2,18.99,64.57,,4.9,4.32,"Jing Yang,ChengtaoLu,WeiSong,JiankangLi,YiDing,YanrongZhu,JinyiCao, Likun Ding, YanyanJia, AidongWenn. Determination of ifenprodil by LC–MS/MS and its application to a pharmacokinetic study in healthy Chinese volunteers. Acta Pharm. Sin.B, 2013, 3, 180-184.","Data digitized from plot reported. N=10, 62 kg median weight assumed, 15 mg dose,  0.5 hr infusion. Highly linear data. Other doses administered: 5 and 10 mg. AUCinf reported as 63.1 ng.h.mL-1. Calculated AUCinf value 62.44 ng.h.mL-1. 1% difference.",,1968,325.44,3,2,43.7,5,cationic,3.6,1.8
CC(C)(C)C1(O)CC2OC(=O)CC23C(=O)OC4OC(=O)C(O)C134,3.321928094887362,0.93372893,Bilobalide,33570-04-6,2.5,10.0,,4.0,3.2,"Fourtillian JB, Brisson AM, Girault J, Ingrand I, Decourt JP, Drieu K, Jouenne P, and Biber A (1995) Proprietes pharmaccinetiques du bilobalide et des ginkgolides A et B chez le sujet sain apres administrations intraveineuses et orales d'extrait de Ginkgo biolba (EGb 761).  Therapie  50: 137-144.",,,1971,326.3,8,2,119.4,0,neutral,-3.4,-3.4
CC(C)(C)NC(=O)[C@@H]1CN(Cc2cccnc2)CCN1C[C@@H](O)C[C@@H](Cc3ccccc3)C(=O)N[C@@H]4[C@H](O)Cc5ccccc45,4.169925001442312,2.635563,Indinavir,150378-17-9,0.82,18.0,0.36,0.76,1.0,"Yeh KC, Stone JA, Carides AD, Rolan P, Woolf E, and Ju WD (1999) Simultaneous investigation of indinavir nonlinear pharmacokinetics and bioavailability in healthy volunteers using stable isotope labeling technique: study design and model-independent data analysis.  J. Pharm. Sci. 88: 568-573.  Boffito M, Hoggard PG, Reynolds HE, Bonora S, Meaden ER, Sinicco A, Di Perri G, and Back DJ (2002) The unbound percentage of saquinavir and indinavir remains constant throughout the dosing interval in HIV positive subjects.  Br. J. Clin. Pharmacol. 54: 262-268.",VDss and t1/2 were calculated from data obtained by digitization of C vs t plots (group C) provided in the report.  Established from PDR that most of radiocativity found in feces was not parent. Thus the compound was absorbed and metabolized before being excreted in feces and urine.,,1957,613.79,9,4,118.0,11,neutral,3.0,2.9
CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@@H](O)[C@H](Cc3ccccc3)NC(=O)[C@H](CC(=O)N)NC(=O)c4ccc5ccccc5n4,3.700439718141092,1.6870835,Saquinavir,127779-20-8,3.6,13.0,0.028,4.6,13.0,"Kupferschmidt HHT, Fattinger KE, Ha HR, Follath F, and Krahenbuhl S (1998) Grapefruit juice enhances the bioavailability of the HIV protease inhibitor saquinavir in man.  Br. J. Clin. Pharmacol. 45: 355-359.  Holladay JW, Dewey MJ, Michniak BB, Wiltshire H, Halberg DL, Weigl P, Liang Z, Halifax K, Lindup WE, and Back DJ (2001) Elevated alpha-1-acid glycoprotein reduces the volume of distribution and systemic clearance of saquinavir.  Drug Metab. Dispos.  29: 299-303.",,,1990,670.84,11,5,166.7,12,neutral,3.6,3.3
CC(C)(C)NC(=O)[C@H]1CC[C@H]2[C@@H]3CC=C4C=C(CC[C@]4(C)[C@H]3CC[C@]12C)C(=O)O,-1.5994620704162712,0.9676887,Epristeride,119169-78-7,0.54,0.33,0.03,27.0,27.0,"Benincosa LJ, Audet PR, Lundberg D, Zariffa N, and Jorkasky DK (1996) Pharmacokinetics and absolute bioavailability of epristeride in healthy male subjects.  Biopharm, Drug Dispos. 17: 249-258.  Li JT, Zheng Z, and Jin J (2000) Pharmacokinetics of epristeride in healthy male volunteers.  Zhongguo Linchuang Yaolixue Zazhi 16: 424-428.",,,1988,399.57,4,2,66.4,2,anionic,4.8,2.2
CC(C)(C)NCC(O)COc1cccc2CC(O)C(O)Cc12,1.5360529002402097,3.2300324,Nadolol,42200-33-9,1.9,2.9,0.14,11.0,9.2,"Morrison RA, Singhvi SM, Creasey WA, and Willard DA (1988) Dose proportionality of nadolol pharmacokinetics after intravenous administration to healthy subjects.  Eur. J. Clin. Pharmacol. 33: 625-628.  Patel L, Johnston A, and Turner P (1984) Nadolol binding to human serum proteins.  J. Pharm. Pharmacol. 36: 414-415.",,,1973,309.4,5,4,81.9,5,cationic,1.1,-0.79
CC(C)(C)NCC(O)c1cc(O)cc(O)c1,1.765534746362977,2.8240902,Terbutaline,23031-25-6,1.5,3.4,0.75,7.4,15.0,"Borgstrom L, Nyberg L, Jonsson S, Lindberg C, and Paulson J (1989) Pharmacokinetic evaluation in man of terbutaline given as separate enantiomers and as the racemate.  Br. J. Clin. Pharmacol. 27: 49-56.  Nyberg L (1984) Pharmacokinetic parameters of terbutaline in healthy man.  An overview.  Eur. J. Resp. Dis. 65(Suppl 134) 149-160.  Leferink JG, van den Berg W, Wagemaker-Engels I, Kreukniet J, and Maes RAA (1982) Pharmacokinetics of terbutaline, a beta2-sympathomimetic, in healthy volunteers and asthmatic patients.  Arz. Forsch. 32: 159-164.",Cited terminal phase t1/2.  Data are for the racemate.,,1969,225.28,4,4,72.7,3,cationic,0.93,-0.41
CC(C)(O)[C@@H]1CC[C@@](C)(O1)[C@H]2[C@@H](O)C[C@@]3(C)[C@@H]4C[C@H](O[C@@H]5O[C@H](CO)[C@@H](O)[C@H](O)[C@H]5O)[C@H]6C(C)(C)[C@H](CC[C@@]67C[C@@]47CC[C@]23C)O[C@@H]8OC[C@@H](O)[C@H](O)[C@H]8O,-0.4344028241457749,0.6175753,Astragaloside IV,84687-43-4,0.12,0.74,0.14,2.78,2.65,"Pharmacokinetics and tolerance of toal astragalosides after intravenous infusion of astragalosides injection in healthy Chinese volunteers. Xu, Meijuan; Yin, Jungang; Xie, Liyan; Zhang, Jun; Zou, Chong; Zou, Jiandong; Liu, Fang; Ju, Wenzheng; Li, Ping Phytomed. 2013, 20, 1105-1111.// ppb: Xu, Duo; Liu, Mei; Yang, Bo; Yin, Qiong-yu; Lu, Yu. Determination of protein-​binding rate of adenosine and astragaloside IV in Anchuanshu pills in human plasma by LC-​MS​/MS. Zhongnan Yaoxue, 2016, 14, 282-285."," N=6, 400 mL variable rate infusion (1 to 4 mL.min-1) infusion, of a 9 mg/100 mL solution, 36 mg total dose, 59.9 kg average weight. AUC 0-inf_obs reported 13. 59 μg/ml*h; AUC 0-inf_obs calculated 13. 49 μg/ml*h; < 1 % difference.",,1982,784.97,14,9,228.2,6,neutral,-0.048,-0.048
CC(C)(O\N=C(/C(=O)N[C@H]1[C@H]2SCC(=C(N2C1=O)C(=O)[O-])C[n+]3ccccc3)\c4csc(N)n4)C(=O)O,1.263034405833794,-0.0022251904,Ceftazidime,72558-82-8,0.31,2.4,0.79,2.2,1.8,"Kalman D, Barriere SL, Johnson BL (1992) Pharmacokinetic disposition and bactericidal activities of cefepime, ceftazidime, and cefoperazone in serum and blister fluid.  Antimicrob. Agents Chemother. 36: 453-457.  Wise R, Armstrong GC, Brown RM, and Andrews JM (1981) The pharmacokinetics and tissue penetration of ceftazidime and cefamandole in healthy volunteers.  J. Antimic. Chemother. 8(SupplB): 277-282.  Lam YWF, Duroux MH, Gambertoglio JG, Barriere SL, and Guglielmo BJ (1988) Effect of protein binding on serum bactericidal activities of ceftazidime and cefoperazone in healthy volunteers.  Antimic. Agents Chemother. 32: 298-302.",VDss calculated for Wise et al from C vs t data provided in the reference.  Plasma analysis done by bioassay.,,1979,546.58,13,3,191.2,9,anionic,-1.7,-4.1
CC(C)([C@H](C(=O)O)N)S,3.412781525338476,1.2690127,"Penicillamine, D-",52-67-5,1.26,10.65,0.12,1.97,3.04,"WALTER R. KUKOVETZ, ECKHARD BEUBLER, FRANZ KREUZIG, ALFRED J. MORITZ,GONTHER NIRNBERGER, and LISBETH WERNER-BREITENECKER. Bioavailability and Pharmacokinetics of D-Penicillamine. J. Rheum. 1983, 10, 90-94.//ppb: M. A. ABOUNASSIF and T. M. JEFFERIES. The determination of D-penicillamine and its disulphide in plasma by reversed-phase ion-pair high-performance liquid chromatography. J. Pharm. Biomed. Anal. 1983, 1, 65-72.","N=6, 60.8 kg average weight, 250 mg bolus dose. 
Digitized from a very clear plot. The AUC corresponds to a calculation with a concentration of 0 at time 0 (run here for comparison) and NOT extrapolated  to t=0 from measured concentrations.The correct calculation was retained via PK solver. Also the clearance reported  uses units of AUC not clearance.//ppb: reported as 8-16% free. Median taken.",,1943,149.21,3,2,63.3,1,zwitterionic,-0.16,-1.8
CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c2cnccn2)B(O)O,4.247927513443585,2.9933407,Bortezomib,179324-69-7,10.0,19.0,0.17,8.8,18.0,"Papandreou CN, Daliani D, Nix D, Yang H, Madden T, Wang X, Pien CS, Millikan RE, Tu SM, Pagliaro L, Kim J, Adams J, Elliott P, Esseltine D, Petrusich A, Dieringer P, Perez C, and Logothetis CJ (2004) Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer.  J. Clin. Oncol. 22: 2108-2121.  Velcade Product Label.",,,1996,384.24,8,4,124.4,9,neutral,0.8,0.8
CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]3(N1C(=O)[C@](O3)(C)NC(=O)[C@@H]4C[C@@H]5c6cccc7c6c(c[nH]7)C[C@H]5N(C4)C)O,3.683696454306516,2.641893,Dihydroergosine,7288-61-1,4.02,12.85,,5.01,8.84,"Cvelbar, Polona; Culig, J.; Kopitar, Z.; Lenardic, A.; Urbancic-Smerkolj, Janja; Zorz, M. Bioavailability of dihydroergosine in healthy volunteers. Proc. - 3rd Eur. Congr. Biopharm. Pharmacokinet., 1987, Volume 3, 147-53","N=8, 0.75 mg dose, 75 kg median weight. Clearance recalculated from dose and AUC. Erroneously reported as 0.96 mL/min when it should have been 0.96 L/min.",Nice example of enterohepatic recirculation.,1943,549.66,10,3,118.2,4,cationic,3.7,3.2
CC(C)Cc1ccc(cc1)C(C)C(=O)O,-0.2863041851566411,1.5188848,Ibuprofen,15687-27-1,0.15,0.82,0.006,3.0,1.6,"Martin W, Koselowske G, Toberich H, Kerkmann T, Mangold B, and Augustin J (1990) Pharmacokinetics and absolute bioavailability of ibuprofen after oral administration of ibuprofen lysine in man.  Biopharm. Drug Dispos. 11: 265-278.  Lee KJ,  Mower R, Hollenbeck T, Castelo J, Johnson N, Gordon P, Sinko PJ, Holme K, and Lee YH (2003) Modulation of nonspecific binding in ultrafiltration protein binding studies.  Pharm. Res. 20: 1015-1021.",,,1961,206.28,2,1,37.3,4,anionic,3.2,0.34
CC(C)N(CCC(C(=O)N)(c1ccccc1)c2ccccn2)C(C)C,-0.1520030934450499,2.6222682,Disopyramide,3737-09-5,0.52,0.9,0.16,9.6,7.0,"Lima JJ, Haughey DB, and Leier CV (1984) Disopyramide pharmacokinetics and bioavailability following the simultaneous administration of disopyramide and 14C-disopyramide.  J. Pharmacokinet. Biopharm. 12: 289-313.",,,1962,339.47,4,1,59.2,8,cationic,2.2,-0.11
CC(C)N1CCC(CC1)N(C(=O)Cc2ccccc2)c3ccc(Cl)cc3,4.0,2.630691,Lorcainide,59729-31-6,6.6,16.0,0.15,6.9,6.5,"Klotz U, Mueller-Seydlitz P, and Heimburg P (1979) Disposition and antiarrythmic effect of lorcainide.  Int. J. Clin. Pharmacol. Biopharm. 17: 152-158.  Klotz U, Mueller-Seydlitz P, and Heimburg P (1978) Pharmacokinetics of lorcainide in man:  a new antiarrhythmic agent.  Clin. Pharmacokinet. 3: 407-418.",,,1977,370.92,3,0,23.5,5,cationic,4.9,3.0
CC(C)NC(=O)NS(=O)(=O)c1cnccc1Nc2cccc(C)c2,-0.9159357352115256,0.16940004,Torsemide,56211-40-6,0.21,0.53,0.01,6.6,5.1,"Spahn H, Knauf H, and Mutschler E (1990) Pharmacokinetics of torasemide and its metabolites in healthy controls and in chronic renal failure.  Eur. J. Clin. Pharmacol. 39: 345-348.  Knauf H and Mutschler E (1998) Clinical pharmacokinetics and pharmacodynamics of torasemide.  Clin. Pharmacokinet. 34: 1-24.",VDss calculated from reported MRT.,,1975,348.42,7,3,100.2,5,anionic,2.9,0.095
CC(C)NCC(O)COc1ccc(CC(=O)N)cc1,1.3219280948873624,3.6768217,Atenolol,29122-68-7,0.95,2.5,0.94,6.3,6.1,"Mason WD, Winer N, Kochak G, Cohen I, and Bell R (1979) Kinetics and absolute bioavailability of atenolol.  Clin. Pharmacol. Ther.  25: 408-415.  Henry JA and Mitchell SN (1981)  Effect of pH on human plasma protein binding of a series of .beta.-adrenoceptor antagonists.    Br. J. Clin. Pharmacol. 11: 119P-120P. ",VDss calculated from reported micro constants. ,,1970,266.34,5,3,84.6,8,cationic,0.35,-1.4
CC(C)NCC(O)COc1ccc(CCOCC2CC2)cc1,1.765534746362977,3.6612291,Betaxolol,63659-18-7,4.8,3.4,0.4,24.0,17.0,"Ludden TM, Boyle DA, Gieseker D, Kennedy GT, Crawford MH, Ludden LK, and Clementi WA (1988) Absolute bioavailability and dose proportionality of betaxolol in normal healthy subjects.  J. Pharm. Sci. 77: 779-783.  Henry JA and Mitchell SN (1981) Effect of pH on human plasma protein binding of a series of .beta.-adrenoceptor antagonists.    Br. J. Clin. Pharmacol. 11: 119P-120P. ",,,1977,307.43,4,2,50.7,11,cationic,2.6,0.81
CC(C)NCC(O)COc1ccc(COCCOC(C)C)cc1,1.8875252707415875,3.15221,Bisoprolol,66722-44-9,2.4,3.7,0.66,11.0,10.0,"Horikiri Y, Suzuki T, and Mizobe M (1998) Pharmacokinetics and Metabolism of Bisoprolol Enantiomers in Humans.  J. Pharm. Sci. 87: 289-294.  Leopold G, Pabst J, Ungethuem W, and Buehring KU (1986) Basic pharmacokinetics of bisoprolol, a new highly beta1-selective adrenoceptor antagonist.  J. Clin. Pharmacol. 26: 616-621.  ",VDss calculated from C vs t data obtained by digitization of the plot provided by Leopold et al.,,1978,325.44,5,2,59.9,12,cationic,2.2,0.46
CC(C)NCC(O)c1ccc(NS(=O)(=O)C)cc1,1.0,2.6011713,Sotalol,3930-20-9,1.3,2.0,0.62,11.0,6.3,"Poirier JM, Jaillon P, Lecocq B, Lecocq V, Ferry A, and Cheymol G (1990) The pharmacokinetics of d-sotalol and d,l-sotalol in healthy volunteers.  Eur. J. Clin. Pharmacol. 38: 579-582.  Salazar DE, Much DR, Nichola PS, Seibold JR, Shindler D, and Slugg PH (1997) A pharmacokinetic-pharmacodynamic model of d-sotalol Q-Tc prolongation during intravenous administration to healthy subjects. J. Clin. Pharmacol. 37: 799-809.   Schnelle K, Klein G, and Schinz A (1979) Studies on the pharmacokinetics and pharmacodynamics of the beta-adrenergic blocking agent sotalol in normal man. J. Clin. Pharmacol. 19: 516-522.  Fiset C, Philippon F, Gilbert M, and Turgeon J (1993) Stereoselective disposition of (+/-)-sotalol at steady-state conditions.  Br. J. Clin. Pharmacol. 36: 75-77.",,,1964,272.36,5,3,78.4,6,cationic,0.43,-1.4
CC(C)NCC(O)c1ccc(O)c(O)c1,5.807354922057604,3.153015,Isoproterenol,7683-59-2,1.5,56.0,0.71,0.43,0.41,"Illi A, Sundberg S, Ojala-Karlsson P, Korhonen P, Scheinin M, and Gordin A (1995) The effect of entacapone on the disposition and hemodynamic effects of intravenous isoproterenol and epinephrine.  Clin. Pharmacol. Ther. 58: 221-227.  Sager G, Bratlid H, and Little C (1987) Binding of catecholamines to alpha-1 acid glycoprotein, albumin and lipoproteins in human serum.  Biochem. Pharmacol. 36:  3607-3612.",Pharmacokinetic parameters were calculated from C vs t data obtained by digitization of the plot provided in the reference.,,1947,211.26,4,4,72.7,4,cationic,0.79,-0.8
CC(C)[C@@H](CC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3[C@H](O)C[C@H]4C[C@H](CC[C@]4(C)[C@H]3CC[C@]12C)NCCCNCCCCN)OS(=O)(=O)O,0.2630344058337938,1.9081546,Squalamine,148717-90-2,0.23,1.2,,3.2,9.5,"Hao D, Hammond LA, Eckhardt SG, Patnaik A, Takimoto CH, Schwartz GH, Goetz AD, Tolcher AW, McCreery HA, Mamun K, Williams JI, Holroyd KJ, and Rowinsky EK (2003) A phase I and pharmacokinetic study of squalamine, an aminosterol angiogenesis inhibitor.  Clin. Canc. Res. 9: 2465-2471.",VDss calculated from C vs t data obtained by digitization of the representative plot provided in the report.,,1993,627.96,8,5,133.9,16,cationic,3.8,0.76
CC(C)c1cccc(C(C)C)c1O,5.169925001442312,3.1795216,Propofol,2078-54-8,4.7,36.0,0.016,2.2,3.2,"Ibrahim A, Park S, Feldman J, Karim A, and Kharasch ED (2002) Effects of parecoxib, a parenteral COX-2-specific inhibitor, on the pharmacokinetics and pharmacodynamics of propofol.  Anesthesiology 96: 88-95.  Servin F, Desmonts JM, Haberer JP, Cockshott ID, Plummer GF, and Farinotti R (1988) Pharmacokinetics and protein binding of propofol in patients with cirrhosis. Anesthesiology 69: 887-891.  Shafer A, Doze VA, Shafer SL, and White PF (1988) Pharmacokinetics and pharmacodynamics of propofol infusions during general anesthesia.  Anesthesiology 69: 348-356.  Costela JL, Jimenez R, Calvo R, Suarez E, and Carlos R (1996) Serum protein binding of propofol in patients with renal failure or hepatic cirrhosis.  Acta Anaesth. Scand. 40: 741-745.",,,1979,178.27,1,1,20.2,2,neutral,4.2,4.2
CC(C)n1c(\C=C\[C@H](O)C[C@H](O)CC(=O)O)c(c2ccc(F)cc2)c3ccccc13,4.0,0.69387996,Fluvastatin,93957-54-1,0.42,16.0,0.0079,0.44,0.7,"Tse F L; Jaffe J M; Troendle A  Pharmacokinetics of fluvastatin after single and multiple doses in normal volunteers.    Journal of clinical pharmacology  (1992),  32(7),  630-8.  Tse FLS, Nickerson DF, and Yardley WS (1993) Binding of fluvastatin to blood cells and plasma proteins.  J. Pharm. Sci. 82: 942-947.",,,1984,411.47,5,3,82.7,8,anionic,2.9,-0.11
CC(CC(c1ccccc1)c2ccccc2)NC(C)(C)C,0.137503523749935,2.7130988,Terodiline,15793-40-5,5.1,1.1,0.08,81.0,56.0,"Hallen B, Gabrielsson J, Palmer L, and Ekstrom B (1993) Pharmacokinetics of R(+)-terodiline given intravenously and orally to healthy volunteers.  Pharmacol. Toxicol.  73: 153-158.  Hallen B, Gabrielsson J, Nyambati S, Johansson A, Larsson E, and Guilbaud O (1995) Concomitant single-dose and multiple-dose pharmacokinetics of terodiline in man, with a note on its enantiomers and major metabolites.    Pharmacol. Toxicol.  76: 171-177.",,,1963,281.44,1,1,12.0,5,cationic,5.0,2.1
CC(CCc1ccccc1)NCC(O)c2ccc(O)c(c2)C(=O)N,4.523561956057013,3.2928107,Labetalol,36894-69-6,4.8,23.0,0.5,3.5,4.4,"Cheymol G, Poirier JM, Carrupt PA, Testa B, Weissenburger J, Levron JC, and Snoeck E (1997) Pharmacokinetics of .beta.-adrenoceptor blockers in obese and normal volunteers. Br. J. Clin. Pharmacol. 43: 563-570.  Martin LE, Hopkins R, and Bland R (1976) Metabolism of labetalol by animals and man.  Br. J. Clin. Pharmacol. (Supp): 695-710",,,1972,328.41,5,4,95.6,8,cationic,1.8,0.97
CC(CN1CCN(CC1)CCOCCO)CN2c3ccccc3Sc4c2cccc4,4.024142345897803,3.0104399,Dixyrazine,2470-73-7,4.06,16.27,,4.16,3.11,"Liedholm H, Lidén A, Kroon L, Melander A, Wåhlin-Boll E. Pharmacokinetics of dixyrazine: low bioavailability improved by food intake. Drug-Nutr. Interact. 1985, 3, 87-92","N =8, median weight 64 kg, 10 mg dose equivalent to 23386 nmol or 365.4 nmol/kg (MW 427.61). Data digitized from plot. First point digitized separately due to Y-axis ""break"". AUC0-12 reported as 2.5-fold of actual to normalize to po dose. After correction calculated AUC0-12 within 6% of reported value. ",,1958,427.6,5,1,39.2,9,cationic,3.8,3.0
CC(Cc1ccc(O)cc1)NCC(O)c2cc(O)cc(O)c2,4.857980995127572,2.920958,Fenoterol,13392-18-2,1.2,29.0,0.53,0.69,0.87,"Warnke K, Hildebrandt R, Gunther K, Langen U, and Gundert-Remy U (1992) The pharmacokinetics of the beta2-adrenoreceptor agonist fenoterol in healthy women.  Eur. J. Clin. Pharmacol.  43: 663-665.  Heel RC, Brigden RN, Speight TM, and Avery GS (1978) Fenoterol: a review of its pharmacological properties and therapeutic efficacy in asthma.  Drugs 15: 3-32.","Study subjects all women, so a body weight of 55 kg was assumed.",,1970,303.35,5,5,92.9,6,cationic,1.5,0.7
CC(Cn1cnc2c1c(=O)n(c(=O)n2C)C)O,0.2265085298086797,2.3532941,Proxyphyllin,603-00-9,0.59,1.17,,8.39,7.8,"M. Kalla, O. Richter, D. Reinhardt. Pharmacokinetics and pharmacodynamics of proxyphylline in asthmatic children. Monatsschrift Kinderheilkunde : Organ der Deutschen Gesellschaft fur Kinderheilkunde. 1985, 133, 520-526.","Oxypropyltheophylline. N=5, 2 children (9 and 11) and three young adults. 8.3 mg/kg dose. Data calculated from average of alpha (4.93 h-1), beta (0.113 h-1) macroconstants and intercepts (A= 18.36 mg/L and B = 11.56 mg/L) reported for each of the subjects. No AUC or clearance reported for iv leg with a VD for po leg of 0.6 L/kg (likely to be completely bioavailable). Data accepted on the basis of available two compartment macroconstant available. 8.3 mg/kg dose. VDss from clearance and MRT.",,1954,238.24,7,1,82.1,2,neutral,-0.044,-0.044
CC(N)C(=O)Nc1c(C)cccc1C,1.1375035237499351,2.1847916,Tocainide,41708-72-9,1.8,2.2,0.87,14.0,12.0,"Lalka D, Meyer MB, Duce BR, and Elvin AT (1976) Kinetics of the oral antiarrhythmic lidocaine congener, tocainide.  Clin. Pharmacol. Ther. 19: 757-766.  Thomson AH, Murdoch G, Pottage A, Kelman AW, Whiting B, and Hillis WS (1986) The pharmacokinetics of R- and S-tocainide in patients with acute ventricular arrhythmias.  Br. J. Clin. Pharmacol. 21: 149-154,  Sedman AJ, Bloedow DC, and Gal J (1982) Serum binding of tocainide and its enantiomers in human subjects.  Res. Comm. Chem Path. Pharmacol. 38: 165-168.",Combined data from individual enantiomers.,,1973,192.26,3,2,55.1,2,cationic,0.65,0.27
CC(c1ccc2c3cc(ccc3[nH]c2c1)Cl)C(=O)O,-0.9714308478032292,0.45184612,Carprofen,53716-49-7,0.22,0.51,0.001,7.2,9.9,"Crevoisier C. Pharmacokinetc properties of carprofen in humans.  Eur J Rheumatol Inflamm. 1982, 5: 492-502",RO 20-5720. Rimadyl. MRT from VDss and clearance.,,1974,273.71,3,2,53.1,2,anionic,4.0,0.95
CC1(C)C(N2C(CC2=O)S1(=O)=O)C(=O)O,2.350497247084133,1.2612245,Sulbactam,68373-14-8,0.32,5.1,0.62,1.0,1.1,"Foulds G, Stankewich JP, Marshall DC, O'Brien MM, Hayes SL, Weidler DJ, and McMahon FG (1983) Pharmacokinetics of sulbactam in human.  Antimic. Agents Chemother. 23: 692-699.  Rho JP, Castle S, Smith K, Bawdon RE, and Norman DC (1992) Effect of impaired renal function on the pharmacokinetics of coadministered cefoperazone and sulbactam.  J. Antimic. Chemother. 29: 701-709.  Foulds G, Miller RD, Knirsch AK, and Thrupp LD (1985) Sulbactam kinetics and excretion into breast milk in postpartum women.  Clin. Pharmacol. Ther. 38: 692-696.  Blum RA, Kohli RK, Harrison NJ, and Schentag JJ (1989) Pharmacokinetics of ampicillin (2.0 grams) and sulbactam (1.0 gram) coadministered to subjects with normal and abnormal renal function and with end-stage renal disease on hemodialysis.  Antimic. Agents Chemother.  (1989),  33: 1470-1476.  de la Pena A and Derendorf H (1999) Pharmacokinetic properties of beta-lactamase inhibitors.  Int. J. Clin. Pharmacol. Ther. 37: 63-75.",,,1978,233.24,6,1,91.8,1,anionic,-0.25,-3.7
CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO,3.232660756790275,1.5961927,Triamcinolone Acetonide,76-25-5,1.4,9.4,0.2,2.5,2.4,"Argenti D, Shah B, Heald D (1999) A pharmacokinetic study to evaluate the absolute bioavailability of triamcinolone acetonide following inhalation administration.  J. Clin. Pharmacol. 39: 695-702.  Mager DE and Jusko WJ (2002) Quantitative structure pharmacokinetic/pharmacodynamic relationships of corticosteroids in man.  J. Pharm. Sci. 91: 2441-2451.",VDss calculated from C vs t data obtained by digitization of the plot provided in the reference.,,1958,434.5,6,2,93.1,2,neutral,2.3,2.3
CC1(C)S[C@@H]2[C@H](\N=C\N3CCCCCC3)C(=O)N2[C@H]1C(=O)O,2.655351828612554,1.4363651,Amdinocillin,32887-01-7,0.37,6.3,0.9,1.0,1.1,"Patel IH, Bornemann LD, Brocks VM, Fang LS, Tolkoff-Rubin NE, and Rubin RH (1985) Pharmacokinetics of intravenous amdinocillin in healthy subjects and patients with renal insufficiency.  Antimicrob. Agents Chemother. 28: 46-50.//ppb: Tan, James S.; Salstrom, Sara Jane; File, Thomas M., Jr. Levels of amdinocillin in human plasma and interstitial fluid following intravenous administration. The American Journal of Medicine 1983, 75, 65-67.",Mecillinam. VDss obtained from C vs t data obtained by digitization of the plot provided in the reference.,,1971,325.43,6,1,73.2,3,zwitterionic,2.4,0.068
CC1(C)\C(=C\C=C\C=C\C=C/C2=[N+](CCCCS(=O)(=O)[O-])c3ccc4ccccc4c3C2(C)C)\N(CCCCS(=O)(=O)O)c5ccc6ccccc6c15,2.765534746362977,0.8249733,Indocyanine Green,3599-32-4,0.035,6.8,0.05,0.086,0.065,"Vanakoski J, Idanpaan-Heikkila JJ, and Seppala T (1996) Exposure to high environmental temperature in the sauna does not change plasma indocyanine green (ICG) clearance in healthy subjects.  Pharmacol. Toxicol. 78: 94-98.   IC-Green Product Label.",,Reported CAS number of Na salt. Structure without Na. CAS number of component: 28782-33-4,1958,752.98,8,1,117.8,14,anionic,5.4,3.1
CC1=C(C=C(C#N)C(=O)N1)c2ccncc2,2.6322682154995127,1.1824211,Milrinone,78415-72-2,0.25,6.2,0.035,0.67,0.8,"Stroshane RM, Koss RF, Biddlecome CE, Luczkowec C, and Edelson J (1984) Oral and intravenous pharmacokinetics of milrinone in human volunteers.  J. Pharm. Sci. 73: 1438-1441.  Woolfrey SG, Hegbrant J, Thysell H, Fox PA, Lendrem DW, Lockwood GF, Lasher K, Rogers J, and Greenslade D (1995) Dose regimen adjustment for milrinone in congestive heart failure patients with moderate and severe renal failure.  J. Pharm. Pharmacol. 47: 651-655.",,,1981,211.22,4,1,65.8,2,anionic,-0.055,-0.57
CC1=C(CCN2CCC(CC2)=C(c2ccc(cc2)F)c2ccc(cc2)F)C(N2C=CSC2=N1)=O,-0.9714308478032292,2.522985,Ritanserin,87051-43-2,1.41,0.51,0.008,46.1,40.0,"De Buck, Stefan S.; Sinha, Vikash K.; Fenu, Luca A.; Nijsen, Marjoleen J.; Mackie, Claire E.; Gilissen, Ron A. H. J. Prediction of human pharmacokinetics using physiologically based modeling: a retrospective analysis of 26 clinically tested drugs. Drug Metabolism and Disposition, 2007, 35(10), 1766-1780. ",70 kg average weight assumed.  MRT calculated from CL and VDss. 5 mg iv dose,,1984,477.57,4,0,35.9,5,cationic,5.7,4.9
CC1=C(CO)C2=C(C)C3(CC3)[C@@](C)(O)C(=O)C2=C1,7.129283016944966,2.2865934,Irofulven,158440-71-2,3.1,140.0,,0.4,0.3,"Paci A, Rezai K, Deroussent A, De Valeriola D, Re M, Weill S, Cvitkovic E, Kahatt C, Shah A, Waters S, Weems G, Vassal G, and Lokiec F (2006) Pharmacokinetics, metabolism, and routes of excretion of intravenous irofulven in patients with advanced solid tumors.  Drug Met. Disp. 34: 1918-1926.",,,1994,246.3,3,2,57.5,1,neutral,1.4,1.4
CC1=CN([C@H]2C[C@H](N=[N+]=[N-])[C@@H](CO)O2)C(=O)NC1=O,4.643856189774724,2.735528,Zidovudine,30516-87-1,1.8,25.0,0.8,1.2,1.3,"Aweeka FT, Mak M, Al-Uzri A, Peter K, Dett C, Franco J, Affrime M, Guerciolini R, Cutler DL, et al.(1995)  Oral and intravenous zidovudine pharmacokinetics: The effect of granulocyte-macrophage colony stimulating factor.  J. Clin. Pharmacol. 35: 856-864.  Blum MR, Liao SHT, Good SS, and deMiranda P (1988) Pharmacokinetics and bioavailability of zidovudine in human.  Am. J. Med. 85(Suppl 2A): 189-194.  Morse GD, Shelton MJ, and O'Donnell AM (1993) Comparative pharmacokinetics of antiviral nucleoside analogues.  Clin. Pharmacokinet. 24: 101-123.  ",,,1951,267.24,9,2,127.6,3,neutral,-0.32,-0.32
CC1=NS(=O)(=O)c2cc(Cl)ccc2N1,-4.058893689053568,0.6737232,Diazoxide,364-98-7,0.21,0.06,0.06,58.0,48.0,"Oglivie RI, Nadeau JH, and Sitar DS (1982) Diazoxide concentration-response relation in hypertension. Hypertension 4: 167-173.   Kirsten R, Nelson K, Kirsten D, and Heintz B (!988) Clinical  pharmacokinetics  of vasodilators. Part I.  Clin. Pharmacokinet. 34: 457-482.  ",,,1961,230.67,4,1,58.5,0,neutral,1.2,1.2
CC1CCN(CCCC(=O)c2ccc(F)cc2)CC1,5.523561956057013,3.8325055,Melperone,3575-80-2,14.0,46.0,,5.0,3.9,"Borgstrom L, Larsson H, and Molander L (1982) Pharmacokinetics of parenteral and oral melperone in man.  Eur. J. Clin. Pharmacol.  23: 173-176.",Data from 20 mg dose.  All pharmacokinetic parameters calculated from digitized C vs t plot in the reported reference.,,1964,263.35,2,0,20.3,5,cationic,3.7,1.7
CCC(=C)C(=O)c1ccc(OCC(=O)O)c(Cl)c1Cl,3.1210154009613658,1.6840168,Ethacrynic Acid,58-54-8,0.26,8.7,,0.5,0.5,"Lacreta FP, Brennan JM, Nash SL, Comis RL, Tew KD, and O'Dwyer P (1994) Pharmacokinetics and bioavailability study of ethacrynic acid as a modulator of drug resistance in patients with cancer.  J. Pharmacol. Exp. Ther. 270:  1186-1191.",Edecrin,,1962,303.14,4,1,63.6,6,anionic,2.8,-0.46
CCC(=O)C(CC(C)N(C)C)(c1ccccc1)c2ccccc2,0.765534746362977,3.1075501,Methadone,76-99-3,4.4,1.7,0.21,43.0,31.0,"Nilsson MI, Gronbladh L, Widerlov E, and Anggard E (1983) Pharmacokinetics of methadone in methadone maintenance treatment: characterization of therapeutic failures.  Eur. J. Clin. Pharmacol. 25: 497-501.  Kristensen K, Blemmer T, Angelo HR, Christrup LL, Drenck NE, Rasmussen SN, and Sjoegren P (1996) Stereoselective pharmacokinetics of methadone in chronic pain patients.  Ther. Drug Monit. 18: 221-227.  Berkowitz BA (1976) The relationship of pharmacokinetics to pharmacological activity: morphine, methadone and naloxone.  Clin. Pharmacokinet. 1: 219-230. ",,,1946,309.45,2,0,20.3,7,cationic,3.7,2.5
CCC(=O)N(c1ccccc1)C2(CCN(CCC(=O)OC)CC2)C(=O)OC,5.20945336562895,2.8658586,Remifentanil,132875-61-7,0.4,37.0,0.3,0.18,0.8,"Egan TD, Lemmens HJM, Fiset P, Hermann DJ, Muir KT, Stanski DR, and Shafer SL (1993) The pharmacokinetics of the new short-acting opioid remifentanil (GI87084B) in healthy adult male volunteers.  Anesthesiology  79: 881-892.  Ultiva Product Label.",Terminal half-life was calculated from a population pharmacokinetic analysis in which clearance and volume of distribution were identical to parameters determined from a standard pharmacokinetic study.,,1959,376.45,7,0,76.1,9,neutral,2.3,2.1
CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]12C,5.169925001442312,2.131647,Beclomethasone dipropionate,5534-09-8,0.29,36.0,0.13,0.1,0.5,"Daley-Yates PT, Price AC, Sisson JR, Pereira A, and Dallow N (2001)  Beclomethasone dipropionate: absolute bioavailability, pharmacokinetics and metabolism following intravenous, oral, intranasal and inhaled administration in man.    Br. J.. Clin. Pharmacol.  51: 400-409.  Beconase AQ Product Label",,,1964,521.04,7,1,107.0,8,neutral,4.0,4.0
CCC(=O)O[C@@]1([C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)SCF,4.087462841250339,2.6603718,Fluticasone propionate,80474-14-2,3.6,17.0,0.1,3.9,6.0,"Brutsche MH, Brutsche IC, Munavvar M, Langley SJ, Masterson CM, Daley-Yates PT, Brown R, Custovic A., and Woodcock A (2000) Comparison of pharmacokinetics and systemic effects of inhaled fluticasone propionate in patients with asthma and healthy volunteers: a randomised crossover study.  Lancet  356: 556-561.  Mackie AE, Ventresca GP, Fuller RW, and Bye A (1996) Pharmacokinetics of intravenous fluticasone propionate in healthy subjects.  Br. J. Clin. Pharmacol. 41: 539-542.",,,1981,500.57,5,1,80.7,6,neutral,3.3,3.3
CCC(C)CC(C)CCCCCCCCC(=O)NC1CC(O)C(NCCN)NC(=O)C2C(O)CCN2C(=O)C(NC(=O)C(NC(=O)C3CC(O)CN3C(=O)C(NC1=O)C(C)O)C(O)C(O)c4ccc(O)cc4)C(O)CCN,-2.8365012677171206,0.7924505,Caspofungin,162808-62-0,0.13,0.14,0.035,15.0,27.0,"Stone JA, Xu X, Winchell GA, Deutsch PJ, Pearson PG, Migoya EM, Mistry GC, Xi L, Miller A, Sandhu P, Singh R, deLuna F, Dilzer SC, Lasseter KC (2004) Disposition of caspofungin: role of distribution in determining pharmacokinetics in plasma.  Antimic. Agents Chemother.  48: 815-823.",VDss was calculated from rate micro-contants provided in the reference.,,1994,1093.31,25,16,412.0,23,cationic,-1.4,-6.3
CCC(C)N1N=CN(C1=O)c2ccc(cc2)N3CCN(CC3)c4ccc(OCC5COC(Cn6cncn6)(O5)c7ccc(Cl)cc7Cl)cc4,2.350497247084133,1.3459704,Itraconazole,84625-61-6,7.4,5.1,0.002,24.0,25.0,"Heykants J, Van Peer A, Van de Velde V, Van Rooy P, Meuldermans W, Lavrijsen K, Woestenborghs R, Van Cutsem J, and Cauwenbergh G (1989) The clinical pharmacokinetics of itraconazole: an overview.  Mycoses  32(Suppl 1): 67-87.  ",VDss was calculated from C vs t data obtained by digitization of the plot provided in the reference.,,1983,705.63,12,0,100.8,11,neutral,5.8,5.8
CCC1(C(=O)NC(=O)NC1=O)c2ccccc2,-3.98850436116217,1.6572134,Phenobarbital,50-06-6,0.54,0.063,0.49,140.0,99.0,"Wilensky AJ, Friel PN, Levy RH, Confort CP, and Kaluzny SP (1982) Kinetics of phenobarbital in normal subjects an epileptic patients.  Eur. J. Clin. Pharmacol. 23: 87-92.  Kurz H, Mauser-Ganshorn A, and Stickel HH (1977) Differences in the binding of drugs to plasma proteins from newborn and adult man. I. Eur. J. Clin. Pharmacol. 11: 463-467.",,,1946,232.24,5,2,75.3,2,neutral,1.3,1.1
CCC1(CCCCN(C)C1)c2cccc(O)c2,4.807354922057604,3.2993402,Meptazinol,54340-58-8,3.3,28.0,0.73,2.0,1.7,"Norbury HM, Franklin RA, and Graham DF (1983) Pharmacokinetics of the new analgesic, meptazinol, after oral and intravenous administration to volunteers.  Eur. J. Clin. Pharmacol. 25: 77-80.  Gepts E, Sonck WA, Camu F, and Vercruysse A (1987) Pharmacokinetics of intravenously administered meptazinol during general anesthesia in man.  Eur. J. Anaesth. 4: 35-43.  Franklin RA (1988) The clinical pharmacokinetics and metabolism of the analgesic meptazinol.  Xenobiotica 18: 105-112.","VDss was calculated from C vs t data provided in the reference by Norbury, et al.",,1976,233.35,2,1,23.5,2,cationic,3.1,1.5
CCC1=C(C)CN(C(=O)NCCc2ccc(cc2)S(=O)(=O)NC(=O)N[C@@H]3CC[C@@H](C)CC3)C1=O,-1.0,0.6290711,Glimepiride,93479-97-1,0.19,0.5,0.005,6.3,10.0,"Badian M, Korn A, Lehr KH, Malerczyk V, and Waldhaust W (1994) Absolute bioavailability of glimepiride (Amaryl) after oral administration.  Drug Metab. Drug Inter. 11: 331-339.  Amaryl Product Label.",Parameters calculated from C vs t data digitized from a plot provided in the reference.  Data reported in the table in the reference did not correspond to data obtained from the plot.,,1988,490.62,9,3,124.7,7,anionic,4.2,2.1
CCC1=C[C@@H]2CN(C1)Cc3c([nH]c4ccccc34)[C@@](C2)(C(=O)OC)c5cc6c(cc5OC)N(C)[C@H]7[C@](O)([C@H](OC(=O)C)[C@]8(CC)C=CCN9CC[C@]67[C@H]89)C(=O)OC,4.321928094887363,2.240057,Vinorelbine,71486-22-1,23.0,20.0,0.87,18.0,26.0,"Sorio R, Robieux I, Galligioni E, Freschi, A, Colussi AM, Crivellari D, Saracchini S, and Monfardini S (1997) Pharmacokinetics and tolerance of vinorelbine in elderly patients with metastatic breast cancer.  Eur. J. Cancer  33: 301-303.   Gebbia V and Puozzo C (2005) Oral versus intravenous vinorelbine: clinical safety profile.  Exp. Op. Drug Safety 4: 915-928. ",,,1979,778.93,12,2,133.9,10,neutral,4.1,3.9
CCC1=C[C@@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C2)(C(=O)OC)c5cc6c(cc5OC)N(C)[C@H]7[C@](O)([C@H](OC(=O)C)[C@]8(CC)C=CCN9CC[C@]67[C@H]89)C(=O)OC)C1,3.584962500721156,2.44756,Anhydrovinblastine,38390-45-3,12.0,12.0,,17.0,18.0,"Ramnath N, Schwartz GN, Smith P, Bong D, Kanter P, Berdzik J, and Creaven PJ (2003) Phase I and pharmacokinetic study of anhydrovinblastine every three weeks in patients with refractory solid tumors.  Canc. Chemother. Pharmacol. 51: 227-230.",VDss was calculated from C vs t data obtained by digitization of the plots provided in the reference.  Median values for CL and t1/2 were reported.,,1971,792.96,12,2,133.9,10,cationic,4.8,4.5
CCCC(=O)OCOC(=O)C1=C(C)NC(=C(C1c2cccc(Cl)c2Cl)C(=O)OC)C,7.149747119504682,2.2778842,Clevidipine,167221-71-8,0.58,142.0,0.0038,0.07,0.3,"Ericsson H, Fakt C, Hoglund L, Jolin-Mellgard A, Nordlander M, Sunzel M, and Regardh CG (1999) Pharmacokinetics and pharmacodynamics of clevidipine in healthy volunteers after intravenous infusion.  Eur. J. Clin. Pharmacol. 55: 61-67.  Ericsson H, Tholander B, and  Regardh CG (1999)  In vitro hydrolysis rate and protein binding of clevidipine, a new ultrashort-acting calcium antagonist metabolized by esterases, in different animal species and man.  Eur. J. Pharm. Sci. 8: 29-37.",Data for the enantiomers were averaged.,,1995,456.32,7,1,90.9,10,neutral,4.4,4.4
CCCC(C)(COC(=O)N)COC(=O)N,-0.7369655941662062,2.3692112,Meprobamate,57-53-4,0.7,0.6,1.0,19.0,14.0,"Held H and Oldershausen HF (1969) Zur pharmakokinetik von meprobamat bei chronischen hepatopathien und arzneimittelsucht. Klin. Wschr. 47: 78-80.  Douglas JF, Bradshaw WH, Ludwig BJ, and Powers D (1964) Interaction of plasma protein with related 1,3-propanediol dicarbamates.  Biochem. Pharmacol. 13: 537-539.",Pharmacokinetic parameters were calculated from C vs t data obtained by digitization of the plot provided in the reference.,,1951,218.25,6,2,104.6,8,neutral,0.91,0.91
CCCC(C)C1(CC)C(=O)NC(=O)NC1=O,-1.0892673380970874,1.7340417,Pentobarbital,76-74-4,0.91,0.47,0.39,32.0,22.0,"Ehrenbo M (1974) Pharmacokinetics and distribution properties of pentobarbital in humans following oral and intravenous administration.  J. Pharm. Sci. 63: 1114-1118.  Bayliff CD, Schwartz ML, and Hardy BG (1985) Pharmacokinetics of high-dose pentobarbital in severe head trauma.    Clin. Pharmacol. Ther. 38: 457-461.  Ehrnebo M and Odar-Cederlof I (1975) Binding of amobarbital, pentobarbital and diphenylhydantoin to blood cells and plasma proteins in healthy volunteers and uraemic patients.  Eur. J. Clin. Pharmacol. 8: 445-453.",VDss calculated using micro rate constants reported in the reference by Ehrenbo.,,1926,226.27,5,2,75.3,4,neutral,2.0,1.9
CCCC(C)C1(CC)C(=O)NC(=S)NC1=O,3.035623909730721,1.3810905,Thiopental,76-75-5,1.2,8.2,0.14,2.4,2.0,"Cordato DJ, Gross AS, Herkes GK, and Mather LE (1997) Pharmacokinetics of thiopentone enantiomers following intravenous injection or prolonged infusion of rac-thiopentone.  Br. J. Clin. Pharmacol. 43: 355-362.  Kurz H, Mauser-Ganshorn A, and Stickel HH (1977) Differences in the binding of drugs to plasma proteins from newborn and adult man. I. Eur. J. Clin. Pharmacol. 11: 463-467.",Data from individual stereoisomers were combined.  Half-life was estimated from the C vs t plot provided in the reference.,,1935,242.34,4,2,58.2,4,anionic,2.8,2.5
CCCC(CCC)C(=O)O,-2.643856189774725,1.4666152,Valproic Acid,99-66-1,0.14,0.16,0.08,15.0,12.0,"Bryson SM, Verma N, Scott PJW, and Rubin PC (1983) Pharmacokinetics of valproic acid in young and elderly subjects.  Br. J. Clin. Pharmacol. 16: 104-105.  Hussein Z, Patterson KJ, Lamm JE, Cavanaugh JH, and Granneman GR (1993) Effect of infusion duration on valproate pharmacokinetics.  Biopharm. Drug Dispos. 14: 389-399.  Gugler R and Meuller G (1978) Plasma protein binding of valproic acid in healthy subjects and in patients with renal disease.  Br. J. Clin. Pharmacol. 5: 441-446.",,,1963,144.21,2,1,37.3,5,anionic,2.6,0.25
CCCC1C(=O)N2N(C1=O)c3cc(C)ccc3N=C2N(C)C,-2.8365012677171206,1.6503862,Azapropazone,13539-59-8,0.12,0.14,0.004,14.0,17.0,"Gikalov I, Kaufmann R, and Schuster O (1982) Humanpharmakokinetik verschiedener i.v. dosen von azapropazon (HPLC-bestimmung).    Arzn. Forsch. 32: 423-426.",VDss was calculated from C vs t data provided in the reference.,,1966,300.36,6,0,56.2,3,anionic,1.3,0.098
CCCC1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO,4.321928094887363,1.8155855,Budesonide,51333-22-3,3.9,20.0,0.13,3.2,2.8,"Ryrfeldt A, Andersson P, Edsbacker S, Tonnesson M, Davies D, and Pauwels R (1982) Pharmacokinetics and metabolism of budesonide, a selective glucocorticoid.  Eur. J. Resp. Dis. 63: 86-95.  Entocort EC Product Label.",VDss was calculated using data obtained by digitization of the C vs t plot provided in the reference.,,1973,430.53,6,2,93.1,4,neutral,3.0,3.0
CCCCC(=O)N(Cc1ccc(cc1)c2ccccc2c3nnn[nH]3)[C@@H](C(C)C)C(=O)O,-1.0291463456595165,1.0006828,Valsartan,137862-53-4,0.22,0.49,0.04,7.5,9.5,"Flesch G, Muller P, and Lloyd P (1997) Absolute bioavailability and pharmacokinetics of valsartan, an angiotensin receptor antagonist, in man.  Eur. J. Clin. Pharmacol. 52: 115-120.  Colussi DM, Parisot C, Rossolino ML, Brunner LA, and Lefevre GY (1997) Protein binding in plasma of valsartan, a new angiotensin II receptor antagonist.  J. Clin. Pharmacol. 37: 214-221.",,,1991,435.52,8,2,112.1,10,anionic,5.0,-0.22
CCCCCCC(C)(C)c1cc(c2c(c1)OC([C@@H]3[C@@H]2CC(=CC3)CO)(C)C)O,4.418189947945766,3.1325336,Dexanabinol,112924-45-5,5.06,21.38,,3.94,7.33,"Brewster, M. E.; Pop, E.; Foltz, R. L.; Reuschel, S.; Griffith, W.; Amselem, S.; Biegon, A. Clinical pharmacokinetics of escalating i.v. doses of dexanabinol (HU-211 ), a neuroprotectant agent, in normal volunteers. International Journal of Clinical Pharmacology and Therapeutics, 1997, 35, 361-365.","HU-211. Data digitized for the 100 mg dose. Highly linear PK between 50, 100 and 200 mg. N=9 and 77.21 kg average weight derived from clearance data in mL/min and in mL/min/kg. AUCinf 60,579 ng.min/mL against reported AUC of 54,315 ng.min/mL. (11% difference).",,1987,386.57,3,2,49.7,7,neutral,7.6,7.5
CCCCCCCCCC(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@H](CC(=O)N)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@H]3[C@@H](C)OC(=O)[C@H](CC(=O)c4ccccc4N)NC(=O)[C@@H](NC(=O)[C@@H](CO)NC(=O)CNC(=O)[C@H](CC(=O)O)NC(=O)[C@@H](C)NC(=O)C(CC(=O)O)NC(=O)[C@H](CCCN)NC(=O)CNC3=O)[C@H](C)CC(=O)O,-2.643856189774725,-0.05903408,Daptomycin,103060-53-3,0.088,0.16,0.083,9.2,8.1,"Dvorchik BH, Brazier D, DeBruin MF, and Arbeit RD (2003)  Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjects. Antimic. Agents Chemother. 47: 1318-1323.  Woodworth JR, Nyhart EH, Brier GL, Wolny JD, and Black HR (1992) Single dose pharmacokinetics and antibacterial activity of daptomycin, a new lipopeptide antibiotic, in healthy volunteers.  Antimic. Agents Chemother. 36: 318-325.  Benvenuto M, Benzinger DP, Yankelev S, and Vigliani G (2006) Pharmacokinetics and tolerability of daptomycin at doses up to 12 milligrams per kilogram of body weight once daily in healthy volunteers.  Antimic. Agents Chemother. 50: 3245-3249.","VDss calculated from C vs t data obtained by digitization of plot provided in the Benvenuto, et al. references.",,1986,1620.67,43,22,702.0,35,anionic,-6.4,-9.0
CCCCCCCCCCCC(=O)CC(=O)N[C@H]1[C@@H](OP(=O)(O)O)O[C@H](CO[C@@H]2O[C@H](COC)[C@@H](OP(=O)(O)O)[C@H](OCC[C@@H](CCCCCCC)OC)[C@H]2NC(=O)CCCCCCCCC\C=C/CCCCCC)[C@@H](O)[C@@H]1OCCCCCCCCCC,-6.265344566520995,-1.1255645,Eritoran,185955-34-4,0.048,0.013,,62.0,51.0,"Wong YN, Rossignol D, Rose JR, Kao R, Carter A, and Lynn M (2003) Safety, pharmacokinetics, and pharmacodynamics of E5564, a lipid A antagonist, during an ascending single-dose clinical study.  J. Clin. Pharmacol. 43: 735-742.  Rossignol DP, Wasan KM, Choo E Yau E, Wong N, Rose J, Moran J, and Lynn M (2004) Safety, pharmacokinetics, pharmacodynamics, and plasma lipoprotein distribution of eritoran (E5564) during continuous intravenous infusion into healthy volunteers.    Antimic. Agents Chemother. 48: 3233-3240.",Protein binding driven by lipoproteins--not reported directly,,1996,1313.66,21,7,293.6,59,anionic,9.0,1.7
CCCCCCCCCCCCCCCC(=O)N[C@@H](CCC(=O)NCCCC[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](Cc2c[nH]c3c2cccc3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)O)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)N)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc4ccc(cc4)O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](Cc5ccccc5)NC(=O)[C@H]([C@@H](C)O)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C)NC(=O)[C@H](Cc6cnc[nH]6)N)C(=O)O,-6.643856189774724,-0.5076926,Liraglutide,204656-20-2,,0.01,0.01,,8.1,"Liraglutide - FDA Approval Package
Pharmacology Review 022341/S-000 Part 01. Accessed through Pharmapendium.",VDss not reported. Vz 0.07 L/kg.,,1998,3751.2,94,54,1513.8,132,anionic,-5.7,-5.7
CCCCCCCCOCCOC(=O)CN(CC(=O)O)c1ccccc1OCCOc2ccccc2N(CC(=O)O)CC(=O)OCCOCCCCCCCC,3.807354922057604,0.47658804,DP-b99,222315-88-0,1.1,14.0,,1.3,3.5,"Rosenberg G, Angel I, and Kozak A (2005) Clinical pharmacology of DP-b99 in healthy volunteers: First administration to humans.  Br. J. Clin. Pharmacol. 60: 7-16. ",,,1999,788.96,14,2,170.6,37,anionic,8.9,4.4
CCCCCCCN(CC)CCCC(O)c1ccc(NS(=O)(=O)C)cc1,4.700439718141092,2.515479,Ibutilide,122647-31-8,12.0,26.0,0.6,7.7,7.0,"Jungbluth GL, Della-Coletta ASA, and VanderLugt JT (1991) Evaluation of the pharmacokinetics and pharmacodynamics of ibutilide fumarate and its enantiomers in healthy male volunteers.  Pharm. Res. 8: S-249.  Howard PA (1999) Ibutilide: an antiarrythmic agent for the treatment of atrial fibrillation or flutter.  Ann Pharmacother. 33: 38-47.",,,1985,384.58,5,2,69.6,14,cationic,4.4,2.4
CCCCCN(CCCOC)C(=O)C(CCC(=O)O)NC(=O)c1ccc(Cl)c(Cl)c1,0.0,1.0372573,Loxiglumide,107097-80-3,0.24,1.0,,4.0,5.2,"Setnikar I, Chiste R, Makovec F, Rovati LC, and Warrington SJ (1988) Pharmacokinetics of loxiglumide after single intravenous or oral doses in man.  Arz. Forsch. 38: 716-720.",VDss was calculated from rate micro-contants provided in the reference.,,1987,461.38,7,2,95.9,14,anionic,4.2,1.0
CCCCCNC(=N)N\N=C\c1c[nH]c2ccc(OC)cc12,4.169925001442312,2.7546327,Tegaserod,145158-71-0,5.3,18.0,0.02,4.9,11.0,"Appel-Dingemanse S, Lemarechal MO, Kumle A, Hubert M, and Legangneux E (1999) Integrated modelling of the clinical pharmacokinetics of SDZ HTF 919, a novel selective 5-HT4 receptor agonist, following oral and intravenous administration.  Br. J. Clin. Pharmacol.  47: 483-491.  Appel-Dingemanse S (2002) Clinical pharmacokinetics of tegaserod, a serotonin 5-HT4 receptor partial agonist with promotile activity.  Clin. Pharmacokinet. 41: 1021-1042.",,,1992,301.39,6,4,85.3,9,cationic,4.3,0.86
CCCCCNC(=O)c1coc(n1)[C@H]2[C@@H](Cc3ccccc3CCC(=O)O)[C@@H]4CC[C@H]2O4,2.678071905112638,1.4435245,Ifetroban,143443-90-7,4.4,6.4,,11.0,22.0,"Dockens RC, Santone KS, Mitroka JG, Morrison RA, Jemal M, Greene DS, and Barbhaiya RH (2000) Disposition of radiolabeled ifetroban in rats, dogs, monkeys, and humans.  Drug Metab. Dispos. 28: 973-980.",,,1992,440.53,7,2,102.0,11,anionic,4.0,1.2
CCCCCOc1ccc(cc1)c2ccc(cc2)c3ccc(cc3)C(=O)N[C@H]4C[C@@H](O)[C@@H](O)NC(=O)[C@@H]5[C@@H](O)[C@@H](C)CN5C(=O)[C@@H](NC(=O)C(NC(=O)[C@@H]6C[C@@H](O)CN6C(=O)C(NC4=O)[C@@H](C)O)[C@H](O)[C@@H](O)c7ccc(O)cc7)[C@@H](C)O,-2.251538766995965,1.0592577,Anidulafungin,166663-25-8,0.57,0.21,0.16,45.0,40.0,"Dowell JA, Schranz J, Baruch A, and Foster G (2005) Safety and pharmacokinetics of coadministered voriconazole and anidulafungin.  J. Clin. Pharmacol. 45: 1373-1382.  Eraxis Product Label.",,,1993,1140.24,24,14,377.4,14,neutral,1.6,1.6
CCCCCOc1ccc(cc1)c2onc(c2)c3ccc(cc3)C(=O)N[C@H]4C[C@@H](O)[C@@H](O)NC(=O)[C@@H]5[C@@H](O)[C@@H](C)CN5C(=O)[C@@H](NC(=O)C(NC(=O)[C@@H]6C[C@@H](O)CN6C(=O)C(NC4=O)[C@@H](C)O)[C@H](O)[C@@H](O)c7ccc(O)c(OS(=O)(=O)O)c7)[C@H](O)CC(=O)N,-2.5563933485243853,0.9465468,Micafungin,235114-32-6,0.21,0.17,0.0023,21.0,16.0,"Hebert MF, Blough DK, Townsend RW, Allison M, Buell D, Keirns J, and Bekersky I (2005) Concomitant tacrolimus and micafungin pharmacokinetics in healthy volunteers.  J. Clin. Pharmacol. 45: 1018-1024.  Hebert MF, Smith HE, Marbury TC, Swan SK, Smith WB, Townsend RW, Buell D, Keirns J, and Bekersky I (2005) Pharmacokinetics of micafungin in healthy volunteers, volunteers with moderate liver disease, and volunteers with renal dysfunction. J. Clin. Pharmacol.  45: 1145-1152.",,,1996,1270.27,32,16,510.4,18,neutral,-3.9,-7.4
CCCCC[C@@H](/C=C/[C@H]1[C@@H](CC(=O)[C@@H]1CCCCCCC(=O)O)O)O,5.504620392403552,1.0835016,Alprostadil,745-65-3,2.4,45.4,,0.9,1.9,"W. Cawello , H. Schweel , R. Miiller, R. Bonn, H.W. Seyberth. Metabolism and pharmacokinetics of prostaglandin E1 administered
by intravenous infusion in human subjects. Eur J Clin Pharmacol (1994) 46:275-277","PGE1. Plot available for digitization. Calculation perforrmed via Phoenix after digitization. Dose 60 ug 2h of infusion, N=12",,1956,354.48,5,3,94.8,13,anionic,3.5,0.93
CCCCCc1cc(O)c2[C@@H]3C=C(C)CC[C@H]3C(C)(C)Oc2c1,1.6780719051126378,3.0306818,"Tetrahydrocannabinol, D9-",1972-08-3,8.9,3.2,0.05,46.0,33.0,"Wall ME, Sadler BM, Brine D, Taylor H, and Perez-Reyes M (1983)  Metabolism, disposition, and kinetics of delta-9-tetrahydrocannabinol in men and women.  Clin. Pharmacol. Ther. 34: 352-363.  Busto U, Bendayan R, and Sellers EM (1989) Clinical pharmacokinetics of non-opiate abused drugs.  Clin. Pharmacokinet. 16: 1-26.",Dronabinol. Δ9-THC. VDss was calculated using C vs t data  provided in the reference.,,1940,314.46,2,1,29.5,4,neutral,7.0,7.0
CCCCCc1cc(c2c(c1)OC([C@H]3[C@H]2C=C(CC3)C(=O)O)(C)C)O,0.2630344058337938,1.5456607,"Tetrahydrocannabinol,11-Nor-9-carboxy-D9-",56354-06-4,1.28,1.2,,18.1,17.6,"A Glaz-Sandberg, L Dietz, H Nguyen, H Oberwittler, Rolf Aderjan and Gerd Mikus. Pharmacokinetics of 11-nor-9-Carboxy-D9- Tetrahydrocannabinol (CTHC) After Intravenous Administration of CTHC in Healthy Human Subjects. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2007, VOLUME 82, 63-69.","N=10, 5 mg iv dose.",,1975,344.44,4,2,66.8,5,anionic,5.9,3.5
CCCCN1CCCC1C(=O)Nc2c(cc(cc2C)C)C,4.262282806420656,2.776839,Bumecaine,30103-44-7,1.73,19.19,,1.51,1.58,"Piotrovskii, V. K.; Blagodatskikh, S. V.; Ryabokon, O. S.; Metelitsa, V. I.; Smirnov, V. K.; Gorshkov, V. A.; Mazur, N. A.; Pryanishnikova, N. T.  Clinical pharmacokinetics of pyromecaine. I. Single intravenous administration Khimiko-Farmatsevticheskii Zhurnal (1983), 17(12), 1427-32","Pyromecaine. N=10 all male patients, 100 mg iv dose. MRT from reported clearance and VDss.",,1970,288.43,3,1,32.3,5,cationic,4.0,3.3
CCCCNC(=O)NS(=O)(=O)c1ccc(C)cc1,-2.251538766995965,0.73334527,Tolbutamide,64-77-7,0.12,0.21,0.05,9.5,7.0,"Zilly W, Breimer DD, and Richter E (1975) Induction of drug metabolism in man after rifampicin treatment measured by increased hexobarbital and tolbutamide clearance.  Eur. J. Clin. Pharmacol. 9: 219-227.  Ayanoglu G, Uihlein M, and Grigoleit HG (1986) A new aspect of serum protein binding of tolbutamide.  Int. J. Clin. Pharmacol. Ther. Toxicol. 24: 65-68.",Concentration-dependent protein binding reported; free fraction value is cited that was collected at relevant circulating concentrations.,,1959,270.35,5,2,75.3,5,anionic,2.3,0.17
CCCC[C@@H]1CC(=O)[C@]2(O)O[C@@H]3[C@@H](NC)[C@@H](O)[C@@H](NC)[C@H](O)[C@H]3O[C@@H]2O1,0.765534746362977,1.9695171,Trospectomycin,88669-04-9,0.7,1.7,0.65,6.9,11.0,"Nichols DJ, Bye A, and Novak E (1991) . Pharmacokinetics of trospectomycin sulphate in healthy subjects after single intravenous and intramuscular doses.British journal of clinical pharmacology  32(2), 255-7   fu from Lombardo et al J. Clin. Pharmacol. 2013, 53(2), 167-177 and 178-191",Averaged data from all dose levels.,,1983,374.43,9,5,129.5,5,cationic,-1.4,-3.8
CCCCc1nc(Cl)c(CO)n1Cc2ccc(cc2)c3ccccc3c4nnn[nH]4,3.035623909730721,1.2165284,Losartan,114798-26-4,0.37,8.2,0.01,0.75,1.8,"Lo MW, Goldberg MR, McCrea JB, Lu H, Furtek CI, and Bjornsson TD (1995) Pharmacokinetics of losartan, an angiotensin II receptor antagonist, and its active metabolite EXP3174 in humans. Clin. Pharmacol. Ther. 58: 641-649.  Kirsten R, Nelson K, Kirsten D, and Heintz B (1988) Clinical  pharmacokinetics  of vasodilators. Part I.  Clin. Pharmacokinet. 34: 457-482.  ",,,1988,422.91,7,2,92.5,8,anionic,4.2,0.7
CCCCc1nc(c(c(=O)n1Cc2ccc(cc2)c3ccccc3c4[nH]nnn4)CC(=S)N(C)C)C,3.263034405833794,2.1559408,Fimasartan,247257-48-3,0.6,9.6,,1.1,5.5,"Jong-Lyul Ghim, Soo Heui Paik,  M. Hasanuzzaman, Yong Ha Chi, Hyang-Ki Choi,  Dong-Hyun Kim,  Jae-Gook Shin.  Absolute Bioavailability and Pharmacokinetics of the Angiotensin II Receptor Antagonist Fimasartan in Healthy Subjects. J. Clin. Pharmacol. 2016, 56, 576-580.","N=16, 30 mg dose, 1 h infusion. No average weight reported but data available on weight basis. ",,1999,501.65,8,1,92.6,10,cationic,4.1,0.71
CCCCc1oc2ccccc2c1C(=O)c3cc(I)c(OCCN(CC)CC)c(I)c3,0.925999418556223,2.185655,Amiodarone ,1951-25-3,60.0,1.9,0.0002,620.0,820.0,"Ujhelyi MR, Klamerus KJ, Vadiei K, O'Rangers E, Izard M, Neefe DL, Zimmerman JJ, and Chow MSS (1996) Disposition of intravenous amiodarone in subjects with normal and impaired renal function.  J. Clin. Pharmacol. 36: 122-130.  Veronese ME, McLean S, and Hendriks R (1988) Plasma protein binding of amiodarone in a patient population: measurement by erythrocyte partitioning and a novel glass-binding method.  Br. J. Clin. Pharmacol 26: 721-731.",,,1962,645.31,4,0,43.0,11,cationic,7.5,6.2
CCCN(CCC)S(=O)(=O)c1ccc(cc1)C(=O)O,-2.0,1.0843331,Probenecid,57-66-9,0.13,0.25,0.13,8.7,5.9,"Kartzinel R, Ebert MH, and Chase TN (1976) Intravenous probenecid loading.  Effect on plasma and cerebrospinal fluid probenecid levels and on monoamine metabolites in cerebrospinal fluid.  Neurology 26: 992-996.  Emanuelsson BM, Beermann B, and Paalzow LK (1987) Non-linear elimination and protein binding of probenecid.  Eur. J. Clin. Pharmacol. 32: 395-401.",Parameters were determined using C vs t data obtained by digitization of the plot provided in the reference.  Protein binding is saturable; the value at half maximum is reported.,,1950,285.36,5,1,74.7,7,anionic,3.3,-0.017
CCCNC(=O)NS(=O)(=O)c1ccc(Cl)cc1,-4.473931188332412,0.39315128,Chlorpropamide,94-20-2,0.19,0.045,0.03,70.0,46.0,Huupponen R and Lammintausta R (1981) Chlorpropamide bioavailability and pharmacokinetics.  Int. J. Clin. Pharmacol. Ther. Toxicol. 19: 331-333.,VDss was calculated from C vs t data obtained by digitization of the plot included in the reference.  ,,1955,276.74,5,2,75.3,4,anionic,2.1,-0.29
CCCNC(C)C(=O)Nc1ccccc1C,4.857980995127572,2.662508,Prilocaine,721-50-6,3.7,29.0,0.72,2.2,1.8,"van der Meer AD, Blum AGL, Stienstra R, van Kleef JW, Vletter AA, and Olieman W (1999) Pharmacokinetics of prilocaine after intravenous administration in volunteers: enantioselectivity.  Aneasthesiol. 90: 988-992.",Data for individual stereoisomers were averaged.,,1946,220.31,3,2,41.1,5,cationic,2.0,1.2
CCC[C@@H]1C[C@H](N(C)C1)C(=O)N[C@H]([C@@H](C)O)[C@H]2O[C@H](SC)[C@H](O)[C@@H](O)[C@H]2O,1.070389327891398,2.4006913,Lincomycin,154-21-2,1.0,2.1,,7.5,5.6,Gwilt PR and Smith RB (1986) Protein binding and pharmacokinetics of lincomycin following intravenous administration of high doses.  J. Clin. Pharmacol.  26: 87-90.,Averaged values over three doses.  Saturable protein binding reported.,,1962,406.54,8,5,122.5,7,cationic,0.001,-0.75
CCCc1nc(C)c2C(=O)NC(=Nn12)c3cc(ccc3OCC)S(=O)(=O)N4CCN(CC)CC4,3.700439718141092,1.4430994,Vardenafil,224785-90-4,3.0,13.0,0.05,3.8,4.5,Levitra Product Label,,,1999,488.6,10,1,109.1,8,cationic,1.2,0.56
CCCc1nc2c(C)cc(cc2n1Cc3ccc(cc3)c4ccccc4C(=O)O)c5nc6ccccc6n5C,3.070389327891398,0.9535538,Telmisartan,144701-48-4,5.3,8.4,0.004,11.0,20.0,"Stangier J, Schmid J, Turck D, Switek H, Verhagen A, Peeters PAM, van Marle SP, Tamminga WJ, Sollie FAE, and Jonkman JHG (2000) Absorption, metabolism, and excretion of intravenously and orally administered [14C]telmisartan in healthy volunteers.  J. Clin. Pharmacol. 40: 1312-1322.",,,1992,514.62,6,1,72.9,7,anionic,7.7,4.7
CCN(C(=O)C)c1cccc(c1)c2ccnc3c(cnn23)C#N,4.0,2.050714,Zaleplon,151319-34-5,1.3,16.0,0.4,1.4,1.1,"Rosen AS, Fournie P, Darwish M, Danjou P, and Troy SM (1999) Zaleplon pharmacokinetics and absolute bioavailability.  Biopharm. Drug Dispos. 20: 171-175.   Sonata Product Label.",,,1986,305.33,6,0,74.3,4,neutral,1.8,1.8
CCN(CC)C(=O)\C(=C\c1cc(O)c(O)c(c1)N(=O)=O)\C#N,3.584962500721156,0.9277827,Entacapone,130929-57-6,0.27,12.0,0.02,0.38,2.4,"Heikkinen H, Saraheimo M, Antila S, Ottoila P, and Pentikainen PJ (2001) Pharmacokinetics of entacapone, a peripherally acting catechol-O-methyltransferase inhibitor, in man. A study using a stable isotope technique.   Eur. J. Clin. Pharmacol. 56: 821-826.   Najib J (2001)  Entacapone: a catechol-O-methyltransferase inhibitor for the adjunctive treatment of parkinson's disease. Clin. Ther. 23: 802-832.",,,1988,305.29,8,2,130.4,6,anionic,1.6,-0.08
CCN(CC)CCS(=O)(=O)[C@@H]1CCN2[C@H]1C(=O)O[C@@H](C(C)C)[C@H](C)\C=C\C(=O)NC\C=C/C(=C/[C@@H](O)CC(=O)Cc3occ(n3)C2=O)/C,4.0,2.7487385,Dalfopristin,112362-50-2,0.39,16.0,0.82,0.41,0.74,"Chevalier P, Rey J, Pasquier O, Rouzier-Panis R, Harding N, and Montay G (2001) Multiple-dose pharmacokinetics and safety of two regimens of quinupristine/dalfopristin (Synercid) in healthy volunteers.  J. Clin. Pharmacol. 41: 404-414.  Bergeron M and Montay G (1997) The pharmacokinetics of quinupristin/dalfopristin in laboratory animals and in humans.  J. Antimic. Chemother. 39(Supp. 1): 129-138.  Bearden DT (2004)  Clinical pharmacokinetics of quinupristin/dalfopristin.  Clin. Pharmacokinet. 43: 239-252.",,,1986,690.85,13,2,176.7,7,neutral,0.6,0.6
CCN(CC)Cc1cc(ccc1O)Nc2ccnc3c2ccc(c3)Cl,7.761551232444479,1.6832968,Amodiaquine,86-42-0,17.4,217.0,,1.34,2.1,"White, N. J.; Looareesuwan, Sornchai; Edwards, G.; Phillips, R. E.; Karbwang, Juntra; Nicholl, Deborah D.; Bunch, C.; Warrell, D. A.. Pharmacokinetics of intravenous amodiaquine. British Journal of Clinical Pharmacology (1987), 23(2), 127-135",N=6 10 mg/kg as 4 hours infusion. 50 kg average weight. Clearance reported as 13 L.kg-1.h-1 in healthy volunteer (data taken) while an average of 5 L.kg-1.h-1 was reported for 10 malaria patients. Same dose and infusion time. MRT from VDss and clearancePlots available. EXTREMELY HIGH CLEARANCE.,,1948,355.86,4,2,48.4,6,cationic,5.4,2.0
CCN1C=C(C(=O)O)C(=O)c2cc(F)c(nc12)N3CCNCC3,2.4329594072761065,0.8762097,Enoxacin,74011-58-8,2.0,5.4,0.8,6.2,5.1,"Nix DE, Lebsack ME, Chapelsky M, Sedman AJ, Busch J, and Norman A (1993)  Effect of oral antacids on disposition of intravenous enoxacin.    Antimic. Agents Chemother. 37: 775-777.   Wise R, Lister D, McNulty CAM, Griggs D, and Andrews JM (1986) The comparative pharmacokinetics and tissue penetration of four quinolones including intravenously administered enoxacin.  Infection  14: S196-S202.  Bergogne-Berezin E (2002)  Clinical role of protein binding of quinolones.  Clin. Pharmacokinet. 41: 741-750.",,,1980,320.32,7,2,85.8,3,zwitterionic,1.4,-1.1
CCN1CCC[C@H]1CNC(=O)c2c(OC)ccc(Br)c2OC,0.765534746362977,2.6251779,Remoxipride,80125-14-0,0.65,1.7,0.16,6.4,5.5,"Widman M, Nilsson LB, Bryske B, and Lundstroem J (1993) Disposition of remoxipride in different species: species differences in metabolism.  Arz. Forsch. 43: 287-297.  von Bahr C, Movin G, Yisak WA, Jostell KG, and Widman M (199) Clinical pharmacokinetics of remoxipride.  Acta Psych Scand. 358(Suppl) 41-44.",Note probable typo in the article by von Bahr et al stating that CL is 119 liter/min--interpreted as 119 mL/min,,1981,371.27,5,1,50.8,6,cationic,2.5,0.86
CCN1C[C@H]2CN(C)C[C@@H](C1)C2OC(=O)c3ccc(Cl)cc3,4.087462841250339,3.0479965,Bisaramil,89194-77-4,9.0,17.0,,8.8,8.6,"Gemesi L, Kapas M, Matos L (1993)  Pharmacokinetic study of bisaramil in man.  Acta Pharm. Hungarica  63: 327-333. ",VDss calculated from reported C vs t data table.,,1982,322.83,4,0,32.8,4,cationic,3.3,1.8
CCN[C@@H]1C[C@H](N)[C@@H](O[C@H]2OC(=CC[C@H]2N)CN)[C@H](O)[C@H]1O[C@H]3OC[C@](C)(O)[C@H](NC)[C@H]3O,-0.862496476250065,1.2123494,Netilmicin,56391-56-1,0.073,0.55,1.0,2.2,3.2,"Welling PG, Baumueller A, Lau CC, and Madsen PO  (1977) Netilmicin Pharmacokinetics After Single Intravenous Doses to Elderly Male Patients.  Antimic. Agents Chemother. 12: 328-334.  Contrepois A, Brion N, Garaud JJ, Faurisson F, Delatour F, Levy JC, Deybach JC, and Carbon C (1985) Renal disposition of gentamicin, dibekacin, tobramycin, netilmicin, and amikacin in humans.  Antimic. Agents Chemother. 27: 520-524.",Used data from group 1 (mean age 54 yr) and analyzed C vs t data provided in the reference by Welling et al.,,1975,475.58,12,8,199.7,8,cationic,-3.8,-7.5
CCOC(=O)C1(CCN(CC1)CCC(c2ccccc2)O)c3ccccc3,4.459431618637297,3.202291,Phenoperidine,562-26-5,5.7,22.0,,4.32,3.22,"M. FISCHLER, J. C. LEVRON, H. TRANG, J. F. VAXELAIRE, B. FLAISLER AND G. VOURC'H. PHARMACOKINETICS OF PHENOPERIDINE IN ANAESTHETIZED PATIENTS UNDERGOING GENERAL SURGERY. Br. J. Anaesth. (1985), 57, 872-876","N=5, anesthetized patients. Average weight 66.4 kg. 2M/3F, 2 mg iv injection. MRT from clearance and VDss.",,1958,367.48,4,1,49.8,8,cationic,4.1,3.6
CCOC(=O)C1=C(C)NC(=C(C1c2cccc(c2)N(=O)=O)C(=O)OC)C,4.643856189774724,2.6172676,Nitrendipine,39562-70-4,6.1,25.0,0.02,4.1,8.2,"Mikus G, Fischer C, Heuer B, Langen C, and Eichelbaum M (1987) Application of stable isotope methodology to study the pharmacokinetics, bioavailability, and metabolism of nitrendipine after i.v. and p.o. administration.  Br. J. Clin. Pharmacol. 24: 561-569.  Soons PA, DeBoer AG, Van Brummelen P, and Breimer DD (1989) Oral absorption ptrofile of nitrendipine in healthy subjects: a kinetic and dynamic study.  Br. J. Clin. Pharmacol. 27: 179-189.  Ramsch KD, Graefe KH, Scherline D, Sommer J, and Ziegler R (1986) Pharmacokinetics and metabolism of calcium-blocking agents nifedipine, nitrendipine, and nimodipine.  Am. J. Nephrol. 6(Suppl 1): 73-80.  ",,,1972,360.36,8,1,110.4,7,neutral,3.0,3.0
CCOC(=O)Nc1ccc(NCc2ccc(F)cc2)nc1N,0.6780719051126377,2.2120261,Flupirtine,56995-20-1,1.1,1.6,0.15,11.0,8.5,Hlavica VP and Niebch G (1985) Untersuchungen zur pharmakokinetik und biotransformation des analgetikums flupirtin beim menschen.  Arz. Forsch. 35: 67-74. ,VDss calculated from C vs t data obtained by digitization of the plots in the reference.,,1979,304.32,6,3,89.3,6,cationic,3.1,2.7
CCOC(=O)c1ncn2c1CN(C)C(=O)c3cc(F)ccc23,4.0,1.8828902,Flumazenil,78755-81-4,0.8,16.0,0.58,1.0,0.78,"Janssen U, Walker S, Maier K, von Gaisberg U, and Klotz U (1989) Flumazenil disposition and elimination in cirrhosis.  Clin. Pharmacol. Ther.  46: 317-323. Pomier-Layrargues G, Giguere JF, Lavoie J, Willems B, and Butterworth RF (1989) Pharmacokinetics of benzodiazepine antagonist RO 15-1788 in cirrhotic patients with moderate or severe liver dysfunction.  Hepatology  10: 969-972.  Klotz U, Ziegler G, and Reimann IW (1984)  Pharmacokinetics of the selective benzodiazepine antagonist Ro 15-1788 in man.  Eur. J. Clin. Pharmacol. 27: 115-117. ",,,1981,303.29,6,0,64.4,3,neutral,1.0,1.0
CCO[C@@H](Cc1ccc(OCCc2ccc(OS(=O)(=O)C)cc2)cc1)C(=O)O,-4.680382065799838,1.3888103,Tesaglitazar,251565-85-2,0.13,0.039,0.0011,56.0,45.0,"Ericsson H, Hamren B, Bergstrand S, Elebring M, Fryklund L, Heijer M, and Ohman KP (2004) Pharmacokinetics and metabolism of tesaglitazar, a novel dual acting peroxisome proliferator-activated receptor alpha/gamma agonist, after a single oral and intravenous dose in humans.  Drug Metab. Dispos.  32: 923-929.",,,1999,408.47,7,1,99.1,11,anionic,2.7,-0.53
CCOc1cc(CC(=O)N[C@@H](CC(C)C)c2ccccc2N3CCCCC3)ccc1C(=O)O,2.963474123974886,1.9328725,Repaglinide,135062-02-1,0.35,7.8,0.0149999999999999,0.75,0.87,"Hatorp V, Oliver S, and Su CAPF (1998) Bioavailability of repaglinide, a novel antidiabetic agent, administered orally in tablet or solution form or intravenously in healthy male volunteers.  Int. J. Clin. Pharmacol. Ther.  36: 636-641.  Plum A, Muller LK, and Jansen JA (2000) The effects of selected drugs on the in vitro protein binding of repaglinide in human plasma.  Meth. Find. Exp. Clin. Pharmacol. 22: 139-143.",AG-EE 388 ZW,,1991,452.59,6,2,78.9,10,anionic,5.8,2.4
CCOc1ccc(NC(=O)C)cc1,4.392317422778761,2.6452568,Phenacetin,62-44-2,1.4,21.0,0.47,1.1,0.92,"Raaflaub J and Dubach UC (1975) On the pharmacokinetics of phenacetin in man.  Eur. J. Clin. Pharmacol.  8: 261-265.  Kurz H, Mauser-Ganshorn A, and Stickel HH (1977) Differences in the binding of drugs to plasma proteins from newborn and adult man. I. Eur. J. Clin. Pharmacol. 11: 463-467.",VDss data calculated from C vs t data reported in the paper.  Values are for whole blood.,,1941,179.22,3,1,38.3,3,neutral,1.7,1.7
CCOc1ccccc1OCC2CNCCO2,1.070389327891398,2.6713715,Viloxazine,46817-91-8,0.73,2.1,,5.8,4.1,"Pisani F, Fazio A, Spina E, Artesi C, Pisani B, Russo M, Trio R, and Perucca E (1986) Pharmacokinetics of the antidepressant drug viloxazine in normal subjects and in epileptic patients receiving chronic anticonvulsant treatment.  Psychopharmacol.  90: 295-298.",VDss calculated from data obtained by digitization of the C vs t plot in the report.,,1972,237.29,4,1,39.7,5,cationic,1.3,0.23
CCOc1ccccc1OCCN[C@H](C)Cc2ccc(OC)c(c2)S(=O)(=O)N,-0.6896598793878495,2.2416425,Tamsulosin,106133-20-4,0.21,0.62,0.01,5.6,6.8,"van Hoogdalem E, Soeishi Y, Matsushima H, and Higuchi S (1997) Disposition of the selective alpha1A-adrenoceptor antagonist tamsulosin in humans: comparison with data from interspecies scaling.  J. Pharm. Sci.  86: 1156-1161.  Matsushima H, Kamimura H, Soeishi Y, Watanabe T, Higuchi S, and Tsunoo M (1998) Pharmacokinetics and plasma protein binding of tamsulosin hydrochloride in rats, dogs, and humans.  Drug Metab. Dispos. 26: 240-245.",,,1986,408.51,7,2,99.9,11,cationic,2.5,1.6
CCOc1ccccc1O[C@@H]([C@H]2CNCCO2)c3ccccc3,-0.2863041851566411,2.5703034,Reboxetine,71620-89-8,0.65,0.82,0.019,13.0,10.0,"Fleishaker JC, Mucci M, Pellizzoni C, and Poggesi I (1999) Absolute bioavailability of reboxetine enantiomers and effect of gender of pharmacokinetics.  Biopharm. Drug Dispos.  20: 53-57.  Hendershot PE, Fleishaker JC, Lin KM, Nuccio ID, and Poland RE (2001) Pharmacokinetics of reboxetine in healthy volunteers with different ethnic descents.  Psychopharmacology 155: 148-53.",Administered as a racemate; averaged data for the two enantiomers.,,1979,313.39,4,1,39.7,6,cationic,2.7,1.5
CCOc1nc2cccc(c2n1Cc3ccc(cc3)c4ccccc4c5[nH]nnn5)C(=O)O,-1.434402824145775,1.1369023,Candesartan,139481-59-7,0.13,0.37,0.002,5.9,9.7,"Reference through PP. 1997-Apr-30  PDF(1259k)
Clinical Pharmacology and Biopharmaceutics Review 020838/S-000 Part 01 NDA 20838.",4 mg 14C of candesartan iv. MRT from VDss and Cl,,1991,440.45,9,2,118.8,7,anionic,4.9,-0.31
CCS(=O)(=O)CCn1c(C)ncc1N(=O)=O,-0.7369655941662062,2.2106297,Tinidazole,19387-91-8,0.59,0.6,0.8,16.0,13.0,"Vinge E, Andersson KE, Ando G, and Lunell E (1983) Biological availability and pharmacokinetics of tinidazole after single and repeated doses.  Scand. J. Infect. Dis.  15: 391-397.  Sawyer PR, Brogden RN, Pinder RM, Speight TM, and Avery GS (1976) Tinidazole: a review of its antiprotozoal activity and therapeutic efficacy.  Drugs 11: 423-440.",VDss calculated from digitized C vs t plot.,,1968,247.27,7,0,97.8,5,neutral,-0.48,-0.48
CC[C@@H](c1cc(c(c(c1)OC)OC)OC)C(=O)N2CCCC[C@H]2C(=O)O[C@H](CCc3ccc(c(c3)OC)OC)c4cccc(c4)OCC(=O)NCCNC(=O)COc5cccc(c5)[C@@H](CCc6ccc(c(c6)OC)OC)OC(=O)[C@@H]7CCCCN7C(=O)[C@@H](CC)c8cc(c(c(c8)OC)OC)OC,2.7246502717329677,1.5274352,Rimiducid,195514-63-7,0.82,6.61,,2.08,7.18,"John D. Iuliucci, Stuart D. Oliver,  Steve Morley,  Chris Ward Janet Ward, David Dalgarno, Tim Clackson,  and Harvey J. Berger. Intravenous Safety and Pharmacokinetics of a Novel Dimerizer Drug, AP1903, in Healthy Volunteers. Journal of Clinical Pharmacology 2001, 41, 870-879","AP1903. Plasma data Table II. Blood parameters also available. Blood/plasma 1.75. N= 4 per dose group. Doses 0.05  0.1, 0.5 and  1 mg,/kg, 2 hr infusion. Averaged across 4 doses. t 1/2 varied from 3.92 to 12 hours (the latter at 1 mg/kg). All other parameters quite reproducicle dose-to-dose.",,1997,1411.63,24,2,262.2,39,neutral,9.0,9.0
CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C,2.9068905956085187,0.7291614,Cyclosporine,59865-13-3,3.3,7.5,0.068,7.3,7.3,"Legg B, Gupta SK, Rowland M, Johnson RWG, and Solomon LR (1988) Cyclosporin: pharmacokinetics and detailed studies of plasma and erythrocyte binding during intravenous and oral administration.  Eur. J. Clin. Pharmacol. 34: 451-460.  Min DI, Lee M, Ku YM, and Flanigan M (2000) Gender-dependent racial difference in disposition of cyclosporine among healthy African American and white volunteers.  Clin. Pharmacol. Ther. 68: 478-486.   ",Reported whole blood parameters converted to plasma parameters using a blood/plasma ratio of 1.3.,,1974,1202.61,23,5,278.8,15,neutral,6.6,6.6
CC[C@@]1(c2cc-3n(c(=O)c2COC1=O)Cc4c3nc5cc6c(cc5c4CN7CCN(CC7)C)OCCO6)O,4.647890091059215,2.7193902,Lurtotecan,149882-10-0,4.77,25.07,,3.5,3.54,"CJH Gerrits, GJ Creemers, JHM Schellens, P Wissel, AS Th Planting, R Kunka, K Selinger,
M de Boer-Dennert, Y Marijnen, M Harteveld, J Verweij. Phase I and pharmacological study of the new topoisomerase I inhibitor G1147211, using a daily x 5 intravenous administration. British Journal of Cancer (1996) 73, 744-750.","GG211 or GI147211. NX211. Quantitation of lactone form. Weight averaged value across several doses, from Table IV (Day 1). N=17 overall. 1.73m2/70 kg factor used.",,1993,518.56,10,1,106.4,3,cationic,1.0,-0.084
CC[C@@]1(c2cc-3n(c(=O)c2COC1=O)Cc4c3nc5ccc(cc5c4)O)O,1.15704371014558,2.5238965,"Hydroxycamptothecin, 10-",19685-09-7,0.22,2.23,,1.63,1.67,"LI Su, ZHANG Li, GUANG Zhong-zhen, ZHAN Jing, LI Yu-yan , JIANG Wen-qi. Absolute bioavailability of hydroxycamptothecin tablets in cancer patients. Chin. J. Clin. Pharmacol. 2005, 22, 46-49.(written in Chinese) ","N=8, 12 mg.m-2 dose, conversion factor 1.73m2/70kg, 30 minutes infusion. Data digitized and PK parameters calculated via PKSolver. AUC reported as 2171 ug.h.L-1 (not specified); AUS (inf) calculated as 2211 ng.h.mL-1. 2% difference.",,1969,364.35,7,2,101.6,1,neutral,1.4,1.4
CC[C@H](C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(=O)O)[C@@H]12,2.84799690655495,1.6785961,Lovastatin (acid),75225-51-3,0.87,7.2,0.0429999999999999,1.3,1.4,"Duggan DE, Chen IW, Bayne WF, Halpin RA, Duncan CA, Schwartz MS, Stubbs RJ, Vickers S (1989) The physiological disposition of lovastatin.  Drug Metab Dispos. 17: 166-173.",Pharmacokinetic paramaters were calculated using C vs t data obtained by digitization of the plot provided in the reference.,,1980,422.55,6,3,104.1,11,anionic,4.2,1.4
CC[C@H](C)C(=O)O[C@H]1C[C@H](O)C=C2C=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(=O)O)[C@@H]12,3.807354922057604,1.7062294,Pravastatin ,81093-37-0,0.46,14.0,0.5,0.59,0.78,"Singhvi SM, Pan HY, Morrison RA, and Willard DA (1990) Dispositon of pravastatin sodium, a tissue-selective HMG-CoA reductase inhibitor, in healthy subjects.  Br. J. Clin. Pharmacol. 29: 239-243.  Quion JA and Jones PH (1994) Clinical pharmacokinetics of pravastatin.  Clin. Pharmacokinet. 27: 94-103.",,,1981,424.53,7,4,124.3,11,anionic,2.3,-0.54
CC[C@H](C)[C@@H](C(=O)NCC(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N)NC(=O)[C@H](C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@@H]2CCCN2C(=O)[C@H](Cc3ccccc3)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](Cc4cnc[nH]4)NC(=O)[C@H](Cc5ccccc5)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](Cc6ccccc6)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](Cc7ccc(cc7)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)N)NC(=O)CNC(=O)[C@H](CS)N,3.321928094887362,1.8773578,Calcitonin,21215-62-3,0.23,10.0,,0.38,0.82,"Antonin, K. H.; Saano, V.; Bieck, P.; Hastewell, J.; Fox, R.; Lowe, P.; Mackay, M. Colonic absorption of human calcitonin in man. Clin. Sci. 1992, 83, 627-631","Cibacalcin. Data digitized from plot reported. N=8, 0.5 mg dose in 90 min infusion. 70.5 kg average weight (males) and 63 kg average weight (females)  reported. Overall average (N=4/gender) as 67 kg. AUCinf calculated 744.8 ng.min/mL, reported AUC 694.8 ng.min/mL",,1968,3419.86,85,45,1359.6,105,cationic,-9.0,-9.0
CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1c[nH]c2c1cccc2)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc3c[nH]c4c3cccc4)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](Cc5c[nH]c6c5cccc6)C(=O)N[C@@H](Cc7ccccc7)C(=O)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](Cc8cnc[nH]8)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](Cc9ccc(cc9)O)NC(=O)C,-1.4739311883324124,-0.3634826,Enfuvirtide,159519-65-0,0.07,0.36,0.08,3.2,4.0,"PP data. 2003-Mar-27  PDF(1771k)
Clinical Pharmacology and Biopharmaceutics Review 021481/S-000 Part 01 ", 70 kg assumed. MRT from VDss and Cl. T 1/2 reported < 4 h.,,1994,4491.88,115,63,1902.9,151,anionic,-9.0,-9.0
CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@@H]([C@@H](C)C(=O)NCCc2ccccc2)OC)OC)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)N(C)C,0.6780719051126377,2.7301834,Soblidotin,149606-27-9,0.42,1.6,,4.6,5.67,"Nobuyuki Yamamoto,Masahiro Andoh,Masaaki Kawahara,Masahiro Fukuoka, Hisanobu Niitani. Phase I study of TZT-1027, a novel synthetic dolastatin 10 derivative and inhibitor of tubulin polymerization, given weekly to advanced solid tumor patients for 3 weeks. Cancer Sci 2009; 100: 316–321. // J. Horti · E. Juhasz · Z. Monostori · K. Maeda · S. Eckhardt · I. Bodrogi.  Phase I study of TZT-1027, a novel synthetic dolastatin 10 derivative, for the treatment of patients with non-small cell lung cancer. Cancer Chemother Pharmacol (2008) 62:173–180","TZT-1027. VDss from clearance and MRT in both cases. Some trend toward lower clearance at higher doses in both reports. However, fairly contained. Very similar number of patient in each cohort across many doses in both studies. NOT WEIGHT AVERAGED.",,1993,701.98,11,2,120.5,20,neutral,3.9,3.8
CC[C@H](C)[C@H](NC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CS)NC(=O)[C@@H](N)CCCCN)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(N)=O,3.9354597478052895,1.3096371,Pramlintide,151126-32-8,0.41,15.3,0.4,0.5,0.6,"Pharmacokinetics and Pharmacodynamics of AC137 (25,28,29 Tripro-amylin, Human) after intravenous bolus and infusion doses in patients with insuline-dependent diabetes. W. A. Colburn, Gottlieb, AB, Koda J., Koltermann, OG. J. Clin. Pharmacol. 1996, 36, 13-24. ppb: The PDR states: SYMLIN does not extensively bind to red blood cells or albumin (approximately 40% of the drug is unbound in plasma). Accessed January 8 2015. http://www.pdr3d.com/detail.php?c=133005#section-14","AC-137, Triproamylin, Symlin.  N=24, avg weight 76.5 kg. Dose range 30-300 ug iv bolus and 30-300 ug 2 hr infusion 
Data from two-compartment constants in Table II (ug/mL corrected units have been used)",,1993,3951.41,104,56,1690.6,122,cationic,-9.0,-9.0
CC[C@H](C)[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)CNC(=O)[C@H](CC(C=CC=C1)=C1)NC(=O)[C@H](CSSC[C@H](NC(=O)CNC(=O)[C@H](CC(C)C)N1)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(=CNC2)N=2)C(=O)O)C(C)C)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC2)N2C(=O)[C@@H](N)CO)C(C)C)C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(NCC1=O)=O)CO)=O)CO)=O)CO)=O)CO)=O,3.2016338611696504,1.6516111,Nesiritide,124584-08-3,0.19,9.2,,0.3,0.3,PDRprescribing information. Accessed July 31 2014. http://www.pdr3d.com/detail.php?c=114674#section-12,"In patients with heart failure (HF), NATRECOR® administered intravenously by infusion or bolus exhibits biphasic disposition from the plasma. The mean terminal elimination half-life (t1/2) of nesiritide is approximately 18 minutes and was associated with approximately 2/3 of the area-under-the-curve (AUC). The mean initial elimination phase was estimated to be approximately 2 minutes. In these patients, the mean volume of distribution of the central compartment (Vc) of nesiritide was estimated to be 0.073 L/kg, the mean steady-state volume of distribution (Vss) was 0.19 L/kg, and the mean clearance (CL) was approximately 9.2 mL/min/kg. MRT from Vss and Cl.",,1989,3464.04,92,56,1512.7,91,cationic,-9.0,-9.0
CC[C@H](CC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)C,-5.643856189774724,2.303556,"Sitosterol, β-",83-46-5,0.3,0.02,,250.0,372.4,"Duchateau, Guus; Cochrane, Brett; Windebank, Sam; Herudzinska, Justyna; Sanghera, Davindera; Burian, Angela; Mueller, Markus; Zeitlinger, Markus; Lappin, Graham. Absolute oral bioavailability and metabolic turnover of β-​sitosterol in healthy subjects. Drug Metab. Disp. 2012, 40, 2026-2030.","Nimbosterol. Betaprost. Angelicin. N=6, male volunteers. 2.9 to 4.2 ug doses. 70 kg assumed as average weight. MRT from clearance and VDss.",,1908,414.71,1,1,20.2,6,neutral,9.0,9.0
CC[C@H](Cc1c(ccs1)Cl)Nc2c3ccn(c3ncn2)[C@@H]4C[C@@H]([C@H]([C@H]4O)O)C(=O)NCC,3.584962500721156,1.3594816,AMP579,213453-89-5,0.84,12.0,0.03,1.18,1.33,"Peter N. Zannikos, PharmD, PhD, Bradford K. Jensen, PhD, Bruno X. Boutouyrie, MD,
Lisa Tripp, BS, Luo Yongyi, MS, Tracy McGowan, MD, Scott A. Waldman, MD, PhD,
and Howard E. Greenberg, MD, MS. Pharmacokinetics and Safety of Single Intravenous Infusions of the Adenosine Agonist, AMP 579, in Patients with End-Stage Renal Insufficiency. Journal of Clinical Pharmacology, 2000;40:745-751","Data taken from Table II. N=6, healthy volunteers, 50 ug/kg as a 6-hour infusion. MRT from clearance and VDss. Seemingly no significant difference with renally impaired patients.",,1998,478.01,8,4,112.3,8,neutral,2.6,2.6
CC[C@H]1CN2CC[C@H]1C[C@@H]2[C@@H](O)c3ccnc4ccc(OC)cc34,2.070389327891398,3.3680053,Dihydroquinidine,1435-55-8,2.8,4.2,0.22,11.0,5.7,"Ueda CT, Williamson BJ, and Dzindzio BS (1976) Disposition kinetics of dihydroquinidine following quinidine administration.  Res. Comm. Chem. Path. Pharmacol. 14: 215-225.  Leroyer R, Varoquaux O, Guillebastres R, Jarreau C, Normand JP, Jaillon P, Advenier C, and Pays M (1986) Study on protein binding of 3-(R)- and 3-(S)-hydroxy derivatives of quinidine and dihydroquinidine.  Therapie  41: 159-162.",,,1913,326.43,4,1,45.6,4,cationic,3.2,1.7
CC[C@H]1NC(=O)[C@@H](NC(=O)c2ncccc2O)[C@@H](C)OC(=O)[C@@H](NC(=O)[C@@H]3CC(=O)[C@H](CS[C@@H]4CN5CCC4CC5)CN3C(=O)C(Cc6ccc(cc6)N(C)C)N(C)C(=O)[C@@H]7CCCN7C1=O)c8ccccc8,4.0,1.2089748,Quinupristin,120138-50-3,0.67,16.0,0.34,0.7,0.87,"Chevalier P, Rey J, Pasquier O, Rouzier-Panis R, Harding N, and Montay G (2001) Multiple-dose pharmacokinetics and safety of two regimens of quinupristine/dalfopristin (Synercid) in healthy volunteers.  J. Clin. Pharmacol. 41: 404-414.  Bergeron M and Montay G (1997) The pharmacokinetics of quinupristin/dalfopristin in laboratory animals and in humans.  J. Antimic. Chemother. 39(Supp. A): 129-138.  Bearden DT (2004) Clinical pharmacokinetics of quinupristin/dalfopristin.  Clin. Pharmacokinet. 43: 239-252.",~16% excreated in urine and feces unchanged,,1987,1022.22,19,4,231.2,10,zwitterionic,3.0,0.59
CC[C@]1(O)C[C@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C2)(C(=O)OC)c5cc6c(cc5OC)N(C)[C@H]7[C@](O)([C@H](O)[C@]8(CC)C=CCN9CC[C@]67[C@H]89)C(=O)N)C1,1.1375035237499351,2.4335217,Vindesine,53643-48-4,5.0,2.2,,38.0,35.0,"Ohnuma T, Norton L, Andrejczuk A, and Holland JF (1995) Pharmacokinetics of vindesine given as an intravenous bolus and 24-hour infusion in humans. Cancer Res. 45: 464-469.  ",VDss calculated using micro rate constants provided in the reference.,,1974,753.93,12,5,164.8,7,cationic,2.3,1.5
CC[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1C=C[C@@]2(O)C#C,-0.3219280948873623,3.0557082,Gestodene,60282-87-3,0.46,0.8,0.023,9.6,10.0,"Tauber U, Tack JW, and Matthes H (1989) Single dose phakmacokinetics of gestodene in women after intravenous and oral administration.  Contraception 40: 461-476.    Kuhnz W, Pfeffer M,and Al-Yacoub G (1990) Protein binding of the contraceptive steroids gestodene, 3-keto-desogestrel and ethinylestradiol in human serum.  J. Steroid Biochem. 35: 313-318.  Gui LQ and Humpel M (1990) Serum protein binding characteristics of cyproterene acetate, gestodene, levonorgestrel and norethisterone in rat, rabbit, dog, monkey and man.  J. Steroid Biochem. 35: 319-326.","VDss deteremined from Cvs t data obtained by digitization of plots in Tauber, 1989.  Protein binding very different in two reports: 0.006 in Kuhnz et al vs 0.04 in Gui and Humpel; value entered is the average.",,1977,310.43,2,1,37.3,2,neutral,4.1,4.1
CC[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C,0.84799690655495,2.9191175,Levonorgestrel,797-63-7,1.5,1.8,0.025,14.0,9.4,"Stead RJ, Grimmer SFM, Rogers SM, Back DJ, Orme MLE, Hodson ME, and Batten JC (1987) Pharmacokinetics of contraceptive steroids in patients with cystic fibrosis.  Thorax 42: 59-64.  Aviane Product Label.",,,1963,312.45,2,1,37.3,2,neutral,3.5,3.5
CC[N+](CC)(CC)CCOc1cccc(c1OCC[N+](CC)(CC)CC)OCC[N+](CC)(CC)CC,0.5945485495503542,2.2944489,Gallamine triethiodide,65-29-2,0.27,1.51,,2.98,2.52,"M.I. Ramzan, E. J. Triggs, C. A. Clarks. Pharmacokinetics studies in man with gallamine triethiodide. Eur.  J. Clin. Pharmacol. 1980, 17, 145-152.",CAS number corresponding to gallamine triethiodide used.  Iodide atoms removed to keep only SMILES for trication neuromuscular blocker.  N=14 with data entered as average of single 4 and 6 mg iv bolus dose. MRT from VDss and clearance.,,1947,510.82,6,0,27.7,21,neutral,-7.7,-7.7
CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(=O)O[C@H]([C@@H](NC(=O)c1ccccc1)c2ccccc2)C(=O)O[C@H]3C[C@@]4(O)[C@@H](OC(=O)c5ccccc5)[C@@H]6[C@@]7(CO[C@@H]7C[C@H](O)[C@@]6(C)C(=O)[C@H](OC(=O)C)C(=C3C)C4(C)C)OC(=O)C,-5.321928094887363,1.4787756,DHA Paclitaxel,199796-52-6,0.068,0.025,0.0038,45.0,60.0,"Sparreboom A, Wolff AC, Verweij J, Zabelina Y, van Zomeren DM, McIntire GL, Swindell CS, Donehower RC, and Baker SD (2003) Disposition of docosahaenoic acid-paclitaxel, a novel taxane, in blood: in vitro and clinical pharmacokinetic studies.  Clin. Cancer Res. 9: 151-159.",Pharmacokinetic paremeters were calculated from C vs t data obtained by digitization of the plot provided in the reference.,,1997,1164.38,16,3,227.4,30,neutral,9.0,9.0
CCc1nc(N)nc(N)c1c2ccc(Cl)cc2,-4.265344566520995,1.6053178,Pyrimethamine,58-14-0,0.43,0.052,0.095,140.0,140.0,"Almond DS, Szwandt ISF, Edwards G, Lee MG, and Winstanley PA (2000) Disposition of intravenous pyrimethamine in healthy volunteers.  Antimic. Agents Chemother.  44: 1691-1693.  Cavallito JC, Nichol CA, Brenckman WD, Deangelis RL, Stickney DR, Simmons WS, and Sigel CW (1978) Lipid-soluble inhibitors of dihydrofolate reductase.  I.  Kinetics, tissue distribution, and extent of metabolism of pyrimethamine, metoprine, and etoprine in the rat, dog, and man.  Drug Metab. Dispos. 6: 329-337.  Rudy AC and Poynor WJ (1990) Binding of pyrimethamine to human plasma proteins and erythrocytes.  Pharm. Res. 7: 1055-1060.",Note: Incorrect calculations in the original paper.,,1951,248.71,4,2,77.8,2,neutral,2.9,2.7
CN(C(=O)C)c1c(I)c(NC(=O)C)c(I)c(C(=O)O)c1I,1.4329594072761065,-0.16567135,Metrizoate,1949-45-7,0.17,2.7,1.0,1.0,1.3,"Back SE, Krutzen E, and Nilsson-Ehle P (1988) Contrast media as markers for glomerular filtration: a pharmacokinetic comparison of four agents.  Scand. J. Clin. Lab Invest.  48: 247-253.",VDss calculated from C vs t data obtained by digitization of the plot provided in the reference. CAS number and structure refer to the free acid.,,1962,627.94,6,2,86.7,3,anionic,1.4,-1.9
CN(C(=O)C1=C(O)c2ccccc2N(C)C1=O)c3ccccc3,-3.608232280044003,0.45599207,Roquinimex,84088-42-6,0.21,0.082,,43.0,31.0,"Strandgarden K, Hoglund P, Nordle O, Polacek J, Wannman H, and Gunnarsson PO.(1999) Dissolution rate-limited absorption and complete bioavailability of roquinimex in man.  Biopharm. Drug Dispos. 20: 347-354. Biopharm Drug Dispos. 2000 Mar;21(2):53-67.
Absorption and disposition including enterohepatic circulation of (14C) roquinimex after oral administration to healthy volunteers.
Strandgården K, Höglund P, Grönquist L, Svensson L, Gunnarsson PO.",,,1982,308.33,5,1,60.9,2,anionic,2.4,-0.95
CN(C)C(=O)CCS[C@H](SCCC(=O)O)c1cccc(\C=C\c2ccc3ccc(Cl)cc3n2)c1,-0.5563933485243852,0.76215863,Verlukast,120443-16-5,0.11,0.68,0.0004,2.7,2.3,"Depre M, Margolskee DJ, Hseih JYK, Van Hecken A, Buntinx A, De Lepeleire I, Rogers JD, and De Schepper PJ (1992) Plasma drug profiles and tolerability of MK-571 (L-660,711), a leukotriene D4 receptor antagonist, in man.  Eur. J. Clin. Pharmacol. 43: 427-430.  Cheng H, Schwartz JI, Lin C, Amin RD, Seibold JR, Lasseter KC, Ebel DL, Tocco DJ, and Rogers JD (1994) The bioavailability and nonlinear pharmacokinetics of MK-679 in humans. Biopharm. Drug Dispos. 15: 409-418.","Parameters were determined using C vs t data obtained by digitization of the plots in the reference by Depre, et al. L-660,711 represents the compound without defined stereochemistry (except for double bond) and with CAS # 115104-28-4  ",,1987,515.09,5,1,70.5,11,anionic,5.1,1.6
CN(C)C(=O)Oc1cc(OC(=O)N(C)C)cc(c1)C(O)CNC(C)(C)C,4.169925001442312,2.2529335,Bambuterol,81732-65-2,1.6,18.0,,1.4,2.6,"Nyberg L, Rosenborg J, Weibull E, Jonsson S, Kennedy BM, and Nilsson M (1998) Pharmacokinetics of bambuterol in healthy subjects.   Br. J. Clin. Pharmacol. 45: 471-478.",,,1982,367.44,8,2,91.3,7,cationic,1.3,-0.27
CN(C)CCC(c1ccc(Cl)cc1)c2ccccn2,1.3219280948873624,2.4840038,Chlorpheniramine,132-22-9,3.3,2.5,0.7,22.0,22.0,"Huang SM, Athanikar NK, Sridhar K, Huang YC, and Chiou WL (1982) Pharmacokinetics of chlorpheniramine after intravenous and oral administration in normal adults.  Eur. J. Clin. Pharmacol. 22: 359-365.  Hiep BT, Gimenez F, Khanh V, Hung NK, Thuillier A, Farinotti R, and Fernandez C (1999) Binding of chlorpheniramine enantiomers to human plasma proteins.  Chirality 11: 501-504.",,,1949,274.79,2,0,16.1,5,cationic,3.3,1.4
CN(C)CCC=C1c2ccccc2CCc3ccccc13,2.608809242675524,4.425905,Amitriptyline,50-48-6,8.7,6.1,0.07,24.0,17.0,Jorgensen A and Hansen V (1976) Pharmacokinetics of amitriptyline infused intravenously in man.  Eur. J. Clin. Pharmacol.  10: 337-341.  Nyberg G and Maartensson E (1984) Determination of free fractions of tricyclic antidepressants.    Naunyn-Sch Arch. Pharmacol. 327: 260-265.,,,1960,277.4,1,0,3.2,3,cationic,4.6,3.3
CN(C)CCCN1c2ccccc2CCc3ccc(Cl)cc13,3.035623909730721,4.155667,Clomipramine,303-49-1,13.0,8.2,0.029,26.0,26.0,"Ollagnier M, Pellet J, Gay JP, Lang F, Ouvry MC, and Blanchon Y (1984) Pharmacocinetique d'une dose unique de clomipramine, en intraveneuse, chez le voluntaire sain.  Therapie  39: 237-245.  Nyberg G and Maartensson E (1984)  Determination of free fractions of tricyclic antidepressants.  Naunyn-Sch. Arch. Pharmacol. 327: 260-265.",Pharmacokinetic parameters were calculated from C vs t provided in the reference. ,,1961,314.85,2,0,6.5,4,cationic,5.1,3.4
CN(C)CCCNc1ncc(C)c2[nH]c3ccc4cc(O)ccc4c3c12,4.169925001442312,2.2330196,Intoplicine,125974-72-3,11.0,18.0,,11.0,19.0,"Abigerges D, Armand JP, Chabot GG, Bruno R, Bissery MC, Bayssas M, Klink-Alakl M, Clavel M, and Catimel G (1996) Phase I and pharmacology study of  intoplicine  (RP 60475; NSC 645008), a novel topoisomerase I and II inhibitor, in cancer  patients.  Anti-Cancer Drugs 7: 166-174",,,1990,348.44,5,3,64.2,5,cationic,3.8,-1.2
CN(C)CCN(Cc1cccs1)c2ccccn2,4.807354922057604,3.7164779,Thionylan (Methapyrilene),91-80-5,3.3,28.0,,2.0,1.6,"Calandre EP, Alferez N, Hassanein K, and Azarnoff DL (1981) Methapyrilene kinetics and dynamics.  Clin. Pharmacol. Ther. 29: 527-532. ",VDss calculated from C vs t data obtained by digitization of the plot included in the reference.,,1946,261.39,3,0,19.4,6,cationic,2.7,1.6
CN(C)CCNc1ccc2c3c(nn2CCNCCO)c4cnccc4C(=O)c13,4.754887502163468,2.9744039,Topixantrone,156090-18-5,57.0,27.0,,39.0,45.0,"Mross K, Scheulen ME, Licht T, Unger C, Richly H, Stern AC, Kutz K, Camboni MG, Barbieri P, Verdi E, Vincenzi B, and Bernareggi A (2004) Phase I clinical and pharmacokinetic study of BBR 3576, a novel aza-anthropyrazole, administered i.v. every 4 weeks in patients with advanced solid tumors: a phase 1 study group trial of the Central European Society of Anticancer Drug Research (CESAR).  Anti-Cancer Drugs 15: 15-22.",BBR 3576,,1994,394.47,8,3,95.3,9,cationic,0.69,-1.4
CN(C)N=Nc1ccc(cc1)C(=O)O,0.3785116232537298,1.4609259,CB 10-277,7203-91-0,0.25,1.3,,3.0,2.5,"Foster BJ, Newell DR, Carmichael J, Harris AL, Gumbrell LA, Jones M, Goodard PM, and Calvert AH (1993) Preclinical, phase I and pharmacokinetic studies with the dimethyl phenyltriazene CB10-277.  Br. J. Canc. 67: 362-368.",Parameters were calculated using C vs t data obtained by digitzation of the plot provided in the reference.,,1965,193.2,5,1,65.3,3,anionic,2.5,-0.32
CN(C)N=Nc1nc[nH]c1C(=O)N,1.3785116232537298,2.510022,Dacarbazine,4342-03-4,1.2,2.6,1.0,7.8,6.2,"Loo TL, Housholder GE, Gerulath AH, Saunders PH, and Farquhar D (1976) Mechanism of action and pharmacology studies with DITC (NSC-45388) Canc. Treatment Rep. 60: 149-152.  DITC-DOME Product Label",Parameters calculated from C vs t data obtained by digitization of a plot provided in the reference.,,1953,182.18,7,2,99.7,3,neutral,-0.12,-0.12
CN(C)[C@H]1[C@@H]2C[C@H]3C(=C(O)[C@]2(O)C(=O)C(=C1O)C(=O)NCN4CCCC4)C(=O)c5c(O)cccc5[C@@]3(C)O,-0.043943347587597,1.8127315,Rolitetracycline,751-97-3,0.54,0.97,0.5,9.3,8.8,Dimmling T and Vanderbeke O (1975) Pharmakokinetik oral und intravenos verabreichbarer tetracyclinpraparate.  Med. Klin. 70: 279-285.  Rinati MV and Fleischmann L (1973) Legame con sieroproteine di alcune tetracicline e loro derivati idrosolubili. Cl. Terap. 71: 57-61.,Calculations made from reported C vs t data.  Plasma concentrations were determined using bioassay.,,1957,527.57,11,6,170.9,4,cationic,0.097,-4.1
CN(CC(=O)N)C(=O)N(CCCl)N=O,3.169925001442312,2.022993,SarCNU,81965-43-7,0.76,9.0,,1.4,1.0,"Panasci L, Stinson SF, Melnychuk D, Sandor V, Miller WH, Batist G, Patenaudr F, Bangash N, Panarello L, Alaoui-Jamali M, and Sausville E (2003) SarCNU, a nitosourea analog on a day 1, 5, and 9 oral schedule: a phase I and pharmacokinetic study in patients with advanced solid tumors.  J. Clin. Oncol. 21: 232-240.",VDss was calculated using C vs t data obtained by digitization of the plot provided in the reference.,,1982,222.63,7,1,96.1,5,neutral,-0.4,-0.4
CN(CCOc1ccc(CC2SC(=O)NC2=O)cc1)c3ccccn3,-0.6214883767462702,1.636041,Rosiglitazone,122320-73-4,0.2,0.65,0.002,5.1,3.9,"Cox PJ, Ryan DA, Hollis FJ, Harris AM, Miller AK, Vousden M, and Cowley H (2000) Absorption, disposition, and metabolism of rosiglitazone, a potent thiazolidinedione insulin sensitizer, in humans.  Drug Metab. Dispos. 28: 772-780.  Miller AK, DiCicco RA, and Freed MI (2002) The effect of ranitidine on the pharmacokinetics of rosiglitazone in healthy adult male volunteers.  Clin. Ther. 24: 1062-1071.  Avandia Product Label",,,1989,357.43,6,1,71.5,7,anionic,3.2,0.25
CN([C@@H]1CCCC[C@H]1N2CCCC2)C(=O)Cc3cccc4c3ccs4,1.584962500721156,3.1481898,RSD921,114419-77-1,1.1,3.0,,5.9,5.5,"Wellington Ribeiro, Demian R. Ifa, Gaetano Corso, John Salmon, Leonardo A. Moraes, Marcos N. Eberlin,  Gilberto de Nucci. Determination of RSD921 in human plasma by high-performance liquid chromatography–tandem mass spectrometry using tri-deuterated RSD921 as internal standard: application to a phase I clinical trial. J. Mass Spectrom. 2001; 36: 1133–1139","PD-123497. Digitized from plot reported but no comparative data offered.  NCA: AUCall (ng*h/mL) = 21.5, AUCinf (ng*h/mL) = 22.3",,1988,356.52,3,0,23.5,4,cationic,4.4,3.2
CN1C(=C(O)c2ccccc2S1(=O)=O)C(=O)Nc3cc(C)on3,-3.8365012677171206,0.08067337,Isoxicam,34552-84-6,0.19,0.07,0.035,44.0,33.0,"Kolle EU and Vollmer KO (1986) Pharmacokinetics of isoxicam following intravenous, intramuscular, oral and rectal administration in healthy volunteers.  Br. J. Clin. Pharmacol. 22(Suppl 2): 135S-141S.  Jolliet P, Simon N, Bree F, Urien S, Pagliara A, Carrupt PA, Testa B, and Tillement JP (1997) Blood-to-brain transfer of various oxicams: effects of plasma binding on their brain delivery.  Pharm. Res. 14: 650-656.",VDss calculated from C vs t data obtained by digitization of plots in the reference.,,1946,335.34,8,2,113.0,2,anionic,2.4,-0.77
CN1C(=C(O)c2ccccc2S1(=O)=O)C(=O)Nc3ncc(C)s3,-3.0588936890535687,0.370589,Meloxicam,71125-38-7,0.15,0.12,0.003,21.0,18.0,"Narjes H, Turck D, Busch U, Heinzel G, and Nehmiz G (1996) Pharmacokinetics and tolerability of meloxicam after i.m. administration.  Br. J. Clin. Pharmacol. 41: 135-139.  Busch U, Heinzel G, and Narjes H (1995) The effect of cholestyramine on the pharmaciokinetics of meloxicam, a new non-steroidal anti-inflammatory drug (NSAID), in man.  Eur. J. Clin. Pharmacol. 48: 269-272.   Turck D, Busch U, Heinzel G, and Narjes H (1997) Clinical pharmacokinetics of meloxicam.  Arz. Forsch. 47: 253-258. Schmid J, Busch U, Heinzel G, Bozler G, Kaschke S, and Kummer M (1995) Meloxicam. Pharmacokinetics and metabolic pattern after intravenous infusion and oral administration to healthy subjects. Drug Metab. Dispos. 23: 1206-1213.  Tuerck D, Schwarz A, Hoeffler D, Narjes HH, Nehmiz G, and Heinzel G (1996) Pharmacokinetics of meloxicam in patients with end-stage renal failure on hemodialysis. A comparison with healthy volunteers.  Eur. J. Clin. Pharmacol.  51: 309-313.",,,1979,351.4,7,2,99.6,2,anionic,2.6,-0.7
CN1C(=C(O)c2sccc2S1(=O)=O)C(=O)Nc3ccccn3,-5.058893689053568,0.48618758,Tenoxicam,59804-37-4,0.19,0.03,0.0085,92.0,67.0,"Heintz RC, Guentert TW, Enrico JF, Dubach UC, Brandt R, and Jeunet FS (1984) Pharmacokinetics of tenoxicam in healthy human volunteers. Eur. J. Rheum. Inflam. 7: 33-44.  Nilsen OG, Aasarod K, Wideroe TE, and Guentert TW (2001) Single- and multiple-dose pharmacokinetics, kidney tolerability and plasma protein binding of tenoxicam in renally impaired patients and healthy volunteers.  Pharmacol. Toxicol. 89: 265-272.","VDss calculated from reported micro rate constants in Heintz, et al..",,1975,337.37,7,2,99.6,2,anionic,2.5,-0.92
CN1C(=O)CN=C(c2ccccc2)c3cc(Cl)ccc13,-1.3959286763311392,1.5356994,Diazepam,439-14-5,1.0,0.38,0.023,44.0,42.0,"Klotz U, Avant GR, Hoyumpa A, Schenker S, and Wilkinson (1975) The effects of age and liver disease on the disposition and elimination of diazepam in adult man.  J. Clin. Invest. 55: 347-359.  Andersson T, Andren K, Cederberg C, Edvardsson G, Heggelund A, and Lundborg P (1990) Effect of omeprazole and cimetidine on plasma diazepam levels.  Eur. J. Clin. Pharmacol. 39: 51-54.  Herman RJ and Wilkinson GR (1996) Disposition of diazepam in young and elderky subjects after acute and chronic dosing.  Br. J. Clin. Pharmacol. 42: 147-155.  Lucek RW and Coutinho CB (1976) The role of substituents in the hydrophobic binding of the 1,4-benzodiazepines by human plasma proteins.    Molec. Pharmacol. 12:  612-619.  Desmond PV, Roberts RK, Wood AJJ, Dunn GD, Wilkinson GR, and Schenker S (1980) Effect of heparin administration on plasma binding of benzodiazepines.  Br. J. Clin. Pharmacol. 9: 171-175.",,,1961,284.74,3,0,32.7,1,neutral,2.8,2.8
CN1C(=O)CN=C(c2ccccc2F)c3cc(ccc13)N(=O)=O,0.4854268271702416,1.6859573,Flunitrazepam,1622-62-4,1.9,1.4,0.17,23.0,25.0,"Kangas L, Kanto J, and Pakkanen A (1982) A pharmacokinetic and pharmacodynamic study of flunitrazepam.  Int. J. Clin. Pharmacol. Ther. Toxicol.  20: 585-588.  Lucek RW and Coutinho CB (!976) The role of substituents in the hydrophobic binding of the 1,4-benzodiazepines by human plasma proteins.  Molec. Pharmacol. 12:  612-619.",VDss calculated from C vs t data obtained by digitization of the plot included in the reference.,,1963,313.28,6,0,78.5,2,neutral,2.1,2.1
CN1C(=O)N(C)c2[nH]cnc2C1=O,-0.2175914350726268,2.138231,Theophylline,58-55-9,0.51,0.86,0.61,9.9,7.2,"Kraan J, Borgstrom L, Koeter GH, Laseur M, Jonkman JHG, and deNoord OE (1988) Creation of four consecutive intantaneous steady-state plasma concentration plateaus of theophylline and enprofylline by repeated infusions with expoonentially decreasing delivery rates. Eur. J. Clin. Pharmacol. 35: 657-661.  Lee KJ, Mower R, Hollenbeck T, Castelo J, Johnson N, Gordon P, Sinko PJ, Holme K, and Lee YH (2003) Modulation of nonspecific binding in ultrafiltration protein binding studies.  Pharm. Res.  20: 1015-1021.  Lombardi TP, Bertino JS, Goldberg A, Middleton E, and Slaughter RL (1987) The effects of a beta-2 selective adrenergic agonist and a beta-nonselective antagonist on theophylline clearance.    J. Clin. Pharmacol. 27: 523-529.",,,1946,180.16,6,1,69.3,0,neutral,-0.22,-0.22
CN1C(=O)N(C)c2ncn(C)c2C1=O,0.4854268271702416,1.8475235,Caffeine,58-08-2,0.63,1.4,0.64,7.5,4.9,Blanchard J and Sawers SJA (1983) Comparative pharmacokinetics of caffeine in young and elderly men.  J. Pharmacokinet. Biopharm. 11: 109-126.,VDss was calculated from C vs t data obtained by digitization of the plot included in the reference.  ,,1968,194.19,6,0,58.4,0,neutral,0.078,0.078
CN1C(=O)N(CCCCC(=O)C)C(=O)c2c1ncn2C,5.285402218862249,2.068738,Pentoxifylline,6493-05-6,1.8,39.0,0.51,0.77,1.2,"Beermann B, Ings R, Mansby J, Chamberlain J, and McDonald A (1985) Kinetics of intravenous and oral pentoxifylline in healthy subjects.  Clin. Pharmacol. Ther. 37: 25-28.  Rames A, Poirier JM, LeCoz F, Midavaine M, Lecocq B, Grange JD, Poupon R, Cheymol G, and Jaillon P (1990) Pharmacokinetics of intravenous and oral pentoxifylline in healthy volunteers and in cirrhotic patients.  Clin. Pharmacol. Ther. 47: 354-359.   fu from Lombardo et al J. Clin. Pharmacol. 2013, 53(2), 167-177 and 178-191",Calculated VDss from C vs t data obtained by digitization of plots included in the references. ,,1959,278.31,7,0,75.5,5,neutral,0.65,0.65
CN1C2CCC1CC(=C3c4ccccc4CSc5c3cccc5)C2,2.316145742293356,4.4003267,Tropatepine,27574-24-9,11.85,4.98,,39.5,29.8,"Bun, H.; Monjanel-Mouterde, S.; Audebert, C.; Du Laurier, M. Vincent; Durand, A.; Cano, J. P. Pharmacokinetics of tropatepine in healthy volunteers. Clinical Drug Investigation, 1997, 14, 53-60.",Data digiztized from plot. 20 mg and N=8. 71.6 kg average weight. Reported AUC 1135 ug.h/L. Clearance 19 L/h. AUCinf 931 ug.h/L (extrapolation 16% due to high t1/2). Clearance calculated as 21.4 L/h (13% difference from reported).,,1970,333.49,1,0,3.2,0,cationic,5.5,3.9
CN1C=CNC1=S,1.8875252707415875,3.137025,Methimazole,60-56-0,0.86,3.7,,3.8,2.4,Hengstmann JH and Hohn H (1985) Pharmacokinetics of methimazole in humans.  Klin. Wochenschr. 63: 1212-1217.,,,1896,114.17,2,1,15.3,0,neutral,-0.12,-0.12
CN1CC(c2ccccc2)c3cccc(N)c3C1,4.459431618637297,2.8721576,Nomifensine,24526-64-5,6.0,22.0,0.4,4.5,6.5,"Lindberg RLP, Syvalahti EKG, and Pihlajamaki KK (1986) Disposition of nomifensine after acute and prolonged dosing.  Clin. Pharmacol. Ther. 39: 384-388.  Heptner W, Hornke I, Cavagna F, Fehlhaber HW, Rupp W, and Neubauer HP (1978) Metabolism of nomifensine in man and animal species.  Arz. Forsch. 28: 58-64",VDss calculated from data obtained by digitization of a plot in the reference. ,,1969,238.33,2,1,29.3,1,cationic,2.3,0.87
CN1CC[C@@H]([C@H](O)C1)c2c(O)cc(O)c3C(=O)C=C(Oc23)c4ccccc4Cl,2.608809242675524,0.6777656,Flavopiridol,146426-40-6,1.5,6.1,0.06,4.0,5.2,"Zhai S Sausville EA, Senderowicz AM, Ando Y, Headlee D, Messmann RA, Arbuck S, Murgo AJ, Melillo G, Fuse E, and Figg WD (2003) Clinical pharmacology and pharmacogenetics of flavopiridol 1-h i.v. infusion in patients with refractory neoplasms.  Anti-Cancer Drugs. 14: 125-135.  Rudek MA, Bauer KS, Lush RM, Stinson SF,  Senderowicz AM, Headlee DJ, Arbuck SG,  Cox MC, Murgo AJ, Sausville EA, and Figg WD (2003) Clinical pharmacology of flavopiridol following a 72-hour continuous infusion.  Ann. Pharmacother. 37: 1369-1374. ",,,1961,401.84,6,3,90.2,2,zwitterionic,3.6,2.4
CN1CC[C@]23c4c5ccc(c4O[C@H]2[C@H](CC[C@H]3[C@H]1C5)O)OC,2.0738202332916718,4.073283,Dihydrocodeine,125-28-0,1.07,4.21,,4.08,3.42,"F. J. Rowell, R. A. Seymour, and M. D. Rawlins. Pharmacokinetics of Intravenous and Oral Dihydrocodeine and its Acid Metabolites. Eur J Clin Pharmacol 1983, 25, 419-424.","Values calculated from A,B, alpha and beta constants reported for N=7 volunteers, 30 mg dose, average weight 70 kg. VDss calculated via V1 and k12,k21 as wellas MRT and clearance obtained via macroconstants. ",,1912,301.38,4,1,41.9,1,cationic,2.0,0.29
CN1CCc2cc3c(c(c2[C@@H]1[C@@H]4c5ccc(c(c5C(=O)O4)OC)OC)OC)OCO3,4.07724299893246,2.570275,Noscapine,128-62-1,2.3,16.88,,2.28,2.13,"B. Dahlström, T. Mellstrand , C.-G.  Löfdahl and M. Johansson. Pharmakokinetic Properties of Noscapine. Eur. J. Clin. Pharmacol. 1982, 22, 535-539.","(-)-Narcotine. N=5, 70 kg average weight reported, 66 mg dose. Data digitized from plot reported. AUCinf 18% higher than reported with AUC0-t calculated almost identical to reported. Data treated as bolus as no sampling during infusion was taken. Structure entered as lactone.",,1891,413.42,8,0,75.7,4,neutral,2.5,2.4
CN1N(C(=O)C=C1C)c2ccccc2,-0.6438561897747246,2.427027,Antipyrine,60-80-0,0.77,0.64,0.93,20.0,12.0,"Andreasen PB and Vesell ES (1974) Comparison of plasma levels of antipyrine, tolbutamide, and warfarin after oral and intravenous administration.  Clin. Pharmacol. Ther. 16: 1059-1065.  Danhof M, vanZuilen A, Boeijinga JK, and Breimer DD (1982) Studies of the different metabolic pathways of antipyrine in man.  Eur. J. Clin. Pharmacol.  21: 433-441.  Lee KJ, Mower R, Hollenbeck T, Castelo J, Johnson N, Gordon P, Sinko PJ, Holme K, and Lee YH (2003)  Modulation of nonspecific binding in ultrafiltration protein binding studies.  Pharm. Res. 20: 1015-1021.",Danhof reference not included for VDss (would require digitization); Andreason reference used a one-compartment model so VDc = VDss.,,1890,188.23,3,0,23.5,1,neutral,0.19,0.19
CN1[C@@H](CCC1=O)c2cccnc2,-0.1681227588083269,2.4996786,Cotinine,486-56-6,1.1,0.89,,21.0,17.0,"Scherer G, Jarczyk L, Heller WD, Biber A, Neurath GB, and Adlkofer F (1988) Pharmacokinetics of nicotine, cotinine, and 3'-hydroxycotinine in cigarette smokers.  Klin. Wochenschr. 66(Supp 11): 5-11.  Curvall M, Elwin CE, Kazemi-Vala E, Warholm C, and Enzell CR (1990) The pharmacokinetics of cotinine in plasma and saliva from non-smoking healthy volunteers.  Eur. J. Clin. Pharmacol. 38: 281-287. ",VDss calculated from C vs t data obtained by digitization of the plots provided in the references.,,1956,176.22,3,0,33.2,1,neutral,-0.33,-0.33
CN1[C@@H](C[C@@H](O)C1=O)c2cccnc2,0.84799690655495,2.2414615,"Hydroxycotinine, 3'-",34834-67-8,0.85,1.8,,7.9,5.9,"Scherer G, Jarczyk L, Heller WD, Biber A, Neurath GB, and Adlkofer F (1988) Pharmacokinetics of nicotine, cotinine, and 3'-hydroxycotinine in cigarette smokers.  Klin. Wochenschr. 66(Supp 11): 5-11.",VDss calculated from C vs t data obtained by digitization of the plot provided in the reference.,,1960,192.21,4,1,53.4,1,anionic,-1.5,-2.0
CN1[C@@H]2CC[C@H]1C[C@H](C2)OC(=O)C(CO)c3ccccc3,2.925999418556223,3.9733543,Atropine,51-55-8,3.3,7.6,0.61,7.2,4.1,"Adams RG, Verma P, Jackson AJ, and Miller RL (1982) Plasma pharmacokinetics of intravenously administered atropine in normal human subjects.  J. Clin. Pharmacol. 22: 477-481.  Kurz H, Mauser-Ganshorn A, and Stickel HH (1977) Differences in the binding of drugs to plasma proteins from newborn and adult man. I. Eur. J. Clin. Pharmacol. 11: 463-467.",,,1878,289.37,4,1,49.8,5,cationic,2.2,0.6
CN1[C@@H]2CC[C@H]1C[C@H](C2)OC(=O)c3c[nH]c4ccccc34,4.700439718141092,3.4257677,Tropisetron,89565-68-4,9.7,26.0,,6.3,5.6,"Kees F, Farber L, Bucher M, Mair G, Morike K, and Grobecker H (2001) Pharmacokinetics of therapeutic doses of tropisetron in healthy volunteers.    Br. J. Clin. Pharmacol. 52: 705-707.",,,1983,284.35,4,1,45.3,3,cationic,3.4,1.8
CNC(=O)c1c(I)c(NC(=O)C)c(I)c(C(=O)O)c1I,1.263034405833794,-0.2890613,Iothalamic acid (Iothalamate),2276-90-6,0.17,2.4,0.98,1.2,1.3,"Back SE, Krutzen E, and Nilsson-Ehle P (1988) Contrast media as markers for glomerular filtration: a pharmacokinetic comparison of four agents.  Scand. J. Clin. Lab Invest.  48: 247-253.  Bollerup AC, Hesse B, and Steiness E (1975) Renal handling of iodamide and diatrizoate.  Evidence of active tubular secretion of iodamide.  Eur. J. Clin. Pharmacol. 9: 63-67.",VDss calculated from C vs t data obtained by digitization of the plot provided in the reference.,,1964,613.91,6,3,95.5,3,anionic,1.4,-2.0
CNC1(CCCCC1=O)c2ccccc2Cl,4.247927513443585,2.58376,Ketamine,6740-88-1,2.9,19.0,0.47,2.5,2.8,"Geisslinger G, Hering W, Thomann P, Knoll R, Kamp HD, and Brune K (1993) Pharmacokinetics and pharmacodynamics of ketamine enantiomers in surgical patients using a stereoselective analytical method.  Br. J. Anaesth. 70: 666-671.  Pedraz JL, Lanao JM, Calvo MB, Muriel C, Hernandez-Arbeiza J, and Dominguez-Gil A (1987) Pharmacokinetic and clinical evaluation of ketamine administered by i.v. and epidural routes.  Int. J. Clin. Pharmacol. Ther. Toxicol. 25: 77-80.  Clements JA and Nimmo WS (1981) Pharmacokinetics and analgesic effect of ketamine in man.  Br. J. Anaesth. 53: 27-30.  Dayton PG, Stiller RL, Cook DR, and Perel JM (1983) The binding of ketamine to plasma proteins:  emphasis on human plasma.  Eur. J. Clin. Pharmacol. 24: 825-831.  Hijazi Y and Boulieu R (2002) Protein binding of ketamine and its active metabolites in human serum.  Eur. J. Clin. Pharmacol. 58: 37-40.",Racemate; data were combined.,,1963,237.73,2,1,29.1,2,cationic,2.6,2.2
CNC1=Nc2ccc(Cl)cc2C(=N(=O)C1)c3ccccc3,-1.434402824145775,1.4012959,Chlordiazepoxide,58-25-3,0.25,0.37,0.056,11.0,8.3,"Desmond PV, Patwardhan RV, Schenker S, and Hoyumpa AM (1980) Short-term ethanol administration impairs the elimination of chlordiazepoxide (Librium) in man.  Eur. J. Clin. Pharmacol. 18: 275-278.  Boxenbaum HG, Geitner KA, Dixon WR, Spiegel HE, Symington J, Christian R, Moore JD, Weissman L, and Kaplan SA (1977) Pharmacokinetic and biopharmaceutic profile of chlordiazepoxide HCl in healthy subjects: single-dose studies by the intravenous, intramuscular, and oral routes.  J. Pharmacokinet. Biopharm. 5: 3-23.  Desmond PV, Roberts, RK, Wood AJJ, Dunn GD, Wilkinson GR, Schenker S (1980) Effect of heparin administration on plasma binding of benzodiazepines.    Br. J. Clin. Pharmacol.  9: 171-175.  ",,,1955,299.75,4,1,53.1,2,neutral,1.4,1.4
CNS(=O)(=O)Cc1ccc2[nH]cc(CCN(C)C)c2c1,4.247927513443585,3.050969,Sumatriptan,103628-46-2,1.7,19.0,0.83,1.5,1.7,"Cosson VF, Fuseau E, Efthymiopoulos C, and Bye A (1997) Mixed effect modeling of sumatriptan pharmacokinetics during drug development.  I Interspecies allometric scaling.  J. Pharmacokinet. Biopharm. 25: 149-167.  Scott AK (1994) Sumatriptan clinical pharmacokinetics. Clin. Pharmacokinet. 27: 337-344.",,,1986,295.4,5,2,65.2,6,cationic,1.5,0.3
CN[C@@H](C)Cc1ccccc1,2.137503523749935,3.5851538,Methamphetamine,537-46-2,4.3,4.4,0.85,16.0,12.0,"Harris DS, Boxenbaum H, Everhart ET, Sequeira G, Mendelson JE, and Jones RT (2003) The bioavailability of intranasal and smoked methamphetamine.  Clin. Pharmacol. Ther. 74: 475-486.  Cook CE, Jeffcoat AR, Hill JM, Pugh DE,  Patetta PK, Sadler BM, White WR, and Perez-Reyes M (1993) Pharmacokinetics of methamphetamine self-administered to human subjects by smoking S-(+)-methamphetamine hydrochloride.  Drug Metab. Dispos. 21: 717-723.  Mendelson J, Jones RT, Upton R, and Jacob P (1995) Methamphetamine and ethanol interactions in humans.  Clin. Pharmacol. Ther. 57: 559-568.  De la Torre R, Farre M, Navarro M, Pacifici R, Zuccaro P, and Pichini S (2004) Clinical pharmacokinetics of amfetamine and related substances: monitoring in conventional and non-conventional matrices.  Clin. Pharmacokinet. 43: 157-185.",Values for individual stereoisomers were averaged.,,1919,149.23,1,1,12.0,3,cationic,2.1,-0.2
CN[C@@H]1C[C@H]2OC(C)([C@@H]1OC)n3c4ccccc4c5c6[C@@H](O)NC(=O)c6c7c8ccccc8n2c7c35,-8.0782590139205,1.0843313,"Hydroxystaurosporine, 7-",112953-11-4,0.15,0.0037,0.0022,680.0,790.0,"Fuse E, Tanii H, Kurata N, Kobayashi H, Shimada Y, Tamura T, Sasaki Y, Tanigawara Y, Lush RD, Headlee D, Figg WD, Arbuck SG, Senderowicz AM, Sausville EA, Akinaga S, Kuwabara T, and Kobayashi S (1998) Unpredicted clinical pharmacology of UCN-01 caused by specific binding to human alpha1-acid glycoprotein.  Canc. Res. 58: 3248-3253.  Dees EC, Baker SD, O'Reilly S, Rudek MA, Davidson SB, Aylesworth C, Elza-Brown K, Carducci MA, and Donehower RC (2005) A phase I and pharmacokinetic study of short infusions of UCN-01 in patients with refractory solid tumors.  Clin. Canc. Res.  11: 664-671.",UCN-01. Used data from 95 mg/m2 group.,,1987,482.53,8,3,89.7,2,cationic,2.5,-0.29
CN[C@@H]1[C@@H](O)[C@@H](O[C@H]2[C@H](N)C[C@H](N)[C@@H](O[C@H]3OC(=CC[C@H]3N)CN)[C@@H]2O)OC[C@]1(C)O,0.0,1.3452654,Sisomicin,32385-11-8,0.19,1.0,0.15,3.2,2.4,"Chung M, Schrogie JJ, and Symchowicz S (1981) Pharmacokinetic study of sisomicin in humans.  J. Pharmacokinet. Biopharm. 9: 535-551.  Lode H, Kemmerich B, and Koeppe P(1975)  Comparative clinical pharmacology of gentamicin, sisomicin, and tobramycin.  Antimic. Agents Chemother. 8: 396-401.  Pechere JC, Pechere MM, and Dugal R (1976) Clinical pharmacokinetics of sisomycin: two-compartment model analysis of serum data after I.V. and I.M. administration.  Eur. J. Clin. Pharmacol. 10: 251-256.  Ramirez-Ronda CH, Holmes RK, and Sanford JP (1975)  Effects of divalent cations on binding of aminoglycoside antibiotics to human serum proteins and to bacteria.  Antimic. Agents Chemother  7: 239-45. ",Siseptin. Rickamicin. Sch 13475,,1960,447.53,12,8,213.7,6,cationic,-4.5,-8.4
CN[C@@H]1[C@@H](O)[C@@H](O[C@H]2[C@H](N)C[C@H](N)[C@@H](O[C@H]3O[C@@H](CC[C@H]3N)[C@@H](C)N)[C@@H]2O)OC[C@]1(C)O,0.0,1.3249867,Gentamicin,1403-66-3,0.33,1.0,1.0,5.5,4.7,"Bertino JS, Booker LA, Franck P, and Rybicki B (1991) Gentamicin pharmacokinetics in patients with malignancies.  Antimic. Agents Chemother.  35: 1501-1503.  Gordon RC, Regamey C, and Kirby WMM (1972) Serum protein binding of the aminoglycoside antibiotics.  Antimic. Agents Chemother. 2: 214-216.",,,1963,463.57,12,8,213.7,6,cationic,-4.1,-7.1
CN[C@@H]1[C@H](O)[C@H](NC)[C@H]2O[C@]3(O)[C@@H](O[C@H](C)CC3=O)O[C@@H]2[C@H]1O,-0.014499569695115,1.2572277,Spectinomycin,1695-77-8,0.13,0.99,,2.2,1.8,"Wagner, JG, Novak, E, Leslie, LG, Metzler, CM (1968) Absorption, distribution and elimination of spectinomycin dihydrochloride in man.  Int. Zeit. Klin. Pharmakol. Ther. Toxikol. 1: 261-285. ",VDss calculated from C vs t data obtained by digitization of plots in the reference.,,1961,332.35,9,5,129.5,2,cationic,-2.9,-5.3
CN[C@H](CC(C)C)C(=O)N[C@@H]1[C@H](O)c2ccc(Oc3cc4cc(Oc5ccc(cc5Cl)[C@@H](O[C@H]6C[C@](C)(N)[C@@H](O)[C@H](C)O6)[C@@H]7NC(=O)[C@H](NC(=O)[C@@H]4NC(=O)[C@H](CC(=O)N)NC1=O)c8ccc(O)c(c8)c9c(O)cc(O)cc9[C@H](NC7=O)C(=O)O)c3O[C@@H]%10O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%10O[C@H]%11C[C@](C)(NCc%12ccc(cc%12)c%13ccc(Cl)cc%13)[C@@H](O)[C@H](C)O%11)c(Cl)c2,-3.8365012677171206,-0.45795834,Oritavancin,171099-57-3,0.3,0.07,0.13,67.2,96.2,"Gerald J. Fetterly, Christine M. Ong, Sujata M. Bhavnani,Jeffrey S. Loutit, Steven B. Porter, Lisa G. Morello, Paul G. Ambrose, and David P. Nicolau. Pharmacokinetics of Oritavancin in Plasma and Skin Blister Fluid following Administration of a 200-Milligram Dose for 3 Days or a Single 800-Milligram Dose. Antimicr. Agents Chemother. 2005, 49, 148-152.","Data digitized from plot (800 mg single dose) reported. N=8, 70 kg average weight assumed, AUC0-t calculated  essentially identical to reported value (2,284 ug.hr.mL-1 vs. 2,267 ug.hr.mL-1 , respectively). 90 minutes infusion.",,1995,1793.1,36,20,561.0,19,cationic,4.3,-0.82
CN[C@H]1C(=O)N[C@@H]2Cc3ccc(Oc4cc5cc(Oc6ccc(cc6Cl)[C@@H](O)[C@@H]7NC(=O)[C@H](NC(=O)[C@@H]5NC(=O)[C@@H](NC2=O)c8cc(Oc9cc1ccc9O)cc(O)c8Cl)c%10ccc(O)c(c%10)c%11c(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]%12O)cc(O)cc%11[C@H](NC7=O)C(=O)NCCCN(C)C)c4O[C@@H]%13O[C@@H]([C@@H](O)[C@H](O)[C@H]%13NC(=O)CCCCCCCCC(C)C)C(=O)O)cc3,-6.643856189774724,-1.2598258,Dalbavancin,171500-79-1,0.14,0.01,0.02,230.0,170.0,"Leighton A, Gottlieb AB, Dorr MB, Jabes D, Mosconi G, VanSaders C, Mroszczak EJ, Campbell KCM, and Kelly E (2004) Tolerability, pharmacokinetics, and serum bactericidal activity of intravenous dalbavancin in healthy volunteers.  Antimic. Agents Chemother. 48: 940-945.   Jabés D, Candiani G, Romanó G, Brunati C, Riva S, and Cavaleri M (2004) Efficacy of Dalbavancin against Methicillin-Resistant Staphylococcus aureus in the Rat Granuloma Pouch Infection Model.  Antimicrob. Agents Chemother. 48: 1118-1123.",,,1995,1816.69,38,21,572.5,22,zwitterionic,4.3,0.73
CN[C@H]1CN(C[C@@H]1OC)c2ccc3c(=O)c(cn(c3n2)c4nccs4)C(=O)O,-0.3400754415976217,0.8108387,Vosaroxin,175414-77-4,1.46,0.79,,30.6,25.5,"C.M. Nijenhuis, L. Lucas, H. Rosing, A.D.R. Huitema, M. Mergui-Roelvink, G. C. Jamieson., J.A. Fox, D.R. Mould, J.H.M. Schellens, J.H. Beijnen. Metabolismand disposition of the anticancer quinolone derivative vosaroxin, a novel inhibitor of topoisomerase II. Invest. New Drugs. DOI 10.1007/s10637-017-0428-1.","AG 7352. Voreloxin. SNS 595. N=6, 1.92 m2/73.6 kg as reported by authors using median weight and BSA. This is the factor that was used in the calculations. Dose 60 mg/m2.",,1995,401.44,9,2,109.6,5,zwitterionic,1.1,-0.23
CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@H]2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](NC(=N)N)[C@@H](O)[C@@H]3NC(=N)N)O[C@@H](C)[C@]2(O)C=O,-0.3584539709124763,1.4226341,Streptomycin,57-92-1,0.34,0.78,0.65,7.3,4.3,"Zhu M, Burman WJ, Jaresko GS, Berning SE, Jeliffe RW, and Peloquin CA (2001) Population pharmacokinetics of intravenous and intramuscular streptomycin in patients with tuberculosis.  Pharmacother. 21: 1037-1045.  Gordon RC, Regamey C, and Kirby WMM (1972) Serum protein binding of the aminoglycoside antibiotics.  Antimic. Agents Chemother. 2: 214-216.",,Seemingly biliary but not clear from EMA package.,1964,581.57,19,14,331.4,11,cationic,-7.8,-9.0
CO/N=C/1\CN(CC1CN)c2c(cc3c(=O)c(cn(c3n2)C4CC4)C(=O)O)F,2.84799690655495,1.0078421,Gemifloxacin ,175463-14-6,3.52,7.2,0.3,8.1,8.3,"PP. Gemifloxacin Mesylate - FDA Approval Package
Microbiology Review 021158/S-000 Part 07. Table 8.","N=23, 250 mg dose, 70 kg assumed. MRT from VDss and Cl.  ppb from label.",,1995,389.38,9,2,123.0,5,zwitterionic,1.7,-0.26
COC(=O)C1=C(C)NC(=C(C1c2cccc3nonc23)C(=O)OC(C)C)C,4.700439718141092,2.3249779,Isradipine,75695-93-1,1.5,26.0,0.04,1.0,3.3,"Christensen HR, Antonsen K, Simonsen K, Lindekar A, Bonde J, Angelo HR, and Kampmann JP (2000) Bioavailability and pharmacokinetics of isradipine after oral and intravenous administration: half-life shorter than expected?  Pharmacol. Toxicol. 86: 178-182.  Kirsten R, Nelson K, Kirsten D, and Heintz B (1988) Clinical  pharmacokinetics  of vasodilators. Part I.  Clin. Pharmacokinet. 34: 457-482.  ",VDss was calculated from C vs t data obtained by digitization of the plot provided in the reference.,,1980,371.39,8,1,103.8,6,neutral,3.0,3.0
COC(=O)C1=C(C)NC(=C(C1c2ccccc2N(=O)=O)C(=O)OCC(C)C)C,3.906890595608519,2.684902,Nisoldipine,63675-72-9,5.5,15.0,0.003,6.5,11.0,"van Harten J, van Brummelen P, Lodewijks MTM, Danhof M, Breimer DD (1988) Pharmacokinetics and hemodynamic effects of nisoldipine and its interaction with cimetidine.  Clin. Pharmacol. Ther. 43: 332-341.  van Harten J, van Brummelen P, Wilson JHP, Lodewijks MTM, and Breimer DD (1988) Nisoldipine: kinetics and effects on blood pressure and heart rate in patients with liver cirrhosis after intravenous and oral administration.  Eur. J. Clin. Pharmacol. 34: 387-394.  ",,,1977,388.41,8,1,110.4,8,neutral,3.7,3.7
COC(=O)CCc1ccc(OCC(O)CNC(C)C)cc1,8.179909090014934,3.5528414,Esmolol,81147-92-4,1.2,290.0,0.59,0.07,0.15,"Sum CY, Yacobi A, Kartzinel R, Stampfli H, Davis CS, and Lai CM (1983) Kinetics of esmolol, an ultra-short-acting beta blocker, and of its major metabolite. Clin. Pharmacol. Ther. 34: 427-434.  Okamura M, Kumagai M, Murasaki Y, Ohkura T, Miyamoto Y, Kawai Y, Tamura T, Takariki Y, and Tomisawa H (2001) Stereoselective pharmacokinetics of esmolol enantiomers.  Yakubutsu Dotai 16: 427-435.",,,1981,295.37,5,2,67.8,10,cationic,2.0,0.18
COC(=O)Nc1nc2cc(ccc2[nH]1)C(=O)c3ccccc3,3.906890595608519,1.9508464,Mebendazole,31431-39-7,1.2,15.0,0.0859999999999999,1.3,1.1,"Dawson M, Braithwaite PA, Roberts MS, Watson TR (1985) The pharmacokinetics and bioavailability of a tracer dose of [3H]-mebendazole in man.  Br. J. Clin. Pharmacol. 19: 79-86.",,,1946,295.29,6,2,84.1,4,neutral,3.0,-0.42
COC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]3(C)[C@@H]2[C@H](OC(=O)c4ccccc4)[C@]5(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)c6ccccc6)c7ccccc7)C(=C([C@@H](OC(=O)C)C3=O)C5(C)C)C,3.104336659814736,1.3989147,"Desacetylpaclitaxel, 4-; 4-methyl carbonate",172481-83-3,6.9,8.6,,13.0,31.0,"du Bois A, Jung B, Loehr A, Schaller-Kranz T, Cohen M, Frickhofen N (2006) A phase I and pharmacokinetic study of novel taxane BMS-188797 and cisplatin in patients with advanced solid tumours.  Br. J. Cancer. 94: 79-84.", BMS-188797,,1995,869.91,16,4,230.5,15,neutral,2.3,2.3
COC(=O)[C@H](c1ccccc1Cl)N2CCc3c(ccs3)C2,4.563768278452033,2.4975576,Clopidogrel,113665-84-2,2.01,23.65,0.02,1.42,5.06,"Daniel J Cushing, Paul F Souney, Warren D Cooper Gerald L Mosher,Michael P Adams, Stephen Machatha, Bing Zhang and Peter R Kowey. Pharmacokinetics and platelet aggregation inhibitory effects of a novel intravenous formulation of clopidogrel in humans. Clin. Exp. Pharmacol. Physiol. 2012 39, 3–8.//ppb: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020839s044lbl.pdf. Accessed May 8 2017.","Data digitized from plot reported. N=24, 300 mg dose, highly linear pharmacokinetics (AUC) from 0.1 to 300 mg. Average weight 75.6 kg.",,1988,321.82,3,0,29.5,4,neutral,3.3,3.3
COC(=O)[C@H]1[C@H](C[C@@H]2CC[C@H]1N2C)OC(=O)c3ccccc3,5.0,3.4523616,Cocaine,50-36-2,2.0,32.0,0.12,1.0,0.76,"Chow MJ, Ambre JJ, Ruo TI, Atkinson AJ, Bowsher DJ, and Fischman MW (1985) Kinetics of cocaine distribution, elimination, and chronotropic effects. Clin. Pharmacol. Ther. 38: 318-324.  Javaid JI, Musa MN, Fischman M, Schuster CR, and Davis JM (1983) Kinetics of cocaine in humans after intravenous and intranasal administration.  Biopharm. Drug Dispos. 4: 9-18.  Edwards DJ and Bowles SK (1988) Protein binding of cocaine in human serum.  Pharm. Res.  5: 440-442.  Parker, Robert B.; Williams, Cheri L.; Laizure, S. Casey; Lima, John J.  Factors affecting serum protein binding of cocaine in humans.    Journal of Pharmacology and Experimental Therapeutics  (1995),  275(2),  605-10.","Paper by Javaid, et al. reported one compartment kinetics so VDss = C0/Dose. ",,1976,303.35,5,0,55.8,5,cationic,2.8,1.9
COCCOC(=O)C1=C(C)NC(=C(C1c2cccc(c2)N(=O)=O)C(=O)OC(C)C)C,3.906890595608519,2.2479174,Nimodipine,66085-59-4,1.1,15.0,0.016,1.2,1.3,"Muck W, Breuel HP, and Kuhlmann J (1996) The influence of age on the pharmacokinetics of nimodipine.  Int. J. Clin. Pharmacol. Ther. 34: 293-298.  Ramsch KD, Graefe KH, Scherline D, Sommer J, and Ziegler R (1986) Pharmacokinetics and metabolism of calcium-blocking agents nifedipine, nitrendipine, and nimodipine.  Am. J. Nephrol. 6(Suppl 1): 73-80.    Hynymen M, Siltanen T, Sahlman A, Pohjasvaara T, Muck W, and Kaste M (1995) Continuous infusion of nimodipine during coronary artery surgery: hemodynamics and pharmacokinetic study.  Br. J. Anaesth.  74: 526-533.",,,1949,418.44,9,1,119.7,10,neutral,3.2,3.2
COCc1c(nc(C(C)C)c(\C=C\[C@@H](O)C[C@@H](O)CC(=O)O)c1c2ccc(F)cc2)C(C)C,1.5360529002402097,0.2618438,Cerivastatin,145599-86-6,0.33,2.9,0.01,1.8,1.8,"Muck W, Ritter W, Ochmann K, Unger S, Ahr G, Wingender W, and Kuhlmann J (1997) Absolute and relative bioavailability of the HMG-CoA reductase inhibitor cerivastatin. Int. J. Clin. Pharmacol. Ther. 35: 255-260.  Baycol Product Label.",,,1994,459.55,6,3,99.9,11,anionic,4.3,1.1
CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(/C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(/C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N4CCCC[C@H]4C(=O)O2)OC)CC[C@@H]1n5cnnn5,-0.5777669993169522,0.67354155,Zotarolimus,221877-54-9,1.3,0.67,0.26,33.0,35.0,"Palaparthy R, Pradhan R, Chan J, Wang Q, Ji Q, Achari R, Chira T, Schwartz LB, O'Dea R (2005) Pharmacokinetics and safety of ABT-578, a sirolimus (rapamycin) analogue, after single intravenous bolus injection in healthy male volunteers.  Clin. Drug. Invest. 25: 491-498.//ppb: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022334s6lbl.pdf.Accessed May 28 2017.",,,1999,966.21,17,2,218.8,7,neutral,5.4,5.4
CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(/C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(/C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N4CCCC[C@H]4C(=O)O2)OC)CC[C@H]1OC(=O)C(C)(CO)CO,2.944858445807539,0.6779053,Temsirolimus,162635-04-3,3.0,7.7,,10.0,18.0,"Raymond E, Alexandre J, Faivre S, Vera K, Materman E, Boni J, Leister C, Korth-Bradley J, Hanauske A, and Armand JP (2004) Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer.  J. Clin. Oncol. 12: 2336-2347.",CCI-779. Additional information indicating strong DDI with CYP3A4. Suggestive of metabolic pathway. However no definitive quantitative data could be found.,,1994,1030.29,17,4,242.0,11,neutral,5.6,5.6
CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C)c(O)c4c(O)c(NC(=O)\C(=C\C=C\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(=O)C)[C@@H]1C)\C)c(\C=N\N5CCN(C)CC5)c(O)c4c3C2=O,1.807354922057604,0.4905488,Rifampin,13292-46-1,0.97,3.5,0.2,4.6,3.8,"Houin G, Beucler A, Richelet S, Brioude R, Lafaix C, and Tillement JP (1983) Pharmacokinetics of rifampicin and desacetylrifampicin in tuberculosis patients after different rates of infusion.  Ther. Drug Monit. 5: 67-72.","One compartment model described, so VD was assumed as VDss.",,1965,822.94,16,6,220.1,5,anionic,4.6,1.7
CO[C@]1(NC(=O)C2SC(=C(C(=O)N)C(=O)O)S2)[C@H]3SCC(=C(N3C1=O)C(=O)O)CSc4nnnn4C,-1.2515387669959646,0.4754864,Cefotetan,69712-56-7,0.13,0.42,0.15,5.2,4.5,"Zimmerman J, Cohen A, and Thyrum P (1989)  Absolute bioavailability and noncompartmental analysis of intravenous and intramuscular Cefotan (cefotetan) in normal volunteers.  J. Clin. Pharmacol. 29: 151-157.  Carver PL, Nightingale CH, and Quintiliani R (1989) Pharmacokinetics and pharmacodynamics of total and unbound cefoxitin and cefotetan in healthy volunteers.    J. Antimic. Chemother. 23:  99-106.",,,1977,575.62,15,4,219.9,9,anionic,-1.8,-7.1
CO[C@]12CC[C@@]3(C[C@@H]1[C@](C)(O)C(C)(C)C)[C@H]4Cc5ccc(O)c6O[C@@H]2[C@]3(CCN4CC7CC7)c56,4.247927513443585,2.889603,Buprenorphine,52485-79-7,4.9,19.0,0.04,4.9,3.2,"Kuhlman JJ, Lalani S, Magluilo, J, Levine B, Darwin WD, Johnson RE, and Cone EJ (1996) Human pharmacokinetics of intravenous, sublingual and buccal buprenorphine.  J. Anal. Toxicol. 20: 369-378.   Elkader A and Sproule B (2005)  Buprenorphine: clinical pharmacokinetics in the treatment of opioid dependence.  Clin. pharmacokinet. 44: 661-680.",,,1968,467.64,5,2,62.2,4,cationic,4.4,3.1
CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(=C(N2C1=O)C(=O)O)COC(=O)C)\c3csc(N)n3,1.4329594072761065,0.13943306,Cefotaxime,63527-52-6,0.19,2.7,0.6,1.2,1.2,"Wise R, Baker S, and Livingston R (1980) Comparison of cefotaxime and moxalactam pharmacokinetics and tissue levels.  Antimic. Agents Chemother.  18: 369-371.  Esmieu F, Guilbert J, Rosenkilde HC, Ho I, LeGo A (1980) Pharmacokinetics of cefotaxime in normal human volunteers.  J. Antimic. Chemother.  6(suppl A): 83-92.","VDss calculated from C vs t data provided in the reference. fu reported as 0.3 by Hamada T, Ueta E, Kodama H, Osaki T. The excretion of cephem antibiotics into saliva is inversely associated with their plasma protein-binding activities. J Oral Pathol Med. 2002, 31, 109-116.",,1957,455.47,12,3,173.5,8,anionic,-0.053,-3.1
COc1c(N2C[C@@H]3CCCN[C@@H]3C2)c(F)cc4C(=O)C(=CN(C5CC5)c14)C(=O)O,1.263034405833794,0.18242401,Moxifloxacin,151096-09-2,1.4,2.4,0.6,9.7,8.2,Avelox IV Product Label. PDR accessed July 31 2014. http://www.pdr3d.com/detail.php?c=49480#section-15,VDss calculated using C vs t data obtained by digitization of the plot provided in the label.,,1993,401.43,7,2,82.1,4,zwitterionic,2.4,-0.36
COc1c2c(ccc(=O)o2)cc3c1occ3,3.584962500721156,1.9085294,"Methoxypsoralen,8-",298-81-7,0.61,12.0,0.09,0.88,,"Billard, Valerie; Gambus, Pedrol L.; Barr, Juliana; Minto, Charles F.; Corash, Laurence; Tessman, John W.; Stickney, Janice L.; Shafer, Steven L. The pharmacokinetics of 8-methoxypsoralen following i.v. administration in humans Br. J. Clin. Pharmacol. 1995, 40, 347-360.","8-MOP. Oxsoralen. 9-Methoxy-7H-furo(3,2-g)(1)benzopyran-7-one. N=18, 79.8 kg average weight. Data averaged across all subjets and 3 doses, 5, 10 and 15 mg by authors.no t 1/2 reported. Ppb taken from reference cited in this work.",,1911,216.19,4,0,53.2,1,neutral,2.1,2.1
COc1cc(Cc2cnc(N)nc2N)cc(OC)c1OC,1.070389327891398,2.6408558,Trimethoprim,738-70-5,1.5,2.1,0.5,12.0,9.6,"Mannisto PT, Mantyla R, Mattila J, Nykanen S, and Lamminsivu U (1982) Comparison of pharmacokinetics of sulphadiazine and sulphamethoxazole after intravenous infusion.  J. Antimic. Chemother.  9: 461-470.   Dudley MN, Levitz RE, Quintiliani R, Hickingbotham JM, and Nightingale CH (1984) Pharmacokinetics of trimethoprim and sulfamethoxazole in serum and cerebrospinal fluid of adult patients with normal meninges.  Antimic. Agents Chemother. 26: 811-814.  Wijkstroem A and Westerlund D (1983) Plasma protein binding of sulfadiazine, sulfamethoxazole and trimethoprim determined by ultrafiltration.  J. Pharm. Biomed. Anal. 1:  293-299.",VDss calculated from C vs t data obtained by digitization of the plot showing the 200 mg dose.,,1959,290.32,7,2,105.5,5,neutral,1.1,0.94
COc1cc(NCc2ccc3nc(N)nc(N)c3c2C)cc(OC)c1OC,-0.3770696490798233,1.6189094,Trimetrexate,52128-35-5,0.77,0.77,0.05,17.0,17.0,"Neutrexin (trimetexate glucuronate) Product Label. PDR, accessed July 28 2014. http://www.pdr3d.com/detail.php?c=1000",,,1975,369.42,8,3,117.5,6,neutral,2.4,2.3
COc1cc(cc(OC)c1O)C2C3C(COC3=O)C(OC4OC5COC(C)OC5C(O)C4N(C)C)c6cc7OCOc7cc26,-1.3219280948873622,0.6764684,NK 611,105760-98-3,0.3,0.4,0.0129999999999999,17.0,14.0,"Mross K, Huettmann A, Herbst K, Hanauske AR, Schilling T, Manegold C, Burk K, and Hossfeld DK (1996) Pharmacokinetics and pharmacodynamics of the new podophyllotoxin derivative NK 611: A study by the AIO groups PHASE-I and APOH. Cancer Chemother. Pharmacol. 38: 217-224. Rassmann I., Thodtmann R, Mross M, Huttmann A, Berdel WE, Manegold C, Fiebig HH, Kaeser-Frohlich A, Burk K, and Hanauske AR (1999) Phase I clinical and pharmacokinetic trial of the podophyllotoxin derivative NK611 administered as intravenous short infusion.  Invest. New Drugs 16: 319-324.",CAS number used refers to the HCl salt. CAS number of parent 105655-99-0,,1986,615.63,13,2,143.8,6,neutral,0.23,0.21
COc1cc(cc(OC)c1O)[C@H]2[C@@H]3[C@H](COC3=O)[C@H](O[C@@H]4O[C@@H]5CO[C@@H](C)O[C@H]5[C@H](O)[C@H]4O)c6cc7OCOc7cc26,-1.0,0.43899432,Etoposide,33419-42-0,0.18,0.5,0.12,6.0,5.7,"Pfluger KH, Schmidt L, Merkel M, Jungelas H, and Havemann K (1987) Drug monitoring of etoposide (VP16-213).  Canc. Chemother. Pharmacol. 20: 59-66.  Kaul S, Igwemezie LN, Stewart DJ, Fields SZ, Kosty M, Levithan N, Bukowski R, Gandara D, Goss G, et al. (1995) Pharmacokinetics and bioequivalence of etoposide following intravenous administration of etoposide phosphate and etoposide in patients with solid tumors.  J. Clin. Oncol. 13: 2835-2841.  Lee, KJ, Mower R, Hollenbeck T, Castelo J, Johnson N, Gordon P, Sinko PJ, Holme K, and Lee YH (2003) Modulation of nonspecific binding in ultrafiltration protein binding studies.   Pharm. Res. 20: 1015-1021.",,,1946,588.56,13,3,160.8,5,neutral,-0.43,-0.43
COc1cc(cc(OC)c1O)[C@H]2[C@@H]3[C@H](COC3=O)[C@H](O[C@@H]4O[C@@H]5CO[C@H](O[C@H]5[C@H](O)[C@H]4O)c6cccs6)c7cc8OCOc8cc27,-2.395928676331139,0.5894884,Teniposide,29767-20-2,0.41,0.19,0.0044,37.0,16.0,"Holthuis JJM, de Vries LGE, Postmus PE, van Oort WWJ, Verleun H, Hulshoff A, Sleijfer DT, and Mulder NH (1987) Pharmacokinetics of high-dose teniposide. Canc. Treatm. Rep. 71: 599-603.  Petros WP, Rodman JH, Relling MV, Christensen M, Pui CH, Rivera GK, and Evans WE (1992) Variability in teniposide plasma protein binding is correlated with serum albumin concentrations.  Pharmacother. 12: 273-277.",,,1953,656.65,13,3,160.8,6,neutral,0.15,0.15
COc1cc2CCN(Cc2cc1OC)c3cc(N)c4cc(OC)c(OC)cc4n3,3.807354922057604,1.6953404,Abanoquil,90402-40-7,6.3,14.0,,7.6,5.9,"Schafers RF, Elliott HL, Meredith PA, Miller SHK, and Reid JL (1991) Studies with abanoquil (UK-52,046) a novel quinoline α1-adrenoceptor antagonist:  II.  Duration of action, pharmacokinetics and concentration-effect relationships in normotensive subjects.  Br. J. Clin. Pharmacol. 32: 605-610.",,,1984,395.45,7,1,79.1,5,cationic,3.5,1.2
COc1cc2CC[N+](C)(CCCOC(=O)CC\C=C\CCC(=O)OCCC[N+]3(C)CCc4cc(OC)c(OC)cc4C3Cc5cc(OC)c(OC)c(OC)c5)C(Cc6cc(OC)c(OC)c(OC)c6)c2cc1OC,2.37851162325373,1.3706682,Mivacurium (cis/cis),106791-40-6,0.27,5.2,0.7,0.87,0.83,"Head-Rapson AG, Devlin JC, Parker CJ, Hunter JM (1994) Pharmacokinetics of the three isomers of mivacurium and pharmacodynamics of the chiral mixture in hepatic cirrhosis. Br J Anaesth.  73: 613-618.  Roy JJ and Varin F (2004) Physicochemical properties of neuromuscular blocking agents and their impact on the pharmacokinetic-pharmacodynamic relationship.  Br. J. Anaesth. 93: 241-248.",,,1986,1029.26,16,0,144.9,30,neutral,2.3,2.3
COc1cc2c(CCN[C@]23CS[C@H]4[C@H]5[C@@H]6N(C)[C@@H](Cc7cc(C)c(OC)c(O)c67)[C@H](O)N5[C@@H](COC3=O)c8c9OCOc9c(C)c(OC(=O)C)c48)cc1O,3.584962500721156,2.0651503,Trabectedin,114899-77-3,25.0,12.0,0.06,35.0,44.0,"Lau L, Supko JG, Blaney S, Harshon L, Seibel N, Krailo M, Qu W, Malkin D, Jimeno J, Bernstein M, and Baruchel S (2005) A phase I and pharmacokinetic study of ecteinascidin-743 (Yondelis) in children with refractory solid tumors.  A children's oncology group study.  Clin. Canc. Res.  11: 672-677. ppb: Jan Handrick Beumer, L. Lopez-Lazaro, Jan H.M. Schellens, Jos H. Beijnen, Olaf van Tellingen. Evaluation of Human Plasma Protein Binding of Trabectedin (Yondelis™,ET-743). Current Clinical Pharmacology, 2009, 4, 38-42",Note: Pharmacokinetic data were determined in children.,,1987,761.84,14,4,168.7,4,cationic,1.8,1.2
COc1cc2c(N)nc(nc2c(OC)c1OC)N3CCN(CC3)C(=O)OCC(C)(C)O,-0.0588936890535685,1.4172815,Trimazosin,35795-16-5,0.18,0.96,,3.1,3.1,"Meredith PA, Elliott HL, Kelman AW, and Reid JL (1985) Application of pharmacokinetic-pharmacodynamic modelling for the comparison of quinazoline alpha-adrenoreceptor agonists in normotensive volunteers.  J. Cardiovasc. Pharmacol. 7: 532-537.",,,1971,435.47,11,2,132.5,6,neutral,1.7,1.6
COc1cc2nc(nc(N)c2cc1OC)N3CCN(CC3)C(=O)C4CCCO4,0.137503523749935,1.7996666,Terazosin,63590-64-7,0.98,1.1,0.08,15.0,9.0,Patterson SE (1985) Terazosin kinetics after oral and intravenous doses.  Clin. Pharmacol. Ther. 38: 423-427.  Sonders RC (1986) Pharmacokinetics of terazosin.  Am. J. Med. 80: 20-24.,VDss calculated from reported micro rate constants.,,1977,387.43,9,1,103.0,4,neutral,2.0,1.9
COc1cc2nc(nc(N)c2cc1OC)N3CCN(CC3)C(=O)C4COc5ccccc5O4,0.6780719051126377,2.160562,Doxazosin,74191-85-8,1.3,1.6,0.017,14.0,10.0,"Meredith PA, Elliott HL, Kelman AW, and Reid JL (1985) Application of pharmacokinetic-pharmacodynamic modelling for the comparison of quinazoline alpha-adrenoreceptor agonists in normotensive volunteers.  J. Cardiovasc. Pharmacol. 7: 532-537.  Vincent J, Meredith PA, Elliott HL, and Reid JL (1986) The pharmacokinetics of doxazosin in elderly normotensives.  Br. J. Clin. Pharmacol. 21: 521-524.  Kaye B, Cussans NJ Faulkner JK, Stopher DA, and Reid JL (1986) The metabolism and kinetics of doxazosin in man, mouse, rat and dog.    Br. J. Clin. Pharmacol. 21(Suppl. 1): 19S-25S.",,,1979,451.48,10,1,112.3,4,neutral,2.6,2.6
COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN4CCOCC4,3.584962500721156,1.7717818,Gefitinib,184475-35-2,23.0,12.0,0.0889999999999999,32.0,34.0,"Swaisland, HC, Smith RP, Laight A, Kerr DJ, Ranson M, Wilder-Smith CH, and Duvauchelle T (2005) Single-dose clinical pharmacokinetics studies of gefitinib.  Clin. Pharmacokinet. 44: 1165-1177.  McKillop D, Hutchison M, Partridge EA, Bushby N, Cooper CMF, Clarkson-Jones JA, Herron W, and Swaisland HC (2004) Metabolic disposition of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, in rat, dog and man.  Xenobiotica 34: 917-934",,,1986,446.9,7,1,68.7,8,cationic,4.3,3.9
COc1ccc(CCNCC(O)COc2cccc(C)c2)cc1OC,2.4594316186372973,3.9800878,Bevantolol,59170-23-9,0.67,5.5,0.0149999999999999,2.0,1.9,"McNeil JJ, Drummer OH, Anderson AIE, and Louis WJ (1986) Pharmacokinetics and concentration-effect relationships of bevantolol (CI-775) in normal volunteers.  J. Cardiovasc. Pharmacol. 8: 1201-1207.  Ichikawa M, Haruki S, Esumi Y, Takaichi M, Seki H, and Shiina M (1992) Metabolic fate of bevantolol hydrochloride.  Absorption, distribution and excretion in rats and dogs after single oral administration.  Yakuri to Chiryo 20: 1695-1708. ",VDss calculated from reported microconstants.,,1976,345.43,5,2,59.9,10,cationic,2.9,1.9
COc1ccc(CN(CCC(=O)O)C(=O)CNC(=O)Cc2ccc(NC(=O)Nc3ccccc3C)c(OC)c2)cc1OC,3.4594316186372973,1.1352162,IVL745,229627-58-1,0.25,11.0,,0.38,1.6,"Rohatagi S, Shah B, Zhang J, Zeng Z, Kirkesseli S, and Jensen BK (2004) Estimating mass balance for inhaled drugs in humans: An example with a VLA-4 antagonist, IVL745.  J. Clin. Pharmacol. 44: 348-358.",,,1999,592.64,12,4,155.5,14,anionic,2.7,-0.014
COc1ccc(Cl)cc1[C@]2(F)C(=O)Nc3cc(ccc23)C(F)(F)F,3.906890595608519,1.9435695,Maxipost,187523-35-9,10.0,15.0,0.0038,11.0,37.0,"Zhang D, Krishna R, Wang L, Zeng J, Mitroka J, Dai R, Narasimhan N, Reeves RA, Srinivas NR, and Klunk LJ (2005) Metabolism, pharmacokinetics, and protein covalent binding of radiolabeled maxipost (BMS-204352) in humans.  Drug Metab. Dispos. 33: 83-93.  Krishna R, Yao M, Kaczor D, Vachharajani N, and Srinivas NR. (2001) In vitro protein binding studies with BMS-204352: lack of protein binding displacement interaction in human serum.  Biopharm. Drug Dispos. 22: 41-44.",Flindokalner. BMS-204352,,1997,359.7,3,1,38.3,2,anionic,4.1,2.5
COc1ccc(cc1)C(CN(C)C)C2(O)CCCCC2,3.807354922057604,2.783803,Venlafaxine,93413-69-5,4.4,14.0,0.73,5.2,5.0,"Patat A, Troy S, Burke J, Trocherie S, Danjou P, LeCoz F, Allain H, and Gandon JM (1998) Absolute bioavailability and electroencephalographic effects of conventional and extended-release formulations of venlafaxine in healthy subjects.  J. Clin. Pharmacol. 38: 256-267.  Effexor Product Label.",,,1984,277.4,3,1,32.7,5,cationic,3.4,1.4
COc1ccc(cc1)c2nc3cc(ccc3[nH]2)C4=NNC(=O)CC4C,3.807354922057604,2.2610586,Pimobendan,74150-27-9,2.0,14.0,0.024,2.2,1.8,"Chu KM, Shieh SM, and Hu OYP (1995) Plasma and red blood cell pharmacokinetics of pimobendan enantiomers in healthy Chinese.  Eur. J. Clin. Pharmacol. 47: 537-542. ",Data from enantiomers averaged.,,1980,334.37,6,2,79.4,3,neutral,3.1,3.1
COc1ccc(cc1OC2CCCC2)[C@@]3(CC[C@H](CC3)C(=O)O)C#N,-1.0,1.5157831,Cilomilast,153259-65-5,0.23,0.5,0.006,8.5,7.9,"Zussman BD, Davie CC, Kelly J, Murdoch RD, Clark DJ, Schofield JP, Walls C, Birrell C, Webber D, Quinlan J, Ritchie SY, and Carr A (2001)  Bioavailability of the oral selective phosphodiesterase 4 inhibitor cilomilast.  Pharmacother. 21: 653-660.  Down G, Siederer S, Lim S, and Daley-Yates P (2006) Clinical pharmacology of cilomilast.  Clin. Pharmacokinet. 45: 217-233.",,,1993,343.42,5,1,79.6,6,anionic,3.6,0.89
COc1ccc2C[C@@H]3c4c(CC[N+]3(C)C)cc(OC)c(OC)c4Oc5ccc(C[C@H]6c7cc(Oc1c2)c(OC)cc7CC[N+]6(C)C)cc5,0.2630344058337938,1.3169017,Metocurine,5152-30-7,0.4,1.2,0.65,5.6,5.1,"Brotherton WP and Matteo RS (1981) Pharmacokinetics and pharmacodynamics of metocurine in humans with and without renal failure.  Anesthesiology 55: 273-276.  Avram MJ, Shanks CA, Henthorn TK, Ronai AK, Kinzer J, and Wilkinson CJ (1987) Metocurine kinetics in patients undergoing operations requiring cardiopulmonary bypass.  Clin. Pharmacl. Ther. 42: 576-581.",VDss calculated from micro rate constants provided in the reference.,,1950,652.82,8,0,55.4,4,neutral,2.3,2.3
COc1ccc2C[C@H]3N(C)CC[C@@]45[C@@H](Oc1c24)C(=O)CC[C@@]35O,2.608809242675524,4.0410237,Oxycodone,76-42-6,2.5,6.1,0.55,6.8,5.5,"Leow KP, Smith MT, Watt JA, Williams BE, and Cramond T (1992) Comparative oxycodone pharmacokinetics in humans after intravenous, oral, and rectal administration.  Ther. Drug Monit. 14: 479-484.  Leow KP, Wright AWE, Cramond T, and Smith MT (1993) Determination of the serum protein binding of oxycodone and morphine using ultrafiltration.  Ther. Drug Monit. 15: 440-447. ",,,1914,315.36,5,1,59.0,1,cationic,0.72,0.17
COc1ccc2c(c1)c(CC(=O)O)c(C)n2C(=O)c3ccc(Cl)cc3,0.3785116232537298,1.4864016,Indomethacin,53-86-1,0.096,1.3,0.01,1.2,1.4,"Yeh KC, Berger ET, Breault GO, and Lei BE (1982) Effect of sustained release on the pharmacokinetic profile of indomethacin in man.  Biopharm. Drug Dispos. 3: 219-230.  Indocin Product Label.",CL and half-life were calculated from C vs t data included in the reference.  VDss was calculated using micro rate constants provided.,,1955,357.79,5,1,68.5,5,anionic,3.4,0.59
COc1ccc2nccc([C@@H](O)[C@@H]3C[C@@H]4CCN3C[C@@H]4C=C)c2c1,0.925999418556223,2.8781984,Quinine,130-95-0,1.8,1.9,0.3,16.0,11.0,"White NJ, Clinical pharmacokinetics of antimaliria drugs.  Clin. Pharmacokinet.  10: 187-215.  White NJ, Chanthavanich P, Krishna S, Bunch C, and Silamut K (1983) Quinine disposition kinetics.  Br. J. Clin. Pharmacol.  16: 399-403.",VDss calculated from reported rat micro-constants.,,1918,324.42,4,1,45.6,4,cationic,2.9,2.1
COc1cccc(OC)c1C(=O)N[C@H]2[C@H]3SC(C)(C)[C@@H](N3C2=O)C(=O)O,2.7224660244710908,1.4581666,Methicillin,61-32-5,0.32,6.6,0.43,0.8,0.64,"Yaffe SJ, Gerbacht LM, Mosovich LL, Mattar ME, Danish M, and Jusko WJ (1977) Pharmacokinetics of methicillin in patients with cystic fibrosis.  J. Infect. Dis. 135: 828-831.  Dittert LW, Griffen WO, LaPiana JC, Shainfeld FJ, and Doluisio JT (1969) Pharmacokinetic interpretation of penicillin levels in serum and urine after intravenous administration.  Antimic. Agents Chemother. 9, 42-48.  Bergan T (1984) Pharmacokinetics of beta-lactam antibiotics.  Scand. J. Infect. Dis. 42(Suppl): 83-98.  Baur G, Kurz H, Trunk H (1977) Alteration of  protein binding during storage of human plasma preparations.  Anaesthesist 26: 148-150.","VDss calculated using micro rate constants reported in the reference by Dittert, et al.  Concentrations determined using a bioassay.  ",,1959,380.42,8,2,105.2,5,anionic,1.7,-1.6
COc1cccc(c1)[C@@]2(O)CCCC[C@@H]2CN(C)C,2.700439718141092,4.099441,Tramadol,27203-92-5,2.8,6.5,0.8,7.2,5.8,"Lintz W, Barth H, Osterloh G, and Schmidt-Boethelt E (1998) Pharmacokinetics of tramadol and bioavailability of enteral tramadol formulations. 3rd communication. Suppositories.  Arz. Forsch. 48: 889-899.  Grond S and Sablotzki A (2004) Clinical pharmacology of tramadol.  Clin. Pharmacokinet. 43: 879-923.","Parameters calculated from data reported in a table in Lintz, et al.",,1973,263.38,3,1,32.7,4,cationic,2.6,0.99
COc1ccccc1N2CCN(CCCNC3=CC(=O)N(C)C(=O)N3C)CC2,1.632268215499513,3.8619862,Urapidil,34661-75-1,0.75,3.1,,4.0,3.5,"Zech K, Steinijans VW, and Radtke HW (1986) Pharmacokinetics of urapidil in normal subjects. In Amery (Ed) Treatment of Hypertension with Urapidil: Preclinical and Clinical Update. 29-38, ICSS 101, RSM Services Ltd, London.",VDss calculated using C vs t data obtained from a digitized plot.,,1971,387.48,8,1,68.4,7,cationic,1.8,1.1
COc1ccccc1Oc2c(NS(=O)(=O)c3ccc(cn3)C(C)C)nc(nc2OCCO)c4ccnc(c4)c5nnn[nH]5,3.017921907997262,1.6405056,Tezosentan,180384-57-0,0.28,8.1,0.0085,0.58,3.8,"Dingemanse J, Clozel M, and Giersbergen PLM (2002) Pharmacokinetics and pharmacodynamics of tezosentan, an intravenous dual endothelin receptor antagonist, following chronic infusion in healthy subjects.  Br. J. Clin. Pharmacol. 53: 355-362.  Treiber A, Van Giersbergen PLM, and Dingemanse J (2003) In vivo and in vitro disposition profile of tezosentan, an intravenous dual endothelin receptor antagonist, in humans.  Xenobiotica 33: 399-414.",,,1996,605.63,15,3,200.1,12,anionic,3.5,-1.6
COc1nc(C)nc(Cl)c1NC2=NCCN2,3.4594316186372973,2.0237627,Moxonidine,75438-57-2,1.8,11.0,0.93,2.7,2.2,"Theodor R, Weimann HJ, Weber W, and Michaelis K (1991) Absolute bioavailability of moxonidine.  Eur. J. Drug Met. and Pharmacokin. 16: 153-159.  Schaefer HG, Toublanc N, and Weimann HJ (1998) The pharmacokinetics of moxonidine.  Rev. Contemp. Pharmacother.  9: 481-490.",,,1980,241.68,6,2,71.4,3,cationic,0.55,0.13
COc1nc(N)nc2c1ncn2[C@@H]3O[C@H](CO)[C@@H](O)[C@@H]3O,6.339850002884624,2.7889225,Nelarabine,121032-29-9,4.9,81.0,0.8,1.0,0.5,PDR Arranon Product Label. Accessed July 31 2014. http://www.pdr3d.com/detail.php?c=103264#section-13,,,1968,297.27,10,4,148.8,3,neutral,-1.9,-1.9
CS(=O)(=O)Nc1cc2c(c(oc2cc1)CCCC)C(=O)c1ccc(cc1)OCCCN(CCCC)CCCC,5.058749412335524,1.8114135,Dronedarone,141626-36-0,20.0,33.33,0.02,10.0,16.0,PDR. Accessed February 20 2013. http://www.pdr3d.com/detail.php?c=77881#section-14,MRT from VDss and Cl. 70 kg assumed. Ppb > 98%,,1992,556.76,7,1,89.1,18,zwitterionic,7.3,4.7
CS(=O)(=O)[N@@](N(S(=O)(=O)C)C(=O)NC)CCCl,4.529820946528695,2.6549382,Laromustine,173424-77-6,0.88,23.1,,0.63,0.49,"A Phase I and Pharmacokinetic Study of VNP40101M, a Novel Sulfonylhydrazine Alkylating Agent, in Patients with Refractory LeukemiaFrancis Giles, Deborah Thomas,Guillermo Garcia-Manero, Stefan Faderl,Jorge Cortes, Srdan Verstovsek, Alessandra Ferrajoli,Sima Jeha,Miloslav Beran, Charles Koller, Michael Andreeff, Ann Cahill,Caroline Clairmont, Mario Sznol, and Hagop Kantarjian Cli. Cancer Res. 2004 Vol. 10, 2908–2917.","VNP40101M or cloretazine. Dose range from 220 to 708 ,g/m2. Weighted average across number of courses for each dose. MRT calculated from VDss and clearance reported. Variable infusion time (15-70 minutes)",,1996,307.78,8,1,103.9,5,neutral,-1.4,-1.4
CSCCNc1nc(SCCC(F)(F)F)nc2n([C@@H]3O[C@@H]([C@H]([C@H]3O)O)CO[P@@](O[P@@](O)(=O)C(Cl)(P(O)(O)=O)Cl)(O)=O)cnc12,3.1795110502715103,0.14630608,Cangrelor,163706-06-7,0.035,9.06,0.02,0.07,0.14," Akers Wendell S; Oh Jennifer J; Oestreich Julie H; Ferraris Suellen; Wethington Mary; Steinhubl Steven R. Pharmacokinetics and Pharmacodynamics of a Bolus and Infusion of Cangrelor: A Direct, Parenteral P2Y12 Receptor Antagonist. Journal of clinical pharmacology (2010), 50(1), 27-35.//ppb: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/204958orig1s000clinpharmr.pdf. Accessed July 12 2017.","Digitized and then averaged from two groups. N=10 and N=9. 81 kg average with total dose 10 677 ug, and 79 kg average with total dose 20704 ug, respectively.",,1994,776.36,17,7,255.9,15,anionic,-1.4,-8.6
CSCC[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](Cc3c[nH]c4c3cccc4)C(=O)NCC(=O)O)N,9.766528908598865,1.2919574,ACHT 4-10,4037-01-8,0.73,871.0,,0.01,0.06,"U. Bickel, J. Born, H.L. Fehm, M. Distler, and K. H. Voigt. The Behaviorally Active Peptide ACTH 4-10: Measurement in Plasma and Pharmacokinetics in Man.  Eur J Clin Pharmacol (1988) 35:371-377","4-10-Corticotropin, ACTH (4-10). MRT from clearance and VDss, 125 ug dose, very high clearance.",,1968,962.09,23,13,384.1,29,zwitterionic,-0.68,-4.5
C[C@@H](C(=O)N)NCc1ccc(cc1)OCc2cccc(c2)F,0.2265085298086797,3.192603,Safinamide,133865-89-1,2.19,1.17,,31.16,21.67,"Annick Seithel‐Keuth, Andreas Johne, Achim Freisleben, Katrin Kupas,
Michael Lissy, and Sonja Krösser. Absolute Bioavailability and Effect of Food
on the Disposition of Safinamide Immediate Release Tablets in Healthy Adult Subjects. Clin.Pharmacol. Drug. dev. 2013, 2, 79-89.","N=14, 7M/7F, 50 mg iv dose as a 30 minutes infusion. Average weight assumed to be 70 kg. Data digitized from plot reported and PK parameters calculated via PKSolver. AUCinf reported 11022 . Calculated AUC0-inf 10168 ng.h.mL-1. AUC0-t highly truncated.",,1990,302.34,4,2,64.3,7,cationic,1.7,1.1
C[C@@H](NCCc1ccc(O)cc1)[C@@H](O)c2ccc(O)cc2,4.954196310386875,3.0819354,Ritodrine,26652-09-5,4.4,31.0,0.64,2.4,2.6,"Caritis SN, Venkataramanan R, Darby MJ, Chiao JP, and Krew M (1990) Pharmacokinetics of ritodrine administered intravenously: recommendations for changes in the current regimen.  Am. J. Obstet. Gynecol. 162: 429-437.  Gross AS and Brown KF (1985) Plasma protein binding of ritodrine at parturition and in nonpregnant women.  Eur. J. Clin. Pharmacol. 28: 479-481.",Data from pregnant women.,,1971,287.35,4,4,72.7,6,cationic,1.9,0.37
C[C@@H](O)[C@@H]1[C@H]2SC(=C(N2C1=O)C(=O)O)SCCOC(=O)N,2.9068905956085187,1.2412238,Sch34343,95415-91-1,0.3,7.5,0.35,0.67,0.8,"Lin CC, Lim J, Radwanski E, Kim, HK, Marco A, Lapiguera A, DiGiore C, and Symchowicz S (1987) Pharmacokinetics and metabolism of an intravenously administered penem (Sch 34343) in humans.  Antimic. Agents Chemother.  31: 84-87.  Eliopoulos GM, Reiszner E, and Moellering RC (1985) In vitro activity of Sch 34343 against enterococci and other Gram-positive bacteria.  Antimic. Agents Chemother. 27: 28-32.",VDss calculated from digitized C vs t plot.,,1984,334.37,8,3,130.2,7,anionic,-1.6,-4.6
C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(=C(N2C1=O)C(=O)O)S[C@@H]3CN[C@@H](C3)C(=O)Nc4cccc(c4)C(=O)O,-1.15200309344505,0.44103742,Ertapenem,153832-46-3,0.12,0.45,0.1,4.4,3.8,"Majumdar AK, Musson DG, Birk KL, Kitchen CJ, Holland S, McCrea J, Mistry G, Hesney M, Xi L, Li SX, Haesen R, Blum RA, Lins RL, Greenberg H, Waldman S, Deutsch P, and Rogers JD (2002) Pharmacokinetics of ertapenem in healthy young volunteers.  Antimic. Agents Chemother. 46: 3506-3511.",Protein binding non-linear over the concentration range studied in vivo; median value used.,,1993,475.51,10,5,156.3,7,anionic,0.43,-4.8
C[C@@H](O[C@H]1OCCN(CC2=NNC(=O)N2)[C@H]1c3ccc(F)cc3)c4cc(cc(c4)C(F)(F)F)C(F)(F)F,0.0,2.0504649,Aprepitant,170729-80-3,0.94,1.0,0.05,16.0,13.0,"Majumdar AK, Howard L, Goldberg, MR, Hickey L, Constanzer M, Rothenberg PL, Crumley TM, Panebianco D, Bradstreet TE, Bergman AJ, Waldman SA, Greenberg HE, Butler K,  Knops A, De Lepeleire I, Michiels N, and Petty KJ (2006) Pharmacokinetics of aprepitant after single and multiple oral doses in healthy volunteers.  J. Clin. Pharmacol. 46: 291-300.  Emend Product Label.",,,1995,534.43,7,2,75.2,6,neutral,4.1,4.1
C[C@@H]([C@@H](O)c1ccc(O)cc1)N2CCC(O)(CC2)c3ccccc3,4.754887502163468,2.5998616,Traxoprodil,134234-12-1,4.4,27.0,0.63,2.6,3.7,"Taylor TJ, Diringer K, Russell T, Venkatakrishnan K, Wilner K, Crownover PH, Benincosa LJ, and Gibbs MA (2006) Absolute oral bioavailability of traxoprodil in cytochrome P450 2D6 extensive and poor metabolizers.  Clin. Pharmacokin. 45: 989-1001.  ",Data from CYP2D6 extensive metabolizers.,,1990,327.42,4,3,63.9,4,cationic,2.1,1.0
C[C@@H]([C@@](O)(Cn1cncn1)c2ccc(F)cc2F)S(=O)(=O)C,-2.395928676331139,1.4983828,Genaconazole,120924-80-3,0.62,0.19,,54.0,49.0,"Mojavrian P, Radwanski E, Affirme MB, Cayen MN, and Lin CC (1994) Pharmacokinetics of the triazole antifungal agent genaconazole in healthy men after oral and intravenous administration.  Antimic. Agents Chemother.  38: 2758-2762.",VDss calculated from digitized plots.,,1989,331.34,6,1,85.1,5,neutral,-0.18,-0.18
C[C@@H](c1ccc2cc(ccc2c1)OC)C(=O)O,-3.8365012677171206,1.2729148,Naproxen,22204-53-1,0.09,0.07,0.002,19.78,16.63,"M.V. Calvo, J.V. Lanao, A. Dominguez-Gil. Bioavailability of rectally administered naproxen. In. J. Pharm. 1987, 38, 117-122.//ppb: R. A. UPTON, R. L. WILLIAMS, J. KELLY  R. M. JONES Naproxen pharmacokinetics in the elderly. Br. J. Clin. Pharmacol. 1984, 18, 207-217.","Data digitized from plot 250 mg dose, N=8 and 63.3 kg average weight reported. Vdarea 7.14 L. Reported AUCinf = 842 ug.hr.mL-1, calculated 813 842 ug.hr.mL-1. PDR reports > 99% bound to plasma proteins.  ppb data from Upton et al. taken from young subjects. Determined at peak plasma at day 9 and not sttistically different than trough. Larger (2-fold) fu in elderly subjects at both peak and trough plasma level on day 9.",,1963,230.26,3,1,46.5,3,anionic,2.9,0.023
C[C@@H](c1ncncc1F)[C@](O)(Cn2cncn2)c3ccc(F)cc3F,3.0531113364595623,1.5120387,Voriconazole,137234-62-9,2.2,8.3,0.42,4.4,5.6,"Purkins L, Wood N, Greenhalgh K, Eve MD, Oliver SD, and Nichols D (2003) The pharmacokinetics and safety of intravenous voriconazole - a novel wide-spectrum antifungal agent.  Br. J. Clin. Pharmacol. 56(Suppl. 1):  2-9.   Roffey SJ, Cole S, Comby P, Gibson D, Jezequel SG, Nedderman ANR, Smith DA, Walker DK, and Wood N (2003) The disposition of voriconazole in mouse, rat, rabbit, guinea pig, dog, and human.  Drug Metab. Dispos. 31: 731-741.",,,1991,349.31,6,1,76.7,5,neutral,1.5,1.5
C[C@@H]1CC(=O)NN=C1c2ccc(NN=C(C#N)C#N)cc2,1.925999418556223,0.88327044,Levosimendan,141505-33-1,0.24,3.8,0.02,1.1,1.1,"Sundberg S, Antila S, Scheinin H, Hayha M, Virtanen M, and Lehtonen L (1998) Integrated pharmacokinetics and pharmacodynamics of the novel calcium sensitizer levosimendan as assessed by systolic time intervals.  Int. J. Clin. Pharmacol. Ther. 36: 629-635.  Lilleberg J, Antila S, Karlsson M, Mieminen MS, and Pentkainen PJ (1994) Pharmacokinetics and pharmacodynamics of simendan, a novel calcium sensitizer, in healthy volunteers.  Clin. Pharmacol. Ther. 56: 554-563.  Wikberg T, Korkolainen T, and Karlsson M (1996) Enantiomeric bioanalysis of simendan and levosimendan by chiral high-performance liquid chromatigraphy.  Chirality 8: 511-517.",,,1992,280.28,7,2,113.4,5,anionic,2.2,0.87
C[C@@H]1CC2=CC(=O)CC[C@@H]2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@H]13,4.321928094887363,2.7044685,"Methylnortestosterone, 7α-, 19-",3764-87-2,0.8,20.0,,0.67,0.65,"Kumar N, Suvisaari J, Tsong YY, Aguillaume C, Bardin CW, Lahteenmaki P, and Sundaram K (1997) Pharmacokinetics of 7a-methyl-19-nortestosterone in men and cynomolgus monkeys.  J. Androl. 18: 352-358.",VDss calculated from C vs t data obtained by digitization of the plot provided in the reference.,,1962,288.42,2,1,37.3,0,neutral,3.5,3.5
C[C@@H]1CCC[C@H](C)N1CCCC(O)(c2ccccc2)c3ccccn3,0.84799690655495,3.0357974,Pirmenol,68252-19-7,1.4,1.8,0.13,13.0,8.4,"Hammill SC, Shand DG, Routledge PA. Hindman MC, Baker JT, and Pritchett ELC (1982) Pirmenol, a new antiarrhythmic agent:  initial study of efficacy, safety and pharmacokinetics.  Circulation 65: 369-375,  ",VDss calculated from reported rate microcnstants.,,1978,338.49,3,1,36.4,6,cationic,4.2,2.1
C[C@@H]1CC[C@H]2[C@@H](C)[C@H](OC(=O)CCC(=O)O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4,10.06339508128851,1.5620772,Artesunate,88495-63-0,15.0,1070.0,0.25,0.32,0.22,"Newton PN, Barnes KI, Smith PJ, Evans AC, Chierakul, W, Ruangveerayuth R, and WhiteNJ (2006) The pharmacokinetics of intravenous artesunate in adults with severe falciparum malaria.    Eur. J. Clin. Pharmacol.  62: 1003-1009.  Li Q, Xie LH, Haeberle A, Zhang J, and Weina P (2006) The evaluation of radiolabeled artesunate on tissue distribution in rats and protein binding in humans.  Am. J. Trop. Med. Hyg. 75: 817-826.",,,1982,384.42,8,1,100.5,5,neutral,3.0,2.9
C[C@@H]1O[C@H](C[C@H](N)[C@@H]1O)O[C@H]2C[C@@](O)(Cc3c(O)c4C(=O)c5ccccc5C(=O)c4c(O)c23)C(=O)C,4.584962500721156,2.508797,Idarubicin,58957-92-9,38.0,24.0,0.0759999999999999,26.0,16.0,"Robert J (1993) Clinical pharmacokinetics of idarubicin.  Clin. Pharmacokinet. 24: 275-288.  Kessel M, Gieseler F, and Woodcock BG (1999) Influence of serum protein on the uptake and retention of idarubicin by sensitive and multidrug resistant human leukemic cells.  Eur. J. Clin. Pharmacol. 55: 369-373.",Compendium of intravenous data with median values.,,1976,497.49,10,5,176.6,3,cationic,1.3,-1.5
C[C@@H]1O[C@H](C[C@H](N)[C@@H]1O)O[C@H]2[C@@H](O)C[C@H](O[C@H]3C[C@@](O)(Cc4c(O)c5C(=O)c6ccccc6C(=O)c5c(O)c34)C(=O)CO)O[C@H]2C,1.3219280948873624,3.000225,MEN-10755 ,211100-13-9,2.4,2.5,,17.0,21.0,"Bos AME, deVries EGE, Dombernovsky P, Aamdal S, Uges DRA, Schrijvers D, Wanders J, Roelvink MWJ, Hanauske AR, Bortini S, Capriati A, Crea AEG, and Vermorken JB (2001) Pharmacokinetics of MEN-10755, a novel anthracycline disaccharide analogue, in two phase 1 studies in adults with advanced solid tumors.  Canc. Chemother. Pharmacol. 48: 361-369.",Sabarubicin. CAS # and structure referring to free base. CAS # for HCl salt = 169317-77-5. The code MEN-10755 is reported only with the salt by SciFinder.,,1998,643.64,14,7,235.5,6,cationic,0.54,-2.2
C[C@@H]1[C@H]2[C@H](O)[C@H]3[C@H](N(C)C)C(=C(C(=O)N)C(=O)[C@@]3(O)C(=C2C(=O)c4c(O)cccc14)O)O,-1.1202942337177118,0.69842046,Doxycycline,564-25-0,0.69,0.46,0.12,25.0,14.0,"Nguyen VX, Nix DE, Gillikin S, and Schentag JJ (1989)  Effect of oral antacid administration on the pharmacokinetics of intravenous doxycycline.  Antimic. Agents Chemother. 33: 434-436.  Houin G, Brunner F, Nebout T, Cherfaoui M, Lagrue G, and Tillement JP (1983) The effects of chronic renal insufficiency on the pharmacokinetics of doxycycline in man.  Br. J. Clin. Pharmacol. 16: 245-252.  Raghuram TC and Krishnaswamy K (1982) Pharmacokinetics and plasma steady-state levels of doxycycline in undernutrition.  Br. J. Clin. Pharmacol. 14: 785-789.",,,1958,444.43,10,6,181.6,2,anionic,-0.64,-3.3
C[C@@]12[C@@H]([C@]3(C)[C@@H](CC2)C(C)(C)[C@H](CC3)O[C@H]2[C@H](O[C@@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O)[C@@H](O)[C@@H]([C@H](O2)CO)O)C[C@H]([C@H]2[C@@]1(C)CC[C@@H]2[C@@](O[C@@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O)(CCC=C(C)C)C)O,-3.473931188332412,0.50052863,Ginsenoside RD,52705-93-8,0.11,0.09,,20.2,18.5,"Pharmacokinetics and Safety of Ginsenoside Rd Following a Single or Multiple Intravenous Dose in Healthy Chinese Volunteers. Xing Zeng, PhD, Yuanhui Deng, BS, Yi Feng, MS, Yiming Liu, PhD, Liu Yang, MS, Yu Huang, MS, Jing Sun, BS, Weixiong Liang, MD, and Yongyuan Guan, MD. J. Clin. Pharmacol. 2010, 50, 285-292.","VDss calculated from reported clearance and MRT. 10, 40 and 75 mg doses, N=10 each cohort. Average values taken.",,1974,947.15,18,12,298.1,13,neutral,-0.39,-0.39
C[C@H](CCC(=O)O)[C@H]1CC[C@H]2[C@@H]3[C@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,2.51096191927738,0.9471659,Chenodeoxycholic acid,474-25-9,0.19,5.7,,0.57,1.42,"van Berge-Henegouwen GP, Hofmann AF. Pharmacology of chenodeoxycholic acid. II. Absorption and metabolism. Gastroenterol. 1977, 73, 300-309.","Chenic acid. Data digitized from plot and converted from % dose/mL into mas/volume units. Radiocativity measured but it was determined that there was no circulating metabolites from GC and total radioactivity determination (same AUC) after po dosing. Data digitized and PK parameters calculated via PKsolver. No usable reported data available. 1 mg total dose assumed to convert concentration data. N=6, 70 kg average weight assumed.",,1924,392.57,4,3,77.8,4,anionic,4.4,2.0
C[C@H](CCCC(C)(C)O)[C@H]1CC[C@@H]\2[C@@]1(CCC/C2=C\C=C/3\C[C@H](C[C@@H](C3=C)O)O)C,-1.6896598793878497,1.6503056,Calcitriol,32222-06-3,0.25,0.31,,13.29,11.0,"L. Brandi, M. Egfjord, K. Olgaard. Pharmacokinetics of 1,25(OH)2D3 and 1a(OH)D3 in normal and uraemic men. Nephrol. Dial. Transpl. 2002, 17, 829-842.","1,25-(OH)2D3. Ro 21-5535.1-alpha,25-Dihydroxycholecalciferol. Data digitization performed from plot (figure 3) reported. AUC0-72 reported as 3378.6 pg.h.mL-1. AUC0-72 reported as 3522.52 pg.h.mL-1. 4% difference.",,1971,416.64,3,3,60.7,5,neutral,6.0,6.0
C[C@H](CCCC(C)C)[C@H]1CC[C@@H]\2[C@@]1(CCC/C2=C\C=C/3\C[C@H](C[C@@H](C3=C)O)O)C,-0.2863041851566411,2.0698407,Alfacalcidol,41294-56-8,,0.82,,,48.6,"L. Brandi, M. Egfjord, K. Olgaard. Pharmacokinetics of 1,25(OH)2D3 and 1a(OH)D3 in normal and uraemic men. Nephrol. Dial. Transpl. 2002, 17, 829-842.","1alpha-Hydroxy-vitamin D3. 1-Hydroxycholecalciferol. No volume of distribution reported. Clearance calculated from AUC0-72 hrs, N=6, 59.2 kg average weight, 4 ug dose iv.",,1954,400.64,2,2,40.5,6,neutral,7.3,7.3
C[C@H](CCc1ccccc1)NC[C@H](O)c2ccc(O)c(c2)C(=O)N,4.857980995127572,3.2928104,Dilevalol,75659-07-3,4.8,29.0,,2.8,3.3,"Neubeck M, Becker C, Henke D, Roesch W, Spahn-Langguth H, and Mutschler E. (1993) Pharmacokinetics of dilevalol and its conjugates in man: assay method for plasma, blood, urine and bile samples and preliminary pharmacokinetic studies.  Arz. Forsch. 43: 953-957.",,,1980,328.41,5,4,95.6,8,cationic,1.8,0.97
C[C@H](CN1CCOCC1)C(C(=O)N2CCCC2)(c3ccccc3)c4ccccc4,1.1309308698264486,2.787886,Dextromoramide,357-56-2,0.47,2.19,,3.88,3.18,"Lancon J.P.; Pechinot A.; D'athis P.; Pechinot M.; Pointaire P.; Obadia J.F.; Caillard B. Dextromoramide pharmacokinetics in surgical patients. Ann. Fr. Anesth. Reanim. 1989, 8, 488-492.","N=9, and 5 mg iv dose. All data reported in table. 59 kg average weight",,1957,392.53,4,0,32.8,6,neutral,3.4,3.4
C[C@H](CS)C(=O)N1CCC[C@H]1C(=O)O,3.584962500721156,1.1655933,Captopril,62571-86-2,0.75,12.0,0.73,1.0,2.0,"Duchin KL, Singhvi SM, Willard DA, Migdalof BH, McKinstry DM (1982)  Captopril kinetics. Clin. Pharmacol. Ther. 31: 452-458.  Creasy WA, Morrison RA, Singhvi SM, and Willard DA (1988) Pharmacokinetics of intravenous captopril in healthy men.  Eur. J. Clin. Pharmacol. 35: 367-370.",Combined data from Creasy and Duchin papers.  Note that protein binding also has S-S bond component.,,1977,217.29,4,1,57.6,3,anionic,0.97,-2.2
C[C@H](N[C@@H](CCc1ccccc1)C(=O)O)C(=O)N2Cc3ccccc3C[C@H]2C(=O)O,-0.1046973786666932,1.5845073,Quinaprilat,82768-85-2,0.13,0.93,0.32,2.3,2.3,"Breslin E, Posvar E, Neub M, Trenk D, and Jahnchen E (1996) A pharmacodynamic and pharmacokinetic comparison of intravenous quinaprilat and oral quinapril.  J. Clin. Pharmacol. 36: 414-421.  Accuretic Product Label.",VDss calculated from C vs t data obtained by digitization of the plot provided in the reference.,,1982,410.46,7,3,106.9,8,anionic,1.8,-2.4
C[C@H]([C@@H](C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCC(=O)O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)N)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N)NC(=O)CNC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](Cc2cnc[nH]2)N)O,2.7506065048355923,1.3572462,Secretin (human),108153-74-8,0.16,6.73,,0.4,2.41,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-136_SecreFlo_BioPharmr.pdf. Accessed on May 17 2017,"Secretin human. Synthetic human peptide. MW= 3039.436. N=12, 0.4 ug/kg iv in human. 77.2 kg average weight. . Cross-over study with porcine peptide. Data digitized from plot reported in biopharmaceutics review. No AUC reported but clearance reported as 580.9 mL/min or 7.52 mL.min-1.kg-1 when normalized by body weight. 12% difference. t1/2 calculated by PK solver using only the last three points. May be overestimated.",,1986,3039.41,84,51,1401.2,109,cationic,-9.0,-9.0
C[C@H]([C@@H]1[C@@H]2N(C1=O)C(=C(S2)CN)C(=O)O)O,2.9392265777282085,1.8931084,CGP31608,107740-67-0,0.23,7.67,,0.5,0.5,"R. Wise, J. M. Webberky, J. M. Andrews and J. P. Asbby. The pharmacokinetics and tissue penetration of intravenously administered CGP 31608. Journal of Antimicrobial Chemotherapy (1988) 21, 85-91",Data digitzed from plot reported. 1 g administered to N=6 volunteers in 1 hr infusion. 82.2 kg average weight. Calculated AUCinf essentially identical to reported value.,,1985,244.27,6,3,103.9,3,zwitterionic,-2.4,-4.7
C[C@H](\C=C\[C@H](C)C(C)(C)O)[C@H]1CC[C@H]2\C(=C\C=C3C[C@@H](O)C[C@H](O)C3)\CCC[C@]12C,-0.1681227588083269,1.3811733,Paricalcitol,131918-61-1,0.41,0.89,0.0016,7.7,5.3,"Carr RA, Andre AK, Chen P, Grabowski BA, Chang MS, Locke CS, Williams LA, and Chojkier M (2006) The effect of hepatic insufficiency on the safety and pharmacokinetics of paricalcitol (ZemplarR).  Nephron  103: c100-c105.",Free fraction calculated by comparing free and total AUC values reported in the reference.,,1990,416.64,3,3,60.7,4,neutral,6.4,6.4
C[C@H](c1c[nH]cn1)c2cccc(C)c2C,3.4594316186372973,2.2803636,Dexmedetomidine,145108-58-3,1.6,11.0,0.06,2.5,2.2,"Anttila A, Penttila J, Helminen A, Vuorilehto L, and  Scheinin H (2003)  Bioavailability of dexmedetomidine after extravascular doses in healthy subjects. Br. J. Clin. Pharmacol. 56: 691-693.  Precedex Product Label.",,,1994,200.28,2,1,28.7,2,neutral,2.8,2.7
C[C@H]1CCC[C@@]2(C)O[C@H]2C[C@H](NC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@H]1O)\C(=C\c3csc(C)n3)\C,3.321928094887362,0.72138596,Ixabepilone,219989-84-1,11.0,10.0,0.2,18.0,17.0,"Abraham J, Agrawal M, Bakke S, Rutt A, Edgerly M, Balis FM, Widemann B, Davis L, Damle B, Sonnichsen D, Lebwohl D, Bates S, Kotz H, and Fojo T (2003)  Phase I trial and pharmacokinetic study of BMS-247550, an epothilone B analog, administered intravenously on daily schedule for five days.  J. Clin. Oncol. 21: 1866-1873.//ppb: Francis Y. F. Lee , Robert Borzilleri, 
Craig R. Fairchild, Amrita Kamath, Richard Smykla, Robert Kramer, Gregory Vite. Preclinical discovery of ixabepilone, a highly active antineoplastic agent. Cancer Chemother Pharmacol 2008,  63, 157–166.",,,1999,506.7,7,3,112.0,2,neutral,3.9,3.9
C[C@H]1CCc2c3n1cc(c(=O)c3cc(c2N4CCC(CC4)O)F)C(=O)O,-0.888968687611256,0.30347136,WCK771,154357-42-3,0.25,0.54,,7.87,6.04,"R.D. Yeole , V.L. Kulkarni, S.B. Latad, R.P. Chavan, Y. Chugh, M.V. Patel, H.F. Khorakiwala. Simple liquid chromatography–tandem mass spectrometry method for determination of novel anti-methicillin-resistant Staphylococcus aureus fluoroquinolone WCK 771 in human serum. J Chromatog. B, 2007, 846 , 306–312.","Levonadifloxacin. S-(-)-nadifloxacin. Data digitized from plot reported. N=6, 600 mg iv infusion. 70 kg average weight assumed. Dosed as arginine salt tetrahydrate. CAS # 306748-89-0. Assumed the dose of parent was NOT corrected for equivalence to 600 mg of salt. No mention of the correction was made and the drug was described as the tetrahydrate salt. (MW tetrahydrate salt = 606.64; free base = 360.38. A dose of 356.43 mg was then used.",,1993,360.38,6,2,82.8,2,anionic,3.0,1.6
C[C@H]1O[C@H](C[C@H](O)[C@@H]1O)O[C@H]2[C@@H](O)C[C@H](O[C@H]3[C@@H](O)C[C@H](O[C@H]4CC[C@@]5(C)[C@H](CC[C@@H]6[C@@H]5CC[C@]7(C)[C@H](CC[C@]67O)C8=CC(=O)OC8)C4)O[C@@H]3C)O[C@@H]2C,-4.539519529959989,0.7318849,Digitoxin,71-63-6,0.44,0.043,0.066,170.0,180.0,"Ochs HR, Grube E, Greenblatt DJ, Arendt R, and Bodem G (1981) Pharmacokinetics and pharmacodynamics of intravenous digoxin and digitoxin.  Klin. Wochenschr. 59: 889-897.  Kurz H, Mauser-Ganshorn A, and Stickel HH (1977) Differences in the binding of drugs to plasma proteins from newborn and adult man. I. Eur. J. Clin. Pharmacol. 11: 463-467.",VDss calculated using C vs t data obtained from digitization of a plot reported in the reference.,,1907,764.94,13,5,182.8,7,neutral,1.2,1.2
C[C@H]1O[C@H]([C@H](O)[C@@H]1O)N2C=C(F)C(=O)NC2=O,3.4594316186372973,1.513559,Doxifluridine,3094-09-5,0.28,11.0,0.61,0.46,0.35,"Schaaf LJ, Dobbs BR, Edwards IR, and Perrier DG (1988) The pharmacokinetics of doxifluridine and 5-fluorouracil after single intravenous infusions of doxifluridine to patients with colorectal cancer.  Eur. J. Clin. Pharmacol. 34: 439-443.  Meynial D, Lopez A, Malet-Martino MC, Hoffmann JS, and Martino R (1988) Application of fluorine-19 nuclear magnetic resonance to the determination of plasma-protien binding of 5'-deoxy-5-fluorouridine, a new antineoplastic fluoropyrimidine.  J. Pharm. Biomed. Anal. 6: 47-59.",Concentration dependent; fu data cited is for the lowest concentration.,,1958,246.19,7,3,99.1,1,neutral,-1.3,-1.5
C[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](Cc3c2c(c4c(c3O)C(=O)c5cccc(c5C4=O)OC)O)(C(=O)C)O)N)O,5.57198012018773,2.8613377,Daunorubicin,20830-81-3,32.05,47.57,0.06,11.23,14.24,"Aquilur Rahman, Anita Goodman, Wayne Foo, Jimmie Harvey, Frederick P. Smith, and Philip S. Schein.  Clinical Pharmacology of Daunorubidn in Phase I Patients With Solid Tumors: Development of an Analytical Methodology for Daunorubicin and Its Metabolites. Sem. Oncol.,  1984, 11, 36-44.//ppb: Gillian Whitaker, Amy Lillquist, Stephanie A. Pasas, Robert O'Connor, Fiona Regan,Craig E. Lunte, Malcolm R. Smyth. CE-LIF method for the separation of anthracyclines: Application to protein binding analysis in plasma using ultrafiltration. J. Sep. Sci. 2008, 31, 1828 – 1833.",30 to 60 mg/m2 to patients with with normal hepatic and renal function. 1.73 m2/70kg conversion factor used. N not reported. MRT from clearance and VDss.,,1953,527.52,11,5,185.8,4,cationic,1.0,-1.6
C[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](Cc3c2c(c4c(c3O)C(=O)c5ccccc5C4=O)O)(C(=O)C)O)N6CC6)OS(=O)(=O)C,4.55704241526372,2.425682,Ladirubicin,171047-47-5,2.95,23.54,0.006,2.09,7.33," de Jonge, M. J. A.; Verweij, J.; van der Gaast, A.; Valota, O.; Mora, O.; Planting, A. S. Th.; Mantel, M. A.; Van Den Bosch, S.; Lechuga, M. J.; Fiorentini, F.; Hess, D; Sessa, C. Phase I and pharmacokinetic studies of PNU-159548, a novel alkycycline, administered intravenously to patients with advanced solid tumours. Eur. J. Cancer 2002, 38, 2407-2415.",PNU 159548. FCE28729. Weighted average of doses between 1 and 16 mg.m-2 with data only from 10' infusion. Data from 1 hr infusion not reported for VDss (only clearance) and not used. Total N=49 across dose. MRT from VDss and clearance.,,1995,601.62,12,3,176.7,6,neutral,1.5,1.4
C[C@]12CCC3=C4CCC(=O)C=C4CC[C@H]3[C@@H]1CC[C@@]2(O)CC#N,0.3673710656485294,2.689572,Dienogest,65928-58-7,0.6,1.29,0.1,8.52,11.0,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022252_Orig-1_ClinPharmR.pdf Accessed May 19 2017,Dinagest. Visanne. ZK 37659. Average weight assumed to be 70 kg. 85 mcg 3H-dienogest. MRT from VDss and clearance.,,1977,311.42,3,1,61.1,2,neutral,2.1,2.1
C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@H]2O,4.906890595608519,2.4890277,Estradiol,50-28-2,1.2,30.0,0.016,0.7,1.7,"Kuhnz W, Gansau C, and Mahler M (1993) Pharmacokinetics of estradiol, free and total estrone, in young women following single intravenous and oral administration of 17beta estradiol.  Arz. Forsch. 43: 966-973.  Bruning PF and Bonfrer JMG (1986) Free fatty acid concentrations correlated with the available fraction of estradiol in human plasma.  Cancer Res. 46: 2606-2609.",,,1946,272.38,2,2,40.5,0,neutral,3.7,3.7
C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@]2(OS(=O)(=O)O)C#C,0.3785116232537298,1.6641937,Ethinylestradiol-17-Sulfate,75803-36-0,0.61,1.3,,7.8,9.3,"Goldzieber JW, Mileikowsky G, Newburger J, Dorantes A, and Stavchansky SA (1988) Human pharmacokinetics of ethinyl estradiol 3-sulfate and 17-sulfate.  Steroids 51: 63-79.",VDss calculated from reported micro-constants.,,1980,376.47,5,2,83.8,3,anionic,1.9,1.8
C[C@]12CC[C@H]3[C@@H](CCc4cc(OC(=O)N(CCCl)CCCl)ccc34)[C@@H]1CC[C@@H]2OP(=O)(O)O,-0.0892673380970874,1.1806283,Estramustine phosphate,4891-15-0,0.12,0.94,0.5,2.1,2.4,"Hudes G, Haas N, Yeslow G, Gillon T, Gunnarsson PO, Ellman M, Nordle O, Eriksson B, Miller L, Cisar L, Kopreski M, Viaro D, and Hartley-Asp B (2002) Phase I clinical and pharmacologic trial of intravenous estramustine phosphate.  J. Clin. Oncol.  20: 1115-1127.  Gunnarsson PO, Andersson SB, Johansson SA, Nilsson T, and Plym-Forshell G (1984) Pharmacokinetics of estramustine phosphate (Estracyt) in prostatic cancer patients.  Eur. J. Clin. Pharmacol. 26: 113-119.//ppb: Charles D. Smith, Jack T. Zilfou, Xinqun Zhang, Gary R. Hudes, and Kenneth D. Tew. Modulation of P-Glycoprotein Activity by Estramustine Is Limited by Binding to Plasma Proteins. Cancer, 1995,75, 2597-2604.","Compartmental model parameters from Gunnarsson, et al. were used in the calculation of VDss.",,1964,520.38,7,2,96.3,8,anionic,5.0,1.0
C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=Cc5c(cno5)C[C@]34C,3.973611275519472,2.218073,Danazol,17230-88-5,5.18,15.71,,5.49,2.31,"Sunesen VH, Vedelsdal R, Kristensen HG, Christrup L, Müllertz A. Effect of liquid volume and food intake on the absolute bioavailability of danazol, a poorly soluble drug. Eur J Pharm Sci. 2005 24, 297-303.","N=8, 50 mg iv dosed as 30' infusion. 86 kg average weight reported. Data digitized and PK parameters calculated via Phoenix v. 6.4.0.768. AUCinf very close to AUCt. AUC(not specified) reported as 531 ng.h.mL-1; calculated AUCinf as 616.7 ng.h.mL-1. 16% error.",,1963,337.46,3,1,46.6,1,neutral,3.7,3.7
C[N+]1(CC2CC2)CC[C@]34[C@H]5Oc6c(O)ccc(C[C@@H]1[C@]3(O)CCC5=O)c46,4.459431618637297,3.1172419,Methylnaltrexone,73232-52-7,2.6,22.0,0.87,2.0,2.5,"Yuan CS, Doshan H, Charney MR, O'Connor M, Karrison T, Maleckar SA, Israel RJ, and Moss J (2005) Tolerability, gut effects, and pharmacokinetics of methylnaltrexone following repeated intravenous administration in humans.  J. Clin. Pharmacol.  45: 538-546. ppb: Reported by PDR as The fraction of methylnaltrexone bromide bound to human plasma proteins is 11.0% to 15.3%, as determined by equilibrium dialysis. Aceessed December 2014. http://www.pdr3d.com/detail.php?c=7437#section-13",CAS # for methyl naltrexone bromide. CAS for parent 83387-25-1. SMILES entered for parent without bromide anion.,,1979,356.44,5,2,66.8,2,neutral,-2.7,-1.4
C[N+]1([C@@H]2C[C@H](C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)c4ccccc4)CC5CC5,4.643856189774724,3.126735,Cimetropium,150521-16-7,1.12,25.0,,0.74,0.83,"B. P. IMBIMBO, S. DANIOTTI, A. VIDI, D. FOSCHI, F . SAPORITI,  L. FERRANTE. Discontinuous Oral Absorption of Cimetropium Bromide, a New Antispasmodic Drug. J. Pharm. Sci. 1986, 75, 680-684. ","N=8, 10 mg dose. Clearance reported in table III. MRT calculated from AUC and AUMC in turn calculated from A, B, α and β. VDss obtained from MRT and clearance. T1/2 reported.",46% excreted unchanged in urine.,1973,358.45,5,1,59.1,7,neutral,-2.8,-2.8
C\C=C\1/NC(=O)[C@H]2CSSCC\C=C\[C@H](CC(=O)N[C@H](C(C)C)C(=O)N2)OC(=O)[C@@H](NC1=O)C(C)C,2.8875252707415875,0.88663137,Romidepsin,128517-07-7,1.2,7.4,0.07,2.6,11.0,"Sandor V, Bakke S, Robey RW, Kang MH, Blagosklonny MV, Bender J, Brooks R, Piekarz RL, Tucker E, Figg WD, Chan KK, Goldspiel B, Fojo AT, Balcerzak SP, and Bates SE (2002) Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms.Clin. Cancer Res. 8: 718-728. ppb: The PDR states: Romidepsin is highly protein bound in plasma (92% to 94%) over the concentration range of 50 ng/mL to 1000 ng/mL with α1-acid-glycoprotein (AAG) being the principal binding protein. Median of 93% taken. Accessed January 8 2015. http://www.pdr3d.com/detail.php?c=134699#section-13",,,1990,540.7,10,4,142.7,2,neutral,-0.14,-0.14
Cc1c(c(=O)n2c(n1)C(CCC2)O)CCN3CCC(CC3)c4c5ccc(cc5on4)F,0.2387868595871164,1.5055424,Paliperidone,144598-75-4,,1.18,0.24,,24.6,"Title of Study: Disposition of Paliperidone Enantiomers After Treatment With Different Formulations of the Racemate and the Separate Enantiomers and the Determination of the Absolute Bioavailability of IR and ER OROS Paliperidone.  
Available on ClinicalTrials.gov. http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_JNJ_6051&studyid=569&filename=CR004216_CSR.pdf. Accessed October 28 2016.","Data for racemate: 83.2 mL/min, iv 30 minutes infusion, 1 mg dose. 70 kg assumed. No VD reported, t1/2 24.6 hr. fu 0.24 for racemate. Very similar PK data for (+) or (-) enantiomer. No VDss data could be found.",,1990,426.48,7,1,84.7,4,cationic,1.5,0.94
Cc1c(ccnc1CS(=O)c2[nH]c3ccc(cc3n2)n4cccc4)OC,-0.4540316308947075,1.7913644,Ilaprazole,172152-36-2,0.19,0.73,,4.32,3.59,"Hongyun Wang, Ning Ou, Liwei Lang, Ruihua Shi, Pei Hu and Ji Jiang. Pharmacokinetics and pharmacodynamics of intravenous ilaprazole in healthy subjects after single ascending doses. Xenobiotica, ahead of press, 2016. Downloaded March 27, 2016.","Data digitized from plot reported. N=15, 62.6 kg average weight reported, 20 mg dose, 45' infusion. AUCinf reported 7057 ng.hr.mL-1; calculated 7334 ng.hr.mL-1. Highly linear also at doses of 5 and 10 mg, but only highest digitized as showing the most interpretable plot.",,1995,366.44,6,1,72.8,5,anionic,2.7,1.9
Cc1cc(O)c2C(=O)c3c(O)cc(O)c4c5c(O)cc(O)c6C(=O)c7c(O)cc(C)c8c1c2c(c34)c(c78)c56,-2.9434164716336326,-0.445386,Hypericin,548-04-9,0.25,0.13,,32.0,42.0,"Kerb R, Brockmuller J, Staffeldt B, Ploch M, and Roots I (1996) Single dose and steady-state pharmacokinetics of hypericin and pseudohypericin.  Antimic. Agents Chemother.  40: 2087-2093.",Data from two subjects with very high variability.,,1912,504.44,8,6,155.5,0,anionic,5.2,1.8
Cc1ccc(cc1)S(=O)(=O)NC(=O)N[C@H]2[C@H]3CC[C@@]([C@H]2O)(C3(C)C)C,-1.5563933485243853,-0.4035406,Glibornuride,26944-48-9,0.27,0.34,,13.0,9.2,"K. STOECKEL, V. TRUEB, U. C. DUBACH, R. C. HEINTZ, V. ASCALONE, I. FORGO, U. HENNES. Lack of effect of tenoxicam on glibornuride kinetics and response. Br. J. clin. Pharmac. (1985), 19, 249-254","20 mg dose, N=8, 69.4 kg average weight.MRT from clearance and VDss",,1968,366.48,6,3,95.5,3,anionic,2.4,0.62
Cc1ccc(cc1NC(=O)c2cccc(NC(=O)Nc3cccc(c3)C(=O)Nc4cc(ccc4C)C(=O)Nc5ccc(c6cc(cc(c56)S(=O)(=O)O)S(=O)(=O)O)S(=O)(=O)O)c2)C(=O)Nc7ccc(c8cc(cc(c78)S(=O)(=O)O)S(=O)(=O)O)S(=O)(=O)O,-7.454822365384707,-0.93038654,Suramin,145-63-1,0.54,0.0057,0.003,1400.0,1200.0,"Collins, JM, Klecker, RW, Yarchoan, R, Lane, HC, Fauci, AS, Redfield, RR, Broder, S, Myers, CE (1986) Clinical pharmacokinetics of suramin in patients with HTLV-III/LAV infection. J Clin Pharmacol. 26: 22-26.",,,1941,1297.28,29,12,483.8,16,neutral,-4.2,-9.0
Cc1ccc(cn1)c2ncc(Cl)cc2c3ccc(cc3)S(=O)(=O)C,-0.3400754415976217,1.2498441,Etoricoxib,202409-33-4,1.5,0.79,0.081,32.0,26.0,"Rodrigues AD, Halpin RA, Geer LA, Cui D, Woolf EJ, Matthews CZ, Gottesdiener KM, Larson PJ, Lasseter KC, and Agrawal NGB (2003) Absorption, metabolism, and excretion of etoricoxib, a potent and selective cyclooxygenase-2 inhibitor, in healthy male volunteers.    Drug Metab. Dispos. 31: 224-232.  Agrawal NGB, Rose MJ, Matthews CZ, Woolf EJ, Porras AG, Geer LA, Larson PJ, Cote J, Dilzer SC,  Lasseter KC, Alam I, Petty KJ, and Gottesdiener KM (2003) Pharmacokinetics of etoricoxib in patients with hepatic impairment.  J. Clin. Pharmacol. 43: 1136-1148.",,,1998,358.84,4,0,59.9,3,neutral,3.5,3.5
Cc1ccnc2N(C3CC3)c4ncccc4C(=O)Nc12,-1.736965594166206,2.1756766,Nevirapine,129618-40-2,1.3,0.3,0.32,81.0,53.0,"Lamson MJ, Sabo JP, MacGregor TR, Pav JW, Rowland L, Hawi A, Cappola M, and  Robinson P (1999) Single dose pharmacokinetics and bioavailability of nevirapine in healthy volunteers.  Biopharm. Drug Dispos. 20: 285-291.  Almond LM, Boffito M, Hoggard PG, Bonora S, Raiteri R,  Reynolds HE, Garazzino S, Sinicco A,  Khoo SH, Back DJ, and Di Perri G (2004) The Relationship between Nevirapine Plasma Concentrations and Abnormal Liver Function Tests.  AIDS Res. Human Retroviruses  20: 716-722.",,,1990,266.3,5,1,58.1,1,neutral,1.3,1.1
Cc1ccsc1C(=CCCN2CCC[C@H](C2)C(=O)O)c3sccc3C,0.6780719051126377,1.8930681,Tiagabine,115103-54-3,1.1,1.6,0.04,12.0,10.0,"Jansen JA, Oliver S, Dirach J, and Mengel HB (1995)  Absolute bioavailability of tiagabine. Epilepsia  36(Suppl. 3): s159",,,1987,375.55,3,1,40.5,6,zwitterionic,5.3,2.4
Cc1cnc(cn1)C(=O)NCCc2ccc(cc2)S(=O)(=O)NC(=O)NC3CCCCC3,-0.8365012677171204,0.49104655,Glipizide,29094-61-9,0.16,0.56,0.02,4.8,3.3,"Pentikainen PJ, Neuvonen PJ, and Penttila A (1983) Pharmacokinetics and pharmacodynamics of glipizide in health volunteers.  Int. J. Clin. Pharmacol. Ther. Toxicol. 21: 98-107.  Fuccella LM, Tamassia V, and Valzelli G (1973) Metabolism and kinetics of the hypoglycemic agent glipizide in man--comparison with glibenclamide.  J. Clin. Pharmacol. New Drugs 13: 68-75.",,,1970,445.54,9,3,130.1,7,anionic,2.1,0.0081
Cc1ncc(N(=O)=O)n1CCO,-0.2344652536370229,2.6880195,Metronidazole,443-48-1,0.4,0.85,0.96,7.8,7.1,"Sanvordekar DR, Chien YW, Lin TK, Lambert HJ (1975) Binding of metronidaole and its derivatives to plasma proteins: an assessment of drug binding phenomenon.  J. Pharm Sci. 64: 1797-1803.   Bergan T and Thorsteinsson SB (1986) Pharmacokinetics of metronidazole and its metabolites in reduced renal function.  Chemotherapy 32: 305-318.",Plasma concentraions determined using a bioassay.,,1946,171.15,6,1,83.9,3,neutral,-0.44,-0.44
Cc1ncsc1CCCl,5.044394119358453,3.3649354,Chlormethiazole,533-45-9,6.6,33.0,0.36,3.3,4.5,"Neuvonen PJ, Pentikainen PJ, Jostell KG, and Syvalahti E (1981) Effect of ethanol on the pharmacokinetics of chlormethiazole in humans. Int. J. Clin. Pharmacol. Ther. Toxicol. 19: 552-560.  Jostell KG, Agurell S, Allgen LG, Kuylenstierna B, Lindgren JE, Aberg G, and Osterlot G (1978) Pharmacokinetics of clomethiazole in healthy adults.  Acta Pharmacol. Toxicol. 43: 180-189.  Moore RG, Triggs EJ, Shanks CA, and Thomas J (1975) Pharmacokinetics of chlormethiazole in humans.  Eur. J. Clin. Pharmacol.  8: 353-357.  Pentikainen PJ, Neuvonen PJ, Jostell KG (1980) Pharmacokinetics of clormethiazole in healthy volunteers and patients with cirrhosis of the liver.  Eur. J. Clin. Pharmacol. 17: 275-284. "," VDss calculated from reported micro rate constants in the references by Moore, et al., and Jostell, et al.",,1935,161.65,1,0,12.9,2,neutral,1.9,1.9
Cc1nnc(SCC2=C(N3[C@H](SC2)[C@H](NC(=O)Cn4cnnn4)C3=O)C(=O)O)s1,-0.1681227588083269,1.0709867,Cefazolin,25953-19-9,0.12,0.89,0.18,2.2,1.7,"Chanson P, Joly V, Contrepois A, Garaud JJ, Bauchet J, Mohler J, Nguyen PC, and Carbon C (1987) Alteration of gentamicin and cefazolin kinetics with control of the hypothyroid state in humans.  Antimic. Agents Chemother. 31: 645-637.  Decroix MO, Zini R, Chaumeil JC, and Tillement JP (1988) Cefazolin serum protein binding and its inhibition by bilirubin, fatty acids and other drugs.  Biochem. Pharmacol. 37: 2807-2814.  Bergan T (1977) Comparatve pharmacokinetics of cefazolin, cephalothin, cephacetril, and cephapirine after intravenous administration.  Chemother. 23: 389-404.","VDss assumed to be equal to reported VD in Chanson, et al., because 1st order kinetic model.",,1969,454.51,12,2,156.1,7,anionic,-1.2,-4.2
Cc1nnc2CN=C(c3ccccc3)c4cc(Cl)ccc4n12,-0.4344028241457749,1.4133259,Alprazolam,28981-97-7,0.8,0.74,0.29,18.0,12.0,"Smith RB, Kroboth PD, Vanderligt JT, Phillips JP, and Juhl RP (1984) Pharmacokinetics and pharmacodynamics of alprazolam after oral and IV administration.  Psychopharmacology 84: 452-456.  Greenblatt DJ and Wright CE (1993) Clinical pharmacokinetics of alprazolam. Therapeutic implications.    Clin. pharmacokinet. 24: 453-471.  ",VDss obtained from C vs t data obtained by digitization of the plot provided in the reference.,,1970,308.76,4,0,43.1,1,neutral,2.0,1.9
Cc1noc(NS(=O)(=O)c2ccc(N)cc2)c1C,-1.736965594166206,0.26254576,Sulfisoxazole,127-69-5,0.17,0.3,0.079,9.4,7.4,"Kaplan SA, Weinfeld RE, Abruzzo CW, and Lewis M (1972) Pharmacokinetic profile of sulfisoxazole following intravenous, intramuscular, and oral administration to man.  J. Pharm. Sci. 61; 773-778.  Oie S, Gambertoglio JG, and Fleckenstein L (1982) Comparison of the disposition of total and unbound sulfisoxazole after single and multiple dosing.  J. Pharmacokinet. Biopharm. 10: 157-72.  Du Souich P, Calvo R, and Erill S (1990) Effects of cefotaxime on the serum protein binding of sulfisoxazole.  Biopharm. Drug Dispos. 11: 371-379.","Pharmacokinetic parameters were calculated from C vs t data provided in the reference by Kaplan, et al..",,1946,267.3,6,2,98.5,3,anionic,0.79,-1.6
Cc1onc(NS(=O)(=O)c2ccc(N)cc2)c1,-1.4739311883324124,0.36996454,Sulfamethoxazole,723-46-6,0.3,0.36,0.23,14.0,9.8,"Dudley MN, Levitz RE, Quintiliani R, Hickingbotham JM, and Nightingale CH (1984) Pharmacokinetics of trimethoprim and sulfamethoxazole in serum and cerebrospinal fluid of adult patients with normal meninges.  Antimic. Agents Chemother. 26: 811-814.  Wijkstroem A and Westerlund D (1983) Plasma protein binding of sulfadiazine, sulfamethoxazole and trimethoprim determined by ultrafiltration. J. Pharm. Biomed. Anal. 1: 293-299.",,,1957,253.28,6,2,98.5,3,anionic,1.1,-0.56
Cc1onc(c2ccccc2)c1C(=O)N[C@H]3[C@H]4SC(C)(C)[C@@H](N4C3=O)C(=O)O,2.655351828612554,0.9473054,Oxacillin,66-79-5,0.19,6.3,0.07,0.5,0.7,"Dittert LW, Griffen WO, LaPiana JC, Shainfeld FJ, and Doluisio JT (1969) Pharmacokinetic interpretation of penicillin levels in serum and urine after intravenous administration.  Antimic. Agents Chemother. 42-48.  Bergan T (1984) Pharmacokinetics of beta-lactam antibiotics.  Scand. J. Infect. Dis. 42(Suppl): 83-98.","VDss calculated using micro rate constants reported in the reference by Dittert, et al.  Concentrations determined using a bioassay.  ",,1961,401.44,8,2,113.0,4,anionic,2.1,-1.2
Cl.O=C(N1[C@@H](CCC1)C(=O)NC(C)(C)C)[C@H]1N(CCC1)C(=O)[C@@H](N(C(=O)[C@@H](NC(=O)[C@@H](N(C)C)C(C)C)C(C)C)C)C(C)C,3.263034405833794,1.0120302,Tasidotin,192658-64-3,0.33,9.6,,0.58,0.57,"Phase I and pharmacokinetic study of the dolastatin-15 analogue tasidotin (ILX651) administered intravenously on days 1, 3, and 5 every 3 weeks in patients with advanced solid tumors. Cunningham, Casey; Appleman, Leonard J.; Kirvan-Visovatti, Miora; Ryan, David P.; Regan, Eileen; Vukelja, Svetislava; Bonate, Peter L.; Ruvuna, Francis; Fram, Robert J.; Jekunen, Antti; et al Clinical Cancer Research (2005), 11(21), 7825-7833","Doses from 3.9 mg/m2 up to 45.7 mg/m2, N-31 patients (total). 1.73m2/70 kg factor assumed. Weighted average of median values for each cohort. 30' infusion.",,1997,643.3,11,2,122.4,11,neutral,3.5,3.4
ClCCN(CCCl)P1(=O)NCCCO1,0.137503523749935,2.111769,Cyclophosphamide,50-18-0,0.73,1.1,0.87,11.0,8.0,"Juma FD, Rogers HJ, and Trounce JR (1979) Pharmacokinetics of cyclophosphamide and alkylating activity in man after intravenous and oral administration. Br. J. Clin. Pharmacol. 8: 209-217.  Juma FD, Rogers HJ, and Trounce JR (1979) The kinetics of salivary elimination of cyclophosphamide in man.  Br. J. Clin. Pharmacol. 8: 455-458.",VDss calculated from microconstants reported in the reference.,,1946,261.09,4,1,41.6,5,neutral,0.79,0.55
ClCCNC(=O)N(CCCl)N=O,6.285402218862249,2.6558688,Carmustine (BCNU),154-93-8,1.2,78.0,0.23,0.26,0.37,"Henner WD, Peters WP, Eder JP, Antman K, Schnipper L, and Frei E (1986) Pharmacokinetics and immediate effects of high-dose carmustine in man.  Canc. Treatm. Rep. 70: 877-880. ",Used VD as VDss because PK was first order.,,1946,214.05,5,1,61.8,5,neutral,1.4,1.4
ClCCNP1(=O)OCCCN1CCCl,0.137503523749935,2.157652,Ifosfamide,3778-73-2,0.62,1.1,1.0,9.4,6.6,"Corlett SA, Parker D, and Chrystyn H (1995) Pharmacokinetics of ifosfamide and its enantiomers following a single 1 h intravenous infusion of the racemate in patients with small cell lung carcinoma.  Br. J. Clin. Pharmacol. 39: 452-455.  ",,,1953,261.09,4,1,41.6,5,neutral,0.88,0.88
Clc1ccc2NC(=O)CN=C(c3ccccc3)c2c1,-3.0588936890535687,1.2076278,Desmethyldiazepam,1088-11-5,0.45,0.12,0.03,63.0,46.0,"Klotz U, Antonin KH, Brugel H, and Bieck PR (1977) Disposition of diazepam and its major metabolite desmethyldiazepam in patients with liver disease.  Clin. Pharmacol. Ther. 21: 430-436.  Lucek RW and Coutinho CB. (1976) The role of substituents in the hydrophobic binding of the 1,4-benzodiazepines by human plasma proteins.  Molec. Pharmacol. 12: 612-619.",,,1961,270.71,3,1,41.5,1,neutral,3.0,3.0
Clc1ccc2NC(=O)CN=C(c3ccccc3Cl)c2c1,-2.5563933485243853,1.3484408,Delorazepam (Chlordesmethyldiazepam),2894-67-9,2.2,0.17,0.0509999999999999,220.0,200.0,"Bareggi SR, Pirola R, Potvin P, and Devis G (1995) Effects of liver disease on the pharmacokinetics of intravenous and oral chlordesmethyldiazepam.  Eur. J. Clin. Pharmacol. 48: 265-268.  Sennesael J, Verbeelen D, Vanhaelst L, Pirola R, and Bareggi SR (1991) Pharmacokinetics of intravenous and oral chlordesmethyldiazepam in patients on regular haemodialysis.  Eur. J. Clin. Pharmacol. 41:65-68.  Lucek RW and Coutinho CB (1976) The role of substituents in the hydrophobic binding of the 1,4-benzodiazepines by human plasma proteins.   Molec. Pharmacol.  12: 612-619.",Parameters were determined from C vs t data obtained by digitization of the C vs t plots for normal subjects provided in the references and averaged (N=2).,,1962,305.16,3,1,41.5,1,neutral,3.6,3.6
Clc1cccc(N2CCN(CCCCOc3ccc4CCC(=O)Nc4c3)CC2)c1Cl,-0.2688167584278,3.4603426,Aripiprazole,129722-12-9,4.9,0.83,0.01,98.0,75.0,Abilify Product Label.,CL value in FDA documents on-line.,,1990,448.39,5,1,44.8,7,cationic,5.2,4.7
Clc1cccc(c1)N2CCN(CCCN3N=C4C=CC=CN4C3=O)CC2,0.4854268271702416,2.5334442,Trazodone,19794-93-5,0.52,1.4,0.08,6.2,7.3,Nilsen OG and Dale O (1992) Single dose pharmacokinetics of trazodone in healthy subjects.  Pharmacol. Toxicol. 71: 150-153. ppb: The PDR states: Trazodone is 89% to 95% protein bound in vitro at concentrations attained with therapeutic doses in humans. Accessed January 8 2015. http://www.pdr3d.com/detail.php?c=82125#section-14,VDss calculated from C vs t data obtained by digitization of the plot provided in the reference.,,1968,371.86,6,0,42.4,5,neutral,4.5,4.3
Clc1ccccc1C2=NCC(=O)Nc3ccc(cc23)N(=O)=O,-0.1844245711374274,1.4305799,Clonazepam,1622-61-3,2.9,0.88,0.15,55.0,38.0,"Crevoisier C, Delisle MC, Joseph I, and Foletti G (2003) Comparative single-dose pharmacokinetics of clonazepam following intravenous, intramuscular and oral administration to healthy volunteers.  Eur. Neurol. 49: 173-177.  Lucek RW and Coutinho CB.  (1976) The role of substituents in the hydrophobic binding of the 1,4-benzodiazepines by human plasma proteins.  Molec. Pharmacol. 12:  612-19.",VDss calculated using C vs t data obtained by digitization of the plot included in the reference.,,1963,315.71,6,1,87.3,2,neutral,2.7,2.7
Cn1c(nc(=O)c(n1)O)SCC2=C(N3[C@@H]([C@@H](C3=O)NC(=O)/C(=N\OC)/c4csc(n4)N)SC2)C(=O)O,-2.1844245711374275,0.32861692,Ceftriaxone,73384-59-5,0.12,0.22,0.1,9.6,7.6,"Data from PDR. Accessed February 19, 2013. http://www.pdr3d.com/detail.php?c=33025#section-4. ","Ro-139904. ROCEPHIN®. Concentration-dependent ppb. 95% at < 25 ug/mLto 85 % at 300 ug/mL.Mid-point taken. 0.5 mg dose in healthy human. 30’ infusion, linear PK at higher doses. Calculation perforrmed via Phoenix with data reported (0.5 mg dose).","Over a 0.15 to 3 gm dose range in healthy adult subjects, the values of elimination half-life ranged from 5.8 to 8.7 hours; apparent volume of distribution from 5.78 to 13.5 L; plasma clearance from 0.58 to 1.45 L/hour; and renal clearance from 0.32 to 0.73 L/hour. Ceftriaxone is reversibly bound to human plasma proteins, and the binding decreased from a value of 95% bound at plasma concentrations of <25 µg/mL to a value of 85% bound at 300 µg/mL. Ceftriaxone crosses the blood placenta barrier.",1980,554.58,15,4,215.2,8,anionic,-3.2,-8.4
Cn1cc(NC(=O)Nc2cc(C(=O)Nc3cc(C(=O)Nc4ccc5cc(cc(c5c4)S(=O)(=O)O)S(=O)(=O)O)n(C)c3)n(C)c2)cc1C(=O)Nc6cc(C(=O)Nc7ccc8cc(cc(c8c7)S(=O)(=O)O)S(=O)(=O)O)n(C)c6,-7.733123527871812,-1.312847,PNU-145156E,154788-16-6,0.27,0.0047,,960.0,730.0,"Groen HJM, deVries EGE, Wynendaele W, van der Graaf WTA, Fokkema W, Lechuga MJ, Poggesi T, Dirix LY, and van Oosterom AT (2001) PNU-145156E, a novel angiogenesis inhibitor, in patients with solid tumors: a phase I and pharmacokinetic study.  Clin. Canc. Res.  7: 3928-3933.",VDss calculated from digitized plot of 200 mg/m2 dose.,,1994,1121.12,27,10,394.7,14,neutral,-2.0,-9.0
Cn1cncc1[C@@](c2ccc(cc2)Cl)(c3ccc4c(c3)c(cc(=O)n4C)c5cccc(c5)Cl)N,2.3305584000308026,0.95054424,Tipifarnib,192185-72-1,0.93,5.03,0.006,3.07,2.52,"Zhang, Steven; Zannikos, Peter; Awada, Ahmad; Piccart-Gebhart, Martine; Dirix, Luc Y.; Fumoleau, Pierre; Verhaeghe, Tom; Francois, Marc; De Porre, Peter. Pharmacokinetics of tipifarnib after oral and intravenous administration in subjects with advanced cancer. J.Clin. Pharmacol. 2006, 46(10), 1116-1127.","Zarnestra. Data digitized from plot reported in Fig. 1. Calculations performed with PKSOlver. N=24, 100 mg dose, 2 hr infusion, 70 kg assumed as average weight, range 48-92 kg and reported median 58 kg.Reported AUC(0-10) 4487 ng.h.mL-1; calculated, 4390 ng.h.mL-1. 2% difference.",,1997,489.4,5,1,65.8,4,neutral,4.1,4.1
FC1=CNC(=O)NC1=O,4.700439718141092,2.3956394,"Fluorouracil, 5-",51-21-8,0.23,26.0,0.64,0.15,0.12,"Port RE, Daniel B, Ding RW, and Herrmann R (1991) Relative importance of dose, body surface area, sex, and age for 5-flurouracil clearance.  Oncology 48: 277-281.  Schaaf LJ, Dobbs BR, Edwards IR, and Perrier DG (1987) Nonlinear pharmacokinetic characteristics of 5-fluorouracil (5-FU) in colorectal cancer patients.  Eur. J. Clin. Pharmacol. 32: 411-418.  Esposito M, Rosso R, and Santi L (1974) Plasma protein binding of antineoplastic drugs in rats and humans.  IRCS Library Compendium 2: 1180.",5-FU shows dose dependent kinetics; low dose data cited.,,1946,130.08,4,2,58.2,0,neutral,-0.93,-1.1
Fc1ccc(cc1)[C@@H]2CCNC[C@H]2COc3ccc4OCOc4c3,4.169925001442312,2.3451781,Paroxetine,61869-08-7,18.0,18.0,0.06,17.0,13.0,"Lund J, Thayssen P, Mengel H, Pedersen OI, Kristensen CB, and Gram LF (1982) Paroxetine: pharmacokinetics and cardiovascular effects after oral and intravenous single doses in man.  Acta Pharmacol. Toxicol. 51: 351-357.  Paxil Product Label.",VDss was calculated from micro rate constants reported in the reference.,,1978,329.37,4,1,39.7,4,cationic,3.8,1.5
N#Cc1ccc(cc1)C(c2ccc(cc2)C#N)n3cncn3,-0.8109661756099832,1.4724545,Letrozole,112809-51-5,1.9,0.57,0.41,59.0,45.0,"Sioufi A, Gauducheau N, Pineau V, Marfil F, Jaouen A, Cardot JM, Godbillon J, Czendlik C, Howald H, Pfister C, and Vreeland F (1997) Absolute bioavailability of letrozole in healthy postmenopausal women.  Biopharm Drug Dispos. 18: 779-89.   Colussi DM, Parisot CY, and Lefevre GY (1998) Plasma protein binding of letrozole, a new nonsteroidal aromatase enzyme inhibitor.  J. Clin. Pharmacol. 38: 727",,,1987,285.3,5,0,78.3,5,neutral,2.1,2.1
N(CCN(CC)CC)C(C(=C(C1CNC=O)S2)C(=O)C(C2=CC=C2OC)=C2)=CC=1,1.632268215499513,2.7902093,SR 271425,155990-20-8,1.01,3.1,,5.4,6.19,"Lockhart AC, Calvo E, Tolcher AW, Rowinsky EK, Shackleton G, Morrison JG Rafi R, VerMeulen W, Rothenberg ML (2009) A Phase I dose-escalation study of SR 271425, an intravenously dosed thioxantone analog, administered weekly in patients with refractory solid tumors. Am J Clin Oncol 2009;32: 9–14","N=16 across 5 dose groups (64-675 mg/m2).  Weight averaged by number of patients. 70 kg average weight assumed. VDss 70.9 L, Cl 13.02 L/h, ",,1994,413.53,6,2,70.7,9,cationic,3.7,2.4
N(Nc1nccnc1)=O,3.919340082442013,2.3720582,"Pyrazine, 2-diazohydroxide",103829-56-7,0.31,15.13,,0.29,0.38,"Supko J, Balcerzak S P, Kraut E H. Phase I evaluation and pharmacokinetic study of pyrazine-2-diazohydroxide administered as a single bolus intravenous injection in patients with advanced solid tumors. Cancer Res. 1993, 53, 4843-4849.","Data averaged across 5 doses and 16 subjects. VDss, clearance and MRT as well as t1/2 reported. 1.73 m2/70 kg conversion factor used.",,1986,124.1,5,1,67.2,2,neutral,0.22,0.22
"N([C@@H](C(=O)N[C@H](C(N[C@H](C(N[C@@H](C(N[C@@H](C(=O)N[C@@H](C(N[C@H](C(N[C@H](C(=O)N1[C@H](C(N[C@@H](C(N)=O)C)=O)CCC1)CCCC\N=C(\NCC)NCC)=O)CC(C)C)=O)CCCC\N=C(/NCC)NCC)Cc1ccc(cc1)O)=O)CO)=O)Cc1cccnc1)=O)Cc1ccc(cc1)Cl)Cc1ccc2c(c1)cccc2)C(=O)C
",-0.6665762662748083,0.79635245,Ganirelix,124904-93-4,0.21,0.63,0.18,5.61,9.09,"Oberyé JJ, Mannaerts BM, Kleijn HJ, Timmer CJ. Pharmacokinetic and pharmacodynamic characteristics of ganirelix (Antagon/Orgalutran). Part I. Absolute bioavailability of 0.25 mg of ganirelix after a single subcutaneous injection in healthy female volunteers. Fertil Steril. 1999 Dec;72(6):1001-1005.","19 female volunteers, 63.1 kg average weight, 0.25 mg dose. Data digitized from plot reported. AUC (0-inf) reported as 105 ng.h.mL-1; calculated value 104.6 ng.h.mL-1. Difference < 1%.",,1989,1570.32,31,16,451.5,48,cationic,5.7,3.4
N(c1cc(ccc1)O)(c1ccc(C)cc1)CC=1NCCN1,5.392317422778761,2.2609725,Phentolamine,50-60-2,,42.0,,,2.5,"Phentolamine Mesylate - FDA Approval Package
Clinical Pharmacology and Biopharmaceutics Review. Accessed through Pharmapendium.",VD (likely to be VDz) reported as 442 L. 70 kg assumed as average weight. AUClast 1.76 ng.hr.mL-1 with AUCinf as 2.76 ng.hr.mL-1.,,1948,281.35,4,2,47.9,4,cationic,2.9,2.5
N1(C)C([C@H](NC([C@@H](NC(CNC([C@H](CCCNC(N)=N)NC([C@@H]1C(C)C)=O)=O)=O)CC(=O)O)=O)Cc1ccccc1)=O,0.2387868595871164,2.4307601,Cilengitide,188968-51-6,0.26,1.18,,3.67,3.6,"Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974), a novel
inhibitor of the integrins avb3 and avb5 in patients with advanced solid tumours F.A.L.M. Eskens, H. Dumezb, R. Hoekstra, A. Perschl, C. Brindley, S. Bottcher,W. Wynendaele, J. Drevs, J. Verweij, A.T. van Oosterom European Journal of Cancer 39 (2003) 917–926",(EMD121974) Weighted averages of 40 total patients across doses from 30 to 1600 mg/m2. MRT calculated from averaged VDss and clearance. ,,1997,588.66,15,8,235.9,10,zwitterionic,-1.4,-3.7
N1([C@H](C(=O)N)CC)C(=O)CCC1,-0.1520030934450499,2.8008657,Levetiracetam,102767-28-2,0.6,0.9,0.9,11.15,8.23,"Steven Ramael, Agnès Daoust, Christian Otoul, Nathalie Toublanc, Mona Troenaru, Zhihong (Sarah) Lu, Armel Stockis. Levetiracetam Intravenous Infusion: A Randomized, Placebo-controlled Safety and Pharmacokinetic Study. Epilepsia, 2006, 47, 1128-1135. ppb: Stuart W. Paine, Karelle Menochet, Rebecca Denton, Dermot F. McGinnity, and Robert J. Riley. Prediction of Human Renal Clearance from Preclinical Species for a Diverse Set of Drugs That Exhibit Both Active Secretion and Net Reabsorption, Drug Metab. Disp. 2011, 39:1008–1013","Keppra. UCB L-059. Data digitize from plot reported. 3000 mg 15 minutes iv infusion. N=6 healthy volunteers, average weight 74.6 kg. Other doses available and linearity observed. AUC(0-inf) reported as 754 ug.h.mL-1. AUC(0-inf) calculated 751 ug.h.mL-1. < 1 % difference.",From PDR. Accessed February 22 2013.http://www.pdr3d.com/detail.php?c=52829#section-4  Levetiracetam is eliminated from the systemic circulation by renal excretion as unchanged drug which represents 66% of administered dose. The mechanism of excretion is glomerular filtration with subsequent partial tubular reabsorption.,1985,170.21,4,1,63.4,3,neutral,-0.48,-0.48
N1(c2ccc(cc2)C(C(=O)O)C)C(=O)c2c(C1)cccc2,-0.6214883767462702,0.84983504,Indoprofen,31842-01-0,0.12,0.65,0.01,2.7,2.11,"Tamassia, V.; Corvi, G.; Moro, E.; Tosolini, G. P.; Fuccella, L. M.  Pharmacokinetics and bioavailability of indoprofen in man. Eur. J. Clin. Pharmacol. (1976), 10(3-4), 257-62",K4277. Data digitized from plot reported at 100 mg dose. N=4. Average weight 68.1 kg. AUC calculated 32.67 ug.h.mL-1; AUC reported 32.43 ug.h.mL-1.,,1972,281.31,4,1,57.6,3,anionic,2.4,-0.59
N1(c2ccccc2)N=C(C)CC1=O,0.5058909297299572,1.7766898,Edaravone,89-25-8,0.23,1.42,0.89,2.65,2.36,"Data from 20 mg dose iv profile shown in Fig. 2 of Hao Li,Kun Xu, Yongqing Wang, Hongwen Zhang, Tianping Li, Ling Meng, Xiaojian Gong, Haibo Zhang, Ning Ou and Jinman Ruan  
Phase I Clinical Study of Edaravone in Healthy Chinese Volunteers. Drugs RD 2012; 12 (2): 65-70.//ppb:Dao-quan Tang, Yin-jie Li, Zheng Li, Ting-ting Bian, Kai Chen, Xiao-xiao Zheng, Yan-yan Yu, Shui-shi Jiang. Study on the interaction of plasma protein binding rate between edaravone and taurine in human plasma based on HPLC analysis coupled with ultrafiltration technique.","Data digitized. Only dose 20mg 0.5h iv infusion, N=10 (5 male/ 5 female, mean body weight = 59.7kg from Table 1) has been used (Dose linearity)
Reported data (Table 2:
AUC0-t:  3.64 mg*h/L
AUC0-inf: 3.79 mg*h/mL
CL:  0.1 L/min (1.68 mL/min/kg)
t1/2:  2.34 h",,1891,174.2,3,0,32.7,1,neutral,2.2,2.2
N12[C@@H](C(S[C@@H]2[C@@H](C1=O)NC(=O)[C@@H](c1ccccc1)NC(=O)NC(=N)N)(C)C)C(=O)O,0.6780719051126377,1.8474972,BLP1654,28889-87-4,0.24,1.6,0.8,2.5,2.09,"JOHN T. CLARKE, ROBERT D. LIBKE, EDWARD D. RALPH, RUEDI P. LUTHY, and WILLIAM M. M. KIRBY. Human Pharmacokinetics of BL-P1654 Compared with Ampicillin. Antimicr. Agents Chemother., 974, 6, 729-733. ",Data average of 2 cohhorts of 4 subjects. 5 and 30' infusion of 1 g of BLP1654. data reported as L/1.73m2 and mL/min/1.73 m2. 1.73m2/70 kg conversion factor used.,,1970,434.47,11,6,177.7,6,zwitterionic,0.061,-2.3
N12[C@@H]([C@@H](NC([C@@H](c3ccccc3)O)=O)C2=O)SCC(=C1C(O)=O)CSc1n(nnn1)CS(O)(=O)=O,-1.3959286763311392,0.8215083,Cefonicid,61270-58-4,0.14,0.38,0.02,5.8,5.1,"Cross-over study of the pharmacokinetics of cefonicid administered intravenously or intramuscularly to healthy adult humans. J.B. FOURTILLAN , A. LEROY, M.A. LEFEBVRE , G. HUMBERT, J.P. FILLASTRE, G. REUMONT and N. RAMIS. EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS, 1985, 10, 225-230. //ppb:Dudley, Michael N.; Shyu, Wen Chyi; Nightingale, Charles H.; Quintiliani, Richard. Effect of saturable serum protein binding on the pharmacokinetics of unbound cefonicid in humans Antimicr. Ag Chemother. 1986, 30, 565-569. Ex vivo data and concentration dependent. 2% free at 100 ug/mL. 18% free immediately after administration iv.","Reported data in Table II:
AUC = 621 ug*h/mL t1/2 = 5.24 h CLt = 25.8 ml/min/l.73m2. Calculated AUC  =  633.2  µg-h/mL. Average weight 68 kg.",,1976,542.57,14,4,204.9,9,anionic,-1.5,-6.7
N12[C@@H]([C@@H](NC(\C(c3csc(n3)N)=N/OC)=O)C2=O)SCC(=C1C(O)=O)CSc1n(nnn1)C,1.867896463992655,0.6373559,Cefmenoxime,65085-01-0,0.2,3.65,0.31,0.77,0.89,"Granneman, G. Rrichard; Sennello, Lawrence T.; Steinberg, Frank J.; Sonders, Robert C. Intramuscular and intravenous pharmacokinetics of cefmenoxime, a new broad-spectrum cephalosporin, in healthy subjects.Antimicrobial Agents and Chemotherapy (1982), 21(1), 141-5. ppb: MASAHIRO KONDO, YUMIKO NOJI and KANJI TSUCHIYA. Binding of cefmenoxime (SCE-1365) to human serum proteins. Chemother. (Tokyo) 1981, 29 (S-1) 200-205.","Average of 30 subjects in 6 cohorts, 3 intravenous infusion and 3 intravenous bolus injections. 500, 1000, 2000 mg doses in each dosing regimen.",,1977,511.56,14,3,190.8,8,anionic,-0.15,-3.2
N12[C@H](C(S[C@@H]2[C@](C1=O)(OC)NC(=O)[C@@H](c1cscc1)C(=O)O)(C)C)C(=O)O,-1.5563933485243853,0.36376595,Temocillin,66148-78-5,0.11,0.34,0.21,5.2,4.1,"M.R. Lockley, R.M. Brown and R. Wise. Pharmacokinetics and Tissue Penetration of Temocillin. Drugs 1985, 29 (Suppl. 5): 106-108//ppb: Overbosch, D.; Van Gulpen, C.; Mattie, H. Renal clearance of temocillin in volunteers. Drugs, 1985, 29, 128-134.","BRL 17421. N=6, 1 g dose and 69.2 kg as average weight reported. Data digitized from plot. AUCinf calculated within 2% of reported if AUCinf (not specified)  or within 10% if AUClast.//ppb concentration dependent. Midpoint taken between 0.17 and 0.26.",,1978,414.45,9,3,133.2,6,anionic,0.81,-5.7
N1C(Cc2c1cccc2CCN(CCC)CCC)=O,4.906890595608519,3.447789,Ropinirole,91374-21-9,7.7,30.0,0.6,4.3,6.0,"Ropinirole Hydrochloride - FDA Approval Package
Pharmacology Review 020658/S-000 Part 01. Accessed through Pharmapendium.","VDss reported but not sure whether from po or iv data. ""absorption"" reported as 100%","   Ropinirole Hydrochloride - FDA Approval Package
Clinical Pharmacology and Biopharmaceutics Review 020658/S-000. Oral data. 88% of radioactivity excreted in urine with less than 10% as unchanged drug.",1984,260.37,3,1,32.3,7,cationic,2.9,1.1
N1C(\C(c2ccccc12)=C/c1[nH]c(cc1C)C)=O,3.807354922057604,1.7029629,Semaxanib,194413-58-6,0.98,14.0,0.008,1.17,0.83," Sukbuntherng, Juthamas; Cropp, Gillian; Hannah, Alison; Wagner, Gregory S.; Shawver, Laura K.; Antonian, Lida. Pharmacokinetics and interspecies scaling of a novel VEGF receptor inhibitor, SU5416.  Journal of Pharmacy and Pharmacology (2001), 53(12), 1629-1636","TSU16. Data in rat, dog and monkey available in the same reference. N=69, 0.1-5 mg/kg iv, cancer patients with advanced malignancies and on a variety of concomitant medications. Human data originally reported by Cropp et al at conference proceedings. Deemed accurate.","Semoxind, SU5416. Mixture of diastereomers reported as semaxinib with CAS# 204005-46-9",1998,238.28,3,2,44.9,1,neutral,2.2,2.2
N1[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)O)Cc2ccc(cc2)O)CCCNC(=N)N)Cc2ccccc2)CO)CC(=O)N)CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](N)CO)CC(C)C)CCCNC(=N)N)CCCNC(=N)N)CO)CO)C(=O)N[C@H](C(=O)NCC(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)NCC1=O)CC(C)C)CO)CCC(=O)N)[C@@H](C)CC)CCCNC(=N)N)CC(=O)O)CCSC)CCCNC(=N)N)Cc1ccccc1,4.666756591884804,1.1403916,α-hANP,85637-73-6,0.2,25.4,,0.13,0.22,"Nakao, K.; Sugawara, A.; Morii, N.; Sakamoto, M.; Yamada, T.; Itoh, H.; Shiono, S.; Saito, Y.; Nishimura, K.; Ban, T.; Kangawa, K.; Matsuo, H.; Imura, H.  The pharmacokinetics of α-​human atrial natriuretic polypeptide in healthy subjects. Eur. J. Clin. Pharmacol., 1986, 31, 101-103.","α-Human Atrial Natriuretic Peptide. MRT calculated from reported VDss and clearance. N=6, 100 ug of synthetic peptide, bolus.",,1982,3080.44,84,53,1403.4,75,cationic,-9.0,-9.0
NC(=N)N1CCC[C@@H](CNC(=O)C[C@H](NS(=O)(=O)c2ccc3ccccc3c2)C(=O)N(CC(=O)O)C4CC4)C1,2.678071905112638,0.71239287,Napsagatran,154397-77-0,0.36,6.4,0.55,0.94,1.9,"Hauptmann J. (2002) Pharmacokinetics of an emerging new class of anticoagulant/antithrombotic drugs A review of small-molecule thrombin inhibitors.  Eur J Clin Pharmacol  57: 751-758. ppb:Marilyn E. Morrisa,, Xinning Yanga, Yash A. Gandhia, Suraj G. Bhansalia, and Lisa J. Benincosa. Interspecies scaling: prediction of human biliary clearance and comparison with QSPKR. BIOPHARMACEUTICS & DRUG DISPOSITION Biopharm. Drug Dispos. 2012, 33: 1–14.",Ro 46-​6240,,1993,558.65,12,5,186.0,12,zwitterionic,0.68,-1.6
NC(=N)Nc1nc(CSCCC(=N)NS(=O)(=O)N)cs1,2.7224660244710908,1.5702689,Famotidine,76824-35-6,1.2,6.6,0.84,3.0,2.8,"Yeh KC, Chremos AN, Lin JH, Constanzer ML, Kanovsky SM, Hucker HB, Antonello J, Vlasses P, Ryan JR, and Williams RL (1987) Single-dose pharmacokinetics and bioavailability of famotidine in man.  Results of multicenter collaborative studies.  Biopharm. Drug Dispos. 8: 549-560.",VDss calculated from C vs t data obtained by digitization of the plots provided in the reference.,,1980,337.45,9,6,170.8,9,neutral,-1.3,-1.4
NC(=N)c1ccc(CNC(=O)[C@@H]2CCN2C(=O)[C@H](NCC(=O)O)C3CCCCC3)cc1,0.925999418556223,2.1292076,Melagatran,159776-70-2,0.23,1.9,0.93,2.0,1.6,"Eriksson UG, Bredberg U, Hoffmann KJ, Thuresson A, Gabrielsson M, Ericsson H, Ahnoff M, Gislen K, Fager G, and Gustafsson D (2003) Absorption, distribution, metabolism, and excretion of ximelagatran, an oral direct thrombin inhibitor, in rats, dogs, and humans.  Drug Metab. Dispos. 31: 294-305.",,,1996,429.51,9,5,148.6,9,cationic,-0.76,-2.6
NC(=N)c1ccc(OCCCCCOc2ccc(cc2)C(=N)N)cc1,6.20945336562895,2.429486,Pentamidine,100-33-4,53.0,74.0,0.09,12.0,25.0,"Conte JE, Duncan S, McKenna E, and Zurlinden E (1999) Effect of gender and race on the pharmacokinetics of pentamidine in HIV-infected patients.  Clin, Drug Invest. 17: 293-299.   fu from Lombardo et al J. Clin. Pharmacol. 2013, 53(2), 167-177 and 178-191. ppb: Sihyung Yang,Tanja Wenzler,Patrik N. Miller, Huali Wu,David W. Boykin, Reto Brun Michael Zhuo Wang Pharmacokinetic Comparison To Determine the Mechanisms Underlying the Differential Efficacies of Cationic Diamidines against First- and Second-Stage Human African Trypanosomiasis. Antimicrobial Agents and Chemotherapy 2014, 58, 4064-4074",,,1939,340.42,6,4,118.2,10,cationic,2.5,-1.2
NC(=N)c1ccc(cc1)C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N3CCC(CC3)OCC(=O)O,0.925999418556223,2.1452978,Lamifiban,144412-49-7,0.29,1.9,0.94,2.5,2.1,"Lave T, Saner A, Coassolo P, Brandt R, Schmitt-Hoffmann AH, and Chou RC (1996) Animal pharmacokinetics and interspecies scaling from animals to man of lamifiban, a new platelet aggergeation inhibitor.  J. Pharm. Pharmacol.  48: 573-577.",,,1992,468.5,10,5,166.0,9,zwitterionic,0.93,-0.3
NC(=O)CC[C@@H]1NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc3ccc(O)cc3)NC(=O)CCSSC[C@H](NC(=O)[C@H](CC(=O)N)NC1=O)C(=O)N4CCC[C@H]4C(=O)N[C@H](CCCNC(=N)N)C(=O)NCC(=O)N,0.4854268271702416,2.1359208,Desmopressin,16679-58-6,0.3,1.4,,3.6,3.0,"Rembratt A, Graugaard-Jensen C, Senderovitz T, Norgaard, JP, and Djurhuus JC (2004) Pharmacokinetics and pharmacodynamics of desmopressin administered orally versus intravenously at daytime versus night-time in healthy men aged 55-70 years. Eur. J. Clin. Pharmacol.  60: 397-402.",DDAVP. ,,1950,1069.22,26,14,435.4,20,cationic,-4.9,-8.4
NC(=O)CN1CC(O)CC1=O,0.84799690655495,2.892974,Oxiracetam,62613-82-5,0.55,1.8,,4.9,7.5,"Perucca E, Albrici A, Gatti G, Spalluto R, Visconti M, and Crema A (1984) Pharmacokinetics of oxiracetam following intravenous and oral administration in healthy volunteers.  Eur. J. Drug Metab. Pharmacokinet.  3: 267-274.",,,1977,158.16,5,2,83.6,2,neutral,-2.5,-2.5
NC(=O)NO,0.5849625007211562,2.6401732,Hydroxyurea,127-07-1,0.52,1.5,1.0,4.8,3.4,"Rodriguez GI, Kuhn JG, Weiss GR, Hilsenbeck SG, Eckardt JR, Thurman A, Rinaldi DA, Hodges S, Von Hoff DD, Rowinsky EK (1998) A bioavailability and pharmacokinetic study of oral and intravenous hydroxyurea.  Blood 91:1533-1541",,,1908,76.05,4,3,75.3,0,neutral,-1.5,-1.5
NC1=C(F)C=NC(=O)N1,1.0,2.3845572,Flucytosine,2022-85-7,0.68,2.0,1.0,5.7,4.2,"Cutler RE, Blair AD, and Kelly MR (1978) Flucytosine kinetics in subjects with normal and impaired renal function.  Clin. Pharmacol. Ther. 24; 333-342.  Lee KJ, Mower R, Hollenbeck T, Castelo J, Johnson N, Gordon P, Sinko PJ, Holme K, and Lee YH (2003) Modulation of nonspecific binding in ultrafiltration protein binding studies.  Pharm. Res. 20: 1015-1021.",,,1957,129.09,4,2,67.5,0,neutral,-2.3,-2.3
NC1=CC(=CNC1=O)c2ccncc2,3.1538053360790355,1.6842973,Amrinone,60719-84-8,1.3,8.9,0.89,2.4,2.0,"Hamilton RA, Kowalsky SF, Wright EM, Cernak P, Benziger DP, Stroshane RM, and Edelson J (1986)  Effect of the acetylator phenotype on amrinone pharmacokinetics.  Clin. Pharmacol. Ther. 40: 615-619.  Koprda V, Trnovec T, and Landmann H (1986) The binding of amrinone to plasma proteins.  Pharmazie 41: 300-301.",CL value from rapid acetylators only.,,1977,187.2,4,2,68.0,1,neutral,-0.67,-0.73
NC1=NC(=O)C2=C(NCC(CNc3ccc(cc3)C(=O)N[C@@H](CCC(=O)O)C(=O)O)N2C=O)N1,2.5360529002402097,0.9255797,Folinic acid,58-05-9,0.25,5.8,0.0869999999999999,0.8,1.3,"Greiner PO, Zittoun J, Marquet J, and Cheron JM (1989) Pharmacokinetics of (-)-folinic acid after oral and intravenous administration of the racemate. Br. J. Clin. Pharmacol. 28: 289-295.  Christophidis N, Louis WJ, Lucas I, Moon W, and Vajda FJ (1981) Renal clearance of methotrexate in man during high-dose oral and intravenous infusion therapy.  Cancer Chemother Pharmacol. 6: 59-64.  ",Data from (-) enantiomer used.,,1948,473.44,14,7,215.6,9,anionic,-2.1,-7.6
NC1=NC(=O)N(C=C1)[C@@H]2CO[C@H](CO)O2,1.263034405833794,2.7042634,Troxacitabine,145918-75-8,1.0,2.4,,6.9,82.0,"Giles FJ, Cortes JE, Baker SD, Thomas DA, O'Brien S, Smith TL, Beran M, Bivins C, Jolivet J, and Kantarjian HM. (2001) Troxacitabine, a novel dioxolane nucleoside analog, has activity in patients with advanced leukemia.  J. Clin. Oncol. 19: 762-771.",,,1992,213.19,7,2,97.4,2,neutral,-1.9,-1.9
NC1=NC(=O)N(C=C1)[C@@H]2O[C@H](CO)[C@@H](O)C2(F)F,5.0,2.8349278,Gemcitabine,95058-81-4,1.5,32.0,1.0,0.81,1.0,"Paitnik A, Eckhardt SG, Izbicka E, Tolcher AA, Hammond LA, Takimoto CH, Schwartz G, McCreery H, Goetz A, Mori M, terada K, Gentner L, Rybak ME, Richards H, Zhang S, and Rowinsky EK (2003) A phase I pharmacokinetic, and biological study of the farnesyltransferase inhibitor tipifarnib in combination with gemcitabine in patients with advanced malignancies.  Clin. Canc. Res. 9: 4761-4771.  Gemzar Product Label.",Parameters calculated from data obtained by digitization of the plot provided in the reference.,,1984,263.2,7,3,108.4,2,neutral,-1.9,-1.9
NC1=NC(=O)N(C=N1)[C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O,5.129283016944966,2.2021675,Azacytidine,320-67-2,0.47,35.0,,0.22,0.36,"Marcucci G, Silverman L, Eller M, Lintz L, and Beach CL (2005) Bioavailability of azacitidine subcutaneous versus intravenous in patients with the myelodysplastic syndromes.  J. Clin. Pharmacol. 45:  597-602. ",VDss was calculated using C vs t data obtained by digitization of the plot provided in the reference.,,1964,244.2,9,4,141.0,2,neutral,-3.0,-3.0
NC1=NC(=O)N(C=N1)[C@H]2C[C@H](O)[C@@H](CO)O2,7.022367813028454,3.2988544,Decitabine,2353-33-5,4.6,130.0,1.0,0.59,0.58,"van Groeningen CJ, Leyva A, O'Brien AMP, Gall HE, and Pinedo HM (1986) Phase I and pharmacokinetic study of 5-aza-2'-deoxycytidine (NSC 127716) in cancer patients.  Cancer Res. 46: 4831-4836.  Dacogen Product Label.",NSC 127716,,1964,228.21,8,3,120.7,2,neutral,-2.0,-2.0
NC1CCN(C1)c2c(F)cc3C(=O)C(=CN(C4CC4)c3c2Cl)C(=O)O,2.232660756790275,1.1205631,Clinafloxacin,105956-97-6,1.9,4.7,0.96,6.7,5.4,"Randinitis EJ, Brodfuehrer JI, Eiseman I, and Vassos AB (2001) Pharmacokinetics of clinafloxacin after single and multiple doses.  Antimic. Agents Chemother. 45: 2529-2535.  Wise R, Ashby JP, and Andrews JM.  In vitro activity of PD 127,391, an enhanced-spectrum quinoline.    Antimic. Agents Chemother.  1988, 32: 1251-1256.",,,1986,365.79,6,2,86.9,3,zwitterionic,2.6,0.29
NCC(CCC(O)=O)=O,0.9107326619029126,2.0860753,Aminolevulinic acid,106-60-5,0.12,1.88,0.88,1.06,0.83,1999-Nov-19  PDF(1255k) Pharmacology Review 020965/S-000. NDA 20-965 page 21.,"Levulan kerastick. N=6, 1.34 mg/kg. MRT from VDss and Cl.",,1948,131.13,4,2,80.4,4,zwitterionic,-2.0,-2.8
NCC1(CC(=O)O)CCCCC1,0.765534746362977,2.175301,Gabapentin,60142-96-3,0.71,1.7,0.97,7.0,5.3,"Vollmer KO, Anhut H, Thomann P, Wagner F, and Jahnchen D (1989) Pharmacokinetic model and absolute bioavailability of the new anticonvulsant gabapentin.  Adv. Epileptol. 17: 209-211.  Neurontin Product Label.",,,1976,171.24,3,2,63.3,3,zwitterionic,0.55,-1.7
NCCCC[C@H](N[C@@H](CCc1ccccc1)C(=O)O)C(=O)N2CCC[C@H]2C(=O)O,0.2630344058337938,1.5782218,Lisinopril,76547-98-3,0.89,1.2,1.0,12.0,42.0,"Beermann B, Till AE, Gomez HJ, Hichens M, Bolognese JA, and Junggren IL (1989) Pharmacokinetics of lisinopril (IV/PO) in healthy volunteers.  Biopharm. Drug Dispos. 10: 397-409.  Kirsten R, Nelson K, Kirsten D, and Heintz B (1988) Clinical  pharmacokinetics  of vasodilators. Part I.  Clin. Pharmacokinet. 34: 457-482. ",VDss calculated using C vs t data obtained by digitization of the plots provided in the reference.  Dose levels averaged.,,1980,405.49,8,4,133.0,12,anionic,0.66,-3.0
NCCCNc1ccc2c(CNCCO)nn3c4c(O)ccc(O)c4C(=O)c1c23,4.169925001442312,2.2119207,KW-2170,207862-44-0,12.0,18.0,,11.0,32.0,"Saeki T, Eguchi K, Takashima S, Sugiura T, Hida T, Horikoshi N, Aiba K, Kuwabara T, and Ogawa M (2004) Phase I and pharmacokinetic study of KW-2170, a novel pyrazoloacridone compound, in patients with malignant tumors.  Cancer Chemother. Pharmacol.  54: 459-468.",,,1998,397.43,9,6,145.7,8,cationic,-0.21,-3.6
NCC[C@H](O)C(=O)N[C@@H]1C[C@H](N)[C@@H](O[C@H]2O[C@H](CN)[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@H]1O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O,0.137503523749935,1.3074199,Amikacin,37517-28-5,0.16,1.1,0.88,2.4,2.4,"Lanao JM, Dominguez-Gil A, Tabernero JM, and De Castro S (1979)  Pharmacokinetics of amikacin (BB-K8) in patients with normal or impaired renal function.  Int. J. Clin. Pharmacol. Biopharm. 17: 171-175.  Clarke JT, Libke RD, Regamey C, and Kirby WMM (1974) Comparative pharmacokinetics of amikacin and kanamycin.  Clin. Pharmacol. Ther.  15: 610-616.  Brunnemann SR and Segal JR (1991) Amikacin serum protein binding in spinal cord injury.  Life Sci. 49: PL1-PL5.",CL calculated from reported compartmental model parameters. Protein binding data averaged from two papers.,,1974,585.6,18,13,331.9,10,cationic,-9.0,-9.0
NC[C@@H](O)C[C@H]5O[C@H]4C[C@H]9O[C@@H](CC[C@@H]1O[C@H](CC1=C)CC[C@@]32O[C@@H]6[C@@H]8O[C@H](C2)[C@H](O3)[C@@H]8O[C@H]7CC[C@H](CC(=O)O[C@@H]4[C@H]5OC)O[C@H]67)C[C@@H](C)C9=C,-0.4150374992788438,1.4344338,Eribulin,253128-41-5,1.46,0.75,0.43,32.5,37.8,"A Phase I Study of EribulinMesylate (E7389), a Mechanistically Novel Inhibitor of Microtubule Dynamics, in Patients with Advanced SolidMalignancies
Sanjay Goel, Alain C.Mita, MonicaMita, Eric K. Rowinsky, Quincy S. Chu, NancyWong, Christopher Desjardins, FangF ang, Mendel Jansen, Dale E. Shuster,SridharMani,and Chris H.Takimoto. Clin Cancer Res 2009;15:4207-. ppb: The PDr reports: The human plasma protein binding of eribulin  at concentrations of 100 ng/mL to 1,000 ng/mL ranges from 49% to 65%. 57% taken as median. Accessed December 31 2014. http://www.pdr3d.com/detail.php?c=128591#section-12","E 7389. 0.25-1.4 mg/m2, 1.73m2/70kg conversion factor. Total number of patients 31. Weighted average",,1999,731.87,13,2,155.6,4,cationic,2.1,0.36
NC[C@@H]1CC[C@@H](N)[C@@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)O1,-0.3219280948873623,1.7271703,Dibekacin,34493-98-6,0.13,0.8,,2.7,2.4,"Arancibia A, Chavez J, Ibarra R, Ruiz I, Icarte A, Thambo S, and Chavez H (1987) Disposition kinetics of dibekacin in normal subjects and in patients with renal failure.  Int. J. Clin. Pharmacol, Ther. Toxicol. 25: 38-43.  Goto M, Sugiyama M, and Ishizaki T (1980) Pharmacokinetic studies with dibekacin, a new aminoglycoside, after intravenous and intramuscular administration to human volunteers.  Antimic. Agents Chemother. 18: 372-376.",Plasma concentrations measured with a bioassay.,,1971,451.52,13,9,247.9,6,cationic,-6.0,-8.0
NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)[C@H](N)C[C@@H]1O,0.6780719051126377,1.8256304,Tobramycin,32986-56-4,0.23,1.6,1.0,2.4,2.0,"Bourget P, Fernandez H, Delouis C, abd Taburet AM (1991) Pharmacokinetics of tobramycin in pregnant women, safety and efficacy of a once-daily dose regimen.  J. Clin. Pharm. Ther.  16: 167-176.  Champoux N, Du Souich P, Ravaoarinoro M, Phaneuf D, Latour J, and Cusson JR (1996) Single-dose pharmacokinetics of ampicillin and tobramycin administered by hypodermoclysis in young and older healthy volunteers.  Br. J. Clin. Pharmacol. 42: 325-331.  Gordon RC, Regamey C, and Kirby WMM (1972) Serum protein binding of the aminoglycoside antibiotics.  Antimic. Agents Chemother. 2: 214-216.",Data from Champeaux et al was digitized to calculate parameters.  ,,1971,467.51,14,10,268.2,6,cationic,-7.0,-8.5
NCc1ccccc1CC(=O)N[C@H]2[C@H]3SCC(=C(N3C2=O)C(=O)O)CSc4nnnn4CC(=O)O,-0.5994620704162712,1.3221848,Ceforanide,60925-61-3,0.17,0.66,0.19,4.3,3.0,"Pfeffer M, Gaver RC, and Van Harken DR (1980) Human pharmacokinetics of a new broad-spectrum parenteral cephalosporin antibiotic, ceforanide.  J. Pharm. Sci. 69: 398-403.",,,1976,519.55,13,4,193.6,10,anionic,-1.3,-4.7
NS(=O)(=O)c1cc(ccc1Cl)C2(O)NC(=O)c3ccccc23,0.5849625007211562,1.7546023,Chlorthalidone,77-36-1,3.9,1.5,0.24,43.0,36.0,"Fleuren HLJ, Thien TA, Verwey-van Wissen CPW, and von Rossum JM (1979) Absolute bioavailability of chlorthalidone in man: a cross over study after intravenous and oral administration.  Eur. J. Clin. Pharmacol. 15: 35-50.  Dieterle W, Wagner J, and Faigle JW (1976)  Binding of chlorthalidone (Hygroton) to blood components in man.  Eur. J. Clin. Pharmacol. 10: 37-42.",,,1959,338.77,6,3,109.5,2,neutral,0.85,0.84
NS(=O)(=O)c1cc2c(NCNS2(=O)=O)cc1C(F)(F)F,3.277984747299765,0.85883707,Hydroflumethiazide,135-09-1,2.2,9.7,,3.8,5.2,Broers O and Jacobsen S (1979) Distribution and elimination of hydroflumethiazide in man.  Eur. J. Clin. Pharmacol. 16: 125-131.,VDss calculated from reported micro constants.  CL calculated from Vdbeta and t1/2,,1959,331.29,7,3,118.4,1,neutral,0.047,0.032
N[C@@H](C)[C@H](O)CCCCCCCCCCCCCCC,5.84799690655495,2.304696,Spisulosine,196497-48-0,30.7,57.6,,8.89,29.7,"Massard, C.; Salazar, R.; Armand, J. P.; Majem, M.; Deutsch, E.; Garcia, M.; Oaknin, A.; Fernandez-Garcia, E. M.; Soto, A.; Soria, J. C. Phase I dose-escalating study of ES-285 given as a three-hour intravenous infusion every three weeks in patients with advanced malignant solid tumors. Investigational New Drugs 2012, 30, 2318-2326.","ES-285. N=54 across doses from 4 to 256 mg/m2. Weight-averaged for number of patients at each dose. 3-hr infusion q3wk. Large range for VDss somewhat less for clearance. Clearance within a factor of 2 from largest to smallest value across dose, but VDss > 1o-fold between largest (3786 L) and smallest (334 L) values. Even larger spread for t1/2 ranging from 51 to 0.6 hours. MRT calculated as VDss/Cl. ",,1997,285.51,2,2,46.3,15,cationic,6.6,4.3
N[C@@H](Cc1ccc(O)c(O)c1)C(=O)O,4.523561956057013,1.894665,Levodopa,59-92-7,1.7,23.0,0.76,1.2,1.3,"Robertson DRC, Wood ND, Everest H, Monks K, Waller DG, Renwick AG, and George CF (1989) The effect of age on the pharmacokinetics of levodopa administered alone and in the presence of carbidopa.  Br. J. Clin. Pharmacol. 28: 61-69.  Rizzo V, Memmi M, Moratti R, Melzi d'Eril G, and Perucca E (1996) Concentrations of L-dopa in plasma and plasma ultrafiltrates.  J. Pharm. Biomed. Anal. 14: 1043-1046",,,1932,197.19,5,4,103.8,3,zwitterionic,-0.25,-1.9
N[C@@H](Cc1ccc(cc1)N(CCCl)CCCl)C(=O)O,2.807354922057604,1.4962838,Melphalan,148-82-3,0.48,7.0,0.14,1.1,1.0,"Woodhouse KW, Hamilton P, Lennard A, and Rawlins MD (1983) The pharmacokinetics of melphalan in patients with multiple myeloma: an intravenous/oral study using a conventional dosing regimen.  Eur. J. Clin. Pharmacol. 24: 283-285.  Hersh MR, Ludden TM, Kuhn JG, and Knight WA (1983) Pharmacokinetics of high dose melphalan.  Invest. New Drugs. 1: 331-334.  Gera S, Musch E, Osterheld HKO, and Loos U (1989) Relevance of the hydrolysis and protein binding of melphalan to the treatment of multiple myeloma.  Canc. Chemother. Pharmacol. 23: 76-80.  Grieg NH, Sweeney DJ, and Rapoport SI (1987) Melphalan concentration dependent protein binding in healthy humans and rats.  Eur. J. Clin. Pharmacol. 32: 179-185.",,,1946,305.2,4,2,66.6,8,zwitterionic,2.0,0.36
N[C@@H]([C@@H]1CC(=NO1)Cl)C(=O)O,-0.5353317329965557,1.3031712,Acivicin,42228-92-2,0.5,0.69,,12.0,9.9,"McGovern JP, Pratt EA, Belt RJ, Taylor SA, Benjamin RS, Ardalan B, and Ohnuma T (1985) Pharmacokinetic and biochemical studies on acivicin in phase I clinical trials.  Canc. Res.  45: 4460-4463.",VDss was calculated from C vs t data obtained by digitization of a plot for one subjected that was included in the reference.  Plasma concentrations were determined by bioassay.,,1973,178.57,5,2,84.9,2,zwitterionic,-0.38,-2.7
N[C@@H]1[C@@H]([C@@H](O[C@H](O[C@@H]2c3c(O)c4C(=O)c5c(OC)cccc5C(=O)c4c(O)c3C[C@@](C2)(O)C(CO)=O)C1)C)O[C@@H]1CCCCO1,5.85049941375812,3.0171018,Pirarubicin,72496-41-4,43.2,57.7,,12.5,11.1,"Dominique Marchiset-Leca,  Francois-Ren, Leca Anne Galeani, Alex Noble, Jacques Catalin Pharmacokinetics and metabolism of pirarubicin in humans: correlation with pharmacodynamics Cancer Chemother Pharmacol (1995) 36:239 243, 1995","Essentially a prodrug of doxorubicin. 80 courses of therapy over 27 patients. 1.73 m2/70 kg used as conversion factor. 25 to 50 mg/m2 in an average of 10 min infusion (5-15 min). Also, Nagasawa et al, J. Pharmacobio-Dynam., 1991, 14, 422-430. Data in 10 pediatric patients in agreement with cited paper.",Based on ratio of metabolites and parent in plasma. No excretion data available.,1978,627.64,13,5,204.3,7,zwitterionic,1.7,1.3
N\N=C\1/NN=Cc2ccccc12,6.409390936137702,2.2764158,Hydralazine,86-54-4,1.5,85.0,0.12,0.29,1.0,"Ludden TM, Shepherd AMM, McNay JL, and Lin MS (1983) Effect of intravenous dose on hydralazine kinetics after administration.  Clin. Pharmacol. Ther.  34: 148-152.  Kirsten R, Nelson K, Kirsten D, and Heintz B (1998) Clinical  pharmacokinetics  of vasodilators. Part I.  Clin. Pharmacokinet. 34: 457-482.  ","From Ludden, et al., used 1.02 umol/kg dose group.  Blood values corrected to plasma using B/P=1.68.  ",,1949,160.18,4,2,62.8,0,cationic,2.4,-1.1
Nc1c(CC(=O)O)cccc1C(=O)c2ccc(Br)cc2,0.3785116232537298,1.7025638,Bromfenac,91714-94-2,0.11,1.3,0.0011,1.5,2.6,"Gumbhir-Shah K, Cevallos WH, DeCleene SA, Halstenson CE, and Korth-Bradley JM (1997) Absolute bioavailability of bromfenac in humans.  Ann. Pharmacother. 31: 395-399.",,,1984,334.16,4,2,80.4,4,anionic,3.3,0.33
Nc1c2CCCCc2nc3ccccc13,5.807354922057604,1.8051407,Tacrine,321-64-2,11.0,56.0,0.25,3.3,3.3,"Lou G, Montgomery PR, and Sitar DS (1996) Bioavailability and pharmacokinetic disposition of tacrine in elderly patients with Alzheimer's disease.  J. Psych. Neurosci.  21: 334-339.  Makela PM, Truman CA, Ford JM, and Roberts CJC (1994) Characteristics of plasma protein binding of tacrine hydrochloride: a new drug for Alzheimer's disease. Eur. J. Clin. Pharmacol. 47:  151-155.",,,1945,198.26,2,1,38.9,0,cationic,3.3,0.83
Nc1ccc(O)c(c1)C(=O)O,3.2172307162206693,1.3385221,"Aminosalicylic acid, 5-",89-57-6,0.33,9.3,0.39,0.59,0.61,"Bondesen S, Hegnhoj J, Larsen F, Hansen H, Hansen CP, and Rasmussen SN (1991) Pharmacokinetics of 5-aminosalicylic acid in man following administration of intravenous bolus and per os slow-release formulation.  Digest. Dis. Sci.  12: 1735-1740.  Way EL, Smith PK, Howie DL, Weiss R, and Swanson R (1948) The absorption, distribution, excretion, and fate of para-aminosalicylic acid.  J. Pharmacol. Exp. Ther. 93: 368-382.  Kurz H, Mauser-Ganshorn A, and Stickel HH (1977) Differences in the binding of drugs to plasma proteins from newborn and adult man. I. Eur. J. Clin. Pharmacol. 11: 463-467.",Mesalamine. Mesalazine. VDss and t1/2 calculated from data obtained by digitization of C vs t plots provided in the references.,,1907,153.14,4,3,83.6,1,anionic,0.67,-2.6
Nc1ccc(cc1)S(=O)(=O)Nc2ncccn2,-0.862496476250065,0.94551575,Sulfadiazine,68-35-9,0.29,0.55,0.44,8.8,7.0,"Mannisto PT, Mantyla R, Mattila J, Nykanen S, and Lamminsivu (1982) Coparison of pharmacokinetics of sulphadiazine and sulphamethoxazole after intravenous administration.  J. Antimic. Chemother. 9: 461-470.  Wijkstroem A and Westerlund D (1983) Plasma protein binding of sulfadiazine, sulfamethoxazole and trimethoprim determined by ultrafiltration. J. Pharm. Biomed. Anal. 1: 293-299. Winter and Unadkat DMD (2005) 33(7) 969-967",VDss deteremined from Cvs t data obtained by digitization of plots in the reference.  ,,1900,250.28,6,2,98.0,3,anionic,0.11,-0.75
Nc1ccc(cc1)S(=O)(=O)c2ccc(N)cc2,-1.0588936890535685,1.354584,Dapsone,80-08-0,0.83,0.48,0.25,29.0,22.0,Pieters FAMJ and Zuidema J (1987) The absolute bioavailability of dapsone in dogs and humans.  Int. J. Clin. Pharmacol. Ther. Toxicol. 25: 396-400.  Biggs JT and Levy L (1971)  Binding of dapsone and monacetyldapsone by human plasma proteins.  Proc. Soc. Exp. Biol. Med. 137: 692-695.,VDss calculated from C vs t data obtained by digitization of plot provided in the reference.,,1908,248.3,4,2,86.2,2,neutral,0.97,0.97
Nc1n[n+]([O-])c2ccccc2[n+]1[O-],3.1538053360790355,2.1182604,Tirapazamine,27314-97-2,0.56,8.9,0.81,1.0,0.78,"Senan S, Rampling R, Graham MA, Wilson P, Robin H, Eckardt N, Lawson N, McDonald A, von Roemeling R, Workman P, and Kaye SB (1997) Phase I and pharmacokinetic study of tirapazamine (SR 4233) administered every three weeks.  Clin. Cancer Res. 3: 31-38.  Robin H, Senan S, Workman P, and Graham MA (1995) development and validation of a sensitive solid-phase extraction and high performance liquid chromatoigraphy assay for the bioreductive agent tirapazamine and its major metabolites in mouse and human plasma for pharmacokinetically guided dose selection.  Canc. Chemother. Pharmacol. 36: 266-270.",,,1957,178.15,6,1,92.8,0,neutral,-1.7,-1.7
Nc1nc(N)c2nc(c(N)nc2n1)c3ccccc3,5.977279923499917,1.6180276,Triamterene,396-01-0,13.0,63.0,0.42,3.4,4.3,"Gilfrich HJ, Kremer G, Mohrke W, Mutschler E, and Volger KD (1983) Pharmacokinetics of triamterene after i.v. administration to man: determination of bioavailability.  Eur. J. Clin. Pharmacol. 25: 237-241.  Hasegawa J, Lin ET, Williams RL, Sorgel F, and Benet LZ  (1982) Pharmacokinetics of triamterene and its metabolite in man.  J. Pharmacokinet. Biopharm. 10: 507-523.",,,1954,253.26,7,3,129.6,1,neutral,1.1,1.1
O(C(=O)C(c1sccc1)(O)c1cccs1)C1C[C@@H]2[C@H]3O[C@H]3[C@H](C1)[N+]2(C)C,3.655351828612554,2.3152666,Tiotropium,186691-13-4,32.0,12.6,0.28,42.3,,"Tiotropium Bromide Monohydrate - FDA Approval Package
Label 021395/S-014. See also, Tiotropium Bromide Monohydrate - FDA Approval Package
Clinical Pharmacology and Biopharmaceutics Review 021395/S-000 Part 01. Accessed through Pharmapendium.",Structure and smiles refer to cation. 70 kg average weight assumed. MRT from VDss and clearance. T1/2 estimated between 5-6 days (~ 132 hours),"Tiotropium Bromide Monohydrate - FDA Approval Package
Label 021395/S-014. Accessed through Pharmapendium. 74% excreted unchanged.",1997,392.51,5,1,59.1,5,neutral,-2.3,-2.3
O(C)c1c2c3c(c(c1OC)Br)CCN([C@H]3Cc1cc(c(cc1)OC)Oc1ccc(C[C@H]3c4cc(O2)c(OC)cc4CCN3C)cc1)C,3.263034405833794,1.7116661,Bromotetrandrine,62067-29-2,51.0,9.6,0.22,88.2,59.4," Zheng L; Qing Y-P; Xu N; Yu Q; Wang Y; Wang F-P; Li Z-Y. Pharmacokinetics and safety of bromotetrandrine (BrTet, W198) after single-​dose intravenous administration in healthy Chinese volunteers. Journal of clinical pharmacy and therapeutics (2010), 35(1), 113-119.//ppb: Xiao SH, Wei GL, Lu R, Liu CX, Wang FP. Pharmacokinetics of bromotetrandrin (W198) in rats and beagle dogs. Yao Xue Xue Bao. 2004, 39, 301-304. ","Data digitized from plot reported. N=10, 30 mg/m2 dose only. AUC reported 1311.3 ug.h/L. Calculated AUC 1279.4 ng.h/mL. From ppb reference (abstract): The plasma protein binding ratio of W198 with human serum protein was 78.0%.",,1977,701.65,8,0,61.9,4,cationic,8.3,7.2
O([C@@H]1[C@@H]([C@H]([C@H](O[C@@H]2[C@H](O[C@@H](OC[C@@H]([C@@H](\C=C\CCCCCCCCCCCCC)O)NC(CCCCCCCCCCCCCCCCC)=O)[C@@H]([C@H]2O)O)CO)O[C@@H]1CO)O)OC[C@@H]([C@@H]([C@H]1[C@@H]([C@H](C[C@](O1)(C(O)=O)O)O)NC(C)=O)O)O)[C@H]1[C@@H]([C@H]([C@@H](O)[C@H](O1)CO)O[C@@H]1O[C@@H]([C@H](O)[C@@H]([C@H]1O)O)CO)NC(C)=O,-5.643856189774724,-1.360401,Ganglioside GM1,37758-47-7,0.07,0.02,,55.0,77.4,"Rost, K. Ludwig; Brockmoeller, Juergen; Weber, Willi; Roots, Ivar. Multiple-dose pharmacokinetics of ganglioside GM1 after intravenous and intramuscular administration to
healthy volunteers. Clin. Pharmacol. Ther. 1991, 50, 141-149.","Ganglioside A2. Ganglioside G4. Ganglioside GM1A. N=3 subjects, 21 d dosing at 100 mg/day iv. 68.8 kg average weight. No data reported but indication that the compound is very highly bound to plasma proteins.",,1969,1546.82,34,20,540.6,52,anionic,-0.53,-4.0
O([C@H]([C@H](NC(c1nc([C@@H](NC[C@@H](C(N)=O)N)CC(N)=O)nc(c1C)N)=O)C(N[C@@H]([C@H]([C@@H](C(N[C@H](C(NCCc1nc(c2nc(C(NCCC[S+](C)C)=O)cs2)cs1)=O)[C@@H](C)O)=O)C)O)C)=O)c1c[nH]cn1)[C@@H]1[C@@H](O[C@@H]2[C@@H]([C@@H]([C@@H](O)[C@@H](O2)CO)OC(N)=O)O)[C@@H]([C@@H](O)[C@@H](O1)CO)O,0.3334237337251918,1.889761,Bleomycin,11056-06-7,0.43,1.26,,5.77,3.9,FDA label Accessed October 1 2018. https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/050443s036lbl.pdf,Data reported in L/m2. 1.73 m2/70 kg. MRT from VDss and clearance.,,1966,1415.55,38,20,627.1,36,cationic,-9.0,-9.0
O1[C@@H](O[C@@]23[C@@]4([C@@H]([C@@]5(C[C@@]2(C)O[C@@H]4O5)O)C3)COC(=O)c2ccccc2)[C@@H]([C@H]([C@@H]([C@H]1CO)O)O)O,1.0356239097307212,2.2977753,Paeoniflorin,23180-57-6,0.22,2.05,0.77,1.83,1.49,"Xiaobing Li  Fuguo Shi, Pan Gua, Lingye Liua, Hua Heb,, Li Dinga. A sensitive LC–MS/MS method for simultaneous determination of amygdalin and paeoniflorin in human plasma and its application.  Journal of Pharmaceutical and Biomedical Analysis 92 (2014) 160–164// ppb: Sun, Bing-ting; Dai, Guo-liang; Zang, Yu-xin; Zhao, Wen-zhu; He, Shu-fen; Zong, Yang; Ju, Wen-zheng; Tan, Heng-shan. Determination of human plasma protein binding rates of three main components in Baixiangdan capsules.Zhongguo Shiyan Fangjixue Zazhi 2016, 22, 68-72.","N=2, 70 kg assumed. 4 hours infusion. Digitized from plot. Huoxue-Tongluo lyophilized powders for injection (6 g, containing 25.3 mg of amygdalin and 35.8 mg of paeoniflorin) were supplied by Jiangsu Kanion Pharmaceutical Co., Ltd. (Lianyun-gang, China). ppb averaged form measurements at three concentrations but very close.",,1963,480.46,11,5,164.4,7,neutral,-1.2,-1.2
O1[C@@H]([C@@H](CC[C@H]1[C@@H](N)C)N)O[C@@H]1[C@H]([C@@H]([C@H](OC)[C@H](N(C)C(CN)=O)[C@H]1O)O)N,0.4541758931858021,1.7255982,Astromicin,55779-06-1,0.23,1.37,,2.8,2.0,"Nakashima, Mitsuyoshi; Takiguchi, Yoshiharu; Inoue, Akinobu; Kobayashi, Satoshi. Phase I study on intravenous drip infusion of astromicin. apanese Journal of Antibiotics. 1986, 39, 1453-1472.","KW-1070. 200 mg dose, N=6, Average weight 70.8 kg. 1 hr intravenous drip. VDss calculated from Vc and k12/k21 ratio. MRT = VDss/clearance.",,1975,405.49,11,6,192.5,6,cationic,-4.6,-7.7
O1[C@@H]2C[C@H]3[C@@H]4C[C@H](F)C5=CC(=O)C=C[C@@]5(C)[C@H]4[C@H](C[C@@]3([C@]2(C(CO)=O)OC1(C)C)C)O,3.2479275134435857,1.7624376,Flunisolide,3385-03-3,1.08,9.5,0.24,1.89,1.68,"Flunisolide metabolism and dynamics of a metabolite.Chaplin MD, Rooks W II, Swenson EW, Cooper WC, Nerenberg C and Chu NI. Clin Pharmacol Ther 1980, 27:402-413.//ppb: Loren M. Berry, Chao Li, and Zhiyang Zhao. Species Differences in Distribution and Prediction of Human Vss from Preclinical Data Drug Metab. Disp. 2011, 39, 2103-2106.","N=9, 1 mg dose. Calculated from reported plot (figure 3) in blood corrected for B/P =0.89. Data in blood and 0.89 B/P reported. Table involving 12 subjects (median weight 81.8 kg) but plot referring to 9 of them. The calculations below were performed after a correction to yield plasma concentration and some adjustment of time points digitized to approach reported AUC (C0 inserted manually). Reported blood AUC for N=12 17.64 hr*ng/mL corresponding to 19.82 hr*ng/mL. 8% difference from computed values.  ",,1963,434.5,6,2,93.1,2,neutral,2.5,2.5
O1[C@H](CC[C@@H](N(C)C)[C@@H]1C)O[C@@H]1[C@@H](C[C@@H]([C@@H]([C@@H](OC)[C@@H](CC(O[C@H](C)CC=CC=C1)=O)O)O[C@@H]1O[C@@H]([C@H]([C@@H]([C@H]1O)N(C)C)O[C@@H]1O[C@H]([C@@H]([C@@](C1)(O)C)O)C)C)CC=O)C,3.678071905112638,2.6681097,Spiramycin,8025-81-8,5.4,12.8,0.26,7.0,5.2,"A. M. Frydmana,Y. Le Rouxa, J. F. Desnottesa,  P. Kaplan, F. Djebbar, A. Cournof, J. Ducbier and J. Gaillofl Pharmacokinetics of spiramycin in man.Journal of Antimicrobial Chemotherapy (1988) 22, Suppl. B, 93-103. ppb: Hashimoto, T. FUNDAMENTAL STUDIES ON PHARMACOKINETICS OF ANTIBIOTICS. PART 1. BINDING OF ANTIBIOTICS TO PLASMA PROTEINS. Chemotherapy (Tokyo). 1973, 21, 38-44","0.5 g dose, 69 kg average weight, N=12, data from Table II study A. MRT from VDss and clearance. 17·1% and 6% binding to albumin and a1-acid glycoprotein respectively",,1954,843.05,16,4,195.4,11,cationic,2.0,0.92
O1[C@H](O[C@H]2[C@@H](C[C@@H]([C@H]([C@@H]2O)O[C@H]2O[C@@H](CC[C@H]2N)CN)N)NC([C@H](CCN)O)=O)[C@H](O)[C@H]([C@@H]([C@H]1CO)O)N,0.3561438102252753,1.7420158,Arbekacin,51025-85-5,0.21,1.28,,2.73,2.46,"HIROMI KUMON, AKIHIRO MIZUNO, YOSHITSUGU NASU, MASAYA TSUGAWA,
MIKIO KISHI and HIROYUKI OHMORI. PHARMACOKINETICS OF ARBEKACIN IN HEALTHY VOLUNTEERS AND PATIENTS WITH RENAL INSUFFICIENCY","HBK. N=3, healthy adults (CCr 100 mL/min). MRT from clearance and VDss, 70 kg average weight assumed.",renal clearance 1.12 mL.min-1.kg-1 (87%),1973,552.62,16,11,297.3,10,cationic,-7.5,-9.0
O1[C@H]2[C@@H]([C@H]([C@H]1[C@H](O)CO)OCCCN(C)C)OC(C)(C)O2,1.7990873060740036,2.9658206,Amiprilose,56824-20-5,1.04,3.48,0.97,5.0,4.07,"Garrett E R; Van Peer A; Altmayer P; Schuermann W; Lucker P. Pharmacokinetics of the immunomodulatory 1,2-O-isopropylidene-3-O-3'-(N',N'-dimethyl-amino-n-propyl)-Dglucofuranose
hydrochloride in normal human volunteers. J. Pharmacokin. Biopharm. 1982, 10, 247-264","3-O-(3-(Dimethylamino)propyl)-1,2-O-(1-methylethylidene)-alpha-D-glucofuranose. 96% excreted in urine. All subjects taken. VDss calculated from MRT and clearance. MRT in turn calculated via C1, C2 and lambda 1 and lambda 2. All values taken from overall means.",,1975,305.37,7,2,80.6,7,cationic,-0.32,-2.4
O=C(Cc1csc(N)n1)Nc3ccc(CCNC[C@H](O)c2ccccc2)cc3,3.765534746362977,2.6326277,Mirabegron,223673-61-8,23.8,13.6,0.29,29.3,50.0,"Mirabegron, prescribing information. PDR. Accessed July 31 2014. http://www.pdr3d.com/detail.php?c=91002#section-12","Assumed 70 kg as average weight.MRT from VDss and clearance.  See also:  Eltink, Charlotte et al. Int. J.  Clin. Pharmacol. Ther., 2012, 50, 838-849.",,1999,396.51,6,4,100.3,9,cationic,1.8,0.34
O=C(N(CCC1)[C@@H]1C(N[C@]([C@@H](C)CC)([H])C(N[C@H](C(N[C@]([C@H](O)C)([H])C(N[C@H](C(NCC(N[C@@H](CCC(O)=O)C(N[C@@H](CC(C)C)C(N[C@@H](CCC(N)=O)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CC(C)C)C(N[C@@H](CCC(N)=O)C(N[C@@H](CCC(O)=O)C(N[C@@H](CCCCN)C(N[C@@H](CCC(O)=O)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CC(N)=O)C(N[C@@H](CCCCN)C(NCC(N[C@@H](CCC(N)=O)C(N[C@H](C(O)=O)CCO)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)CC2=CC=C(O)C=C2)=O)=O)CC3=CC=CC=C3)=O)=O)[C@H](C(C)C)NC([C@@H](N)CC4=CC=CC=C4)=O,3.0143552929770703,1.1101191,SK-896,131418-27-4,0.07,8.08,0.03,0.14,0.08,"Yoshiyuki Furuta, Yukiharu Nakayama, Mitsuyoshi Nakashima, Yoshio Suzuki. Pharmacokinetic and
Pharmacodynamic Studies of SK-896, a New Human Motilin Analogue, in Healthy Male Volunteers. Clin Pharmacokinet 2003; 42 (6): 575-584
",Table I. SK-896 pharmacokinetic parameters during and after single intravenous infusion of the indicated doses over 20 minutes in healthy male volunteers. The values are geometric means (geometric SD) [range] for n = 6 ppb cited from ref. 21 in the reported reference. All data are average of different doses in the 10-80 ug infusion.,,1990,2782.11,72,41,1215.5,98,cationic,-9.0,-9.0
O=C(O[C@@H]1C[C@@H]2CC3C[C@H](C1)N2CC3=O)c4c[nH]c5ccccc45,7.491853096329675,3.0554168,Dolasetron,115956-12-2,2.0,180.0,0.49,0.19,0.13,"Dimmit DC, Choo YS, Martin LA, Arumugham T, Hahne WF, and Weir SJ (1999) Intravenous pharmacokinetcs and absolute oral bioavailability of dolasetron in healthyl volunteers: part 1.  Biopharm. Drug Disp. 20, 29-39. ppb: Stuart W. Paine, Karelle Menochet, Rebecca Denton, Dermot F. McGinnity, and Robert J. Riley. Prediction of Human Renal Clearance from Preclinical Species for a Diverse Set of Drugs That Exhibit Both Active Secretion and Net Reabsorption, Drug Metab. Disp. 2011, 39:1008–1013",Pharmacokinetic parameters were calculated from C vs t data obtained by digitization of the plot provided in the reference.,,1988,324.37,5,1,62.4,3,cationic,3.3,2.4
O=C([C@@H](N)CO)NC1=C(OC)C=CC(/C=C\C2=CC(OC)=C(OC)C(OC)=C2)=C1,4.498250867527825,2.3069959,Ombrabulin,181816-48-8,0.44,22.6,,0.32,0.26,"H. Murakami,T. Kurata, Y. Onozawa, J. Watanabe, A. Ono,T. Takahashi, N. Yamamoto, Y. Fujisaka, H. Kiyota, H. Hayashi,K. Tanaka, K. Nakagawa, S. Kuroda. An open‑label, dose‑escalation, safety, and pharmacokinetics
phase I study of ombrabulin, a vascular disrupting agent, administered as a 30‑min intravenous infusion every 3 weeks in Japanese patients with advanced solid tumors. Cancer Chemother Pharmacol (2014) 73:623–630",AVE8062. Weighted average of data reported in ref. 30' infusion. 70 kg average weight assumed. Dose range 15.5 to 50 mg/m2.,,1996,402.44,8,3,112.3,9,neutral,1.0,0.91
O=C([C@H](CSCCCC(N[C@@H](C1=O)CC2=CC=CC=C2)=O)NC([C@@H](NC([C@@](C)(NC([C@@H](N1)CC3=CC=CS3)=O)CC)=O)CC(N)=O)=O)N(C[C@H](O)C4)[C@@H]4C(N[C@@H](C(NCC(N)=O)=O)CCCNC(N)=N)=O,-0.2009126939259964,2.2507863,F992,162277-99-8,0.31,0.87,,5.63,4.28,"T. Callréus, J. Lundahl, A. Broeders, P. Höglund.  Pharmacokinetics and antidiuretic effect of a new vasopressin analogue (F992) in overhydrated male volunteers. Eur J Clin Pharmacol (1999) 55: 293-298.",Average of data reported in Table 1. 4 and 8 ug dose (N=8 in each case). Average weight 76.3,,1995,1028.21,24,13,392.3,18,cationic,-2.9,-6.0
O=C(c1ccccc1)c1sc(cc1)[C@@H](C(=O)O)C,-0.6896598793878495,0.683833,Tiaprofenic acid,33005-95-7,0.08,0.62,0.015,2.3,2.1,"Human Pharmacokinetics of Tiaprofenic Acid. Pottier J. Cousty-Berlin D., Busigny M. Rheumatol. 1982, 7, 70-77.// ppb reported as > 98.5 %. Fakhreddin Jamali, ALAIN, ANTHONY S . RUSSELL,C ARMEN  LEHMANN, AND BRIAN W . BERRY. Pharmacokinetics of taiprofenic acid in healthy and arthritic subjects. J. Phar.Sci.. 1985, 74, 953-956","Digitized from plot reported. N=5 female subjects, 400 mg dose, iv bolus. 60 kg average weight assumed.",,1971,260.31,3,1,54.4,4,anionic,2.7,-0.53
O=C1C(CCS(=O)c2ccccc2)C(=O)N(N1c3ccccc3)c4ccccc4,-1.5563933485243853,0.6376848,Sulfinpyrazone,57-96-5,0.12,0.34,0.017,5.9,6.2,"Lecaillion JB, Souppart C, Schoeller JP, Humbert G, and Massias P (1979) Sulfinpyrazone kinetics after intravenous and oral administration.  Clin. Pharmacol. Ther. 26: 611-617.  Schlicht F, Staiger C, de Vries J, Gundert-Remy U, Hildebrandt R, Harenberg J, Wang NS, and Weber E (1985) Pharmacokinetics of sulphinpyrazone and its major metabolites after a single dose and during chronic treatment.  Eur. J. Clin. Pharmacol. 28: 97-103.",VDss calculated from rate microconstants reported in the reference.,,1954,404.48,5,0,57.7,6,anionic,2.2,-1.2
O=C1CN(\N=C\c2oc(cc2)N(=O)=O)C(=O)N1,3.277984747299765,1.1074252,Nitrofurantoin,67-20-9,0.57,9.7,0.17,0.98,0.97,"Hoener BA and Patterson SE (1981) Nitrofurantoin disposition.  Clin. Pharmacol. Ther. 29: 808-816.  Kurz H, Mauser-Ganshorn A, and Stickel HH (1977) Differences in the binding of drugs to plasma proteins from newborn and adult man. I. Eur. J. Clin. Pharmacol. 11: 463-467.  Mannisto PT and Lamminsivu U (1982) Nitrofurantoin is highly bound to plasma protein. J. Antimic. Chemother. 9: 327-328.",,,1952,238.16,9,1,121.0,3,anionic,-0.64,-0.98
O=C1CN(\N=C\c2oc(cc2)c3ccc(cc3)N(=O)=O)C(=O)N1,-1.217591435072627,1.201638,Dantrolene,7261-97-4,0.37,0.43,,14.0,10.0,"Podranski T, Boullion T, Schumacher PM, Taguchi A, Sessler DI, and Kurz A (2005) Compartmental pharmacokinetics of dantrolene in adults: do malignant hyperthermia association dosing guidelines work? Anesth. Analg.  101: 1695-1699. ",,,1967,314.25,9,1,121.0,4,anionic,1.4,1.0
O=C1CN=C(c2ccccc2)c3cc(ccc3N1)N(=O)=O,-0.2175914350726268,1.4316142,Nitrazepam,146-22-5,1.7,0.86,0.13,33.0,26.0,"Jochemsen R, VanBeusekom BR, Spoelstra P, Janssens AR, and Breimer DD (1983) Effect of age and liver cirrhosis on the pharmacokinetics of nitrazepam.  Br. J. Clin. Pharmacol. 15: 295-302.  Jochemsen R, Hogendoorn JJH, Dingemanse J, Hermans J, Boeijinga JK, and Breimer DD (1982) Pharmacokinetics and bioavailability of intravenous, oral, and rectal nitrazepam in humans.  J. Pharmacokinet. Biopharm. 10: 231-245.",VDss calculated using C vs t data obtained by digitization of the plot provided in the references.,,1960,281.27,6,1,87.3,2,neutral,2.1,2.1
O=C1N(CCCCNC[C@H]2CCc3ccccc3O2)S(=O)(=O)c4ccccc14,1.1375035237499351,2.8353193,Repinotan,144980-29-0,0.21,2.2,,1.6,1.2,"Heining R,  Sundaresan P, Shah A and Boettcher M (2005) Effect of Gender and Age on the Pharmacokinetics of Repinotan.  Clin. Drug. Invest. 25: 125-134.  ",,,1992,400.49,6,1,75.7,7,cationic,3.9,3.5
O=C1N(C[C@H]2CCCc3cccc1c23)[C@@H]4CN5CCC4CC5,1.3785116232537298,2.3859465,Palonosetron,135729-61-2,6.3,2.6,0.38,40.0,39.0,"Stoltz R, Cyong JC, Shah A, and Parisi S (2004) Pharmacokinetic and safety evaluation of palonosetron, a 5-hydroxytryptamine-3 receptor antagonist, in U.S. and Japanese healthy subjects.  J. Clin. Pharmacol. 44: 520-531.   Siddiqui M, Asif A, and Scott LJ.(2004) Palonosetron.    Drugs 64: 1125-1132.",VDss was calculated from C vs t data obtained by digitization of the plot provided in the reference.,,1991,296.41,3,0,23.5,1,cationic,2.9,1.9
O=C1NC=Nc2[nH]ncc12,3.4594316186372973,2.1629605,Allopurinol,315-30-0,0.58,11.0,0.97,0.88,0.8,"Breithaupt H and Tittel M (1982) Kinetics of allopurinol after sinlge intravenous and oral doses.  Eur. J. Clin. Pharmacol. 22: 77-84.  Elion GB, Kovensky A, Hitchings GH, Metz E, and Rundles RW (1966) Metabolic studies of allopurinol, an inhibitor of xanthine oxidase.    Biochem. Pharmacol. 15: 863-889.",,,1913,136.11,5,2,70.1,0,neutral,-1.3,-1.4
O=C1NCC2(CCN(CCc3ccccc3)CC2)O1,1.3785116232537298,2.888118,Fenspiride,5053-06-5,3.0,2.6,,19.0,14.0,"Montes B, Catalan M, Roces A, Jeanniot JP, and Honorato JM (1993) Single-dose pharmacokinetics of fenspiride hydrochloride: phase I clinical trial.  Eur. J. Clin. Pharmacol. 45: 169-172.  ",VDss calculated from C vs t data included in the reference.,,1965,260.33,4,1,41.6,3,cationic,2.0,0.16
O=C1[C@@]23[C@@H]([C@@]4(OC(=O)C)[C@@H](C[C@@H]2C3)OC4)[C@H](OC(=O)c2ccccc2)[C@]2(C(C(=C(C)[C@H](C2)OC(=O)[C@@H]([C@@H](NC(=O)OC(C)(C)C)c2ccccc2)O)C1OC(=O)C)(C)C)O,3.4329594072761065,1.7960188,Larotaxel,156294-36-9,17.0,10.8,,26.1,33.9,"Nobuyuki Yamamoto · Narikazu Boku ·Hironobu Minami. Phase I study of larotaxel administered as a 1-h intravenous infusion every 3 weeks to Japanese patients with advanced solid tumours. Cancer Chemother Pharmacol (2009) 65:129–136. RPR109881A has also been reported (dihydrate of larotaxel, CAS # 192573-38-9) by Sessa C, Cuvier C, Caldiera S, Bauer J, Van Den Bosch S, Monnerat C, Semiond D, Perard D, Lebecq A, Besenval M, and Marty M (2002) Phase I clinical and pharmacokinetic studies of the taxoid derivative RPR 109881A administered as a 1-hour or a 3-hour infusion in patients with advanced solid tumors.  Ann. Oncol. 13: 1140-1150. VDss 12 L/kg, clearance 14 mL/min/kg, MRT 14 h and t1/2 20 h. Larotaxel kept.","Weighted average of 3 cohorts with a total of 18 patients. Doses 60, 75 and 90 mg/m2. Table 4.",,1994,831.9,15,3,210.3,14,neutral,3.3,3.3
O=C2N1/C(=C(\CS[C@@H]1[C@@H]2NC(=O)[C@@H](c3ccc(O)cc3)NC(=O)C\4=C\N\C(=C/C/4=O)C)CSc5nnnn5C)C(=O)O,-1.0588936890535685,1.0419409,Cefpiramide,70797-11-4,0.15,0.48,0.03,5.2,5.4,Conte JE (1987) Pharmacokinetics of cefpiramide in volunteers with normal or impaired renal function. Antimicr. Agents Chemother. 31(10) 1585-1588.,"N=10, weight assumes as 70 kg, 2 gram dose as 30 minutes iv infusion.  Clp reported as 2 L/h/1.73 m2 and converted using the factor 1.73 m2/70 kg. ppb taken as mid-point as variable across concentrations taken ex-vivo from fu 0.05 at 205 ug/mL (1 hour) to 0.01at 41.1 ug/mL at 8 hours.",,1979,612.64,15,5,208.7,9,anionic,-0.78,-3.9
O=N(=O)O[C@H]1CO[C@@H]2[C@@H](CO[C@H]12)ON(=O)=O,4.954196310386875,1.2487049,Isosorbide Dinitrate,87-33-2,1.9,31.0,0.72,1.0,1.7,"Platzer R, Reutemann G, and Galeazzi RL (1982) Pharmacokinetics of intravenous isosorbide dinitrate.  J. Pharmacokinet. Biopharm. 10: 575-586.  Santoni Y, Iliadis A, Cano JP, Luccioni R, and Frances Y (1986) Pharmacokinetics of isosorbide dinitrate and its mononitrate metabolites after intravenous infusion.  J. Pharmacokinet. Biopharm. 14: 1-17.  Straehl P and Galeazzi RL (1985) Isosorbide dinitrate bioavailability, kinetics, and metabolism. Clin Pharmacol Ther. 38:140-149",,,1939,236.14,10,0,128.6,4,neutral,0.82,0.82
O=S(=O)(N1CCCNCC1)c2cccc3cnccc23,6.2761244052742375,2.233022,Fasudil,103745-39-7,1.22,77.5,,0.26,0.44,"HAN Min, CHEN Huaying, LIN Yang , ZHOU Zijie, WANG Lifeng, BAI Mei, LI Jing, WANG K. The Investigation on Pharmacokinetics of FasudilAfter a Single Dose Intravenous infusion. Chin Pharm. J. 2011, 46, 293-296.","Fasudil mesylate, N=12, 59 kg average weight, 35 mg dose = 26.31 mg free base. Data digitized from Figure 2. Fairly large error on the plot. Digitization deemed accurate although results differ from error range reported. Data accepted after discussion.",,1986,291.37,5,1,62.3,2,cationic,1.2,0.49
O=S(=O)(N1Cc2cc(ccc2N(Cc3cnc[nH]3)C[C@H]1Cc4ccccc4)C#N)c5cccs5,3.263034405833794,2.232111,BMS-214662,195987-41-8,0.84,9.6,0.01,1.4,1.6,"Ryan DP, Eder JP, Puchlaski T, Seiden MV, Lynch TJ, Fuchs CS, Amrein PC, Sonnichsen D, Supko JG, and Clark JW (2004) Phase I clinical trial of the farnesyltransferase inhibitor BMS-214662 given as a 1 hour intravenous infusion in patients with advanced solid tumors.  Clin. Canc. Res.  10: 2222-2230.//ppb: Helen J. Mackay, Ronald Hoekstra, Ferry A. L. M. Eskens, Walker J. Loos, Donna Crawford, Maurizio Voi, Anne Van Vreckem, T. R. Jeffrey Evans, Jaap Verweij. A Phase I Pharmacokinetic and Pharmacodynamic Study of the Farnesyl Transferase Inhibitor BMS-214662 in Combination with Cisplatin in Patients with Advanced Solid Tumors. Clin. Cancer Res. 2004, 10, 2636-2644.",,,1997,489.61,7,1,93.1,7,neutral,3.6,3.5
O=S(=O)(O)c1c(O)ccc(O)c1,-0.2009126939259964,2.0742447,Dobesilic acid,88-46-0,0.12,0.87,,2.41,2.01,"G. Franke, T. Schneider, W. Siegmund, A. Scherber. Bioavailability studies of calcium dobesilate- a case of flip-flop kinetics. Pharmazie, 1985, 40, 562-563. ","N=10, iv bolus, 500 mg dose, 68.7 kg average weight. AUCinf digitized 139.7 mg.h.L-1, reported 139 mg.hr.L-1 (AUC0-t digitized 137.4 mg.hr.L-1). ",Administered as calcium salt. Structure and CAS# refers to neutral compound.,1923,190.17,5,3,94.8,1,neutral,-1.1,-4.0
OC(=O)C(Cl)Cl,2.405992359675837,1.2411546,Dichloroacetic Acid,79-43-6,0.19,5.3,,0.6,0.65,"Jia M, Coats B, Chadha M, Frentzen B, Perez-Rodriguez J, Chadik PA, Yost RA, Henderson GN, and Stacpoole PW (2006) Human Kinetics of Orally and Intravenously Administered Low-Dose 1,2-13C-Dichloroacetate.  J. Clin. Pharmacol.  46: 1449-1459.",,,1885,128.94,2,1,37.3,1,anionic,0.9,-2.5
OC(=O)C1=CN(C2CC2)c3cc(N4CCNCC4)c(F)cc3C1=O,3.0531113364595623,1.350399,Ciprofloxacin,85721-33-1,2.1,8.3,0.7,4.2,3.8,"Bergogne-Berezin E (2002) Clinical role of protein binding of quinolones.  Clin. Pharmacokinet 41:  741-750.  Jaehde U, Soergel F, Reiter A, Sigl G, Naber KG, and Schunack W (1995)  Effect of probenecid on the distribution and elimination of ciprofloxacin in humans.    Clin. Pharmacol. Ther. 58: 532-541.  Lettieri JT, Rogge MC, Kaiser L, Echols RM, and Heller AH (1992) Pharmacokinetic profiles of ciprofloxacin after single intravenous and oral doses.  Antimic. Agents Chemother. 36: 993-996.  Ljungborg B and Nilsson-Ehle I (1988) Pharmacokinetics of intravenous ciprofloxacin at three different doses.  J. Antimic. Chemother. 22: 715-720.",,,1983,331.34,6,2,72.9,3,zwitterionic,1.8,-0.63
OC(=O)C1CCn2c1ccc2C(=O)c3ccccc3,-1.5145731728297585,1.0557672,Ketorolac,74103-06-3,0.11,0.35,0.00679999999999999,5.2,5.1,"Jung D, Mroszczak E, and Bynum L (1988) Pharmacokinetics of ketorolac tromethamine in humans after intravenous, intramuscular and oral administration.  Eur. J. Clin. Pharmacol. 35: 423-425.  Reed MD, Myers CM, and Blumer JL (2001) Influence of midazolam on the protein binding of ketorolac.  Curr. Ther. Res.  62: 558-565.  Mroszczak EJ, Lee FM, Combs D, Sarnquist FH, Huang BL, Wu AT, Tokes LG, Maddox ML, and Cho DK (1987) Ketorolac tromethamine absorption, distribution, metabolism, excretion, and pharmacokinetics in animals and humans.  Drug Metab. Dispos. 15: 618-626",,,1978,255.27,4,1,59.3,3,anionic,2.5,-0.76
OC(=O)CCNC(=O)c1ccccc1,3.2016338611696504,1.8981754,Betamipron,3440-28-6,0.28,9.2,0.17,0.51,0.59,"Saito A (1991) Pharmacokinetics of panipenem/betamipron.  Chemotherapy (Tokyo)  39(Suppl. 3): 227-235.  Kurihara A, Naganuma H, Hisaoka M, Tokiwa H, and Kawahara Y (1992) Prediction of human pharmacokinetics of panipenem-betamipron, a new carbapenem, from animal data.    Antimic. Agents Chemother. 36: 1810-1816.",VDss calculated from C vs t data provided in the reference.,,1920,193.2,4,2,66.4,4,anionic,0.56,-2.5
OC(=O)CN1C(=O)C(=O)Nc2cc(c(cc12)n3ccnc3)N(=O)=O,2.405992359675837,1.119407,Zonampanel,210245-80-0,0.19,5.3,,0.6,0.78,"Minematsu T, Sohida KY, Hashimoto T, Imai H, Usui T, and Kamimura H (2005) Identification of metabolites of [14C]zonampanel, an alpha-amino-3-hydroxy-5-methylisoxazole-4-propionate receptor antagonist, following intravenous infusion in healthy volunteers.  Xenobiotica  35: 359-371.",,,1998,331.24,11,2,150.4,4,anionic,-0.45,-3.8
OC(=O)[C@@H]1C[C@H](CN1C(=O)CP(=O)(O)CCCCc2ccccc2)C3CCCCC3,-1.6438561897747246,0.6721531,Fosinoprilat,95399-71-6,0.13,0.32,0.006,6.8,9.4,"Kostis JB, Garland WT, Delaney C, Norton J, and Liao WC. Fosinopril: pharmacokinetics and pharmacodynamics in congestive heart failure.  Clin. Pharmacol. Ther. 1995, 58, 660-665",,,1985,435.49,6,2,94.9,9,anionic,4.2,-1.0
OC(=O)c1cc(ccc1O)c2ccc(F)cc2F,-3.321928094887362,0.89805835,Diflunisal,22494-42-4,0.097,0.1,0.0016,14.0,10.0,Nuernberg B and Brune K (1989) Buffering the stomach content enhances the absorption of diflunisal in man.  Biopharm. Drug Dispos. 10: 377-387.   Lin JH (1989) Species differences in protein binding of diflunisal.  Drug Metab. Dispos. 17: 221-223.,Parameters calculated from a digitized C vs t plot provided in the report.  Note: N=1,,1968,250.2,3,2,57.5,2,anionic,3.7,0.31
OC(C(O)CC1=CC(O)=C(O)C=C1)=O,4.149747119504682,1.3776145,Tanshinol,23028-17-3,0.38,17.75,,0.53,0.37,"Xiuxue Li , Chen Cheng , Fengqing Wang , Yühong Huang , Weiwei Jia , Olajide E. Olaleye ,
Meijuan Li , Yanfen Li , Chuan Li. Pharmacokinetics of catechols in human subjects intravenously receiving XueBiJing injection, an emerging antiseptic herbal medicine. Drug Metab. Pharmacokin. 2015. http://dx.doi.org/10.1016/j.dmpk.2015.10.005",3 different dosage regimens to 6 M and 6 F each. (three different infusions). Actual doses not reported. Standardized solution? Data averaged across all patients (N=36). 70% eliminated in urine.,Structure drawn in ChemDraw and exported as SMILES,1952,198.17,5,4,98.0,3,anionic,0.19,-3.0
OC(CCN1CCCC1)(C2CCCCC2)c3ccccc3,-0.2175914350726268,2.7450352,Procyclidine,77-37-2,0.74,0.86,,14.0,12.0,"Whiteman PD, Fowle ASE, Hamilton MJ, Peck AW, Bye A, dean K, and Webster A (1985) Pharmacokinetics and pharmacodynamics of procyclidine in man.  Eur. J. Clin. Pharmacol. 28: 73-78.",VDss calculated from digitized C vs t plot.,,1951,287.44,2,1,23.5,5,cationic,4.2,2.2
OC(CN1CCOCC1)Cn2c(cnc2C)[N+]([O-])=O,0.6780719051126377,2.1178098,Morinidazole,92478-27-8,0.75,1.6,,7.9,6.2,"Gao, Ruina; Li, Liang; Xie, Cen; Diao, Xingxing; Zhong, Dafang; Chen, Xiaoyan. Metabolism and pharmacokinetics of morinidazole in humans: identification of diastereoisomeric morpholine N+-​glucuronides catalyzed by UDP glucuronosyltransferase 1A9. Drug Metabolism & Disposition (2012), 40(3), 556-567:","Data from FIG. 6 in 
Reported data (Table 1):
AUC0-t(ng*h/mL) 74,866
AUC0–inf(ng*h/mL) 75,964
t1/2 6.15 h
dose 500 mg 0.7 h infusion, N=12, 70 kg body weight assumed ",,1994,270.29,8,1,93.7,5,neutral,-0.81,-0.88
OC(CNCCNC(=O)N1CCOCC1)COc2ccc(O)cc2,1.584962500721156,3.42969,Xamoterol,81801-12-9,0.64,3.0,0.97,3.6,7.7,"Bastain W, Boyce MJ, Stafford LE, Morton PB, Clarke DA, and Marlow HF (1988) Pharmacokinetics of xamoterol after intravenous and oral administration to volunteers. Eur. J. Clin. Pharmacol. 34: 469-473.  ",,,1982,339.39,8,4,103.3,8,cationic,-0.65,-1.1
OC1=C(Oc2cc(O)cc(O)c2C1=O)c3ccc(O)c(O)c3,3.4594316186372973,1.1178463,Quercetin,117-39-5,0.12,11.0,0.00899999999999999,0.2,0.6,"Ferry DR, Smith A, Malkhandi J, Fyfe DW,DeTakats PG, Anderson D, Baker J, Kerr DJ (1996) Phase I clinical trial of the flavonoid quercetin: Pharmacokinetics and evidence for in vivo tyrosine kinase inhibition. Clin. Cancer Res. 2: 659-668.  Boulton DW, Walle UK, and Walle T (1998) Extensive binding of the bioflavonoid quercetin to human plasma proteins. J. Pharm. Pharmacol. 50: 243-249.  ",,,1948,302.24,7,5,127.4,1,anionic,2.1,-0.38
OC1=C([C@@H]2CC[C@H](CC2)c3ccc(Cl)cc3)C(=O)c4ccccc4C1=O,-2.736965594166206,0.50424325,Atovaquone,95233-18-4,0.6,0.15,0.001,67.0,63.0,Mepron Product Label,,,1984,366.84,3,1,54.4,2,anionic,5.5,3.4
OC1N=C(c2ccccc2Cl)c3cc(Cl)ccc3NC1=O,0.0,1.295877,Lorazepam,846-49-1,1.3,1.0,0.09,22.0,17.0,"Wermeling DPH, Miller JL, Archer SM, Manaligod JM, and Rudy AC (2001) Bioavailability and pharmacokinetics of lorazepam after intranasal, intravenous, and intramuscular administration. J. Clin. Pharmacol. 41: 1225-1231.  Desmond PV, Roberts RK, Wood AJJ, Dunn GD, Wilkinson, GR, Schenker S (1980) Effect of heparin administration on plasma binding of benzodiazepines.  Br. J. Clin. Pharmacol. 9: 171-175.  ",,,1963,321.16,4,2,61.7,1,neutral,2.9,2.9
OCC(CO)NN1C(=O)c2c(C1=O)c3c4ccc(O)cc4n([C@@H]5O[C@H](CO)[C@@H](O)[C@H](O)[C@H]5O)c3c6[nH]c7cc(O)ccc7c26,4.661065479806948,1.430618,Edotecarin,174402-32-5,1.45,25.3,,0.95,4.01,"Hurwitz, Herbert I.; Cohen, Roger B.; McGovren, J. Patrick; Hirawat, Samit; Petros, William P.; Natsumeda, Yutaka; Yoshinari, Tomoko. A phase I study of the safety and pharmacokinetics of edotecarin (J-107088), a novel topoisomerase I inhibitor, in patients with advanced solid tumors. Cancer Chemother. Pharmacol. 2007, 59, 139-147.","PF-804950. J-107088. N=9, 15 mg/m2 iv infusion over 2 h. 1.73 m2/70 kg assumed. 
Reported AUC(0-last) 200 ± 49.3 ng.h.mL-1; calculated 240 ng.h.mL-1. 20% difference, data accepted.",,1995,608.55,15,10,241.2,6,anionic,-2.3,-2.8
OCCN1CCN(CCCN2c3ccccc3Sc4ccc(Cl)cc24)CC1,4.754887502163468,3.3185594,Perphenazine,58-39-9,18.0,27.0,0.07,11.0,9.4,"Eggert Hansen C, Rosted CT, Elley J, Bolvig Hansen L, Kragh-Sorensen P, Larsen NE, Naestoft J, and Hvidberg  (1976) Clinical pharmacokinetics studies of perphenazine.  Br. J. Clin. Pharmacol. 3: 915-923.  Verbeek RK, Cardinal JA, Hill AG, and Midha KK (1983) Binding of phenothiazine neuroleptics to plasma proteins.  Biochem. Pharmacol. 32: 2565-2570.",VDss was determined from C vs t data obtained by digitization of the plots presented in the reference.,,1956,403.97,4,1,29.9,6,cationic,4.3,3.5
OCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO,0.765534746362977,2.8670268,Miglitol,72432-03-2,0.28,1.7,1.0,2.7,2.3,"Ahr AH, Boberg M, Brendel E, Krouse HP, and Steinke W (1997) Pharmacokinetics of miglitol.  Absorption, distribution, metabolism, and excretion following administration to rats, dogs, and man.  Arz. Forsch. 47: 734-745.",Pharmacokinetic parameters were calculated from plasma total radioactivity measurements after administration of radiolabelled miglitol.  Analysis of samples showed that miglitol parent drug was the only drug-related entity.,,1979,207.22,6,5,104.4,3,neutral,-3.1,-3.3
OCCNCCNc1ccc(NCCNCCO)c2C(=O)c3c(O)ccc(O)c3C(=O)c12,2.9818526532897405,1.67059,Mitoxantrone,65271-80-9,12.0,7.9,0.25,25.0,53.0,"Canal P, Attal M, Chatelut E, Guichard S, Huguet F, Muller C, Schlaifer D, Laurent G, Houin G, and Bugat R (1993) Plasma and cellular pharmacokinetics of mitoxantrone in high dose chemotherapeutic regimen for refractory lymphomas.  Canc. Res. 53: 4850-4854.  Scott LJ and Figgitt DP (2004) Mitoxantrone: a review of its use in multiple sclerosis.  CNS Drugs 18: 379-396.",,,1952,444.48,10,8,163.2,12,cationic,-0.37,-3.2
OC[C@@H](NC(=O)C(Cl)Cl)[C@H](O)c1ccc(cc1)N(=O)=O,1.263034405833794,2.4860756,Chloramphenicol,56-75-7,0.94,2.4,0.34,6.5,4.6,"Narang APS, Datta DV, Nath N, and Mathur VS (1981) Pharmacokinetic study of chloramphenicol in patients with liver disease.  Eur. J. Clin. Pharmacol. 20: 479-483.  Kurz H, Mauser-Ganshorn A, and Stickel HH (1977) Differences in the binding of drugs to plasma proteins from newborn and adult man. I. Eur. J. Clin. Pharmacol. 11: 463-467.","One compartment pharmacokinetics, so VDc = VDss.",,1970,323.13,7,3,115.4,6,neutral,0.54,0.54
OC[C@@H](O)[C@@H](O)[C@H](O[C@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](CCC(=O)N[C@@H](C)C(=O)NCCOP(O)(=O)OC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(N)=O)[C@H](C=O)NC(C)=O,5.60584986719498,0.5320841,Mifamurtide,83461-56-7,5.8,48.7,,1.98,2.05,"Karthik Venkatakrishnan,William G. Kramer, Timothy W. Synold, Daniel B. Goodman ,Evin Sides III, Cristina Oliva. A pharmacokinetic, pharmacodynamic,
and electrocardiographic study of liposomal mifamurtide
(L-MTP-PE) in healthy adult volunteers.  J Clin Pharmacol (2012) 68:1347–1355.",MTP-PE. Open form (sugar) reported by Scifinder and ChemIDPlus. Data reported in L and L/m2 (or corresponding units for clearance). 70 kg assumed. 4 mg dose in 30 minutes infusion. N=21. Liposomal preparation. MEPACT (approved in Europe),,1982,1237.5,25,10,383.9,58,anionic,4.9,1.4
OC\C=C/1\C[N@+]2(CC=C)CC[C@@]34[C@@H]2C[C@@H]1C5=CN6[C@H]7C(=CN([C@H]35)c8ccccc48)[C@H]9C[C@H]%10[C@@]7(CC[N@@+]%10(CC=C)C/C/9=C/CO)c%11ccccc6%11,0.3785116232537298,2.0890498,Alcuronium,23214-96-2,0.32,1.3,,4.1,3.6,"Walker J, Shanks CA, and Triggs EJ (1980)  Clinical pharmacokinetics of alcuronium chloride in man.  Eur. J. Clin. Pharmacol. 17: 449-457. ",,,1960,666.89,6,2,46.9,6,neutral,-4.8,-4.8
ONC(=O)CCCCCCC(=O)Nc1ccccc1,4.807354922057604,2.1407204,Vorinostat,149647-78-9,0.5,28.0,0.29,0.3,0.76,"Kelly WK, Richon VM, O'Connor O, Curley T, MacGregor-Curtelli B, Tong W, Klang M, Schwartz L, Richardson S, Rosa E, Drobnjak M, Cordon-Cordo C, Chiao JH, Rifkind R, Marks PA, Scher H (2003) Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously.  Clin. Cancer Res.  9: 3578-3588.  Zolinza Product Label.",VDss calculated from digitized C vs t plot.,,1993,264.32,5,3,78.4,8,neutral,1.6,1.6
O[C@@H](CNC[C@H](O)[C@H]1CCc2cc(F)ccc2O1)[C@@H]3CCc4cc(F)ccc4O3,3.807354922057604,2.0628104,Nebivolol,118457-14-0,11.0,14.0,0.02,13.0,10.0,"Cheymol G, Poirier JM, Carrupt PA, Testa B, Weissenburger J, Levron JC, and Snoeck E (1997) Pharmacokinetics of .beta.-adrenoceptor blockers in obese and normal volunteers. Br. J. Clin. Pharmacol. 43: 563-570. ppb: The PDR states: The in vitro human plasma protein binding of nebivolol is approximately 98%, mostly to albumin, and is independent of nebivolol concentrations. Accessed January 7 2015. http://www.pdr3d.com/detail.php?c=53808#section-12",,,1987,405.44,5,3,70.9,6,cationic,3.9,3.3
O[C@@H]([C@@H]([C@@H](CO)O)O)[C@@H](CO)O,0.2630344058337938,1.9771296,Mannitol,69-65-8,0.24,1.2,,3.5,4.7,"EMA assessment report of Mannitol (EMEA/H/C/001252):
study DPM-PK-101","Data digitized from Table 3 in the report. N=18 male, 70 kg body weight assumed. 500 mg dose.

Reported data (Table 2):
AUC0-inf = 100236 ng*h/mL
CL = 5099 mL/h (1.21 mL/min/kg)
CLr = 4439 mL/h (mainly renally excreted)
t1/2 = 4.5 h
Vd = 34.3 L (0.49 L/kg)",,1946,182.17,6,6,121.4,5,neutral,-3.6,-3.6
O[C@@H]1C[C@@](C[C@@H](OC(=O)\C=C\c2ccc(O)c(O)c2)[C@@H]1O)(OC(=O)\C=C\c3ccc(O)c(O)c3)C(=O)O,3.1210154009613658,0.045980126,"1,3-DCQA",19870-46-3,0.79,8.7,,1.5,1.37,"Wen-Zheng Ju,Yang Zhao,Fang Liu,Ting Wua,Jun Zhang,Shi-Jia Liu,Lin gZhou,Guo-Liang Dai,Ning-Ning Xiong,Zhu-Yuan Fang. Clinical tolerability and pharmacokinetics of Erigerontis hydroxybenzene injection: Results of a randomized phase I study in healthy Chinese volunteers. Phytomed. 2015, 22, 319–325","1,3-dicaffeoylquinic acid. Data digitized from plot reported. All from average males/females. 6 vials EH product tested for content via HPLC. 1.26 mg total dose, N=6, 57 kg average weight. 1 hr infusion. All AUCinf data within 10% of reported.",,1964,516.45,12,7,211.3,9,anionic,2.1,-1.6
O[C@@H]1[C@@H](C[C@](O)(C[C@H]1OC(=O)\C=C\c2ccc(O)c(O)c2)C(=O)O)OC(=O)\C=C\c3ccc(O)c(O)c3,6.244316259891207,-0.015423626,"3,5-DCQA",2450-53-5,4.82,75.81,,1.05,3.17,"Wen-Zheng Ju,Yang Zhao,Fang Liu,Ting Wua,Jun Zhang,Shi-Jia Liu,Lin gZhou,Guo-Liang Dai,Ning-Ning Xiong,Zhu-Yuan Fang. Clinical tolerability and pharmacokinetics of Erigerontis hydroxybenzene injection: Results of a randomized phase I study in healthy Chinese volunteers. Phytomed. 2015, 22, 319–325","3,5-dicaffeoylquinic acid. Data digitized from plot reported.  All from average males/females. 6 vials EH product tested for content via HPLC. 16.44 mg total dose, N=6, 57 kg average weight. 1 hr infusion. All AUCinf data within 10% of reported.",,1963,516.45,12,7,211.3,9,anionic,2.6,-1.1
O[C@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5O[C@@H]1[C@]2(CCN3CC6CCC6)c45,4.459431618637297,3.2441337,Nalbuphine,20594-83-6,4.6,22.0,0.5,3.5,3.7,"Aitkenhead AR, Lin ES, and Achola KJ (1988) The pharmacokinetics of oral and intravenous nalbuphine in healthy volunteers.  Br. J. Clin. Pharmacol. 25: 264-268.   Jaillion P, Gardin ME, Lecocq B, Richard MO, Meignan S, Blondel Y, Grippat JC, Bergnieres J, and Vergnoux O (1989) Pharmacokinetics of nalbuphine in infants, young healthy volunteers, and elderly patients.  Clin. Pharmacol. Ther. 46: 226-233",,,1967,357.44,5,3,73.2,2,cationic,2.0,1.2
Oc1ccc(cc1)/C=C/C(=O)CCN(C)CCc2ccc3OCOc3c2,9.477758266443889,3.2018316,Piperphentonamine,712260-52-1,2.13,713.0,,0.05,0.1," Determination of piperphentonamine and metabolites M1 and M6 in human plasma and urine by LC/MS/MS and its application in a pharmacokinetics study in Chinese healthy volunteersFull Text By Shi, Aixin; Hu, Xin; Li, Kexin; Li, Jian; Han, Liping; Wan, Huayin; Li, Rubing 
Journal of Chromatography, B: Analytical Technologies in the Biomedical and Life Sciences (2012), 908, 87-93",Data digitized from figure 3 (plot)  N=9 (assumed from study design 27 subject for 3 doses). 0.6 mg/kg dose digitized (0.2 and 0.4 mg/kg available). 10 minutes bolus treated as infusion due to time of sampling (40 min total). 5 minutes time point not reported in plot but assumed to be 93.2 ng/mL as reported Cmax (see table).  Reported AUC0-t 767.4 ng/mL min. t1/2 reported as 5.6 minutes. Clearance reported as 1 L.kg-1.min-1 which is quite different from calculated. Error found to be quite high for all parameters.,,1991,353.41,5,1,59.0,8,cationic,3.4,2.4
Oc1ccc2C[C@H]3N(CC4CC4)CC[C@@]56[C@@H](Oc1c25)C(=O)CC[C@@]36O,5.832890014164741,3.19499,Naltrexone,16590-41-3,7.6,57.0,0.79,2.2,1.9,"Wall ME, Brine DR, and Perez-Reyes M (1981) Metabolism and disposition of naltrexone in man after oral and intravenous administration.  Drug Metab. Dispos.  9: 369-375.  Ludden TM, Malspeis L, Baggot JD, Sokoloski TD, Frank SG, and Reuning RH (1976) Tritiated naltrexone binding in plasma from several species and tissue distribution in mice.  J. Pharm. Sci. 65: 712-716",Calculated from C vs t data provided in the report.,,1967,341.4,5,2,70.0,2,neutral,1.3,1.0
Oc1ccc2C[C@H]3N(CC4CCC4)CC[C@@]5(CCCC[C@@]35O)c2c1,5.357552004618084,3.7731953,Butorphanol,42408-82-2,12.0,41.0,0.17,5.3,4.8,"Vachharajani NN, Shyu WC, Garnett WR, Morgenthien EA and Barbhaiya RH (1996) The absolute bioavailability and pharmacokinetics of butorphanol nasal spray in patients with hepatic impairment.  Clin. Pharmacol. Ther. 60: 283-294.   Gaver RC, Vasiljev M, Wong H, Monkovic I, Swigor JE, Van Harken DR, and Smyth RD (1980) Disposition of parenteral butorphanol in man.  Drug Metab. Dispos. 8: 230-235.",,,1973,327.46,3,2,43.7,2,cationic,3.2,2.1
Oc1ccc2C[C@H]3N(CC=C)CC[C@@]45[C@@H](Oc1c24)C(=O)CC[C@@]35O,4.523561956057013,3.0662682,Naloxone,465-65-6,1.7,23.0,0.54,1.2,1.1,"Ngai SH, Berkowitz BA, Yang JC, Hempstead J, and Spector S (1976) Pharmacokinetics of naloxone in rats and man: basis for its potency and short duration of action.  Anesthesiology 44: 398-401.  Asali LA and Brown KF (1984) Naloxone protein binding in adult and fetal plasma. Eur. J. Clin. Pharmacol. 27: 459-463.",Pharmacokinetic parameters were calculated from C vs t data obtained by digitization of the plot provided in the reference.,,1971,327.37,5,2,70.0,2,neutral,1.1,0.89
Oc1ccc2c(Oc3cc(O)ccc3C24OC(=O)c5ccccc45)c1,0.3785116232537298,1.672036,Fluorescein,2321-07-5,0.14,1.3,0.11,1.8,1.6,"Larsen M, Loft S, Hommel E, and Lund-Andersen H (1988) Fluorescein and fluorescein glucuronide in plasma after intravenous injection of fluorescein.  Acta Opthamol. 66: 427-432.  ",Pharmacokinetic parameters were calculated from C vs t data obtained by digitization of the plot provided in the reference.,,1931,332.31,5,2,76.0,0,neutral,3.9,3.9
P(=O)(OCC)(OCC)C(NC(=O)N(CCCl)N=O)C,4.20945336562895,2.918603,Fotemustin,92118-27-9,0.62,18.5,,0.55,0.38,"R.M. J. Ings, A. J. Gray, A.R. Taylor, B.H. Gordon, M. Breen, M. Hiley, R. Brownsill, N. Marchant, R. Richards, D. Wallace, T. Hughes, R. Thomas, J. Williams, C. Lucas and D.B. Campbell Disposition, Pharmacokinetics, and Metabolism of 14C-Fotemustine in Cancer Patients. Eur. J. Cancer, 1990, 26,  838-842.","N=2. Double digitization and average of PK data. Patient 1 and 2 52.4 and 73.9 kg weight, F and M, respectively. 133.9 and 176.1 mg dose, respectively. 1 hr infusion and excellent agreement with reported clearance and Vz. Patient 1 1365 mL/min calculated and 1426 mL/min reported; patient 2 787 mL/min calculated and 764 mL/min reported.",,1984,315.69,8,1,97.3,9,neutral,1.5,1.5
P(O[C@H]1[C@@H]([C@H]([C@H](O)[C@H](O1)CO)O)O)(=O)(NCCCl)NCCCl,0.6780719051126377,2.2378728,Glufosfamide,132682-98-5,0.24,1.6,0.71,2.49,2.37," Data (N=13, doses 3200-6000 mg/m2 6h i.v. infusion) reported in Table 5 in Shimizu, Toshio; Okamoto, Isamu; Tamura, Kenji; Satoh, Taroh; Miyazaki, Masaki; Akashi, Yusaku; Ozaki, Tomohiro; Fukuoka, Masahiro; Nakagawa, Kazuhiko.  Phase I clinical and pharmacokinetic study of the glucose-conjugated cytotoxic agent d-19575 (glufosfamide) in patients with solid tumors.    Cancer Chemotherapy and Pharmacology  (2010),  65(2),  243-250.  MRT calculated from CL and VDss.      fu as average of all human serum and human plasma measures reported in Table 4 in Stueben, Joerg; Port, Ruediger; Bertram, Barbara; Bollow, Ursula; Hull, William E.; Schaper, Marianne; Pohl, Joerg; Wiessler, Manfred.  Pharmacokinetics and whole-body distribution of the new chemotherapeutic agent .beta.-D-glucosylisophosporamide mustard and its effects on the incorporation of [methyl-3H]-thymidine in various tissues of the rat.    Cancer Chemotherapy and Pharmacology  (1996),  38(4),  355-365.","Data as weighted average of three doses across 13 patients (3,200/4,500/6000 mg/m2, N-3/7/3). Conversion factor used 1.73m2/70 kg. 6-hour infusion. Also reported as D 19575 ",,1990,383.16,9,6,140.5,9,neutral,-2.3,-2.3
"S(=O)(=O)(O)OC[C@@H]1[C@H]([C@@H]([C@@H](NS(=O)(=O)O)[C@H](O1)OC)O)O[C@H]1[C@H](OS(=O)(=O)O)[C@H]([C@@H]([C@H](C(=O)O)O1)O[C@@H]1[C@H](NS(=O)(=O)O)[C@H]([C@@H]([C@H](O1)COS(=O)(=O)O)O[C@@H]1O[C@@H]([C@H]([C@@H]([C@H]1O)O)O[C@@H]1[C@@H]([C@H]([C@@H]([C@H](O1)COS(=O)(=O)O)O)O)NS(=O)(=O)O)C(=O)O)OS(=O)(=O)O)O
",-3.8365012677171206,-1.3245294,Fondaparinux,104993-28-4,,0.07,0.21,,19.3,"François Donat, Jean Pierre Duret, Alix Santoni, Roger Cariou, José Necciari, Harry
Magnani and Rik de Greef. The Pharmacokinetics of Fondaparinux
Sodium in Healthy Volunteers. Clin Pharmacokinet 2002; 41 Suppl. 2: 1-9. ppb: Paolucci F , Claviés MC , Donat F , Necciari. Fondaparinux Sodium Mechanism of Action Identification of Specific Binding to Purified and Human Plasma-Derived Proteins J . Clin Pharmacokinet 2002; 41 Suppl. 2: 11-18","two sd at 4 mg averaged in elderly subjects. Fairly close values across other doses. N= 66. Only Vz reported. 7.9 and 10.8 L for the same two groups.t1/2 18.4 and 20.3 h, respectively. Ppb: 79% reported as unspecific binding in plasma. Table II in reference cited.",Almost completely excreted renally unchanged.,1986,1508.26,52,19,805.5,30,anionic,-9.0,-9.0
S(c1ccc(C(=O)CCC(=O)O)cc1)(=O)(=O)CCCOc1c(c(O)c(cc1)C(=O)C)CCC,4.124328135002202,1.0202472,L-648051,91541-18-3,,17.44,,,0.04,"Biollaz, J.; Stahl, E.; Hsieh, J. Y.; Distlerath, L.; Jaeger, A.; Leuenberger, P.; Schelling, J. L.. Tolerability and pharmacokinetics of L 648051. A leukotriene D4-receptor antagonist, in healthy volunteers. Eur. J.  Clin. Pharmacol. (1988), 33(6), 603-607.","N=3, 68.8 kg, 5 minutes infusion. Average across doses (35-72 mg total). VD refers to Vdbeta and only individual plots (difficult to digitized) were reported.",,1984,476.54,8,2,135.0,13,anionic,2.7,0.13
S1([C@@]([C@@H](N2C(=O)C[C@@H]12)C(O)=O)(Cn1ccnn1)C)(=O)=O,2.266036893995317,1.1160204,Tazobactam,89786-04-9,0.26,4.81,0.7,0.89,0.97,"Pharmacokinetics and safety of intravenous ceftolozane-tazobactam in healthy adult subjects following single and multiple ascending doses Miller, Benjamin; Hershberger, Ellie; Benziger, David; Trinh, My My; Friedland, Ian 
Antimicrobial Agents and Chemotherapy (2012), 56(6), 3086-3091. ppb. The PDR states: Both piperacillin and tazobactam are approximately 30% bound to plasma proteins.  Accessed January 15 2015. http://www.pdr3d.com/detail.php?c=137294#section-13.","BRN 4787943, Cl 298741. Average of 500 and 750 mg doses, administered alone to healthy volunteers, N=5 per dose, day 1 only. No accumulation noted at day 10.  71.4 kg average weight. MRT calculated from Cl and VDss. Renal clearance calculated as 66% across the two doses.",,1984,300.29,9,1,122.5,3,anionic,-1.7,-5.2
S1SC[C@@H]2NC([C@@H](CCCCN)NC([C@@H](NC(CNC([C@@H](NC(CNC([C@@H](NC([C@@H](CSSC[C@@H]3NC([C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC2=O)CO)=O)CCCNC(=N)N)=O)CC(C)C)=O)CCSC)=O)Cc2ccc(cc2)O)CC(O)=O)CSSC[C@@H](NC([C@@H](NC(CNC([C@@H](NC([C@@H](NC([C@@H](C1)NC([C@@H](NC(CNC(=O)[C@@H]([C@@H](C)O)NC3=O)=O)CO)=O)=O)CCCNC(=N)N)=O)CO)=O)=O)CCCCN)=O)C(=O)N)=O)N)=O)CCCCN)=O)=O)CCCCN)=O)=O)C)=O)=O,2.017921907997262,0.4391284,Ziconotide,107452-89-1,0.43,4.05,0.5,1.8,1.3,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/21-060_Prialt_Biopharmr.PDF. Accessed December 18 2016.,70 kg average weight assumed. Ppb reported as 50%. MRT from clearance and VDss.,,1987,2639.13,68,42,1133.8,40,cationic,-9.0,-9.0
S=C1NC=Nc2[nH]cnc12,3.906890595608519,2.8851776,"Mercaptopurine, 6-",50-44-2,1.0,15.0,0.85,1.1,1.0,"Coffey JJ, White CA, Lesk AB, Rogers WI, and Seppick AA (1972) Effect of allopurinol on the pharmacokinetics of 6-mercaptopurine (NSC 755) in cancer patients.  Cancer Res. 32: 1283-1289.  Esposito M, Rosso R, and Santi L (1974)  Plasma protein binding of antineoplastic drugs in rats and humans.    IRCS Library Compendium  2: 1180.",Purinethiol.U 4748. Pharmacokinetic parameters were calculated using the mean C vs t values from three study subjects receiving intravenous 500 mg/m2. ,,1953,152.18,4,2,53.1,0,neutral,-1.8,-2.0
[C@@H]12[C@@H]([C@@]3(C(=CC(=O)CC3)CC2)C)CC[C@]2([C@H]1CC[C@@H]2O)C,4.614709844115208,2.4588652,Testosterone,58-22-0,0.35,24.5,0.057,0.25,0.17,"Täuber U, Schröder K, Düsterberg B, Matthes H.  Absolute bioavailability of testosterone after oral administration of testosterone-undecanoate and testosterone. Eur J Drug Metab Pharmacokinet. 1986, 11,145-149.//ppb: Forest MG, Rivarola MA, Migeon CJ. Percentage binding of testosterone, androstenedione and dehydroisoandrosterone in human plasma. Steroids, 1968, 12, 323-343.","1.5 ug/kg, N=5 (all females). VDss calculated from the mean C vs t data provided in a plot in the paper.//for ppb: averaged the men and women; excluded the pregnant women (very different value).  Used the equilibrium dialysis data only.",,1946,288.42,2,1,37.3,0,neutral,3.3,3.3
[C@@]12([C@H]([C@H]3[C@H](C(=C)C2)[C@@H]2C(=CC(=O)CC2)CC3)CC[C@]1(C#C)O)CC,1.0,3.4327714,Etonogestrel,54048-10-1,2.87,2.0,0.02,23.6,25.0,"PP. FDA approval package. 2006-Jun-16  PDF(2755k)
Clinical Pharmacology and Biopharmaceutics Review 021529/S-000",Vdss reported with large s.d.  201 +/- 149 L. MRT from VDss and Cl. 70 kg assumed.150 ug low bolud dose,,1974,324.46,2,1,37.3,2,neutral,4.0,4.0
[C@H]1(C(=C(C(=O)O1)O)O)[C@H](CO)O,0.070389327891398,1.6251404,Ascorbic acid,50-81-7,0.35,1.05,0.26,5.5,11.4,"Zetler, G. Seidel, G., Siegers, G-P, Iven. H. Pharmacokinetics of ascorbic acid in man. Eur. J. Clin. Pharmacol. 1976, 10, 273-282.// (L. John Hoffer, Line Robitaille, Robert Zakarian, David Melnychuk, Petr Kavan, Jason Agulnik,Victor Cohen, David Small Wilson H. Miller, Jr. High-Dose Intravenous Vitamin C Combined with Cytotoxic Chemotherapy in Patients with Advanced Cancer: A Phase I-II Clinical Trial. PLOS ONE  DOI:10.1371/journal.pone.0120228 April 7, 2015)","N=3, dosed as 500 mg of sodium ascorbate (435 mg of ascorbic acid). 79 kg average weight. Not clear whether lactone or acid was followed as the analysis was performed colorimetrically. Structure entered as lactone//Also, the work of Hoffer et al. PLoS was utilized for calculations after digitization. 0.6 g/kg over 90 minutes, N=12, 76 kg average weight. Only Cmax and C5.5 hr were reported (= Clast) and were digitized very accurately. VDss = 0.21 L/kg and clearance 1.07 mL/min/kg, MRT 3.24 hr and t1/2 2.36 hr. NEW DATA ENTERED MAY 23 2016 and  NOT AVERAGED ACROSS THE TWO REPORTS.",,1923,176.12,6,4,107.2,2,anionic,-3.0,-5.5
[C@H]1(n2c(=O)nc(cc2)N)O[C@@H]([C@]([C@H]1O)(O)C#C)CO,0.6780719051126377,2.374049,TAS-106,180300-43-0,1.1,1.6,,11.7,10.9,"A Phase I Study to Determine the Safety and Pharmacokinetics of Intravenous Administration of TAS-106 Once per Week for Three Consecutive Weeks Every 28 Days in Patients with Solid Tumors. BENJAMIN FRIDAY, YVONNE LASSERE, CHRISTINA A. MEYERS,.AKIRA MITA, JAMES L. ABBRUZZESE and MELANIE B. THOMAS. Anticancer Res. 2012, 32,1689-1695.",3'-c-Ethynylcytidine. Ecyd. Weighted average of 15 subjects. Doses of 0.33 to 2.64 mg/m2 across 15 subjects in total. Data reported corrected for weight. ,,1996,267.24,8,4,130.8,3,neutral,-3.2,-3.2
[C@]12([C@H]([C@H]3[C@@H](CO2)OC(O3)(C)C)OC(O1)(C)C)COS(=O)(=O)N,-1.888968687611256,1.1034994,Topiramate,97240-79-4,0.8,0.27,0.72,48.7,34.8,"Intravenous topiramate: Comparison of pharmacokinetics and safety with the oral formulation in healthy volunteers Anne M. Clark, Robert L. Kriel, Ilo E. Leppik,  Susan E. Marino, Usha Mishra,Richard C. Brundage, and James C. Cloyd. Epilepsia, 2013, 54, (6), 1099–1105. ppb: The PDR states: Topiramate is 15% to 41% bound to human plasma proteins over the blood concentration range of 0.5 to 250 mcg/mL. The fraction bound decreased as blood concentration increased. Median value of 28% taken. Accessed January 6 2015. http://pdr3d.com/detail.php?c=13144#section-3","Data digitized from plots reported in reference cited. N=10, 78.2 kg average weight, 100 mg dose, 15' infusion.
Reported AUC0-a (h*lg/ml) 72.6   
Reported CL (L/h) 1.33 (= 0.28 mL/min/kg)
",,1985,339.36,9,1,115.5,3,neutral,0.47,0.44
[H]N(C(C)=O)c1ccc(cc1)C1[C@H](C)CC(N([H])N=1)=O,-1.15200309344505,1.7293528,OR-1896,220246-81-1,2.38,0.45,0.4,88.0,70.0,"Puttonen, J. Eur. J. Pharm. Sci. 2007, 32, 271-277. 200 ug dose, HPLC analysis on OR-1896 after 14C OR-1896 dose. N=5, average weight 74 kg, VDss = 176 L, Cl reported as 2.0 L/h. ppb from Antila et al. Eur. J. Pharm. Sci. 2004, 23, 213-222.",A metabolite of levosimedan,,1991,245.28,5,2,70.6,2,neutral,0.71,0.71
[H]N(C(C=Cc1c2c(cc(cc2n([H])c1C(=O)O[H])[Cl])[Cl])=O)c1ccccc1,-3.4900508536956893,0.6627799,Gavestinel,153436-22-7,0.12,0.089,0.002,22.47,,"Iavarone L et al. First time in human for GV196771: interspecies scaling applied on dose selection. J Clin Pharmacol, 1999, 39, 560-566. ","Data from 100 mg iv dose, 70 Kg weight. MRT calculated from CL and VDss. GV150526. 
fu reported as fu% but unlikely to be %.  Likely to be fu.",,1993,375.21,5,3,82.2,5,anionic,4.6,1.8
[H]N(C([C@@H](Cc1ccccc1)CS(C(C)(C)C)(=O)=O)=O)[C@@H](Cc1cn([H])cn1)C(N([H])[C@@H](CC1CCCCC1)[C@H](C(C1CC1)O[H])O[H])=O,3.5360529002402097,1.7803553,Remikiren,126222-34-2,0.77,11.6,0.0558128882681065,1.1,5.2,"Kleinbloesem CH, Weber C, Fahrner E, Dellenbach M, Welker H, Schroter V, Belz GG (1993) Hemodynamics, biochemical effects, and pharmacokinetics of the renin inhibitor remikiren in healthy human subjects. Clin. Pharmacol. Ther. 53, 585-592.   fu from Lombardo et al J. Clin. Pharmacol. 2013, 53(2), 167-177 and 178-191","n=6, 40 mg dose used",,1989,630.84,10,5,161.5,17,neutral,2.0,2.0
[H]N([H])C1(CC1)C(=O)O[H],0.5849625007211562,1.8143322,1-Aminocyclopropanecarboxylic Acid,22059-21-8,0.73,1.5,,7.8,5.9,"Cherkofsky, S.C. (1995) 1-Aminocyclopropylcarboxylic acid: mouse to man interspecies pharmacokinetic comparisons and allometric relationships.  J. Pharm. Sci.  84: 1231-1235.",,,1922,101.1,3,2,63.3,3,zwitterionic,-0.66,-2.4
[H]N([H])C1C=CN(C(N=1)=O)[C@H]1[C@H]([C@@H]([C@@H](CO[H])O1)O[H])O[H],5.380937194927824,2.1883056,Cytarabine,147-94-4,0.67,41.67,0.87,0.28,0.17,"Breithaupt H et al.,  Clinical results and pharmacokinetics of high-​dose cytosine arabinoside (HD ARA-​C). Cancer, 1982, 50, 1248-1257. ppb: Van Prooijen, H. C.; Vierwinden, G.; Wessels, J.; Haanen, C. Cytosine arabinoside binding to human plasma proteins. Arch. Int. Pharmacodyn. Ther. 1977, 229, 199-205.",MK 8242. Tarabine. AC-1075. Data from 1-12 g doses with 2-3.5 hours iv infusion N=5 (see table 2 and 4) (Ara-C),,1966,243.22,8,4,128.6,6,neutral,-3.0,-3.0
[H]N([H])[C@@H]1[C@@H]([C@@H](O[C@@H]2C[C@H]3[C@H](C(=O)O[H])[C@H](C[C@@](C[C@H](C[C@H]([C@@H](CC[C@H](C[C@H](CC(=O)O[C@@H](C)[C@H](C)[C@@H]([C@@H](C)C=CC=CC=CC=CC=CC=CC=C2)O[H])O[H])O[H])O[H])O[H])O[H])(O[H])O3)O[H])O[C@H](C)[C@H]1O[H])O[H],-2.5563933485243853,0.35898483,Amphotericin B,1397-89-3,0.62,0.17,0.03,61.0,40.0,"Kan, V. L.; Bennett, J. E.; Amantea, M. A.; Smolskis, M. C.; McManus, E.; Grasela, D. M.; Sherman, J. W. Comparative safety, tolerance, and pharmacokinetics of amphotericin B lipid complex and amphotericin B deoxycholate in healthy male volunteers. J. Infect. Dis. 1991, 164, 418-421.","Bellmann, R. Curr. Clin. Pharmacol., 2007, 2, 37-58. VDss 0.62 L/kg. PK parameters variability due to formulation and disease state, reported in a plethora of references, cited by the same author. Actual data data taken from Kan et al. J. Infect. Dis. 1991, 164, 418-421. N=16 healthy volunteers.",,1945,924.08,18,12,319.6,15,zwitterionic,3.1,0.41
[H]N([H])[C@H]1C[C@H](O[C@H]2C[C@@](Cc3c2c(c2C(c4c(cccc4OC)C(c2c3O[H])=O)=O)O[H])(C(CO[H])=O)O[H])O[C@@H](C)[C@H]1I,7.129283016944966,3.8959126,Iododoxorubicin,83997-75-5,53.6,140.0,,6.4,10.3,"Robert J; Armand J P; Huet S; Klink-Alakl M; Recondo G; Hurteloup P. Pharmacokinetics and metabolism of 4'-​iodo-​4'-​deoxy-​doxorubicin in humans. J. Clin. Oncol. 1992,10(7), 1183-1190.","N=16, across several dose. Average of VDss 2,171 +/- 1,551 L/m2. Clearance 340+/- 133 L/hr/m2. Conversion factor 1.73 m2/70 kg. ",,1982,653.42,11,5,185.8,10,cationic,1.9,-0.74
[H]N([H])c1c2cc(c(cc2nc(n1)N1CCN(CC1)C([C@H](C)OC)=O)OC)OC,-0.9159357352115256,1.5063536,Metazosin,95549-92-1,0.44,0.53,,13.7,,"Lapka R. et al. (1989) Interspecies pharmacokinetics scaling of metazosin, a novel alpha-adrenergic antagonist. Biopharm. Drug Disp. ,10, 581-589.","Average of 6 volunteers receiving a 10 mg dose as a 3-min infusion, plus 6 volunteers receiving a 6 mg dose in a 30-min infusion. 73 kg average weight. Data essentially identical among cohorts. Compound also referred as kenosin or VUFB15111. t 1/2 not reported but plot available.",,1984,375.42,9,1,103.0,6,neutral,1.1,0.99
[H]N([H])c1nc(C(C(N([H])[C@H]2C(N3C(=C(CN4C=CN5C4=CC=C[N-]5)CS[C@H]23)C(=O)O[H])=O)=O)=NOC)ns1,1.070389327891398,-0.028188229,Cefozopran,113359-04-9,0.24,2.1,0.74,2.0,1.7,"Shiba, K; Hori, S; Yoshida, M; Shimada, J; Saito, A; Sakai, O.  Fundamental and clinical investigation of cefozopran. Chemotherapy (Tokyo) (1993), 41(Suppl. 4), 187-194. fu from Lombardo et al J. Clin. Pharmacol. 2013, 53(2), 167-177 and 178-191","Calculated via WinNonLin from reported plasma data. Fu 0.92 from Hamada T, Ueta E, Kodama H, Osaki T. The excretion of cephem antibiotics into saliva is inversely associated with their plasma protein-binding activities. J Oral Pathol Med. 2002, 31, 109-116.",,1986,516.53,14,3,180.7,9,anionic,-1.3,-4.8
[H]N([H])c1nc(cs1)C(C(N([H])[C@@H]1C(N2C(=C(CS[C@H]12)C=C1CCN(CC(F)(F)F)C1=O)C(=O)O[H])=O)=O)=NO[H],-1.3959286763311392,0.2601533,Ro25-6833,161672-76-0,0.11,0.38,0.0429999999999999,4.8,3.8,"Weidekamm E, Schweizer J, McClelland G, Joubert P, Heizmann P (1995) Pharmacokinetics of the new cephalosporin Ro25-6833 in humans. Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, 122.; Richter WF, Heizmann P, Meyer J, Starke V, Lave T (1998) Animal pharmacokinetics and interspecies scaling of Ro 25-6833 and related (lactamylvinyl)cephalosporins. J. Pharm. Sci. 87, 496-500. ",500 mg infusion,,1994,546.5,12,4,178.5,9,anionic,0.36,-2.6
[H]N(c1c(C)cccn1)S(c1ccc(C#Cc2ccc(c(c2)C(=O)O[H])O[H])cc1)(=O)=O,-3.8365012677171206,0.13984382,Susalimod,149556-49-0,0.1,0.07,0.0019,23.8,16.0,"Pahlman I, Edholm M, Kankaanranta S, Odell M-L (1998) Pharmacokinetics of susalimod, a highly biliary excreted sulphasalazine analogue, in various species. Nonpredictable human clearance by allometric scaling. Pharm. Pharmacol. Commun. 4, 493-498.","100 mg dose, n=3, fu measured at 25uM ED",,1993,408.43,7,3,116.6,8,anionic,4.1,0.52
[H]N(c1c(c(nc(c2ccnc(c2)c2nnnn2[H])n1)OCCO[H])Oc1ccccc1OC)S(c1ccc(C)cn1)(=O)=O,3.39231742277876,1.19755,Clazosentan,180384-56-9,0.23,10.5,0.02,0.4,2.6,"van Giersbergen, Paul L. M.; Gunawardena, Kulasiri A.; Dingemanse, Jasper. Influence of ethnic origin and sex on the pharmacokinetics of clazosentan. J. Clin. Pharmacol. 2007, 47, 1374-1380.//ppb: P.L.M. van Giersbergen, A. Treiber and J. Dingemanse. In vitro and in vivo pharmacokinetic characteristics of clazosentan, an intravenous endothelin receptor antagonist, in humans.  Int. J. Clin. Pharmacol. Ther., 2009,  47, 169-177","12 Caucasian and 12 Japanese subjects. 3 sequential 4-h infusion at 1, 5 and 15 mg/h.  Average weight 61 kg. Compartmental analysis with V1,V2,V3 and Vss reported. MRT calculated from Cl and Vss. t1/2 taken as the g phase.",,1996,577.57,15,3,200.1,12,anionic,2.9,-2.3
[H]N1Cc2cc(ccc2[C@H]1C)c1ccc2C(C(=CN(C3CC3)c2c1OC(F)F)C(=O)O[H])=O,0.2986583155645151,1.5471158,Garenoxacin,194804-75-6,1.0,1.23,0.25,13.7,,"Hayakawa, Hiroyoshi; Fukushima, Yoko; Kato, Hiroshi; Fukumoto, Hiroyuki; Kadota, Takumi; Yamamoto, Hiroyuki; Kuroiwa, Hiroyuki; Nishigaki, Junko; Tsuji, Akira. (2003) Metabolism and disposition of novel des-fluoro quinolone garenoxacin in experimental animals and an interspecies scaling of pharmacokinetic parameters. Drug Metab. Disp. 31 (11) 1409-1418.","Also known as ganefloxacin and T 3811. Human data reported from a presentation bY Gajjar, D. et al at 2001 ICAAC.  Average weight taken as 70 kg. MRT from VDss and Cl. Data to be confirmed.",,1997,426.41,6,2,78.9,6,zwitterionic,3.4,1.1
[H]OC(CCCCON=C(c1cccc(c1)C(F)(F)F)c1cccnc1)=O,0.070389327891398,1.9913728,Ridogrel,110140-89-1,0.43,1.05,0.033,6.8,7.54,"De Buck, Stefan S.; Sinha, Vikash K.; Fenu, Luca A.; Nijsen, Marjoleen J.; Mackie, Claire E.; Gilissen, Ron A. H. J. Prediction of human pharmacokinetics using physiologically based modeling: a retrospective analysis of 26 clinically tested drugs. Drug Metabolism and Disposition, 2007, 35(10), 1766-1780.  ",70 kg average weight assumed.  MRT calculated from CL and VDss. 100 mg iv dose,,1987,366.33,5,1,71.8,9,anionic,3.5,0.95
[H]OC(CCCOCC=C1C[C@H]2C[C@H]([C@@H](C#C[C@H]([C@@H](C)CC#CCC)O[H])[C@H]2C1)O[H])=O,6.048759311919856,1.635472,Eptaloprost,90693-76-8,2.4,66.2,,0.59,0.41,"Hildebrand M, Inter-species Extrapolation of Pharmacokinetic Data of Three Procyclin-Mimetics, Prostaglandins, 1994, 48, 297-312."," t1/2=0.693/kel. 
Data reported and used for allometric scaling were taken from other publications by the same author.",,1984,402.52,5,3,87.0,15,anionic,3.0,0.22
[H]OC(COc1cccc2C[C@H]3[C@H](CC[C@@H](CCCCC)O[H])[C@H](C[C@H]3Cc12)O[H])=O,3.4195388915137843,2.160432,Treprostinil,81846-19-7,0.23,10.7,0.09,0.36,0.82,"Absolute Bioavailability and Pharmacokinetics of Treprostinil Sodium Administered by Acute Subcutaneous Infusion. Michael Wade ,F. Jo Baker, Robert Roscigno, Wayne DellaMaestra, Thomas L. Hunt and Allen A. Lai J. Clin. Pharmacol. 2004, 44, 83-88.  ppb: The PDR states: In vitro treprostinil is 91% bound to human plasma proteins over the 330-10,000 mcg/L concentration range. Accessed January 6 2015. http://pdr3d.com/detail.php?c=128637#section-13.","Remodulin, Uniprost. Data digitized and calculations performed via WinNonLin. N=15, 150' infusion, 15 ng/kg/min, data very in very good agreement to reported PK parameters.",,1981,390.51,5,3,87.0,13,anionic,4.6,1.4
[H]OC([C@@H]1[C@H]([C@@H]([C@H]([C@@H](O1)O[C@@H]1[C@H]([C@@H]([C@@H](C(=O)O[H])O[C@@H]1O[C@@H]1CC[C@@]2(C)C3C(C=C4[C@H]5C[C@@](C)(CC[C@@]5(C)CC[C@]4(C)[C@@]3(C)CC[C@@H]2C1(C)C)C(=O)O[H])=O)O[H])O[H])O[H])O[H])O[H])=O,-4.321928094887363,-1.5835202,Isoglycirrhizinate (acid),691410-17-0,0.09,0.05,,30.9,23.1,"Sun L. et al. Phase I safety and pharmacokinetic study of magnesium isoglycyrrhizinate after single and multiple intravenous doses in Chinese healthy volunteers. J. Clin.Pharmacol. 2007, 47, 767-773."," CAS number reported is the one of the Mg salt. 1405-86-3 for the acid. N=9, 63 kg average weight, 30' inf.; 100 mg dose. Dosed as magnesium salt. Data (VDss) verified by plot (100 mg dose) digitization and PK analysis via Phoenix.",The acid (as well as glycyrrhizine) was reported in 1880.The 2003 ref. was found for the Mg salt.,1880,822.93,16,8,267.0,15,anionic,1.5,-7.5
[H]OC([C@@]1(CCN(C[C@H]1C)C1CCC(CC1)(C#N)c1ccc(cc1)F)c1ccccc1)=O,-1.217591435072627,0.6417928,Levocabastine,79516-68-0,1.17,0.43,0.453,45.3,33.0,"De Buck, Stefan S.; Sinha, Vikash K.; Fenu, Luca A.; Nijsen, Marjoleen J.; Mackie, Claire E.; Gilissen, Ron A. H. J. Prediction of human pharmacokinetics using physiologically based modeling: a retrospective analysis of 26 clinically tested drugs. Drug Metabolism and Disposition, 2007, 35(10), 1766-1780.  ",70 kg average weight assumed.  MRT calculated from CL and VDss. 0.2 mg iv dose,,1962,420.52,4,1,64.3,6,zwitterionic,4.3,2.0
[H]OC[C@@H](C(=O)OC1C[C@@H]2CC[C@H](C1)[N+]2(C)C(C)C)c1ccccc1,4.972692654004264,3.5082629,Ipratropium,60205-81-4,5.1,31.4,0.95,2.7,1.64,"Ensing K., de Zeeuw R.A., Nossent  G.D., Koeter G.H, Cornelissen, P.J.G. et al. ( 1989)  Pharmacokinetics of ipratropium bromide after single dose inhalation and oral and intravenous administration. Eur. J. Clin. Pharmacol. 36, 189-194.   fu from Lombardo et al J. Clin. Pharmacol. 2013, 53(2), 167-177 and 178-191","N=10, 74 kg average weight VDss calculated as sum of Vc, Valpha and Vbeta reported. 2 mg/dose administered in 20'. ",,1962,332.46,4,1,46.5,7,neutral,-0.72,-0.72
[H]O[C@@H](CN1CCC(CC1)N(C)c1nc2ccccc2s1)COc1ccc(c(c1)F)F,0.765534746362977,2.7396166,Lubeluzole,144665-07-6,2.6,1.7,0.003,26.0,21.6,"Herron, Jerry; Lee, Peter; Pesco-Koplowitz, Luana; Gajjar, Diptee; Soo, Yuh Wen; Woestenborghs, Robert. Determination of the dose proportionality of single intravenous doses (5, 10, and 15 mg) of lubeluzole in healthy volunteers. Clin. Ther. 1998, 20(4), 682-690. Three-way cross-over study in 11,10 and 12 healthy subjects at 5, 10 and 15 mg dose respectively as 1-hr inf. Male and female subjects, 70 kg reported average weight. Weight-averaged VDss 220 L; 3.1 L/kg, Cl= 1.8 mL/min/kg; MRT = 28.7 h; t1/2 = 23.5h//Van de Velde, V.; Crabbe, R.; Van Peer, A.; Woestenborghs, R.; Van Osselaer, N.; Hantson, L.; Heykants, J. Pharmacokinetics of lubeluzole (Prosynap) after single intravenous doses in healthy subjects. Int. J. Clin. Pharmacol. Ther. 1998, 36, 490-493. N=8, total of 31 administrations across 6 doses 2.5 to 25 mg, each separated by 13 days. 30' inf. 79 kg average weight. Weight averaged data: VDss= 2.15 L/kg, Cl= 1.54 mL/min/kg; MRT = 23.3 h; t1/2 = 19.8h. fu from De Buck, Stefan S.; Sinha, Vikash K.; Fenu, Luca A.; Nijsen, Marjoleen J.; Mackie, Claire E.; Gilissen, Ron A. H. J. Prediction of human pharmacokinetics using physiologically based modeling: a retrospective analysis of 26 clinically tested drugs. Drug Metabolism and Disposition, 2007, 35(10), 1766-1780.  ",AVERAGED ACROSS TWO REPORTS (N almost identical); Weight averaged within each report. ,,1992,433.51,5,1,48.8,8,cationic,4.9,4.4
[H]O[C@H]1[C@H](C)O[C@@H](C[C@@H]1OC)O[C@@H]1[C@@H](C)C(=O)O[C@H](C)[C@H](C)[C@@H]([C@@H](C)C([C@]2(C[C@H](C)[C@@H]([C@H]1C)O[C@@H]1[C@@H]([C@@H](C[C@H](C)O1)N(C)C)O[H])CO2)=O)O[H],3.1858665453113337,1.3228168,Oleandomycin,3922-90-5,0.77,9.1,0.4,1.41,1.05,"Duthu G S. Interspecies correlation of the pharmacokinetics of erythromycin, oleandomycin, and tylosin. J Pharm Sci, 1985, 74(9), 943-946. ","Data in 70.0 Kg weight subjects (see Ref. 7). MRT calculated from CL and VDss.   fu from Lombardo et al J. Clin. Pharmacol. 2013, 53(2), 167-177 and 178-191",,1955,687.86,13,3,166.0,9,cationic,2.0,0.7
[H]O[C@](Cn1cncn1)(c1cc(ccc1F)F)[C@@H](C)c1nc(cs1)c1ccc(C#N)cc1,-0.2344652536370229,1.0829737,Isavuconazole,241479-67-4,5.37,0.85,0.01,105.5,86.9,"Schmitt-Hoffmann A. et al. Single-​ascending-​dose pharmacokinetics and safety of the novel broad-​spectrum antifungal triazole BAL4815 after intravenous infusions (50, 100, and 200 milligrams) and oral administrations (100, 200, and 400 milligrams) of its prodrug, BAL8557, in healthy volunteers. Antimicrobial Agents and Chemotherapy, 2006, 50(1), 279-285. //ppb: Robert W. Townsend,corresponding author1 Shahzad Akhtar,1 Harry Alcorn, Jolene K. Berg, Donna L. Kowalski, Salim Mujais, and Amit V. Desai. Phase I trial to investigate the effect of renal impairment on isavuconazole pharmacokinetics. Eur J Clin Pharmacol. 2017, 73, 669–678.","PK profiles refer to BAL4815 after iv infusion of prodrug BAL8557. BAL4815 = Isavuconazole
Data from 50,100,200 mg equivalents of BAL4815 iv infusion (1 h) dose of prodrug BAL8557, N=18, 77.1(SD 10.4) average weight (57-100Kg). t½ taken as the β phase",,1999,437.47,6,1,87.6,8,neutral,4.0,4.0
[H]O[C@]1(CC)CC(=O)OCC2=C1C=C1c3c(CN1C2=O)cc1cc(c(cc1n3)F)F,3.0738202332916718,1.9785403,Diflomotecan,220997-97-7,1.42,8.42,0.125682020829098,3.87,3.1,"Scott L; Soepenberg O; Verweij J; de Jonge M J A; Th Planting A S; McGovern D; Principe P; Obach R; Twelves C. A multicentre phase I and pharmacokinetic study of BN80915 (diflomotecan) administered daily as a 20-​min intravenous infusion for 5 days every 3 weeks to patients with advanced solid tumours. Annals of Oncology, 2007, 18(3), 569-575.    fu from Lombardo et al J. Clin. Pharmacol. 2013, 53(2), 167-177 and 178-191",Data corrected for body surface area from weight averaged 0.05-0.15 mg/m2 iv infusion (20 min) doses (N=3 to N=11) (see Table 5). Conversion of 1.73 m2 to 70 Kg.,,1999,398.36,6,1,79.7,2,neutral,-0.7,-0.7
[H]Oc1ccc2c(C[C@H](CCCCCCCCCS(CCCC(C(F)(F)F)(F)F)=O)C3[C@@H]2CC[C@@]2(C)[C@H]3CC[C@@H]2O[H])c1,3.560714954474479,1.867746,Fulvestrant,129453-61-8,4.15,11.8,0.01,5.86,16.0,"Robertson JFR, Harrison M. Fulvestrant: pharmacokinetics and pharmacology. British Journal of Cancer, 2004, 90(Suppl 1), S7-S10. ppb: The PDR states: Fulvestrant is highly (99%) bound to plasma proteins; VLDL, LDL and HDL lipoprotein fractions appear to be the major binding components. Accessed January 11 2015. http://www.pdr3d.com/detail.php?c=82597#section-12.",  Data from 1-h iv infusion doses. MRT calculated from CL and VDss,,1989,606.77,3,2,57.5,16,neutral,9.0,9.0
[H]n1c2ccncc2nc1c1ccc(cc1OC)S(C)=O,4.371558862611963,2.3592384,Isomazole,86315-52-8,1.67,20.7,0.48,1.3,1.2,"Woodworth, James R.; Delong, A. F.; Fasola, A. F.; Oldham, S. Isomazole disposition in man as a function of dose and route of administration. Biopharm. Drug Disp. 1991, 12, 673-686."," fu = 0.48. N=9, 70 kg average weight assumed. 16.1 mg dose and 30' infusion. 
Data digitized from plots reported by Woodworth et al. Data normalized to middle dose as reported as average in the plot from multiple doses. Calculated data within 8% of reported. VDb = 1.82 L.kg-1 and AUCinf = 201 ng.hr.mL-1.",,1983,287.34,5,1,67.9,3,neutral,1.0,1.0
[nH]1cnc2c([nH]cc2[C@@H]2N[C@@H]([C@H]([C@H]2O)O)CO)c1=O,0.6415460290875237,2.0759423,Forodesine,209799-67-7,,1.56,,,11.6,"A proof-of-principle pharmacokinetic, pharmacodynamic, and clinical study with purine nucleoside phosphorylase inhibitor immucillin-H (BCX-1777, forodesine)
Varsha Gandhi, John M. Kilpatrick, William Plunkett, Mary Ayres, Leigh Harman, Min Du, Shanta Bantia, Jan Davisson, William G. Wierda, Stefan Faderl, Hagop Kantarjian, and Deborah Thomas. BLOOD, 2005   VOLUME 106, (13)4253-4260.",Only Vz reported. Infusion across 5 patients. One patient received 4 doses. N = 8 total. ,,1998,266.25,8,6,134.3,2,cationic,-3.9,-4.3
[nH]1cncc1C1(Cc2c(C1)cccc2)CC,4.292781749227846,2.965051,Atipamizole,104054-27-5,2.7,19.6,,2.3,1.7,"SAKARI KARHUVAARA, ANTERO KALLIO, MIKA SCHEININ, MARKKU ANTTILA, JARMO S. SALONEN & HARRY SCHEININ. Pharmacological effects and pharmacokinetics of atipamezole, a novel 0L2-adrenoceptor antagonista randomized, double-blind cross-over study in healthy male volunteers. Br. J. clin. Pharmac. (1990), 30, 97-106","Data digitized from plot at 100 mg dose (linear PK). N=6, 73 kg average weight. N= 6, 73 kg average weight. Reported AUC = 1.19 mg.h.L-1; Clearance = 1.14 L.h-1.kg-1. ",,1986,212.29,2,1,28.7,2,neutral,2.6,2.4
c1(C(c2ccc(SC)cc2)=O)c([nH]c([nH]1)=O)C,4.255500733148386,2.046246,Enoximone,77671-31-9,1.48,19.1,0.3,1.33,1.94,"SHlGEMlCHl MORITA, YONElCHl SAWAI, JOEL F . HEEG,  YUlCHl KOIKE. Pharmacokinetics of Enoximone after Various Intravenous Administrations to Healthy Volunteers. J. Pharm. Sci. 1995, 84, 152-157. Data averaged with Alken RG, Belz GG, Haegele KD, Meinicke T, and Schechter PJ (1984) Kinetics of fenoximone, a new cardiotonic, in healthy subjects. Clin. Pharmacol. Ther. 36: 209-216.  Hook RH, Boxenbaum H, Thompson GA, and Okerholm RA (1988) Human serum and plasma protein binding of enoximone and its sulfoxide metabolite.  J. Pharm. Sci. 77: 1012-1017. VDss 1.8 L/kg, clearance 29 mL/min/kg, MRT 1 h and t1/2 1 h.","doses from 0.25 mg/kg to 2 mg/kg N=6 for each dose. Data as average across doses. Fenoximone, same compound. Data weight-averaged. Enoximone kept",,1980,248.3,4,2,65.7,3,neutral,1.3,1.3
c1(C2(C(=O)N(C)CC)CCN(CC2)CCCCCC)ccccc1,4.584962500721156,3.0963814,Sameridine,143257-97-0,,24.0,,,3.6,"Åsa Österlund, MD, Eva Arlander, MScPharm, Lars I. Eriksson, MD, PhD, Sten G. E. Lindahl, MD, PhD, FRCA. The Effects on Resting Ventilation of Intravenous Infusions of Morphine or Sameridine, a Novel Molecule with Both Local Anesthetic and Opioid Properties. Anesth Analg 1999, 88:160 –165.",N=12. Clearance and t 1/2 reported in text. 0.73 mg/kg dose. 70 kg average weight assumed. Ref. 6 cited in the paper (abstract) with clearance of 1.4 L/min (20 mL/min/kg),,1986,330.51,3,0,23.5,8,cationic,4.1,2.5
c1(N2CCCCC2)cc(n(=O)c(n1)N)N,3.523561956057013,2.0702837,Minoxidil,38304-91-5,0.9,11.5,1.0,1.3,1.5,Minoxidil - FDA Approval Package Administrative documents 019501 Part 01. Accessed through Pharmapendium.//ppb: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/018154s026lbl.pdf. Accessed July 10 2017.,"N=8, 76.3 kg average weight. Average of two doses.",,1967,209.25,6,2,91.1,1,neutral,0.9,0.9
c1(OC(N(CCCCCCN(C(Oc2c[n+](ccc2)C)=O)C)C)=O)c[n+](ccc1)C,-2.321928094887362,1.9428443,Distigmine,17299-00-2,1.0,0.2,,82.4,59.8,"Vree TB, Waitzinger J, Hammermaier A, Radhofer-Welte S.Absolute bioavailability, pharmacokinetics, renal and biliary clearance of distigmine after a single oral dose in comparison to i.v. administration of 14C-distigmine-bromide in healthy volunteers. International journal of clinical pharmacology and therapeutics, 1999,37, 393-403.","UBRETID. CAS number and SMILES entered dication only (no Br-). N=6, 86.2 kg average weight. 3' infusion. Bromide salt CAS # = 15876-67-2",85% excreted unchanged after renally (14.8 mL/min vs. totl of 17.1 mL/min) from ref. cited.,1957,416.51,8,0,66.8,11,neutral,-5.7,-5.7
c1(OCCCN(C)C)c2c(n(n1)Cc1ccccc1)cccc2,1.189033824390017,3.1800299,Benzydamine,642-72-8,1.53,2.28,0.8,11.4,8.1,"G. A. BALDOCK, R. R. BRODIE, L. F. CHASSEAUD, T. TAYLOR AND L. M. WALMSLEY. PHARMACOKINETICS OF BENZYDAMINE AFTER INTRAVENOUS, ORAL, AND TOPICAL DOSES TO HUMAN SUBJECTS. BIOPHARMACEUTICS & DRUG DISPOSITION, 1991, 12, 481-492.//ppb: Chasseaud LF, Catanese B. Pharmacokinetics of benzydamine. Int J Tissue React. 1985, 7, 195-204.","Benzidamine. N=6 (male subject) 70 kg average weight reported, 5 mg dose",,1964,309.41,4,0,30.3,7,cationic,4.2,0.76
c1(S(Nc2ccccn2)(=O)=O)ccc(\N=N\c2cc(c(O)cc2)C(O)=O)cc1,-1.9434164716336324,0.5198874,Sulfasalazine,599-79-1,0.11,0.26,0.004,6.8,7.6,"Sulfasalazine - FDA Approval Package
Label 007073/S-124. See also Sulfasalazine - FDA Approval Package
Bioequivalence Review 007073.  Accessed through PharmaPendium. Ppb: Kochansky, Christopher J.; McMasters, Daniel R.; Lu, Ping; Koeplinger, Kenneth A.; Kerr, Haley H.; Shou, Magang; Korzekwa, Kenneth R. Impact of pH on Plasma Protein Binding in Equilibrium Dialysis. Mol. Pharm. 2008, 5, 438-448",70 kg assumed.  MRT from VDss and clearance.,renal clearance estimated as 37% of total. Anecdotally assigned to metabolic. See FDA package.,1944,398.39,9,3,141.3,6,anionic,3.6,0.17
c1([C@@H](c2ccccc2)CC)c(c2c(cccc2)oc1=O)O,-5.643856189774724,0.76195025,Phenprocoumon,435-97-2,0.2,0.02,0.57,182.0,126.0,"Haustein KO, Hüller G. Pharmacokinetics of phenprocoumon. International journal of clinical pharmacology and therapeutics, 1994, 32, 192-7","Data digitized from plot reported. 40% extrapolation to AUC inf. Not clear whether reported AUC is to infinity. Reported AUC 121 ug.h.mL-1. Calculated AUC(inf)  116.5ug.h.mL-1. N=18, 9 mg dose (iv bolus), 71.6 Kg average weight. ppb reported by these authors from another citation. Held H, van Busse G, MeissnerJ 1980 Beobachtungen bei Phenprocoumon(Marcumar) Vergiftung. Dtsch Med Wochenschr 105: 860-863. NOT CHECKED.",,1953,280.32,3,1,50.7,3,anionic,4.0,1.2
c1(\C(CCCCOC)=N\OCCN)ccc(C(F)(F)F)cc1,4.997744026059632,3.1063483,Fluvoxamine,54739-18-3,23.5,31.95,0.2,12.26,12.5,"J. van Harten, F. Kok, A. Lönnebo  and A. Grahnén. Pharmacokinetics of fluvoxamine after intravenous and oral administration. Eur. Neuropsychopharmacology, 1994, 4, 331.","Average of two doses, N=17 per dose, 70 kg/average weight assumed. 10 and 30 mg doses as iv infusion in 60 minutes. Clearance from dose/AUC, then averaged. MRT from VDss and clearance. ","Ppb from PDR label. Absolute BA from paper 53% (po dose 50 mg, crossover with iv doses)",1977,318.33,4,1,56.8,9,cationic,3.1,1.2
c1(\C=C\C(NCCO)=O)ccccc1,-0.014499569695115,2.9224863,Idrocilamide,6961-46-2,0.11,0.99,,1.93,1.35,"H. Maier-Lenz, L. Ringelski, A. Windhorfer zur.Pharmakokinetik nnd Bioverfiigba1·keit des Myotonolytikums N-(Hydroxy-2-athyl)-cinnarnid. Arzneim.-Forsch. 1980, 30, 1813-1816.","LCB-29. Brolitene. N=10, 60 mg iv dose, 68 kg average weight
Reported AUC = 11.31 +/- 4.9 ug.hr/mL AUC computed as  14.8 ug.h/mL from plot digitization but within sd and thus accepted.
lambda z = 0.7 hr-1
VD reported = 7.4 L",,1948,191.23,3,2,49.3,4,neutral,0.86,0.86
c1(c(OC)cc2c(c1)c(nnc2)N1CCC(CC1)OC(NCC)=O)OC,5.232660756790275,2.207636,Carbazeran,70724-25-3,0.67,37.6,0.08,0.25,0.25,"Kaye B, Offerman JL, Reid JL, Elliott HL, Hillis WS. A species difference in the presystemic metabolism of carbazeran in dog and man. Xenobiot. 1984, 14, 935-945,// ppb: Zientek M, Jiang Y, Youdim, K, and Obach RS (2010) In vitro-in vivo correlation for intrinsic clearance for drugs metabolized by human aldehyde oxidase.  Drug Metab. Dispos. 38: 1322-1327.",VDss calculated from mean C vs t data in the paper,,1978,360.41,8,1,85.8,6,neutral,2.3,2.3
c1(c(c(c(Cl)c(n1)OC)OC)Cl)C(Cl)(Cl)Cl,4.902073579310743,1.6302965,Penclomedine,108030-77-9,9.1,29.9,,5.1,3.8,"Phase I and Pharmacologic Study of Penclomedine,
a Novel Alkylating Agent, in Patients With Solid Tumors Seamus O'Reilly, Louise B. Grochow, Ross C. Donehower, Tian-Ling Chen, Katherine Bowling, Neil R. Hartman,Robert F. Struck, and Eric K. Rowinsky. Journal of Clinical Oncology, 1997, Vol 15 1974-1984.","70 kg assumed. Average from Table 6. Data from day 1 taken. Day 5 very similar. N=6, 5 mg/kg 5 minutes infusion. 75.3 kg average weight. 45  to 550 mg/m2/day doses. ",,1987,325.4,3,0,31.3,2,neutral,4.4,4.4
c1(c(c(c(cc1C)OC[C@@H](CNC(C)C)O)C)C)O,4.017921907997263,2.82669,Deacetyl metipranolol,57193-14-3,3.6,16.2,,3.7,3.1,"U. Abshagen, G. Betzien, B. Kaufmann, G. Endele. Pharmacokinetics of Metipranolol in normal man. Eur. J. Clin. Pharmacol, 1982, 21, 293-301.","Data digitized from 20 mg PK profile in figure 3 in . N=10, 20 mg dose, 0.8 h infusion, 78 kg.
Reported AUC 283 hr*ug/L
t1/2 = 2.91 h
Clearance = 20.3 mL/sec (= 15.6 mL/min/kg)",very low renal clearance (12%),1974,267.36,4,3,61.7,6,cationic,2.6,0.77
c1(c(c(cc(c1O)Cl)Cl)OC)C(=O)NC[C@H]1N(CCC1)CC,0.2630344058337938,2.2934384,Raclopride,84225-95-6,1.1,1.2,0.06,15.3,14.0,"MOVIN-OSSWALD G. ; NORDSTRÖM A.-L. ; HAMMARLUND-UDENAES M. ; WAHLEN A. ; FARDE L. Pharmacokinetics of raclopride formulations : influence of prolactin and tolerability in healthy male volunteers. Clin. Pharmacokin. 1992, 22, 152-161.",MRT from VDss and clearance. 78 kg average weight reported. 3.6 mg of raclopride tartrate (2.8 mg of free base) admisntered over 10'. N=15.,reported in ref. as extensively metabolized. Very low renal excretion of unchanged drug.,1982,347.24,5,2,61.8,5,zwitterionic,2.9,2.1
c1(c(c2c(c(F)c(cc2n(c1)C1CC1)N1C[C@@H](C)NCC1)C)=O)C(=O)O,2.560714954474479,0.8200122,Grepafloxacin,119914-60-2,,5.9,0.82,,9.2,"PP. Grepafloxacin Hydrochloride - FDA Approval Package Review 020695
ppb: Clinical Pharmacology and Biopharmaceutics . Determination of protein binding of gyrase inhibitors by means of continuous ultrafiltration G Zlotosa, M Oehlmannb, P Nickelb, U Holzgrabe. Journal of Pharmaceutical and Biomedical Analysis, 1998, 18,  847–858","N=5/dose, 100 and 200 mg iv dose. No VDss reported. ",,1988,359.39,6,2,74.6,3,zwitterionic,2.8,-0.015
c1(c(c2ccc(O)cc2)sc2c1ccc(c2)O)C(c1ccc(OCCN2CCCCC2)cc1)=O,3.4329594072761065,2.2955532,Raloxifene,84449-90-1,7.5,10.8,0.05,11.6,12.1,"Raloxifene Hydrochloride - FDA Approval Package Clinical Pharmacology and Biopharmaceutics Review 020815/S-000. Accessed through Pharmapendium. Ppb: the PDR states: Raloxifene and the monoglucuronide conjugates are highly (95%) bound to plasma proteins. Raloxifene binds to both albumin and α1-acid glycoprotein, but not to sex-steroid binding globulin. http://www.pdr3d.com/detail.php?c=127942#section-14. Accessed January 5 2015.","Evista. N=6, 1 mg infusion iv.",Interconverted with glucuronide and subject to enterohepatic recycling.,1982,473.58,5,2,70.0,7,cationic,6.4,4.3
c1(c(cc(N)c(c1)Cl)OC)C(N[C@@H]1[C@@H](C[N@@](CCCOc2ccc(F)cc2)CC1)OC)=O,0.5849625007211562,2.111836,Cisapride,81098-60-4,1.2,1.5,0.02,12.9,11.7,"Ref. through PP. 1992-Mar-17  PDF(7171k) Medical/Clinical Review 020210/S-000. ppb: PDR states: PROPULSID® binds to an extent of 97.5-98% to plasma proteins, mainly to albumin. Accessed December 301 2014. http://www.pdr3d.com/detail.php?c=10088#section-5",Calculation perforrmed via Phoenix after digitization. 4 mg dose. N=6 ,Ref. through PP. 1992-Mar-17  PDF(7171k) Medical/Clinical Review 020210/S-000 ,1983,465.95,7,2,86.0,9,cationic,3.5,3.0
c1(c(cc(c(=O)[nH]1)C#N)c1ccc2n(c1)ccn2)C,3.4594316186372973,1.4674151,Olprinone,106730-54-5,0.64,11.0,,0.97,1.13,"QIN Yong-ping，MIAO Jia，MEI Ya-jun, WANG Ying，NAN Feng，ZHU Xiao-hong, XIANG Jin，SHU Shi-qing，YU Qin，LI Mei，LIANG Mao-zhi. Pharmacokinetic study of olprinone hydrochloride injection in healthy volunteers. Chinese Journal of New Drugs 2015, 24(12), 1397-1403. ","Abstract in English. Article in Chinese. Seemingly 62% excreted unchanged in urine. VDss from clearance and MRTinf reported. Very tight data with N=9 across three doses (averaged) at 5, 10 and 20 ug/kg injected in 5 minutes.",,1986,250.26,5,1,74.0,2,neutral,0.59,-2.9
c1(c(ccc(c1)S(=O)(=O)N)OC)C(NC[C@@H]1[N@@](CCC1)CC)=O,0.925999418556223,1.9780337,Sulpiride,15676-16-1,0.94,1.9,1.0,8.01,6.5," Bres, Janine; Bressolle, Francoise. Pharmacokinetics of sulpiride in humans after intravenous and intramuscular administrations  Journal of Pharmaceutical Sciences (1991), 80(12), 1119-24. ",Dogmatil. Reported as not bound to plasma protein and essentially all cleared renally. Blood/plasma ratio ~ 1.,,1967,341.43,7,2,101.7,6,cationic,0.7,-0.75
c1(c2[nH]c(c(c3nc(c(c4cc(ccc4)O)c4[nH]c(c(c5nc1CC5)c1cc(ccc1)O)cc4)C=C3)c1cc(ccc1)O)cc2)c1cc(ccc1)O,-4.058893689053568,0.39115092,Temoporfin,122341-38-2,,0.06,0.14,,91.5,"Temoporfin - EMA Approval Package
Scientific Discussion. Accessedd through Pharmapendium.","average of two studies at 0.15 mg/kg in healthy volunteers. VD reported as 0.39 and 0.46 L/kg, without definition and likely to be VDz.",Metabolic pthway not identified. EMA Package,1989,690.83,8,8,136.6,4,neutral,5.1,5.0
c1(c2c(cccc2)[nH]c1)C[C@@H](NC([C@@H](Cc1c[nH]cn1)NC([C@@H]1CCC(N1)=O)=O)=O)C(N[C@@H](C(N[C@@H](Cc1ccc(O)cc1)C(N[C@@H](Cc1cc2c(cccc2)cc1)C(N[C@@H](C(N[C@@H](C(N1[C@@H](CCC1)C(NCC(N)=O)=O)=O)CCCNC(N)=N)=O)CC(C)C)=O)=O)=O)CO)=O,-0.4739311883324124,1.5758991,Nafarelin,76932-56-4,0.14,0.72,0.19,3.33,3.5,"Chaplin  ML (1992). Bioavailability of nafarelin in healthy volunteers. Am J Obstet Gynecol, 166, 762-765. ppb: Reported as 78-84% bound (81% taken as median) by  Chan R L; Chaplin M D . Plasma binding of LHRH and nafarelin acetate, a highly potent LHRH agonist. Biochemical and biophysical research communications (1985), 127(2), 673-9. ","70 kg assumed as average weight but likely to be lower. AUCinf from data digitized digitized calculated as 8.26 ng.hr.mL-1 vs. reported as 7.9 ng.hr.mL-1.  Yet clearance reported as 0.93 mL.min-1.kg-1 vs. calculated as 43.22 mL.hr-1.kg-1, or 0.72 mL.min-1.kg-1. Likely to be due to a different dose in mg/kg basis, and thus due to weight. Total dose 25 ug. N=15 (average plot).",25 ug (microdose),1980,1322.47,30,17,472.1,34,cationic,-0.4,-4.4
c1(c2c(nc(N3CCN(C)CC3)nc2)N)c(c(cc(c1)Cl)Cl)Cl,4.38543103719352,1.7240217,Sipatrigine,130800-90-7,15.31,20.9,,12.26,10.98,"A. J. MERCER, R. J. LAMB, HUSSEIN, S. HOBBIGER, J. POSNER. The Tolerability, Pharmacokinetics and Pharmacodynamics of Increasing Intravenous Doses of 619C89, a Novel Compound for the Acute Treatment of Stroke, in Healthy Volunteers. Ann N. Y. Acad. Sci., 1995, 754, 324-326."," 619C89. Data digitized from reported plot. 1 mg/kg only but linear PK. N=8, 70 kg average weight assumed. Reported AUCinf = 885 ng.hr.mL-1. Calculated 798 ng.hr.mL-1 (11% difference). Clearance reported 1.2 L.hr-1.kg-1. Calculated 1.25 L.hr-1.kg-1.","in STROKE PATIENTS: Z. HUSSEIN, I. J. FRASER, K. R. LEES, K. W. MUIR, M. W. LUNNON, S. F. HOBBIGER, J. POSNER. Pharmacokinetics of 619C89, a novel neuronal sodium channel inhibitor, in acute stroke patients after loading and discrete maintenance infusions. Br J Clin Pharmacol 1996; 41: 505–511//619C89. 5 dose groups (loading and maintenance infusion). Data were weight averaged accoding to number of patients. N=23 overall (N=22 for t1/2). Reported mean body weight 74 kg.",1990,372.68,5,1,58.3,2,cationic,4.4,3.6
c1(c2nc3c(c(=O)[nH]2)n(nc3CCC)C)c(ccc(c1)S(=O)(=O)N1CCN(CC1)C)OCC,3.169925001442312,1.8386574,Sildenafil,139755-83-2,1.36,9.0,0.04,2.5,2.2,"Sildenafil 2009-Dec-21  PDF(322k)
Assessment Report EMEA/H/C/638/X/0019",EMEA review through PP. weighted average of N=12 (50 mg) and 3 (25mg). 70 kg average weight assumed.,PDR. Accessed February 14 2013.  http://www.pdr3d.com/detail.php?c=75609#section-3,1992,474.58,10,1,113.4,7,cationic,1.6,1.1
c1(cc(CCN[C@@H](CCc2ccc(cc2)O)C)ccc1O)O,6.845490050944375,3.4208415,Dobutamine,34368-04-2,,115.0,,,,"R A Berg, J F Padbury, R L Donnerstein, S E Klewer, J J Hutter, Jr. Dobutamine pharmacokinetics and pharmacodynamics in normal children and adolescents.  J.Pharmacol. Exp. Ther. 1993 265 (3) 1232-1238.",No other data reported.,,1974,301.38,4,4,72.7,7,cationic,3.4,1.7
c1(cc(c(O)cc1)O)CCN,6.04220656012069,3.296197,Dopamine,51-61-6,0.74,65.9,0.87,0.19,0.42,"Data digitized from Fig. 1 P.-0. JARNBEG, L. BENGTSSOJN, E KSTRANaD, B. HAMBERCER Dopamine Infusion in Man. Plasma Catecholamine Levels and Pharmacokinetics. Acta anaesth. scand. 1981, 25, 328-331.//ppb: Gunhild Franksson and Erik Änggård The Plasma Protein Binding of Amphetamine,  Catecholamines and  Related Compounds. Acta Pharmacol. Toxicol.1970, 28,  209-214.","N=8 for 2 and 5 ug/kg/min, 30' infusion. Data digitized from Fig.1",,1910,153.18,3,3,66.5,2,cationic,0.56,-2.0
c1(cc(c(c(c1)OC)OC)OC)/C=C\c1ccc(c(c1)OP(=O)(O)O)OC,2.550900664647523,0.33713794,Combretastatin A4 Phosphate,222030-63-9,0.11,5.86,0.23,0.3,0.47,"Afshin Dowlati, Kelly Robertson, Matthew Cooney, William P. Petros, Michael Stratford, John Jesberger, Niusha Rafie, Beth Overmoyer, Vinit Makkar, Bruce Stambler, Anne Taylor, John Waas, Jonathan S. Lewin, Keith R. McCrae and Scot C. Remick. A Phase I Pharmacokinetic and Translational Study of the Novel Vascular Targeting Agent Combretastatin A-4 Phosphate on a Single-Dose Intravenous Schedule in Patients with Advanced Cancer. Cancer Res. 2002 62, 3408-3416","70 kg average weight assumed. Data reported across doses and N=25. High variability. MRT from VDss and clearance. ppb:  Plasma protein binding characteristics of anti-​tumor drug Combretastatin A4 phosphate in several species. Huaxi Yaoxue Zazhi, 2009, 24, 45-47. From abstract in English. Some variability with concentration but data seemingly tight (0.13-0.29 fu range). Mid-concentration data taken.",,1989,396.33,8,2,103.7,8,anionic,2.9,-0.95
c1(ccc(NC(C)=O)cc1)OC[C@@H](CNC(C)C)O,1.189033824390017,2.442051,Practolol,6673-35-4,,2.28,0.93,,12.2,"Tjandramaga TB, Altered Pharmacokinetics of beta-Adrenoreceptor Blocking Drugs in Patients with Renal Insuffency. Archives Internationales de Pharmacodynamie et de Therapie 1980, Suppl., Pages 38-53. ppb: reported by Henry JA, Mitchell, SN. Effect of pH on human plasma protein binding of a series of β-adrenoceptor antagonists. British Journal of Clinical Pharmacology  1981 11(1):119-120P",CL and T1/2 from Table III (N=7 dose 160 mg). BW assumed to be 70 kg. Fig. 3 to be digitized to confirm reported values,Renal > 90% (renal clearance and other properties are available for other beta-adrenergic),1966,266.34,5,3,70.6,7,cationic,0.95,-0.84
c1(ccc(O)cc1)OC[C@H](CNC(C)C)O,4.465974464504069,3.2550313,Prenalterol,57526-81-5,4.28,22.1,,3.23,2.85,"Clarke, A. F.; Jack, D. B.; Kendall, M. J.; Smith, S. R.  The pharmacokinetics of oral and intravenous prenalterol in young, healthy volunteers.    Biopharmaceutics & Drug Disposition  (1986),  7(1),  47-52.  ",5 mg dose. Data digitized. 71.3 kg reported average weight. N=10. ratio AUC digit/rep = 1.13,,1975,225.28,4,3,61.7,6,cationic,1.2,-0.55
c1(ccc(cc1)CCCCCCCC)CCC(CO)(N)CO,0.6135316529179271,2.9156556,Fingolimod,162359-55-9,17.3,1.53,0.002,189.0,144.0,"PP. Fingolimod Hydrochloride - FDA Approval Package
Pharmacology Review 022527/S-000 Part 04","MRT from VDss and Cl. N=11, (5M/6F) 1 mg dose iv injection, reported average weight 69.1 kg. Reported source, study A0108. ppb reported as 99.7 to 99.9% across species. 99.8% taken","PDR. Accessed February 21 2013. http://www.pdr3d.com/detail.php?c=64159#section-13.  After oral administration, about 81% of the dose is slowly excreted in the urine as inactive metabolites. Fingolimod and fingolimod-phosphate are not excreted intact in urine but are the major components in the feces with amounts of each representing less than 2.5% of the dose. ",1994,307.47,3,3,66.5,12,cationic,3.7,2.6
c1(ccc(cc1)S(=O)(=O)N)S(=O)(=O)Nc1cccc2c(c[nH]c12)Cl,-0.4739311883324124,0.5317415,Indisulam,165668-41-7,0.68,0.72,0.001,16.9,20.3,"E. Raymond, W.W. ten Bokkel Huinink, J. Taı¨eb, J.H. Beijnen, S. Faivre, J. Wanders, M. Ravic, P. Fumoleau, J.P. Armand, and J.H.M. Schellens. Phase I and Pharmacokinetic Study of E7070, a Novel Chloroindolyl Sulfonamide Cell-Cycle Inhibitor, Administered as a One-Hour Infusion Every Three Weeks in Patients With Advanced Cancer. J. Clin. Onc., 2002, Vol 20, 3508-3521. ppb: SATURABLE BINDING TAKEN at 3.5 uM total concentration. Saturable binding of indisulam to plasma proteins and distribution to human erythrocytes Zandvliet, Anthe S.; Copalu, William; Schellens, Jan H. M.; Beijnen, Jos H.; Huitema, Alwin D. R. Drug Metabolism and Disposition 2006, 34, 1041-1046, 2006 ",E7070. Weighted average of 6 patients across 100 and 200 mg/m2 (linear). Generally non-linear pharmacokinetics and high percentage of extrapolated AUC. 70-kg average weight assumed.,,1995,385.85,7,3,122.1,4,neutral,1.3,1.0
c1(ccccc1)[C@@](O)(C1CCCC1)CO[C@@H]1CN2CCC1CC2,0.9927684307689242,2.6147974,Penehyclidine,87827-02-9,2.12,1.99,,17.84,15.73,"Libo Zhao, Yannan Zang, Yuwen Sun, Zhongn Wei, Shan Jing, Qian Wang,Youzhong An, Yi Fang, Wanyu Feng. Development and validation of an improved HPLC-MS/MS method forcomparative pharmacokinetics of penehyclidine hydrochloridefollowing a single intravenous or intramuscular injection.  J. Chrom. B, 2015, 1004, 37–45.",3-(2 -Phenyl-2 -cyclopentyl-2 -hydroxyl-ethoxy) quinuclidine. Penequinine. N=18 crossover patients with a 0.5 mg dose.  i.m./i.v and i.v/i.m. in two groups of 9. Average reported weight 62.1 kg. VDss from MRTinf and clearance.,,1983,315.45,3,1,32.7,5,cationic,3.1,1.4
c1(cn[nH]c1)C,-0.4540316308947075,2.6411948,Fomepizole,7554-65-6,0.35,0.73,,7.94,4.42,"KENNETH E. MCMARTIN , C. SIMON SEBASTIAN, DAVID DIES , DAG JACOBSEN. Kinetics and metabolism of fomepizole in healthy humans. Clin. Toxicol. 2012, 50, 375–383","N=5, average weight assumed to be 70 kg. 7 mg/kg = 85.3 umol/kg (MW 82.1). Data digitized from plot reported and analyzed via PKSolver. AUC reported 1880 umol.h.L-1; calculated 1953.3 umol.h.L-1.",,1930,82.1,2,1,28.7,0,neutral,0.72,0.72
c1(nc(c(n1Cc1ccc(cc1)c1c(cccc1)c1nnn[nH]1)C(=O)O)C(C)(C)O)CCC,-1.7858751946471527,0.62815464,Olmesartan,144689-24-7,,0.29,,,10.8,"Lee R. Schwocho and Harvey N. Masonson. Pharmacokinetics of CS-866, a New Angiotensin II Receptor Blocker, in Healthy Subjects. Journal of Clinical Pharmacology, 2001;41:515-527","Angiosartan, CS-866 as medoxomil prodrug. RNH-6270. VD reported as VDz. Weighted average of studies C and D where RNH-6270 was administered as such. Data from Table V. This compound is a metabolite of CS-866 (prodrug) but dosed as RNH-6270. clearance 1.3 L/h. Average weight 76 kg. VDz 20.82 L. N=58 across doses",,1992,446.5,9,3,129.8,7,anionic,4.5,-0.93
c1(nnc(s1)C)SCC=1CS[C@H]2N(C1C(O)=O)C([C@H]2NC(Cn1cc(c(c(c1)Cl)=O)Cl)=O)=O,-0.0740005814437769,0.98268676,Cefazedone,56187-47-4,0.13,0.95,,2.3,1.91,"Pharmacokinetic study of cefazedone sodium given by intravenous drip infusion in healthy volunteers. Ren, Ping; Zheng, Heng; Liu, Xinxia; Yuan, Shiying; Wang, Jing; Qian, Zhenyu; Wu, Dan; Gu, Shifen; Chen, Hui 
Zhongguo Yaoxue Zazhi (Beijing, China) (2012), 47(4), 291-295 (Chin, Pharm. J.)","Refosporene. 0.5, 1 and 2 g infusion. N=10/dose. Healthy volunteers. Reported 20.8 kg/m2 weight index. Seemingly a very low value and 70 kg weight assumed. VDss from clearance and MRT reported.",,1975,548.44,10,2,134.5,7,anionic,0.66,-2.3
c12C(=NCC(=O)Nc1ccc(c2)Br)c1c(cccc1)Cl,-4.321928094887363,1.2269251,Phenazepam,51753-57-2,0.089,0.05,,28.31,14.88,"Maksutova E L; Sariev A K; Zherdev V P; Voronina T A; Zheleznova E V. The pharmacokinetic characteristics of fenazepam in epileptics. Eksperimental'naia i klinicheskaia farmakologiia. 1994, 57, 16-18.","VDss from clearance and MRT. N=5, 70 kg average weight assumed, 2 mg dose.",In house translation from Russian.,1974,349.61,3,1,41.5,1,neutral,3.8,3.8
c12CC(c3c(N(c2cccc1)C(=O)N)cccc3)O,-0.1844245711374274,2.6740825,Licarbazepine,29331-92-8,0.72,0.88,0.7,13.6,9.8,"Pharmacokinetics of the Monohydroxy Derivative of Oxcarbazepine and Its Enantiomers after a Single Intravenous Dose Given as Racemate Compared with a Single Oral Dose of Oxcarbazepine. G. Flesch, C. Czendlik, D. Renard, and P. Lloyd. Drug Metab. Disp. 2011, 39:1103–1110.//ppb: Fortuna, Ana; Alves, Gilberto; Falcao, Amilcar; Soares-da-Silva, Patricio. Binding of licarbazepine enantiomers to mouse and human plasma proteins. Biopharm.  Drug Disp., 2010, 31, 362-366.","MHD or GP 47779 or BIA 2-005. Sum of data on racemate. CAS number of racemate. N=12. Small differences between enantiomers. Administered iv as racemate at 250 mg, via 30' minutes infusion. 70-kg average weight assumed. Renal clearance available. MRT = VDss/Cl.",,1970,254.28,4,2,66.6,0,neutral,1.9,1.9
c12[C@@H]([N@@]3[C@@H]([C@@H]4C[C@@H]([C@@H]([N@@]4C)[C@@H]3Cc1cccc2OC)C(=O)O)C#N)CO,1.613531652917927,2.884315,DX-52-1,96251-59-1,0.23,3.06,,1.23,1.52,"Bunnell, Craig A.; Supko, Jeffrey G.; Eder, Joseph Paul, Jr.; Clark, Jeffrey W.; Lynch, Thomas J.; Kufe, Donald W.; Shulman, Lawrence N. Phase I clinical trial of 7-​cyanoquinocarcinol (DX-​52-​1) in adult patients with refractory solid malignancies. Cancer Chemotherapy and Pharmacology. 2001, 48, 347-355.","NSC607097. 1.73 m2/70 kg conversion factor used. VDss reported as 9.53 L/m2 and clearance 7.43 L/m2/h, in Table 4. N=12.",,1984,357.4,7,2,97.0,4,anionic,-0.018,-3.2
c12[C@@H](c3ccc(O)cc3)CNCCc1c(c(O)c(c2)O)Cl,5.3750394313469245,1.9247197,Fenoldopam,67227-56-9,0.5,41.5,0.12,0.2,1.0,"PP. Fenoldopam Mesylate - FDA Approval Package
Clinical Pharmacology and Biopharmaceutics Review 019922 1997-Sep-25  PDF(1763k)",N=12 healthy volunteers. 1 ug/kg/min dose. MRT from VDss and clearance.,"PP. Fenoldopam Mesylate - FDA Approval Package
Clinical Pharmacology and Biopharmaceutics Review 019922 1997-Sep-25  PDF(1763k)",1980,305.76,4,4,72.7,1,cationic,2.7,1.9
c12[C@@]3([C@@H](N(C)c1ccc(c2)OC(NC)=O)[N@@](C)CC3)C,6.169925001442312,3.1732152,Physostigmine,57-47-6,3.9,72.0,0.64,0.9,1.0,"Walter, K.; Mueller, M.; Barkworth, M. F.; Nieciecki, A. V.; Stanislaus, F. Pharmacokinetics of physostigmine in man following a single application of a transdermal system. British Journal of Clinical Pharmacology (1995), 39(1), 59-63// ppb: Unni, Latha K.; Somani, Satu M. Binding of physostigmine to rat and human plasma and crystalline serum albumins.",Dose 495 ug 6h infusion. N=6. BW=76 kg. Data from Table 1. MRT reported not corrected with half-time of infusion. PK from NCA of digitized profile shown on Figure 1. Reported t1/2 = 0.5h and CL = 75 mL/min/kg (5.7 L/min)// ppb: 29 to 43% bound over 50-fold increase of concentration.,,1906,275.35,5,1,44.8,2,cationic,1.6,0.79
c12[C@@]3([C@H]([C@@H](CCCCC3)Cc1ccc(c2)O)N)C,4.78135971352466,3.0446842,Dezocine,53648-55-8,5.6,27.5,0.08,4.6,3.9,"Wilson JM, Cohen RI, Kezer EA, Schange SJ, Smith ER. Single- and multiple-dose pharmacokinetics of dezocine in patients with acute or chronic pain.J Clin Pharmacol. 1995 Apr;35(4):398-403.",Doses from 5-20. averaged by authors.,,1976,245.36,2,2,46.3,0,cationic,3.0,1.1
c12c(C(=N)N)cccc1\C(=N\NC(=N)N)CC2,1.6780719051126378,3.1875124,Sardomozide,149400-88-4,20.0,3.2,,104.1,65.4,"A Phase I and Pharmacokinetic Study of SAM486A, a Novel Polyamine Biosynthesis Inhibitor, Administered on a Dailytimes-five every-three-week Schedule in Patients with Advanced Solid Malignancies. Lillian L. Siu, Eric K. Rowinsky, Lisa A. Hammond, Geoffrey R. Weiss,Manuel Hidalgo, Gary M. Clark, Judy Moczygemba, Les Choi, Ron Linnartz, Nicholas C. Barbet, Ivo T. Sklenar, Renaud Capdeville, Gregory Gan, Carl W. Porter, Daniel D. Von Hoff, and S. Gail Eckhardt. Clin. Cancer Res. 2002, 8, 2157–2166. ",SAM486A or CGP48664.  Weighted average across several doses (3.6 to 202.8 mg/m2/day) and 18 patients. Total VDss calculated 811 L/m2 for 18 patients. Clearance 7.75 L/h/m2. 1.73m2/70 factor used.  T1/2 on 19 patients. MRT = VDss/Cl. Highly variable PK. ,,1993,230.27,6,5,124.1,3,cationic,-0.14,-5.0
c12c(CC[C@@H](C1)[N@@](CCc1cccs1)CCC)c(ccc2)O,5.20945336562895,3.9416885,Rotigotine,99755-59-6,5.7,37.0,0.08,2.6,4.0,"Cawello W, Braun M, Boekens H. (A)DME of the dopamine agonist rotigotine in man- Administration by intravenous infusion or transdermal delivery. DMD Fast Forward article published July 16 2009. ppb:The PDR states: The binding of rotigotine to human plasma proteins is approximately 92 % in vitro and 89.5 % in vivo. 92% taken as the vast majority of data were from in vitro determinations. Accessed January 8 2015. http://www.pdr3d.com/detail.php?c=121976#section-13.","Data digitized from plot reported. N=6, 1.2 mg dose, 12 hour infusion, 83.6 kg average weight. Reported AUC 6.13 = ng*h/mL, calculated 6.43 ng*h/mL, reported t1/2 = 2.5 hours. In Avalon as PKF209-495-NX-1",,1985,315.47,2,1,23.5,6,cationic,5.0,3.4
c12c(C[C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](Cc3c[nH]cn3)NC([C@@H](NC(CNC([C@@H](NC([C@@H](NC([C@@H](Cc3c[nH]cn3)NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](CO)N)=O)C(C)C)=O)CO)=O)CCC(O)=O)=O)[C@@H](CC)C)=O)CCC(N)=O)=O)CC(C)C)=O)CCSC)=O)=O)CC(N)=O)=O)CC(C)C)=O)=O)CCCCN)=O)=O)CC(C)C)=O)CC(N)=O)=O)CO)=O)CCSC)=O)CCC(O)=O)=O)CCCNC(N)=N)=O)C(C)C)=O)CCC(O)=O)=O)C(N[C@@H](C(N[C@@H](C(N[C@@H](C(N[C@@H](C(N[C@@H](C(N[C@@H](C(N[C@@H](C(N[C@@H](C(N[C@@H](Cc3c[nH]cn3)C(N[C@@H](C(N[C@@H](Cc3ccccc3)C(O)=O)=O)CC(N)=O)=O)=O)C(C)C)=O)CC(O)=O)=O)CCC(N)=O)=O)CC(C)C)=O)CCCCN)=O)CCCCN)=O)CCCNC(N)=N)=O)CC(C)C)=O)c[nH]c1cccc2,4.419538891513785,1.2112006,Teriparatide,52232-67-4,0.17,21.4,,0.13,0.14,"Teriparatide (Rdna Origin) - FDA Approval Package
Clinical Pharmacology and Biopharmaceutics Review 021318/S-000. Accessed through Pharmapendium.","Data digitized and calculations performed via Phoenix. Calculated AUC 195 pg.h/mL, reported 205 pg.h/mL  ppb not determined Structure and smiles refer to cation. ",,1974,4117.72,106,60,1752.6,146,cationic,-9.0,-9.0
c12c(N(C(c3cc4cc(NC(Nc5cc6c([nH]c(c6)C(N6c7c(c8c([nH]cc8C)c(c7)O)[C@@H](C6)CCl)=O)cc5)=O)ccc4[nH]3)=O)C[C@H]2CCl)cc(O)c2c1c(c[nH]2)C,-1.0,0.4341914,Bizelesin,129655-21-6,0.05,0.5,,1.7,1.6,"Pitot, Henry C.; Reid, Joel M.; Sloan, Jeff A.; Ames, Matthew M.; Adjei, Alex A.; Rubin, Joseph; Bagniewski, Pamela G.; Atherton, Pamela; Rayson, Daniel; Goldberg, Richard M; Erlichman, Charles. A phase I study of bizelesin (NSC 615291) in patients with advanced solid tumors. Clin. Cancer Res. 2002, 8, 712-717.",Weighted average over 17 patients with doses ranging from 0.1 ug/m2 to 1 ug/m2.  1.73m2/70 kg conversion factor used.,,1990,815.7,13,8,185.4,6,neutral,5.9,5.9
c12c(c(=O)c(cn1CC)C(=O)O)cc(c(c2)N1CCNCC1)F,2.799087306074004,1.2598481,Norfloxacine,70458-96-7,1.88,6.96,0.13,4.5,4.45,"Chen, Xijing; Liu, xiaoquan; Huang, Shengkai; Wang, Fengchen. Pharmacokinetics of norfloxacin by constant rate infusion. Zhongguo Linchuang Yaolixue Zazhi 1992, 8, 82-86//ppb: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/019384s066lbl.pdf. Accessed May 30 2017","N=8, 63.4 kg average weight, 1 hr infusion, 400 mg dose. MRT from clearance and VDss. VDss from Vc and k12, k21 and clearance from dose/AUC reported.",56% excreted unchanged in urine.,1979,319.33,6,2,74.6,3,zwitterionic,1.7,-0.72
c12c(c3c(c(cc(o3)C(O)=O)=O)cc1c(cc(n2CC)C(O)=O)=O)CCC,3.350497247084133,0.77416253,Nedocromil,69049-73-6,0.43,10.2,0.11,0.7,0.9,"M. G. NEALE, K. BROWN, R. A. FOULDS, S. LAL1, D. A. MORRIS & D. THOMAS. The pharmacokinetics of nedocromil sodium, a new drug for the treatment of reversible obstructive airways disease, in human volunteers and patients with reversible obstructive airways disease. Br. J. Clin. Pharmacol.  (1987), 24, 493-501//ppb: https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020750ap_Tilade_clinphrmr.pdf. Accessed June 15 2017.",420 ug total dose administered as 0.2 ug.kg-1.min-1 in 30 minutes. 70 kg average weight N=6 healthy. MRT from VDss and clearance.,80% excreted unchanged also reported in the FDA approval package. Very small amount excreted in urine after po or inhalation.,1978,371.34,8,2,127.1,5,anionic,2.8,-3.1
c12c(cc(C#Cc3ccc(C(OCC)=O)cn3)cc1)C(CCS2)(C)C,5.217230716220669,3.545896,Tazarotene,118292-40-3,3.55,37.2,,1.56,6.22,"Tazarotene - FDA Approval Package
Clinical Pharmacology and Biopharmaceutics Review 020600/S-000 Part 01","15 ug/kg, 20' infusion. N=8",,1988,351.46,3,0,39.2,5,neutral,5.3,5.3
c12c(ccc(c2)OC)nccc1CCC[C@@H]1[C@@H](CNCC1)C=C,4.700439718141092,3.4668047,Viqualine,72714-74-0,24.4,26.0,,15.6,12.1,"J. B. Fourtillan, S. Bouquet, J. Girault, M. A. Lefebvre, C. Maulet, Ph. Courtois. Pharmacokinetics and bioavailability of viqualine a new antidepressant. European Journal of Drug Metabolism and Pharmacokinetics. 1985, 10(1) , 3-10","Mean BW = 64.8 kg (N=5), 25 mg infusion dose. ",,1979,310.43,3,1,34.1,6,cationic,4.3,2.0
c12c(ccc(o1)=O)cccc2,4.560714954474479,2.1407535,Coumarin,91-64-5,1.1,23.6,0.17,0.78,0.8,"Pharmacokinetics of coumarin and its 7-hydroxy-metabolites upon intravenous and peroral administration of coumarin in man. Ritschel, W. A.; Brady, M. E.; Tan, H. S. I.; Hoffmann, K. A.; Yiu, I. M.; Grummich, K. W. European Journal of Clinical Pharmacology (1977), 12(6), 457-461. ppb: Loren M. Berry, Chao Li, and Zhiyang Zhao. Species Differences in Distribution and Prediction of Human Vss from Preclinical Data Drug Metab. Disp. 2011, 39, 2103-2106.",Vc = Dose/Co reported. VDss = Vc*(1+ k12/k21). MRT = VDss/Cl. 68 kg average weight. N=4 16.78 mg dose.,,1884,146.14,2,0,30.5,0,neutral,1.6,1.6
c12c(cccc1cncc2)OCC(N[C@H](C(N[C@H]([C@@H](C(N1[C@@H](CSC1)C(NC(C)(C)C)=O)=O)O)Cc1ccccc1)=O)CSC)=O,3.39231742277876,2.2380476,KNI-272,147318-81-8,0.11,10.5,,0.17,0.44,"BRIGITTA U. MUELLER, BARRY D. ANDERSON, MAUREEN Q. FARLEY, ROBERT MURPHY, JUDY ZUCKERMAN, PAUL JAROSINSKI, KAREN GODWIN, CINDY L. MCCULLY, HIROAKI MITSUYA, PHILIP A. PIZZO, FRANK M. BALIS. Pharmacokinetics of the Protease Inhibitor KNI-272 in Plasma and Cerebrospinal Fluid in Nonhuman Primates after Intravenous Dosing and in Human Immunodeficiency Virus-Infected Children after Intravenous and Oral Dosing. Antimicr. Agents Chemother. 1998, 42, 1815-1818.","Kynostatin 272. Dosed to children at 200 mg/m2 to children. Median age 9.7 years, N=5 from data in table 2. MRT from VDss and clearance.",,1992,667.84,11,4,150.0,13,neutral,2.0,1.9
c12c(n(c(=O)nc1c1ccccc1)C(C)C)cc(C)cc2,3.24031432933371,1.5726511,Proquazone,22760-18-5,0.52,9.45,0.02,0.92,1.27,"PETER H. HINDERLING and ANDRÉ ROOS. Pharmacokinetics of the Antirheumatic Proquazone in Healthy Humans. J. Pharm. Sci. 1984, 73, 332-340. //ppb:  Roos, Andre; Hinderling, Peter H. Protein binding and erythrocyte partitioning of the antirheumatic proquazone.  J. Pharm. Sci. 1981, 70, 252-257.","N=5, 75.2 kg average weight, data averaged across two doses (75 and 122 mg) reported in table I. MRT from VDss and clearance. Dosed in 40% human sterile albumine solution.",,1969,278.35,3,0,34.9,2,neutral,3.8,3.8
c12c3C(N(CCN(C)C)C(c1cccc2cc(c3)N)=O)=O,4.2720231890610485,2.278873,Amonafide,69408-81-7,7.33,19.32,,6.34,4.78,"Clinical Pharmacokinetics of Amonafide (NSC 308847) in 62 Patients. W. Kreis, M.D., Ph.D.,l K. Chan, Ph.D., D. R. Budman, M.D.,S. L. Allen, M.D., D. Fusco, B.S.N., A. Mittelman, M.D., J. Freeman, M.S., K. Hock, B.A., S. Akerman, B.S., A. Calabro, M.S., C. Puccio, M. Spigelman, M.D.Cancer Investigation, 1996, 14(4), 320-327.","Data reported in Table 1. Weight-averaged across all patients. Linear PK. VDss from CL and MRT reported, t1/2 from compartmental analysis.",,1978,283.33,5,1,66.6,3,neutral,1.5,1.3
c12c3c(OC(c1ccc(c2)C)(C)C)cc(CCCCC)cc3O,4.157852169141737,2.6298425,Cannabinol,521-35-7,16.98,17.85,,15.86,25.51,"Eva Johansson, Agneta Ohlsson, Jan-Erik Lindgren, Stig Agurell, Hampton Gillespie, Leo E. Hollister. Single-dose Kinetics of Deuterium-labelled Cannabinol in Man After Intravenous Administration and Smoking. BIOMEDICAL AND ENVIRONMENTAL MASS SPECTROMETRY, 1987, 14, 495-499","DEUTERATED COMPOUND. Calculation performed from data reported in Table. AUC inf reported within 3% of calculated. N=6, 20 mg dose, 72.2 kg average weight.",,1896,310.43,2,1,29.5,4,neutral,6.7,6.7
c12c3c([C@@]4(O[C@@H](O3)[C@@H](O)[C@@H]([C@@H]4O)N(C)C)C)cc(c1C(c1c(c3[C@@H](C[C@@](Cc3cc1C2=O)(C)O)OC)O)=O)O,3.5372960670908418,1.3463631,Menogaril,71628-96-1,9.14,11.61,,13.13,13.22,"Merrill J. Egorin, David A. Van Echo, Margaret Y. Whitacre, Alan Forrest, Lawrence M. Sigman, Kathrin L. Engisch, and Joseph Aisner (1986). Human Pharmacokinetics, Excretion, and Metabolism of the Anthracycline Antibiotic Menogaril (7-OMEN, NSC 269148) and Their Correlation with Clinical Toxicities. CANCER RESEARCH 46, 1513-1520",NSC 269148. Menogarol. 7-OMEN. Average clearance and VDss as reported by authors. 1.73 m2/70 factor used. Overall 24 stuides at different doses (infusion). MRT from clearance and VDss.,"From paper cited: In humans, as in rabbits (8), neither urinary or biliary excretion of 7-OMEN and its fluorescent metabolites represented a major route of drug clearance.",1978,541.55,11,5,166.2,2,zwitterionic,1.4,-1.2
c12c3c4c(ccc(c4O)O)C[C@H]1[N@@](CCc2ccc3)C,5.321928094887363,3.0496814,Apomorphine,58-00-4,1.6,40.0,0.05,0.67,0.68,"van der Geest R, van Laar T, Kruger PP, Gubbens-Stibbe JM, Boddé HE, Roos RA, Danhof M.Pharmacokinetics, enantiomer interconversion, and metabolism of R-apomorphine in patients with idiopathic Parkinson's disease. Clin. Neuropharmacol. 1998, 21, 159-168.  Smith RV, Velagapudi RB, McLean AM, and Wilcox RE (1985) Interactions of apomorphine with serum and tissue proteins.  J. Med. Chem. 28:  613-620.",Apokyn. N=10 (5M and 5F) 30 ug/kg in 15 minutes. MRT from VDss and clearance. Monocompartmental fit.,,1891,267.32,3,2,43.7,0,cationic,3.0,2.1
c12c3cccc1cc(cc2C(=O)N(C3=O)CCN(C)C)[N+](=O)[O-],5.112700132749362,2.3278008,Mitonafide,54824-17-8,11.3,34.6,,5.6,28.7,"Pharmacokinetics characterization of mitonafide in man. Brode E, Poveda Velasco A, Díaz-Rubio E, Rosell Costa R, Benavides Fissure A. Meth. Find. Exp. Clin. Pharmacol. 1992, 14(2), 131-140",Individual subject plasma levels and PK data reported. Data corrected for individual surface area and weight and then averaged. Very long t1/2 (gamma),,1975,313.31,7,0,83.8,4,neutral,2.3,2.1
c12ccccc1c(c(c(n2)C1CC1)\C=C\[C@H](C[C@H](CC(=O)O)O)O)c1ccc(cc1)F,2.548436624696042,0.47021252,Pitavastatin,147511-69-1,0.9,5.85,0.005,2.7,4.6,Pitavastatin Calcium - FDA Approval Package Clinical Pharmacology and Biopharmaceutics Review 022363/S-000 Part 01. Accessed via Pharmapendium.,"Followed as acid. VDss from MRT and clearance. Vd reported as 148.1 L. N=18, 2 mg dose, 70 kg weight assumed.",,1997,421.46,5,3,90.6,8,anionic,3.9,0.54
c1c(c(=O)[nH]c(=O)n1C2CCCO2)F,-0.0740005814437769,1.9160584,Tegafur,17902-23-7,0.62,0.95,,10.75,8.69,"Markku I. Anttila, Eero A. Sotaniemi, Matti I. Kairaluoma, Risto E. Mokka, and Hannu T. Sundquist. Pharmacokinetics of Ftorafur After Intravenous
and Oral Administration. Cancer Chemother Pharmacol (1983) 10:150-153.","Ftorafur. Fluorofur. Citofur. 5-Fluoro-1-(tetrahydrofuran-2-yl)uracil. Data digitized from figure 1. 2 g dose, iv bolus, N=7, average weight 55.7 kg. AUC0-inf 617 mg.h.L-1. Calculated AUC0-inf 624 ug.h.mL-1. 1% difference.",,1967,200.17,5,1,64.1,1,neutral,0.078,-3.4
c1c(c2c(cc1)C(=O)c1c(c(O)c3c(c1O)[C@@H](O)[C@@](O)(CC)C[C@@H]3O[C@@H]1C[C@@H]([C@@H]([C@@H](O1)C)O)N1CCOCC1)C2=O)O,5.419538891513785,2.6390433,KRN8602,105026-50-4,20.9,42.8,0.09,8.0,10.7,"Kerrie Clarke, Russell L. Basser, Darryl Maher, Denis J. Morgan, Jonathan Cebon, Richard M. Fox, John S. Hill, Carole Alt, Jane Bartlett, Howard Geldard, Andrew H. Kaye, and Michael D. Green. Phase I and Pharmacokinetic Study of KRN8602 Alone and With Filgrastim in Patients With Advanced Cancer. J Clin Oncol. 1998, 16:2181-2187.",Weighted average of 27 patients receiving KRN 8062 only. 10-50 mg/m2 dose range. 70-kg weight assumed. AUC units not reported. CAS of HCl salt.,,1986,585.6,12,6,186.4,4,neutral,1.4,1.2
c1c(cc(c(C(Cn2ncnc2)(O)Cn2cncn2)c1)F)F,-1.6896598793878497,1.9993387,Fluconazole,86386-73-4,0.75,0.31,0.89,40.0,30.0,"Foulds G, Wajszczuk C, Weidler DJ, Garg DJ, and Gibson P (1988) Steady state parenteral kinetics of fluconazole in man.  Ann. N.Y. Acad. Sci. 544: 427-30.  Humphrey MJ, Jevons S, and Tarbit MH (1985) Pharmacokinetic evaluation of UK-49,858, a metabolically stable triazole antifungal drug, in animals and humans. Animic. Agents Chemother. 28: 648-653.",,"From PDR. Accessed march 6 2013.http://www.pdr3d.com/detail.php?c=9255#section-4.  In normal volunteers, fluconazole is cleared primarily by renal excretion, with approximately 80% of the administered dose appearing in the urine as unchanged drug. About 11% of the dose is excreted in the urine as metabolites.",1930,306.27,7,1,81.7,5,neutral,0.19,0.19
c1c(cc2[nH]c(n3C[C@@H]([N@@](Cc1c23)C\C=C(\C)C)C)=S)Cl,3.3798981635246923,2.3647845,R 82913,126347-69-1,21.98,10.41,,35.17,25.96,"De Wit S; Hermans P; Sommereijns B; O'Doherty E; Westenborghs R; van de Velde V; Cauwenbergh G F; Clumeck N. Pharmacokinetics of R 82913 in AIDS patients: a phase I dose-​finding study of oral administration compared with intravenous infusion. Antimicr. Agents Chemother. 1992, 36, 2661-2663.","9-Cl-TIBO. TIBO-R 82913. N=5, Day 29 infusion, 1 hr, 100 mg dose. Data digitized from plot. 70 kg average weight assumed. Only AUC0-24 after Day 29 and Day 0 was reported and the AUC 24 after digitization was about ~86% and thus considered acceptable. However, all data were calculated using the calculated AUCinf (2286 ng.hr.mL-1) obtainded from digitization. SOme accumulation observed (Day 0 to Day 29) but limited to 40%.  ",,1990,321.87,3,1,24.0,2,neutral,5.0,1.7
c1c(ccc(c1)C(F)(F)F)NC(=O)/C(=C(/C)O)C#N,-7.158429362604483,0.44640288,Teriflunomide,163451-81-8,0.16,0.007,0.01,367.0,350.0,PDR prescribing information for teriflunomide (Aubagio). Accessed July 29 2014.http://www.pdr3d.com/detail.php?c=78104#section-13,"Leflunomide metabolite (A 771726, CAS 108605-62-5) ppb > 99%. Assumed 70 kg as average weight.MRT from VDss and clearance. t1/2 not reported. Probably extremely long.","Teriflunomide - FDA Approval Package
Label 202992/S-000. Some indication of biliary excretion but no accurate mass balance or certain figures. Also marketed as parent, leflunomide.",1991,270.21,4,2,73.1,3,anionic,3.9,2.4
c1c(cn(c1C(=O)NCC/N=C(/N)N)C)NC(=O)c1n(cc(c1)NC(=O)c1cc(cn1C)NC(=O)c1cc(cn1C)NC(=O)C(=C)Br)C,2.364572432295856,0.73766226,Brostallicin,203258-60-0,0.36,5.15,,1.2,8.3,"A Phase I Dose-Escalation and Pharmacokinetic Study of Brostallicin (PNU-166196A), a Novel DNA Minor Groove Binder, in Adult Patients with Advanced Solid TumorsA. Craig Lockhart,1 Martin Howard, Kenneth R. Hande, Bruce J. Roth,Jordan D. Berlin, Franzanne Vreeland, Angela Campbell, Erminia Fontana,Francesca Fiorentini, Camilla Fowst, Victoria A. Paty, Odessa Lankford, and Mace L. Rothenberg Clin. Cancer. Res. 2004, v. 10, 468-475.","Reported AUC(0-inf) = 385.6 ng.h/mL, N= 6, 4.8 mg/m2, 1.73 m2/70 kg conversion factor. 10' infusion.",,1998,723.58,17,7,229.6,12,neutral,1.9,1.9
c1c(csc1COc2c3c(nc[nH]3)nc(n2)N)Br,4.429615964201735,2.547373,Lomeguatrib,192441-08-0,,21.55,,,2.92,"Ranson, Malcolm; Middleton, Mark R.; Bridgewater, John; Lee, Siow Ming; Dawson, Martin; Jowle, Debra; Halbert, Gavin; Waller, Sue; McGrath, Helen; Gumbrell, Lindsey, R. Stanley McElhinney,Dorothy Donnelly, T. Brian H. McMurry, and Geoffrey P.Margison. Lomeguatrib, a Potent Inhibitor of O6-Alkylguanine-DNA-Alkyltransferase: phase I Safety, Pharmacodynamic, and Pharmacokinetic Trial and Evaluation in Combination with Temozolomide in Patients with Advanced Solid Tumors. Clin. Cancer Res. 2006, 12, 1577-1584.","N=3, 70 kg average weight assumed. N=30 across 10, 20 and 40 mg/m2 doses. All data from DAY 1. Only Vc was reported and averaged to 1.11 L/kg across 30 patients and three doses.","O(6)-(4-Bromothenyl)guanine. 
6-((4-Bromo-2-thienyl)methoxyl)purin-2-amine
",1997,326.17,6,2,89.7,3,neutral,2.2,2.2
c1c2c(c(c(c1F)N3CC(C3)O)Cl)n(cc(c2=O)C(=O)O)c4c(cc(c(n4)N)F)F,1.2203299548795556,-0.16721994,Delafloxacin,189279-58-1,0.35,2.33,0.16,2.5,2.1,"Randall Hoover; Thomas Hunt; Michael Benedict; Susan K. Paulson; Laura Lawrence; Sue Cammarata and Eugene Sun. Safety, Tolerability,and Pharmacokinetic Properties of
Intravenous Delafloxacin After Single and Multiple Dosesin Healthy Volunteers. Clin. Ther. 2016, 38, 53-65. // ppb: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208610s000,208611s000lbl.pdf.","Data digitized from plot reported at 750 mg dose, 1-hr iv infusion,  N=8, 73.8 kg as average weight reported across entire cohort. T1/2 taken as very long in report but concentration at < 2% of Cmax after 12 hours. Extrapolation using 3-12 hr interval (5 points). AUCinf reported 74.4 ug.hr.mL-1 and calculated as 72.2 ug.hr.mL-1 (3% deviation). Clearance not linear across entire range and a mid point (750 mg) was chosen from range of 300 to 1200 mg.  35% excreted unchanged renally.",,1997,440.76,8,3,121.7,3,anionic,2.5,-0.0083
c1c2c(c(c(c1F)N3C[C@H]4[C@H](C3)OCCN4)C#N)n(cc(c2=O)C(=O)O)C5CC5,2.523561956057013,0.14625129,Finafloxacin,209342-40-5,1.42,5.75,0.75,4.11,13.42,"Max Taubert, Joseph Chiesa, Mark Lückermann, Carsten Fischer, Axel Dalhoff,Uwe Fuhr. Pharmacokinetics of intravenous finafloxacin in healthy volunteers. Antimicr. Agents Chemother. 2017. Posted on line August 7 2017. doi:10.1128/AAC.01122-17.","MRT from VDss and clearance. N=29 (total), 1 hr infusion across doses from 200 to 1000 mg. average weight 75.9 kg. All data weight-averaged by number of subjects with very high concordance across doses (linear PK).",,1998,398.39,8,2,107.6,4,anionic,1.1,-1.9
c1cc(c(cc1C[C@H](C(=O)O)OC(=O)/C=C/c2ccc(c3c2[C@@H]([C@H](O3)c4ccc(c(c4)O)O)C(=O)OC(Cc5ccc(c(c5)O)O)C(=O)O)O)O)O,2.84197311892718,0.4812662,Salvianolic acid B,121521-90-2,0.14,7.17,0.08,0.42,0.29,"Xiuxue Li , Chen Cheng , Fengqing Wang , Yühong Huang , Weiwei Jia , Olajide E. Olaleye ,
Meijuan Li , Yanfen Li , Chuan Li. Pharmacokinetics of catechols in human subjects intravenously receiving XueBiJing injection, an emerging antiseptic herbal medicine. Drug Metab. Pharmacokin. 2015. http://dx.doi.org/10.1016/j.dmpk.2015.10.005//ppb: Yuan, Hai-jian; An, Yi-qiang; Chen, Yi-gang . Determination of protein binding rates of salvianolic acid B and danshensu with different plasmas. Zhongguo Shiyan Fangjixue Zazhi. 2014, 20, 136-139.",3 different dosage regimens to 6 M and 6 F each. (three different infusions). Actual doses not reported. Standardized solution? Data averaged across all patients (N=36). Reported to be eliminated by bile after methylation in rat.,,1981,718.61,16,9,278.0,14,anionic,3.7,-3.1
c1cc(c(cc1Cl)Cl)COC(Cn2ccnc2)c3ccc(cc3Cl)Cl,3.2448870591235344,2.011074,Miconazole,22916-47-8,7.14,9.48,0.08,12.55,19.75,"P. J. Lewi , J. Boelaert, R. Daneels, R. De Meyere, H. Van Landuyt, J. J. P. Heykants. Pharmacokinetic profile of intravenous miconazole in man. Comparison of Normal Subjects and Patients with Renal Insufficiency. Eur. J. Clin. Pharmacol. 1976, 10, 49-54.//ppb: Stevens DA, Levine HB, Deresinski SC: Miconazole in coccidioidomycosis II. Therapeutic and pharmacologic studies in man. Am J Med 1976, 60, 191-202.","Monistat. MJR1762. R 18134. PK parameters calculated from tabular data reported for 4 normal subjects. AUCinf within 16% if AUC reported as 0-inf. 11% if AUC0-t was reported. 522 mg dose, iv bolus. 70 kg average weight assumed.",,1948,416.13,3,0,27.0,6,neutral,5.8,5.8
c1cc(cc(c1)O)[C@@H]([C@@H]1[C@@H](CCCC1)O)N(C)C,1.1375035237499351,2.629306,Ciramadol,51356-59-3,,2.2,,,3.85,"M. T. ROSSEEL, M. G. BOGAERT,  and W. OOSTERLINCK. Preliminary pharmakokinetics of intravenous ciramadol in humans. Int. J. Pharmacol. Ther. Toxicol. 1984, 22, 304-306.","N=8, 70 kg average weight assumed, 30 mg dose. Data difficult to digitize from plot resulting in exceesive extrapolation to Co. Clearance and t1/2 taken from reported values. Vdarea 0.8 L/kg.",,1977,249.35,3,2,43.7,3,cationic,2.7,2.1
c1cc(ccc1C(=O)N[C@@H](CCC(=O)O)C(=O)O)NCc2cnc3c(n2)c(=O)nc([nH]3)N,5.700439718141092,0.56332314,Folic acid,59-30-3,9.7,52.0,0.5,3.1,2.6,"Menke A; Weimann H J; Achtert G; Schuster O; Menke G. Absolute bioavailability of folic acid after oral administration of a folic acid tablet formulation in healthy volunteers. Arzneimittel-Forschung (1994), 44(9), 1063-1067// ppb: Elsborg L. Binding of Folic Acid to Human Plasma Proteins. Acta Haematol 1972,48, 207–212.","N=17. Dose = 5 mg  6min infusion. BW = 87.5 kg
PK iv profile reported in table 1. Concentration corrected from predose level of 18.2 ng/mL. MRT Calculated from VDss and CL.
AUC0-12h (ng*h/mL) = 1546 (reported 1550). AUC0-inf (ng*h/mL) = 1601",,1946,441.4,13,6,213.3,9,anionic,-1.3,-8.6
c1cc(ccc1C(=O)Oc2ccc3cc(ccc3c2)C(=N)N)NC(=N)N,6.356848079236522,2.3019595,Nafamostat,81525-10-2,5.71,81.96,,1.15,1.84,"Cao, Yan-guang; Zhang, Ming; Yu, Dan; Shao, Jing-ping; Chen, Yuan-cheng; Liu, Xiao-quan. A method for quantifying the unstable and highly polar drug nafamostat mesilate in human plasma with optimized solid-phase extraction and ESI-MS detection: more accurate evaluation for pharmacokinetic study. Anal. Bioanal Chem. 2008, 391, 1063-1071",N=10. 5M/5F 70 kg average weight assumed 40 mg dose iv 120 minutes drip.,5M/5F,1981,347.37,7,5,138.1,6,cationic,1.9,-3.2
c1cc(ccc1Cl)SC(P(O)(O)=O)P(O)(O)=O,-1.3219280948873622,0.22698945,Tiludronate,89987-06-4,0.23,0.4,0.1,9.5,7.7,"Sansom LN, Necciari J and Thiercelin JF (1995) Human pharmacokinetics of tiludronate. Bone
17:479S-483S.","Data digitized from plot reported. Average of 10, 20 and 30 mg 30' minutes infusion. Terminal phase extended and prone to error. AUCinf/AUClast 1.22. Prossibly overestimation of clearance due to tight binding and slow release form bone tissue. 70 kg average weight assumed. ",,1984,318.61,6,4,115.1,4,anionic,0.35,-4.4
c1cc(ccc1c2cc(=O)c3c(o2)cc(c(c3O)O)O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)C(=O)O)O)O)O)O,5.541638734436141,0.047171324,Scutellarin,27740-01-8,0.88,46.58,0.1,0.31,1.18,"Wen-Zheng Ju,Yang Zhao,Fang Liu,Ting Wua,Jun Zhang,Shi-Jia Liu,Lin gZhou,Guo-Liang Dai,Ning-Ning Xiong,Zhu-Yuan Fang. Clinical tolerability and pharmacokinetics of Erigerontis hydroxybenzene injection: Results of a randomized phase I study in healthy Chinese volunteers. Phytomed. 2015, 22, 319–325.//ppb: Huang, Yong; Chen, Hui; Zheng, Lin; He, Feng; Zhang, Zhirong; Wang, Yonglin . Determination of plasma protein binding rates of protocatechuic acid, isoorientin and scutellarin in Compound Hongcao freeze-​dried powder for injection by ultrafiltration combined with UPLC-​ESI-​MS​/MS. Zhongguo Yaoxue Zazhi (Beijing, China). 2011, 46, 1200-1204.","Data digitized from plot reported.  All from average males/females. 6 vials EH product tested for content via HPLC. 37.2 mg total dose, N=6, 57 kg average weight. 1 hr infusion. All AUCinf data within 10% of reported.",,1889,462.36,12,7,207.6,4,anionic,0.29,-4.5
c1cc(sc1)/C(=C/2\c3cc(ccc3N(C2=O)C(=O)N)Cl)/O,-4.107803289534515,0.5615965,Tenidap,120210-48-2,0.11,0.058,0.01,31.6,22.7,"Gardner, M. J.; Wilner, K. D.; Hansen, R. A.; Fouda, H. G.; McMahon, G. F.
Single- and multiple-dose pharmacokinetics of tenidap sodium in healthy subjects.
British Journal of Clinical Pharmacology (1995), 39(Suppl. 1), 11S-15S.//ppb: Madhok, Rajan. Tenidap. Lancet, 1995, 346, 481-485.","CAS# and struture entered for the enolic tautomer. Keto tautomer CAS# 100599-27-7. Data iv from table 2 only for deuterated compound (Day 1), N=12; BW=74.4 kg, Dose = 20 mg 1h infusion. MRT from VDss and clearance.",,1988,320.75,5,2,83.6,1,anionic,2.1,0.95
c1cc2n3c(cnc3CO)CN=C(c3ccccc3F)c2cc1Cl,3.279471295644468,2.2094316,Hydroxymidazolam,59468-90-5,0.77,9.71,0.1,1.3,1.1,"Mandema, Jaap W.; Tuk, Bert; Van Steveninck, Alfred L.; Breimer, Douwe, D.; Cohen, Adam F.; Danhof, Meindert.   Pharmacokinetic-pharmacodynamic modeling of the central nervous system effects of midazolam and its main metabolite  -hydroxymidazolam in healthy volunteers.    Clinical Pharmacology & Therapeutics (St. Louis, MO, United States)  (1992),  51(6),  715-28.","1-hydroxymidazolam, a-hydroxymidazolam. 70 kg assumed using data reported in table 1 (average obtained from dose in mg and mg/kg was 69.2). MRT from VDss and clearance. N=8 at doses around 0.1 mg/kg.",,1976,341.77,4,1,50.4,2,neutral,1.9,1.9
c1ccc([C@H]2Oc3cc(O)cc(c3C(C2)=O)O)cc1,4.754887502163468,2.5248864,Pinocembrin,480-39-7,0.8,27.0,,0.47,0.7,"Determination of pinocembrin in human plasma by solid-phase extraction and LC/MS/MS: application to pharmacokinetic studies Bei Yan, Guoying Cao, Taohua Sun, Xi Zhao, Xin Hu, Jiling Yan, Yueying Peng, Aixin Shi, Yang Li, Wei Xue, Min Lia, Kexin Li*and Yingfa Liu*. Biomedical Chromatography, April 2014. (wileyonlinelibrary.com) DOI 10.1002/bmc.3186.","Digitized from plot reported. 30 minutes infusion, 20 mg, N=8, 70 kg average weight assumed.data in very good agreement with reported values in table.",,1928,256.25,4,2,66.8,1,neutral,2.5,2.3
c1ccc(cc1)C(Cc2ccccn2)N,0.84799690655495,2.2751536,Lanicemine,153322-05-5,1.62,1.8,,15.06,10.4,"Khanh H. Bui,  Diansong Zhou, Felix Agbo, and Jian Guo. Effect of Multiple Intravenous Doses of Lanicemine (AZD6765) on the Pharmacokinetics of Midazolam in Healthy Subjects. J. Clin. Pharmacol. 2015, 55(9) 1024–1030.","AZD6765. N=46, 75.1kg  average weight1 hr infusion of 150 mg of lanicemine. MRT from clearance and MRT. See also, Guo J, Zhou D, Grimm SW, Bui KH. Pharmacokinetics,metabolism and excretion of [(14)C]-lanicemine (AZD6765), a novel low-trapping N-methyl-d-aspartic acid receptor channel blocker, in healthy subjects. Xenobiotica. 2015;45(3):244– 255.",,1993,198.26,2,1,38.9,3,cationic,1.6,0.31
c1ccc(cc1)C(c2ccccc2)(C(=O)O[C@@H]3C[C@@H]4CCC(C3)[N+]45CCCC5)O,3.797012977836145,2.3925653,Trospium,47608-32-2,5.1,13.9,0.33,6.1,5.0,Trospium Chloride - FDA Approval Package. Clinical Pharmacology and Biopharmaceutics Review 021595/S-000 Part 03. Accessed via Pharmapendium. Ppb: the PDR states: Protein binding ranged from 50 to 85% when concentration levels of trospium chloride (0.5 to 50 ng/mL) were incubated with human serum in vitro.  Accessed January 6 2015. http://pdr3d.com/detail.php?c=104533#section-13. Median value of 67% taken.,Structure and smiles refer to cation. 70 kg assumed. MRT reported. Ppb reported as range between 50 and 85%.,"72% of dose elininated in urine, of which 80% is unchanged. ~ 60% total unchanged. Trospium Chloride - FDA Approval Package
Clinical Pharmacology and Biopharmaceutics Review 021595/S-000 Part 03. Accessed via Pharmapendium.",1997,392.51,4,1,46.5,5,neutral,0.83,0.83
c1ccc(cc1)C2(C(=O)NC(=O)N2)c3ccccc3,-1.434402824145775,1.5703543,Phenytoin,57-41-0,0.43,0.37,0.13,17.6,16.8,"Roland Gugler, Carl V. Manion, Daniel L. Azarnoff. Phenytoin: pharmacokinetics and bioavailability. Clin. Pharmacol. Ther. 1976, 19, 145-132//fu (concentration dependent, caverage 2.3 ug.mL). Ulf W Wiegand, Kenneth L. Hintze, John T. Slattery, Gerhard Levy. Protein binding of several drugs in serum and plasma of healthy subjects. Clin. Pharmacol. Ther. 1980, 27, 297-300.","N=6, 300 mg dose. VDss calculated from C vs. t data given in paper.",,1946,252.27,4,2,58.2,2,neutral,1.7,1.6
c1ccc(cc1)CN(CC2=NCCN2)c3ccccc3,4.297925052503806,2.1486905,Antazoline,91-75-8,3.9,19.67,,3.45,2.29,"Joanna Giebułtowicza,, Roman Piotrowski, Jakub Baran, Piotr Kułakowski,Piotr Wroczyński.  Application of a novel liquid chromatography/tandem massspectrometry method for the determination of antazoline in humanplasma: Result of ELEPHANT-I [ELEctrophysiological, pharmacokineticand hemodynamic effects of PHenazolinum (ANTazoline mesylate)]human pharmacokinetic study. J. of Pharm. Biomed. Anal.  2016, 123, 113–119.","N=9, intravenous dose, 100 mg. Data reported as median. ",,1944,265.35,3,1,27.6,5,cationic,2.8,0.28
c1ccc(cc1)[C@H](C(=O)O)NC(=O)[C@H](CS(=O)(=O)CCOP(=O)(N(CCCl)CCCl)N(CCCl)CCCl)NC(=O)CC[C@@H](C(=O)O)N,4.832890014164741,0.9734193,TLK286,158382-37-7,0.46,28.5,,0.27,0.28,"Lee S. Rosen, Joseph Brown, Bernadette Laxa, Leny Boulos, Laura Reiswig, William D. Henner,
Robert T. Lum, Steve R. Schow, Christopher A. Maack, James G. Keck, Julie C. Mascavage, Jacqueline A. Dombroski, Reinaldo F. Gomez, and Gail L. Brown. Phase I Study of TLK286 (Glutathione S-Transferase P1-1 Activated Glutathione Analogue) in Advanced Refractory Solid Malignancies. Clinical Cancer Research, 2003, 9, 1628-1638.","Canfosfamide. (TLK286 is the R-isomer) DATA in BLOOD. No b/p ratio reported. N=6 for each two doses averaged (180 and 720 mg/m2, in the middle of range) very reproducible and largest two cohorts. 64 kg average weight of two cohorts derived from clearance in mL/min and mL/min/kg reported. MRT from VDss and clearance. Range 60 to 1280 mg/m2. Clearance from largest dose (N=5) ~3-fold smaller than smallest dose. Possible saturation observed at 960 mg/m2 as well. Authors report dose dependent clearance at the highest doses.",,1994,787.47,15,5,225.7,25,anionic,-1.0,-5.9
c1ccc2c(c1)/C(=C/CCN3CCN(CC3)CCO)/c4cc(ccc4S2)C(F)(F)F,2.0496307677246004,3.5664582,Flupentixol,2709-56-0,,4.14,,,34.2,"Joergensen, A.; Andersen, J.; Bjoerndal, N.; Dencker, S. J.; Lundin, L.; Malm, U. Serum concentrations of cis(Z)-flupentixol and prolactin in chronic schizophrenic patients treated with
flupentixol and cis(Z)-flupentixol decanoate. Psychopharmacol.1982, 77, 58-65.","N-7009. Flupenthixol. Siplaril. Administered iv at 2 mg dose, to N=9 schizophrenic patients, as a mixture 1:1 of diastereomers. Not clear whether the analysis referred to Z-flupentixol (CAS # 53772-82-0). CAS number and structure refers to compound with unspecified double bond geometry. Average weight calculated as exactly 70 kg.No VDss reported.",,1963,434.52,3,1,26.7,5,cationic,4.8,3.9
c1ccccc1CC[C@H](N[C@@H](C(N1[C@@H](CC2(C1)SCCS2)C(=O)O)=O)C)C(=O)OCC,3.572889668420581,1.9129871,Spirapril,83647-97-6,0.43,11.9,,0.61,8.6,"    Spirapril Hydrochloride - FDA Approval Package
Clinical Pharmacology and Biopharmaceutics Review 020240 Part 01. Accessed through Pharmapendium.","Data digitized and calculations performed via Phoenix. Data digitized from Figure 7.1 in FDA report (NDA: 20-240):
Reported ""readable"" data (table 7.1): N=5, 70kg body weight assumed AUCinf = 92 ng*h/mL, CL = 0.96 L/min (13.7 mL/min/70kg)",Transformed into diacid spiraprilat in analogy with other ACE inhibitors.,1982,466.61,7,2,95.9,10,anionic,2.7,-0.81
c1cn(c(=O)nc1N)[C@H]2CO[C@H](S2)CO,1.584962500721156,2.65272,(-)dOTC,160707-69-7,1.18,3.0,,6.5,19.2,"PATRICK F. SMITH, ALAN FORREST, CHARLES H. BALLOW, DAVID E. MARTIN,AND LOUISE PROULX. Absolute Bioavailability and Disposition of (-) and (+) 2'-Deoxy-3'-Oxa-4'-Thiocytidine (dOTC) following Single Intravenousand Oral Doses of Racemic dOTC in Humans. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY,2000, 44,1609–1615.",Dosed as 100 mg of racemate. (-) form called apricitabine or (-) BCH10652. Data for (+) form reported as well. MRT from VDss and clearance. ,,1994,229.26,6,2,90.4,2,neutral,-1.9,-1.9
c1nc2c(nc(nc2n1[C@H]3[C@@H]([C@@H]([C@H](O3)CO)O)O)N/N=C/C4CCCCC4)N,5.161887682376894,1.7409809,Binodenoson,144348-08-3,0.4,35.8,,0.19,0.21,"Richard J. Barrett, PhD, Michael J. Lamson, PhD, James Johnson, PhD, William B. Smith, MD, FACC.  Pharmacokinetics and safety of binodenoson after
intravenous dose escalation in healthy volunteers. Journal of Nuclear Cardiology, 2005, Volume 12, Number 2;166-171","Data digitized from plot (3 ug/kg) reported. N=6, 75.6 kg average (overall) weight. 10 minutes infusion. AUCinf calculated within 2% of AUCinf reported.",,1992,391.42,11,5,163.9,5,cationic,-0.18,-0.18
c1nccc2C(c3c(C(c12)=O)c(ccc3NCCN)NCCN)=O,4.145677455195635,1.9759156,Pixantrone,144510-96-3,10.1,17.7,,8.9,13.4,"A Phase I and Pharmacokinetic Study of the Novel Aza-Anthracenedione Compound BBR 2778 in Patients with Advanced Solid Malignancies. Sandrine Faivre, Eric Raymond,1 Valerie Boige, Michel Gatineau, Xavier Buthaut, Olivier Rixe, Alberto Bernareggi, Gabriella Camboni, and Jean-Pierre Armand. Clin Cancer Res 2001;7:43-50","BBR2278. Weighted average of doses: 25 mg/m2 (N=6), 37.5 mg/m2 (N=1),  75 mg/m2 (N=1), 112.5 mg/m2 (N=3), 150 mg/m2 (N=2)",,1992,325.37,7,4,123.1,6,cationic,-0.21,-2.4
n1(Cc2ccc(cc2)F)c(N2CCC(CC2)N(C)c2nccc([nH]2)=O)nc2c1cccc2,0.0426443374084937,1.8011996,Mizolastine,108612-45-9,0.38,1.03,,6.0,9.6,"Florence Mesnil, Catherine Dubruc, France Mentre, Sylvie Huet, Alain Mallet, and Jean-Paul Thenot. Pharmacokinetic Analysis of Mizolastine in Healthy Young Volunteers After Single Oral and Intravenous Doses: Noncompartmental Approach and Compartmental Modeling  J. Pharmacokin. and Biopharm. Vol. 25. No. 2, 1997, 125-147.","Assumed 70 kg. N=18. 10 mg in 30' infusion. 5 mg iv 30 min infusionN=1, PK profile of the single subject 15. Data digitized from Figure 2 in ref cited
70kg BW assumed

Reported mean data for all 18 subjects (Table I):
N=18
AUC = 1059 ng*h/mL
CL = 4.9 L/h (1.17 mL/min/kg)
t1/2 = 12.9 h",,1987,432.49,7,1,70.1,5,neutral,3.5,3.5
n1([C@H]2[C@@H]([C@@H](O)[C@@H]([C@H](O2)CO)OC)O)c2c3c(c4C(=O)N(C(c4c2c2c1c(Cl)ccc2)=O)CCN(CC)CC)c1cccc(c1[nH]3)Cl,1.6461626571578936,2.835908,Becatecarin,119673-08-4,8.9,3.13,,45.4,48.9,"Anthony W. Tolcher, S. Gail Eckhardt, John Kuhn, Lisa Hammond, Geoffrey Weiss, Jinee Rizzo, Cheryl Aylesworth, Manuel Hidalgo, Amita Patnaik, Garry Schwartz, Sally Felton, Elizabeth Campbell, and Eric K. Rowinsky. Phase I and Pharmacokinetic Study of NSC 655649, a Rebeccamycin Analog With Topoisomerase Inhibitory Properties. Journal of Clinical Oncology, 2001, 19, 2937-2947.","NSC655649. BMS 181176. N= 43 total, doses from 20 a 744 mg/m2. Data reported here as weighted average across all doses in Table 5.",,1988,669.55,11,4,140.5,8,cationic,3.0,2.5
n1([nH]c(nc1=O)C[N@@]1[C@H]([C@H](OCC1)O[C@H](C)c1cc(cc(c1)C(F)(F)F)C(F)(F)F)c1ccc(cc1)F)P(=O)(O)O,4.217230716220669,0.78314257,Fosaprepitant,172673-20-0,0.07,18.6,0.02,0.06,2.2,"Kenneth C. Lasseter, Jay Gambale, Bo Jin, Art Bergman, Marvin Constanzer, James Dru, Tae H. Han, Anup Majumdar,Judith K. Evans and M. Gail Murphy. Tolerability of Fosaprepitant and Bioequivalency to Aprepitant in Healthy Subjects. J Clin Pharmacol 2007 47: 834-840.",average of two doses iv. Very tight data. MRT from VDss and Cl.,"PP.     Fosaprepitant Dimeglumine - EMA Approval Package
Assessment Report EMEA/42754/2008 ",1995,614.41,10,3,129.9,7,anionic,2.4,-3.5
n1(c(=O)n(c(=O)cc1NCC[N@@](CCCc1ccc(cc1)[N+](=O)[O-])CCO)C)C,4.384740587292384,2.7876592,Nifekalant,130636-43-0,1.96,20.89,0.09,1.56,1.52,"ZHANG Heng, WANG Ben-jie, GUO Rui-chen. Pharmacokinetics of Nifekalant Hydrochloride in Chinese Healthy Volunteers. Chin Pharm J，2009, 44, 136-140.//ppb: Haruaki Nakaya and Hiroko Uemura, Electropharmacology of Nifekalant, a New Class III Antiarrhythmic Drug. Cardiovascular Drug Reviews, 1998, 16, 133-144.","PK calculated from tabulated data in the paper. Average of 0.3 and 0.4 mg/kg doses as HCl, N=8 each. Corrected for HCl salt weight. 65.2 kg average weight. ppb taken as the midpoint of values reported from reference 19 in Nakaya et al. The actual ref. (Kato et al 1997) could not be found.",,1980,405.45,10,2,122.6,11,cationic,1.2,0.5
"n1(c(cnc1C)[N+](=O)[O-])C[C@@H](CCl)O
",0.1110313123887439,2.2759013,Ornidazole,16773-42-5,1.16,1.08,0.88,18.1,12.0,"Tolerability,Safety and Pharmacokinetics of ( S) -Ornidazole in Ascending Dose Study in Healthy Chinese Volunteers. ZHAO Ya-nan，WU Pei，SUN Hua，YANG Jing-jing,GUO Yi-yun，LIU Xiao-quan. Chin. Pharm. J. 2011, 46, 454-457. ppb: Schwartz DE, Jeunet F. Comparative pharmacokinetic studies of ornidazole and metronidazole in man. Chemotherapy, 1979, 22, 19-29.","S-enantiomer. 3 doses N=10 each, 500, 1000 and 1500 mg total dose. likely 1 hr infusion. Reported clearance likely to be in L/h. Cheched via cross-calculations of dose/auc and t1/2.",,1966,219.63,6,1,81.2,4,neutral,0.23,0.22
n1(c2c(nc1)[C@@H](CNC=N2)O)[C@@H]1O[C@H]([C@@H](C1)O)CO,0.7048719644563528,3.1008255,Pentostatin,53910-25-1,0.59,1.63,0.96,6.0,5.3,"Pentostatin pharmacokinetics and dosing recommendations in patients with mild renal impairment. Lathia, Chetan; Fleming, Gini F.; Meyer, Mark; Ratain, Mark J.; Whitfield, Lloyd.Cancer Chemother. Pharmacol. 2002,50 (2) 121-126. ppb: The PDR states: The plasma protein binding of pentostatin is low, approximately 4%. Accessed January 8 2015. http://www.pdr3d.com/detail.php?c=21514#section-4","2'-Deoxycoformycin, NSC 218321. Average of N=6, dose range 4 mg/m2. Only patients with Clcr > 60 used. 70 kg average weight assumed.
",,1974,268.27,8,4,112.1,2,neutral,-2.7,-2.7
n1(nnnc1SCC1=C(N2[C@H](OC1)[C@@](C2=O)(OC)NC(=O)CSC(F)F)C(O)=O)CCO,2.035623909730721,0.7510483,Flomoxef,99665-00-6,0.19,4.1,0.64,0.77,0.6,"Saito, Haruo; Kimura, Tadashi; Takeda, Taizo; Kishimoto, Seiji; Oguma, Takayoshi; Shimamura, Kenji. Pharmacokinetics of flomoxef in mucosal tissue of the middle ear and mastoid following intravenous administration in humans. Chemotherapy (Basel, Switzerland), 1990, 36, 193-199.//ppb:Hamada, Toshihiro; Ueta, Eisaku; Kodama, Hiroyuki; Osaki, Tokio. The excretion of cephem antibiotics into saliva is inversely associated with their plasma protein-​binding activities. J. Oral Pathol. Med. 2002, 31, 109-116. ","VDss from Vc and k12/k21. Clearance from dose/AUC. MRT from Clearance and VDss. 1 g dose, N=6, 70 kg weight assumed.",,1984,496.47,13,3,169.0,11,anionic,-0.98,-4.0
n1c(=O)c2cc(CN(c3ccc(C(=O)N[C@@H](CCc4nnn[nH]4)C(=O)O)c(c3)F)CC#C)c(C)cc2[nH]c1C,-1.7858751946471527,0.26020548,ZD-9331,153537-73-6,0.53,0.29,0.01,30.38,78.5,"Maja JA de Jonge, B Glimelius, Jaap Verweij, C van Groening en, J Bonneterre, EGE de Vries, S Culine, J Young ,7 Rob Smith,  J Droz. E¡ects of impaired renal function on the pharmacokinetics and toxicity of i.v. ZD9331, a novel non-polyglutamated thymidylate synthase inhibitor, in adult patients with solid tumors. Anti-Cancer Drugs 2002, 13,  645–653",Plevitrexed. NSC 696259. Data from subject with normal renal function. N=10. 70 kg average weight assumed. MRT from clearance and VDss.,,1993,532.53,12,4,169.8,11,zwitterionic,2.4,-2.6
n1c2c(nc[nH]2)c([nH]c1N)=S,3.944858445807539,1.7716523,Thioguanine,154-42-7,2.89,15.4,,3.13,24.35," Kitchen, Brenda J.; Balis, Frank M.; Poplack, David G.; O'brien, Michelle; Craig, Catherine E.; Adamson, Peter C.  A pediatric phase I trial and pharmacokinetic study of thioguanine administered by continuous i.v. infusion. Clinical Cancer Research, 1997, 3, 713-717.","2-amino-6-mercaptopurine. 6-mercaptoguanine. Data digitized from plot 20 mg/m2/h, 24 hr infusion. N=13. 70 kg average weight assumed. 1.73 m2/70 kg conversion factor used. Reported clearance 608 mL/min/m2 corresponding to 15.02 mL/min/kg.",,1948,167.19,5,3,83.4,0,anionic,-1.2,-4.7
n1cnc(c2cc(c(cc12)OCCOC)OCCOC)Nc1cc(ccc1)C#C,0.7570232465074596,1.8198855,Erlotinib,183321-74-6,0.77,1.69,0.07,7.55,6.5,"A phase I dose-escalation and bioavailability study of oral and intravenous formulations of erlotinib (Tarceva®, OSI-774) in patients with advanced solid tumors of epithelial origin M. Ranson · H. Shaw · J. Wolf · M. Hamilton ·S. McCarthy · E. Dean · A. Reid · I. Judson. Cancer Chemother Pharmacol (2010) 66:53–58. ppb; The PDR states: Following absorption, erlotinib is approximately 93% protein bound to albumin and alpha-1 acid glycoprotein (AAG). Accessed december 31 2014. http://www.pdr3d.com/detail.php?c=3144#section-3","Data weighted across 25, 50 and 75 mg infusion doses. Median data reported and used.",,1996,393.44,7,1,74.7,11,neutral,3.8,3.8
o1c(=O)c(c(c2ccc(cc12)OCCCN1CCN(CC1)Cc1ccc(cc1)Cl)C)C,0.3785116232537298,2.578027,Picumast,39577-19-0,1.3,1.3,0.05,16.5,19.2,"Neugebauer G, Wittenbrink-Dix AM, Woelke-Seidl E, Kaufmann B, Ponton T, Dahmen W, Mosberg H, Nieder N, Besenfelder E. Pharmacokinetics of picumast dihydrochloride and its active metabolites M1 and M2 in humans. Arzneimittelforschung. 1989 Oct;39(10A):1336-9.","N=11, 72 kg average weight, 10 mg iv dose. Median values reported: clearance 95 mL/min,  VDss 97 L,  MRT and t1/2 19.2 and 16.5, respectively.",Reported as almost exclusively celared by hepatic metabolism but no quantitative data in Neugebauer et al.,1972,440.96,5,0,46.2,7,cationic,4.7,3.9
s1c(C(OC)=O)c(NC([C@@H](C)NCCC)=O)c(c1)C,6.985272714253447,2.3813865,Articaine,23964-58-1,7.7,126.7,0.46,1.04,0.98,"Vree, Torn B.; Simon, Marc A. M.; Gielen, Mathieu J. M.; Booij, Leo H. D. J. Regional metabolism of articaine in 10 patients undergoing intravenous regional anesthesia during day case surgery. British Journal of Clinical Pharmacology, 1997, 44, 29-34.//ppb:  Oertel, Reinhard; Richter, K. Plasma protein binding of the local anesthetic drug articaine and its metabolite articainic acid. Pharmazie, 1998, 53, 646-647.","Average weight reported as 70.5 kg. 200 mg dose, N=10. // ppb: In the range of 0.5-​5 μg​/mL articaine had a linear protein binding. Data at pH 7.5. Much higher binding (71%) at pH 8.5.",,1969,284.37,5,2,67.4,7,cationic,1.9,1.2
s1c(cnn1)SCC1=C(N2[C@H](SC1)[C@@H](NC(\C(c1csc(n1)N)=N/OC)=O)C2=O)C(=O)O,2.035623909730721,0.48317298,Cefuzonam,82219-78-1,0.2,4.1,0.12,0.82,1.14,"M. TOMISAWA, I. NAKAYAMA, and A. SAITO.  Antimicrobial Activity and Pharmacokinetics of L-105, a New Cephem Antibiotic Agent. RECENT ADV. CHEMOTHER.1985, Antimicr. Sect. 2, 891-892.//ppb: Hamada T, Ueta E, Kodama H, Osaki T. The excretion of cephem antibiotics into saliva is inversely associated with their plasma protein-binding activities. J Oral Pathol Med. 2002, 31, 109-116","L-105. Cosmosin. 1 gm dose, N=21 70 kg average weight assumed. MRT from VDss and clearance. Structure refers to neutral compound.",~ 50% urinary excretion.,1982,513.59,12,3,173.0,8,anionic,0.51,-2.5
s1c(nc2c1cc(cc2)OC(F)(F)F)N,3.4982508675278257,2.0455098,Riluzole,1744-22-5,3.5,11.3,0.04,5.2,,"Riluzole - FDA Approval Package
Clinical Pharmacology and Biopharmaceutics Review 020599. Accessed through Pharmapendium.","N=15, 50mg dose iv, 70 kg assumed, MRT from VDss and clearance. t/12 not found.",91.5% of oral dose recovered in urine with only 2% as ntact riluzole.,1963,234.2,3,1,48.1,1,neutral,3.1,3.1
